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Abstract
Abstract
Vaccinia virus is a good model system for studying host cell biology and enhancing our 
understanding o f microtubule-based transport. Whilst the key viral proteins involved in 
microtubule-based transport of intracellular enveloped virus (IEV) have been identified, 
their exact mechanistic relationship to each other and to microtubule motor proteins has 
not been fully established. This thesis aims to address how the viral protein F12L and 
kinesin-1 are recruited to IEV particles and how the viral proteins A33R and A36R are 
also involved in this process.
It is known that the movement of IEV particles, from the perinuclear viral factories to 
the plasma membrane, is microtubule-dependent and involves the A36R protein as well 
as the recruitment o f kinesin-1. At the plasma membrane, actin tail formation has been 
shown to be dependent on phosphorylation o f A36R. However, A36R is dependent 
upon an interaction with the A33R protein in order to be recruited to the virion. It has 
also been shown that A33R is heavily phosphorylated at serine residues but its role is 
currently unknown. The initial part o f my studies examined the potential role of 
phosphorylation o f A33R and its effect on viral egress. No effect on viral transport was 
observed upon dephosphorylation of A33R.
The viral protein F12L also has a proposed role in microtubule-dependent transport, as 
an accumulation o f particles is observed in the region of the viral factories and transport 
to the cell surface does not occur in the absence of the protein. However, the mode of 
interaction of F12L with IEV and its association with kinesin-l is unclear. The precise 
structure of F12L is also unknown. In order to investigate the relationship between 
F12L, A36R, A33R and kinesin-l, a new range of tools was developed, including: a 
F12L antibody, GFP-F12L fusion constructs, deletion mutants to determine which 
regions of F12L are involved in virus transport, constructs to investigate whether F12L 
undergoes any post-translational modification event(s), as well as designing F12L and 
A33R recombinant viruses. No direct interaction has been established between F12L 
and A36R, or A33R, or kinesin-1.
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1.1 Cytoplasm ic Transport
The basic structural and functional unit o f all living organisms is the cell, which is 
highly organised, performs numerous specialised functions and is connected by an array 
of complex communication systems. Eukaryotic cells must utilise these communication 
networks in order to function efficiently. They transport various cellular cargos to their 
specific destinations within the cell and between neighbouring cells, in both a spatially 
and temporally controlled manner. Intracellular movement of molecules that are greater 
than 500KDa in size are dependent on this active transport, due to the high 
concentration o f cytosolic proteins that results in molecular crowding and restricts the 
free diffusion of macromolecules in the cytoplasm (Sodeik 2000; Luby-Phelps 2000; 
Lukacs et al. 2000; Minton 2006). Thus, many cytosolic particles, vesicles and 
organelles possess a size that exceeds this diffusion exclusion limit. Likewise, this is 
also true for numerous invading pathogens. Therefore they have evolved mechanisms to 
manipulate their host cell, allowing them to be transported through the cytoplasm along 
cytoskeletal tracks, powered by molecular motors.
Micro-organisms and viruses are well documented to abuse the microtubule-mediated 
cytoplasmic transport systems (reviewed in Greber and Way 2006; Schepis et al. 2006; 
Gouin et al. 2005; Hayward et al. 2006). Exploitation of this cellular transport is 
analogous to that of a train travelling between various stations along railway tracks. The 
tracks compare to the microtubules, the train represents the motor and the cargo that is 
being transported relates to the passengers that board or disembark. Together with their 
respective motor proteins, the actin cytoskeleton is employed to cover short distances, 
while long-range transport of cellular cargo is usually mediated by microtubules. In the 
following sections, our current understanding of the proteins that control the 
cytoskeleton will be addressed, before focusing in greater depth on the regulation of 
microtubule-based transport and the use o f vaccinia virus as a powerful tool to study 
host cell biology and enhance our knowledge of the mechanisms mediating the spread 
of infection. These concepts are used to investigate cytoplasmic transport during viral 
infection, while considering and drawing parallels to conventional intracellular 
trafficking mechanisms in eukaryotic cells.
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1.2 T h e  C y to sk e le to n
Cytoplasmic transport and cell motility are dependent upon the dynamic, spatio- 
temporal regulation of the cytoskeleton of the cell. The overall structure, morphology 
and internal organisation of a eukaryotic cell is maintained by its cytoskeleton, which is 
an intricate three-dimensional, protein scaffold, composed of three major classes of 
polymers: actin filaments, microtubules and intermediate filaments. These filaments are 
interdependent entities, with each type possessing a unique set of mechanical properties 
to ensure that they function optimally alone and in co-ordination with each other as a 
dynamic and adaptable network (Goode et al., Drubin et al. 2000; Howard 2001). Each 
filament is constructed from smaller protein subunits, which unlike their assembled 
filaments, can diffuse rapidly through the cytoplasm and facilitate structural 
reorganisations through disassembly of filaments at one site and reassembly at another 
distant site. These filaments are considered in more detail in the following sections and 
an example of their organisation within intestinal epithelial cells is illustrated below in 
Figure 1.1.
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Figure 1.1: Cytoskeletal filaments of intestinal epithelial cells. All three types of filament are 
present in the epithelial cells of the intestine and their location within this cell-type, together with 
an enlarged view of the structure of each filament is depicted. (A) actin filaments project into the 
villi, providing shape to the cell surface; (B) microtubules grow out of the centrosome to the cell 
periphery; (C) intermediate filaments connect adjacent cells through desmosomes. (Figure 
reproduced from Alberts et al. 2002).
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The cytoskeleton varies between different cell-types and during the various stages of the 
cell-cycle. Actin and microtubules are present in all eukaryotic cells, while intermediate 
filaments are cell-type specific, so differ in their composition from one tissue to 
another; e.g. intermediate filaments are not present in oligodendrocytes (Siegel et al. 
1999). In each case, the cytoskeleton is comprised of a specific set of proteins, 
molecular motor proteins and other proteins that are responsible for performing the 
different mechanical processes needed by that cell-type. Once the filaments are 
assembled they must be organised into functional arrays according to the requirements 
of the cell. For example, the focused array of microtubules that comprises the mitotic 
spindle during cell division, which all cells need (see Section 1.2.2), and the bundled 
actin filaments that are found in microvilli of intestinal epithelium (see Section 1.2.1 
and Figure 1.1).
1.2.1 Actin
Actin was initially discovered and purified from muscle, complexed to the motor 
protein myosin (see Section 1.4.1) and many years later the crystal structure o f actin 
was determined (Halliburton 1887; Straub 1942; Kabsch 1990; Holmes et al. 1990). 
Actin is also present in non-muscle cells and most multicellular organisms contain three 
principle, highly conserved, isoforms of actin: a , p, and y, whose distribution in 
vertebrates is tissue-specific (Pollard 1986; Adelmann et al. 1968; reviewed in Bonetta 
2005; reviewed in Herman 1993 and Khaitlina 2001). Vertebrates possess at least six 
isoforms o f actin: cardiac a-actin and skeletal a-actin (expressed in striated muscle), 
vascular a-actin and enteric y-actin (expressed in smooth muscle) and cytoplasmic p- 
actin and cytoplasmic y-actin (Herman 1993; Khaitlina 2001; 
http://www.cbilupenn.edu/MTIR/gammaActin E-toc.html).
Actin is a 42KDa protein, consists of 375 amino acids, is a major constituent of the 
cytoskeleton and is one of the most abundant proteins in the majority o f eukaryotic 
cells. Electron microscopy revealed that actin filaments possess the smallest diameter of 
the three classes of cytoskeletal filaments, with a diameter of only ~6nm. Actin 
filaments are cable-like structures formed from two intertwined chains of globular G- 
actin monomers. Each G-actin monomer possesses structurally different ends that are 
arranged in a head-to-tail fashion, creating a polar, double helical filament, F-actin
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(filamentous), in the presence of adenosine triphosphate (ATP), magnesium (Mg2+) and 
potassium (K+) ions (Figure 1.2a) (Moore et al. 1970, Huxley et al. 1970; Hanson 
1973). Actin filaments have a dynamic, fast-growing plus-end and a slower-growing 
minus-end. The plus-ends are also referred to as the ‘barbed-ends’ and the minus-ends 
as the ‘pointed ends’, due to the arrowhead orientation they adopt upon interaction of 
the actin filament with a specific region of the motor protein myosin, subfragment S 1 
(see Section 1.4.1 for details on myosin) (Craig et al. 1985).
actin molecule
plus end
Figure 1.2a: Actin monomer and actin filament structures. (A) The actin monomer has a 
nucleotide (either ATP or ADP) bound in a deep cleft in the centre o f the molecule. (B) 
Arrangement of monomers in a filament. Although the filament is often described as a single 
helix of monomers, it can also be thought of as consisting of two protofilaments, held together 
by lateral contacts, which wind around each other as two parallel strands of a helix, with a twist 
repeating every 37hm. All the subunits within the filament have the same orientation. (C) 
Electron micrographs of negatively stained actin filaments. (Figure reproduced from Alberts et 
al. 2002).
COOH
plus end
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Actin polymerisation is a dynamic process, regulated by the hydrolysis o f a tightly 
bound ATP to each actin molecule. Although actin polymerisation is independent of 
ATP hydrolysis, it is required to destabilise the bonds that hold the polymer together 
and thus promote depolymerisation. The crystal structure shows that actin contains a 
deep cleft into which the nucleotide ATP, or adenosine diphosphate (ADP) and the 
Mg2+/K+ ions bind (Kabsch et al. 1990). This nucleotide is responsible for regulating 
actin polymerization and depolymerisation. As new filaments are nucleated, there is an 
initial lag phase, followed by a rapid polymerisation phase as the short filaments 
elongate. After polymerisation, the terminal ATP phosphate bound to actin is 
hydrolysed, trapping the resulting ADP within the polymer (Pollard and Borisy 2003).
The rate at which actin nucleation proceeds is proportional to the cube of the actin 
concentration, while the rate at which each filament elongates is proportional to the 
concentration of the free subunit in vitro. This indicates that elongation occurs by the 
addition of one actin molecule at a time. The concentration of G-actin is, therefore, also 
critical, as above this critical concentration (Cc) the molecule will polymerise and 
below the Cc the actin filaments will depolymerise (See Figure 1.2b). This continuous 
addition of actin molecules at the plus end of the filament and their continuous loss 
from the minus end, with no net change in the filament length, results in a dynamic 
behaviour called treadmilling. Treadmilling is driven by the energy provided by the 
ATP-hydrolysis that accompanies polymerisation (Pollard and Borisy 2003).
Filament
Monomer
Actin concentration
Figure 1.2b: Critical concentration (Cc) of actin. The Cc is the concentration of G-actin 
monomers in equilibrium with actin filaments. At monomer concentrations below the Cc, no 
polymerisation occurs. At monomer concentrations above the Cc, filaments assemble until the 
monomer concentration reaches Cc. (Reproduced from Cooper 2000).
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1.2.2 Microtubules
Microtubules are long, hollow, cylindrical structures that are composed of alpha (a) and 
beta (p) tubulin dimers. Microtubules form an intricate network within cells and 
perform a wide variety o f cellular functions, including: cell polarity and organisation, 
chromosome segregation and long-distance transport o f proteins and organelles 
(Howard and Hyman 2003). The a -  and p-subunits are tightly bound together by non- 
covalent bonds to form heterodimers, which are constructed into 13 parallel 
protofilaments that are arranged in a head-to-tail-fashion. The resulting microtubule has 
an outer diameter of ~25nm, an inner diameter of ~18nm and is reinforced by lateral 
interactions between the fdaments (Figure 1.3). Nogales et al. published the first atomic 
model of the ap-tubulin dimer in 1998 (3.5A resolution), by using cryo-electron 
crystallography of zinc-induced tubulin sheets (Nogales et al. 1998; Downing and 
Nogales 1999). And, as a consequence of improved methodology they presented a 
refined model in 2001 (Lowe et al. 2001). In addition, the first X-ray crystal structure 
o f a monomeric tubulin, human y-tubulin-GTPyS complex, has recently been 
determined by using the molecular replacement technique {2.1 k  resolution) (Aldaz et 
al. 2005).
Microtubules are highly polar structures in vitro, with continuous polymerisation 
occurring at their fast-growing plus-ends (‘growing state’) and depolymerisation at their 
less dynamic minus-ends (‘shrinking state’) (Kirschner and Mitchison 1986; Guzik and 
Goldstein 2004). The addition of a - and p-tubulin heterodimers is regulated by the 
dynamics of the plus-end (i.e. monomer loss or addition) and is thus dependent upon the 
GTP-binding abilities o f the tubulin subunits. Once attached at the plus-end, the GTP- 
bound to p-tubulin is slowly hydrolysed and the consecutive loss of this GTP-tubulin, 
exposing the GDP-end, results in catastrophic microtubule depolymerisation (or 
‘shrinkage’). In contrast, the change to the growing state is referred to as ‘rescue’. This 
efficient turnover of microtubules is tightly controlled in space and time and the rapid 
conversion between the growing and shrinkage states, while maintaining a uniform free 
subunit concentration, is called ‘dynamic instability’ (Figure 1.3F) (Alberts et al. 2002; 
Mitchison and Kirschner 1984).
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Figure 1.3: The structure of a microtubule and its subunit. (A) Each protofilament is 
composed of tubulin heterodimers, formed from a tightly linked pair of a- and /3-tubulin 
monomers. The GTP molecule in the a-tubulin monomer is so tightly bound that it can be 
considered as an integral part of the protein. However, the /3-tubulin monomer is less tightly 
bound and has an important role in filament dynamics. Both nucleotides are shown in red. (B) 
One tubulin subunit (a-(3 heterodimer) and one protofilament are shown schematically. Each 
protofilament consists of many adjacent subunits with the same orientation. (C) Microtubules 
are stiff, hollow tubes formed from 13 protofilaments aligned in parallel. (D) Electron micrograph 
of a short segment of a microtubule, together with a cross-section of a microtubule showing 13 
distinct protofilaments (E). (F) The plus-ends of microtubules alternate between two states: 
growth and shrinkage, which is called ‘dynamic instability’. During the growth phase, the 
elongating microtubules are thought to form an open sheet of tubulin polymer that comprises 
GDP a-[3-tubulin heterodimers containing GTP /3-tubulin at the tips. During the shrinkage phase 
microtubule plus-ends have curved protofilaments that peel away from the microtubule wall. 
(Images A-E are taken from Alberts et al. 2002, while image F is reproduced from Watanabe et 
al. 2005).
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The minus ends of microtubules are attached to a microtubule-organising centre 
(MTOC), which is usually centrally-located in the vicinity o f the nucleus, while the 
positive ends radiate towards the cell periphery (Howard and Hyman 2003; Guzik and 
Goldstein 2004). The MTOC consists of different proteins such as y-tubulin and 
pericentrin and is the term used to represent structures within the cell that nucleate and 
organise microtubules (Joshi 1993; Joshi 1994; Doxsey et al. 1994). The two most 
important types of MTOCs are the centrosome and basal bodies, which are associated 
with cilia and specific intercellular junctions within epithelial cells (Mitchison and 
Kirschner 1984). Other examples of MTOCs include the kinetochore and the poles of 
the mitotic spindle during mitosis, as well as the blephaoplast and plasmelemma in plant 
cells (Maiato and Sunkel 2004; Cassimeris and Skibbens 2003; McGill and Brinkley 
1975; Hayden et al. 1990; Vaughn and Harper 1998). The centrosome is involved in the 
nucleation of microtubules, intracellular transport, spatial organisation o f proteins and 
organelles, the cell cycle and mitosis as well as the degradation o f ubiquitin (Doxsey
2001). Importantly, dysfunction of the centrosome can result in many human diseases, 
including tumorogenesis (e.g. mis-segregation of chromosomes, aneuploidy, are seen in 
the majority o f human tumour types) (reviewed in Fukasawa 2005).
Many proteins are known to bind to microtubules (microtubule-associated proteins, 
MAPs) and play important roles in regulating their function. Some proteins can alter the 
assembly/disassembly at the both the plus and minus ends of microtubules. Other 
proteins are able to tether microtubules and motor proteins and use ATP to transport 
different cargoes up and down the length of the microtubule, diversifying the 
functioning of microtubules. There are essentially two classes o f microtubule motor 
proteins: the kinesins, which are generally plus-end directed motors and dyneins, which 
are minus-end directed motors (Sections 1.4.2.1 and 1.4.2.2, respectively).
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Microtubules adopt distinct orientations within different cell types, in order to facilitate 
their various transport functions (Figure 1.4).
(A) Interphase cell (B) Ciliated cell
cilium/flagellum
basal body
cen tro so m e
(C) Dividing cell (D) Nerve cell
spindle
pole
c en tro so m e
axon
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Figure 1.4: Orientation of microtubules in different metazoan cell-types. The organisation 
of microtubules within (A) an interphase cell, (B) a ciliated cell, (C) a dividing cell and (D) a 
nerve cell are illustrated. The polarity of each microtubule is indicated by either a minus-end (-) 
or a plus-end (+). (Figure adapted from Alberts et al. 2002).
For example, in interphase cells the microtubules emanate outwards from the MTOC, 
usually placed in the middle of the cell, with their plus-ends towards the plasma 
membrane. Similarly, within flagella and cilia the minus-ends of microtubules are 
continuous with the basal bodies, which act as the MTOC in these structures. When a 
cell enters mitosis, the microtubule network rearranges itself to form a mitotic spindle, 
whereby all the minus-ends of the spindle microtubules point toward one of the two 
MTOCs (poles). In nerve cells, the structure of axons is dependent on all three types of 
cytoskeletal filament, with the axon cortex being lined with actin filaments. However, 
the microtubule organisation is more complex, whereby the filaments are all orientated 
in the same direction within axons; the minus ends all face towards the cell body
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(MTOC) and the plus end points forward towards the axon terminals. As these 
microtubules are typically only a few microns in size (3.87pm ±3.8pm) they are 
staggered in an overlapping array throughout the axon (Yu and Baas 1994; Alberts et al.
2002). Also, dendrites contain microtubules of mixed polarity until they reach a certain 
stage during development, whereas polarized epithelial cells demonstrate an apical- 
basal array (Dammermann et al. 2003; Hirokawa and Takemura 2005; Radtke et al. 
2006).
1.2.3Intermediate Filaments
The intermediate filament (IF) family of proteins is structurally diverse (including: 
keratins, vimentin, desmin, glial fibrillary acidic protein, lamins) but each IF monomer 
possesses a common structural unit of -340 amino acids in the central (alpha-helical) 
rod domain, flanked by an amino-terminal head and a carboxyl-terminal tail (Figure 
1.5A) (Howard 2001). IF have a smooth filament appearance, with a diameter of 
~10nm, and form fibrous, rope-like structures that are composed of several intertwined 
alpha-helical polypeptide strands. Each monomer pairs with another to form a dimer, in 
which the conserved central regions align and wind together, to form a coiled coil 
(Figure 1.5B). They assemble as a result of the strong lateral contacts formed between 
the alpha-helical coiled coils (Stewart 1993). The assembly and disassembly o f IF is 
regulated by phosphorylation (Inagaki et al. 1987; Eriksson et al. 2004). Two o f the 
dimer subunits then associate, in a staggered, anti-parallel manner, to form a tetramer 
that is the same at both ends (Figure 1.5C). Each tetramer is analogous to the aP-tubulin 
dimer or the actin monomer and associates with another tetramer (Figure 1.5D). The 
final IF consists of 8 tetramers packed tightly together in a helical array, i.e. 16 dimers 
in cross-section (Figure 1.5E). Therefore, unlike actin filaments and microtubules, IF do 
not possess inherent polarity and, as there are no known motor proteins that use them 
for transporting cargo, they do not appear to play a role in intracellular transport 
(Dohner and Sodeik 2005).
IF are thought to be principally responsible for providing tensile strength to a cell, to 
help withstand any external tension applied from outside of the cell. They are present in 
the cytoplasm of most eukaryotic cells but are cell-type specific and particularly 
abundant in cells that are subject to mechanical stress, such as keratinocytes (Omary
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Figure 1.5: Intermediate filament construction. The monomer shown in (A) pairs with an 
identical monomer to form a dimer (B), in which the conserved central rod domains are aligned 
in parallel and wound together into a coiled coil. (C) Two dimers then line up side by side to 
form an anti-parallel tetramer of four polypeptide chains. The tetramer is the soluble subunit of 
intermediate filaments. (D) Within each tetramer, the two dimers are offset with respect to one 
another, thereby allowing it to associate with another tetramer. (E) In the final 10nm rope-like 
filament, tetramers are packed together in a helical array, which has 16 dimers in cross-section. 
Half of these are pointing in each direction. An electron micrograph of intermediate filaments is 
shown on the upper left. (Figure reproduced from Alberts et al. 2002).
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and Ku 1997). Several mutations in intermediate filament genes have been linked to 
various human diseases that possess defects in tissue or cell durability. In particular, 
keratin mutations can result in skin blistering and hypertrophy, diseases in which 
keratinocytes are not able to resist mechanical stress (Fuchs and Cleveland 1998). 
Furthermore, recent evidence proposes that IFs may play a role in organelle positioning 
and in membrane protein targeting after all (reviewed in Styers et al. 2005; Kowalczyk 
et al. 2005). IFs achieve this by interacting with both the microtubule and actin 
networks. There is evidence that they can associate with the motor proteins kinesin, 
dynein and myosin Va, in addition to interacting directly with the cytoskeletons, e.g. via 
the plakin family proteins (Chang and Goldman 2004; Helfand et al. 2003; Helfand et 
al. 2004; Rao et al. 2002; Jefferson et al. 2004).
1.3 Principles o f Cell M otility
Cell motility is critically required for numerous cellular processes throughout the life­
time of metazoans. For example, it is crucial during embryogenesis, skin renewal, 
wound healing and immune surveillance (Fenteany et al. 2000). However, inappropriate 
motile behaviour of cells can contribute to many human diseases, including cancer 
metastasis (Condeelis and Segall 2003).
Cancer metastasis is a complex process that involves the breakdown in adhesion 
between neighbouring cells and remodelling of the extracellular matrix, which permits 
the invasion of tumour cells into surrounding tissue by cell migration. The invading 
cells gain access and travel via the bloodstream and lymphatic system before invading, 
surviving and proliferating in other parts of the body. The more extensively a cancer 
metastasizes, the harder it becomes to eliminate (Hanahan and Weinberg 2000). 
Therefore, a greater understanding of the mechanisms underlying cell migration has the 
ultimate goal of developing specific therapeutic drugs to prevent metastasis of primary 
tumours.
1.3.1 Directed Cell M ovement
Cell migration was observed in vitro and comprehensively described by Abercrombie, 
who divided the process of a cell crawling into the following discrete stages that occur 
simultaneously within a cell (Figure 1.6) (Abercrombie and Heaysman 1976):
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Figure 1.6: Schematic of cell migration. Cell migration can be divided into four principle 
stages that occur simultaneously within a cell. (A) The cell is attached to the substratum in a 
resting state via focal contacts. (B) Lamellipodial protrusion and the subsequent movement in 
the direction o f travel, occurs as a result o f actin polymerization. (C) New focal contacts are 
established beneath the extending lamellipodium that promotes cell adhesion. Actin/myosin- 
mediated contraction of the cell body generates traction and old focal contacts at the posterior 
of the cell are dissolved, resulting in cell retraction that promotes forward cell movement. (D) In 
a migrating cell, this cycle is repeated continuously. The newly polymerised cortical actin is 
shown in red. (Figure taken from Alberts et al. 2002).
lamellipodium substratumactin cortex
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(A) Adherent cells become polarised in response to ‘motility-promoting agents’ 
present in the environment and extend broad, flat actin-rich membrane 
protrusions, called lamellipodium, in the desired direction of travel (Small et al.
2002). These environmental cues can be both physical and chemical. 
‘Chemotaxis’ refers to directed cell movement that is controlled by a gradient of 
a diffusible chemical, e.g. the chemotactic migration of neutrophils toward 
bacteria. Non-diffusible chemical cues can also influence the direction of cell 
movement, such as the chemical cues attached to the extracellular matrix or to 
the surface of surrounding cells. In such cases, receptor activation by these 
signals can result in increased cell adhesion and directed actin polymerisation, 
although most long-distance migration in animals involves a combination of 
both types of signalling (Alberts et al. 2002).
(B) One of the most striking functions o f the cytoskeleton is its participation in cell 
motility. During directed cell movement, the continuous turnover of actin 
polymerisation at the plasma membrane and depolymerisation within the cell 
body facilitate the forces that enable a cell to be driven forward (Pollard and 
Borisy 2003; Ridley et al. 2003). Actin polymerisation provides the primary 
driving force responsible for the protrusion of the lamellipodium (Krause et al. 
2003; Dent et al. 2003; Pollard and Borisy 2003).
(C) Focal contacts are established upon adhesion of the lamellipodium with the 
substratum, which anchors the cell into its new position. The cell body then 
contracts, powered by the sliding actin and myosin fibres that span the cell, 
which pushes the cytoplasm forward into the lamellipodium. Concomitantly, the 
contacts between the cells posterior and the substrate are weakened, allowing the 
rear end to retract into the cell body. Therefore, the loss o f cell adhesion in the 
rear is coupled with contraction of the cell body and the older rear contacts are 
also degraded by calpains (Franco and Huttenlocher 2005).
(D) Repetition of these co-ordinated events results in directed, forward movement of 
the cell at speeds of up to lpm/s, in the case of cultured keratinocyte cells 
(Euteneuer and Schliwa 1984).
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1.3.2 Actin-based Transport
1.3.2.1 Actin polymerisation drives cell motility
Actin polymerisation is the driving force for cell motility and it has been established 
that the growing plus-ends generate a pushing force on the plasma membrane to create 
cell protrusion. It is generally thought that this mechanism relies on the ratchet 
mechanism, which proposes that the force is generated as the actin monomers are added 
to the growing filaments at the plasma membrane (Mogilner and Oster 2003). In 
contrast to other studies, recent research by Soo and Theriot (2005) proposed an 
alternative model in which the speed is dependent upon adhesion, rather than just 
polymerisation. This implies that several additional mechanisms are likely to exist in 
order to regulate the proteins that control cell motility.
Electron microscopy has clearly demonstrated that actin filaments are the most 
dominant structure in lamellipodia, which are devoid of organelles (Svitkina and Borisy
1999). Lamellipodia are also the principle sites o f actin incorporation within a cell, as 
seen upon microinjection with fluorescent G-actin (Glacey 1983; Taylor and Wang 
1978). When cells are in motion, it is found that the barbed ends are always orientated 
towards the leading edge of the lamellipodium (Small and Celis 1978). Photobleaching 
studies showed that the actin cytoskeleton in motile cells remains static in comparison 
with the cell body and thus indicates that the rate of actin polymerisation at the barbed 
ends directly correlates with the protrusion rate o f a motile cell (Theriot and Mitchison 
1991).
Cell motility is dramatically inhibited when cells are treated with the drug cytochalasin 
D (CD). CD inhibits F-actin polymerisation by preventing the association of G-actin 
with the fast-growing barbed ends of F-actin filaments in vitro (even at low 
concentrations) (Cooper 1987). Thus, the ultimate effect is to stop filament elongation 
in vitro (Sampath and Pollard 1991). When CD is applied to living cells, protrusion of 
the lamelliopodia is inhibited, which suggests that G-actin monomer addition to the 
barbed ends at the leading edge is essential for cell motility (Yahara et al. 1982; 
Forscher and Smith 1988). Understanding how G-actin assembles to form actin 
filaments and how actin polymerisation is regulated is, therefore, fundamental to 
understanding cell motility. To date, two principle, independent nucleation mechanisms
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have been recognised: Arp2/3-mediated nucleation and actin nucleation mediated by 
formins (FH2 domains) (Higgs and Pollard 2001; reviewed in Cvrckova et al. 2004; 
Kovar and Pollard 2004; Pollard 2004). Above the critical concentration, although G- 
actin can form filaments in vitro in the absence o f other proteins, and whilst there are 
many ways in which actin can be nucleated, the Arp2/3 complex is considered to be the 
dominant mechanism at the leading edge of motile cells.
1.3.2.2 The Arp2/3 complex is essential for the regulation the actin cytoskeleton
The Arp2/3 complex (220KDa) was originally isolated from Acanthamoeba, using a 
profilin affmity-column (Machesky and Pollard 1992). It is comprised of seven protein 
subunits: five unique polypeptides (ARPC1-5) and two actin-related proteins, Arp2 and 
Arp3. Genetic studies in yeast subsequently demonstrated that loss o f components o f 
the Arp2/3 complex is lethal, emphasising that the Arp2/3 complex plays an essential 
role in regulation of the actin cytoskeleton (Winter et al. 1997). The first evidence to 
implicate the Arp2/3 complex in the control of actin polymerisation was published by 
Welch et al. in 1997. They determined that an eight-polypeptide complex, containing 
Arp2 and Arp3, initiates actin polymerisation at the surface of the bacterium Listeria 
monocytogenes, to mediate actin tail formation and promote its motility (Welch et al. 
1997a). They also demonstrated that the human Arp2/3 complex is evolutionarily 
conserved in eukaryotes, can also promote actin assembly in the lamellipodia o f 
fibroblasts and that it interacts with the Listeria monocytogenes ActA protein in actin 
filament nucleation (See Section 1.9.3.2; Welch et al. 1997b; Welch et al. 1998).
The crystal structure of the Arp2/3 complex has been determined (2A) and subsequent 
analysis revealed that it has the capacity to weakly stimulate the formation of actin 
filaments (Mullins et al. 1998; Robinson et al. 2001). Actin polymerisation de novo is 
stimulated by the Arp2/3 complex, which nucleates branched actin filaments at the 
leading edge (Figure 1.7) (Pollard and Borisy 2003). Numerous studies, including video 
microscopy analysis by Blanchoin et al., demonstrated that the Arp2/3 complex plays 
an essential role in nucleating actin filament growth, at a 70° angle, from the side of 
pre-existing filaments and for forming branched actin networks in lamellipodium 
(Blanchoin et al. 2000; Amann and Pollard 2001). The Arp2/3 complex can be seen 
localised to both the pointed end tips and branch points, thus it was predicted that Arp2
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Figure 1.7: Treadmilling model for the regulation of actin filament protrusion at the 
leading edge. (1) Extracellular stimuli activate receptors. (2) The receptors initiate a signal 
transduction pathway that produces active Rho-famity GTPases and PIP2 that (3) activate 
WASp/Scar proteins. (4) WASp/Scar proteins bring together the Arp2/3 complex and an actin 
monomer on the side of a pre-existing filament to form a branch. (5) Rapid growth at the barbed 
end of the new branch. (6) The growing filaments push the membrane forward. (7) Capping 
protein associates with the barbed end, terminating the elongation o f the filament. (8) Hydrolysis 
of ATP bound to each actin subunit (white subunits turn yellow) followed by dissociation of the 
y-phosphate (subunits turn red) causes aging of the filament. (9) ADF/cofilin promotes 
phosphate dissociation, severs ADP-actin filaments and promotes dissociation of ADP-actin 
from filament ends. (10) Profilin catalyzes the exchange of ADP for ATP (turning the subunits 
white), returning subunits to (11) the pool of ATP-actin bound to ready to elongate barbed ends 
as they become available. (Figure reproduced from Pollard and Borisy 2003).
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and Arp3 acted together as a minus (pointed) end template for the nucleation of actin 
filaments (Mullin et al. 1997; Mullins and Pollard 1999). However, upon crystallisation 
of the complex it was unexpectedly revealed that, at least in the inactive conformation, 
the two proteins do not come into contact with each other and therefore could not act as 
a G-actin dimer to promote actin nucleation (Robinson et al. 2001). The Arp2/3 
complex does not nucleate actin efficiently alone and its nucleating activity is enhanced 
and regulated by the presence of additional nucleation promotion factors (NPFs), which 
bind to the complex. However, this initial kinetic barrier is reduced in the presence of F- 
actin, which autocatalytically stimulates the activity of Arp2/3 activity in vitro 
(Machesky and Gould 1999).
There are several families of NPFs, including: the Wiskott-Aldrich syndrome protein 
(WASP), formins and the recently described Spire protein (Machesky and Insall 1998; 
Machesky et al. 1999; Yarar et al. 1999; Pruyne et al. 2002; reviewed in Baum and 
Kunda 2005). It seems likely that NPFs stimulate activity o f the Arp2/3 by binding to 
the Arp2/3 complex and inducing a conformational change in the Arp2/3 complex, 
which aligns the Arp2 and Arp3 in an orientation that is capable o f recruiting a G-actin 
monomer to form a nucleation-competent trimer (and also to promote filament binding) 
(reviewed in Stradal and Scita 2006). WASP is also involved in this cascade as it binds 
to the Arp2/3 complex and it is its most well-characterised activator and regulator. It is 
known that over-expression of the WA domain of WASP (at its carboxyl-terminal) 
interferes with the recruitment of the Arp2/3 complex and thus prevents actin 
polymerisation (Machesky and Way 1998).
The dynamic properties of actin are also modulated by a host o f additional proteins. 
They include those that attach actin filaments to the cell surface (Ena/Mena/vasodilator- 
stimulated phosphoprotein (VASP)), cross-link them (a-actinin, fascin, filamin), cap 
their barbed ends (capping protein, Arp2/3 complex, gelsolin), sever existing filaments 
(gelsolin, ADF/cofilin), promote dissociation from the pointed ends (ADF/cofilin) and 
regulate association at the barbed ends (profilin) (Borisy and Svitkina 2000; reviewed in 
Cooper and Schafer 2000: Bartles et al. 2000; Kwiatkowski 1999).
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1.4 M olecular M otor Proteins
Actin filaments and microtubules provide networks to facilitate the directed transport of 
protein and organelle cargo, from one region of a cell to another (Howard 2001). In 
eukaryotic cells, there are three main superfamilies of motor proteins that mediate the 
transport of various cargo: the myosins (Section 1.4.1), which move along actin 
filaments and are thought to travel short distances within the cell and the dyneins 
(Section 1.4.2.1) and kinesins (Section 1.4.2.2), which move along microtubules and are 
used to cover longer distances. In addition to intracellular transport, they participate in 
intraciliary transport, cell division, cell nucleokinesis, cell motility and morphogenesis. 
Each motor also moves in a uni-directional manner. For example, most members of the 
kinesin superfamily move to the plus end of microtubules (anterograde transport), 
whereas members of the dynein superfamily move to the minus end (retrograde 
transport). The majority of myosin-superfamily proteins move to the plus-end of actin 
filaments, although there is at least one class that moves to the minus end (class VI) 
(Schliwa et al. 1999; Wells et al. 1999; Hirokawa and Takemura 2003). To understand 
intracellular transport at the molecular level, a thorough understanding of the activity 
and interactions of the individual motor proteins is required.
Microtubule motor proteins also play a significant role in many diseases and recent 
work has shown that impaired microtubule transport can play a direct role in neuronal 
degenerative diseases such as Alzheimer’s (Goldstein 2001). Pathogens, such as the 
herpes virus, are also known to hijack the motors to help them get from the cell 
periphery to the nucleus where they replicate. Therefore, motor proteins perform 
incredibly important functions within a cell and understanding their behaviour and 
underlying mechanisms has wider medical implications (Dohner and Sodeik 2005).
Motor proteins generally consist of two structural parts: a motor domain and a tail 
domain. The motor region binds reversibly to the cytoskeleton and converts chemical 
energy in the form of ATP into motion, while the tail domain is responsible for 
interacting with its cargo. The tail domains are relatively diverse from each other and 
the majority o f motor proteins can multitask by employing different regions of the 
protein to bind and transport a wide variety of cargo (Karcher et al. 2002). During 
intracellular transport, multiple motors o f different classes are often employed on the
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same organelle (reviewed in Mallik and Gross). For example, many different viral 
proteins are known to interact with both kinesin and dynein to enable bidirectional 
transport along microtubules (see Table 7.1; Figure 7.3), and multiple kinesins and 
dyneins have also been shown to attach to, and move, single lipid droplets along 
microtubules (in both directions) inside the syncytial Drosophila embryo (reviewed in 
Greber and Way 2006; Welte et al. 1998; Gross et al. 2002). Furthermore, in some 
systems the same cargo is capable of moving on both microtubule and actin filaments, 
switching between motors during the course of its motion. This often occurs for 
organelles and vesicles, including: pigment granules, axonal vesicles, mitochondria and 
endosomes (Rodionov et al. 2003; Gross et al. 2002; Langford 1995; Lalli et al. 2003; 
Morris and Hollenbeck 1995). The co-operation between kinesin and myosin V has 
been particularly well studied within neurons, whereby kinesin transports vesicles into 
the neuronal termini, where the motor protein is degraded and the vesicles continue to 
travel through the actin-rich neuron terminus on myosin V (Langford 2002; Huang et al. 
1999; reviewed in Mallik and Gross 2004).
1.4.1 Myosin
Myosins are composed of eighteen different classes, based on phylogenetic analysis of 
their motor domain sequences and there are often many isoforms in each class, e.g. 
skeletal myosin II and non-muscle myosin II (Foth et al. 2006). The phylogenetic tree 
of the myosin superfamily and an alignment of the motor domains are available at 
http://www.mrc-lmb.cam.ac.uk/mvosin/mvosin.html. They each possess a globular 
motor domain (-500 amino acids) at the N-terminus, which binds to actin filaments in 
an ATP-dependent fashion, followed by an extended coiled coil in some, but not all, 
myosin families (e.g. myosin II and V) and then a globular tail domain that interacts 
with its cargo (Figure 1.8).
The majority of myosins move towards the plus-ends of actin where filament growth 
occurs. This is analogous to the movement of kinesin towards the plus ends of 
microtubules. However, there are exceptions to this rule, such as myosin VI and 
possibly myosin IXb, which are minus-end directed motors that move towards the slow 
growing ends of F-actin (Huang et al. 1999; Kieke et al. 2003; Krendel et al. 2005).
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Myosin V
1  /EEC
Figure 1.8: The structure of Myosin V. The motor catalytic domains (blue), mechanical 
amplifiers (light blue), tail domain (DIL, purple; implicated in cargo attachment) and tightly 
associated motor subunits, i.e. light chains (green) are all indicated. (Image reproduced from 
(Vale 2003).
1.4.1.1 Conventional and Unconventional Myosins
Myosins are considered as being either conventional or unconventional (Hirokawa and 
Takemura 2003). Conventional myosin refers to members that possess independent 
motor-containing domains, a low duty-ratio and an ability to form thick filaments; and 
includes the most extensively studied founding member of the myosin family, the 
skeletal muscle motor myosin II (Rosenfeld et al. 2003). Myosin II members are able to 
self-assemble into bipolar filaments and are responsible for generating the contractile 
forces during cytokinesis, maintaining cortical tension and are crucial for cell motility 
(see Section 1.3.1 and Figure 1.6) (Reckman-Peterson et al. 2000). Unconventional 
myosins make up approximately two-thirds of the human myosin genes and do not self- 
assemble into filaments. Instead, they are involved in the transport of various 
intracellular cargoes, although the exact functions for many of them still remain to be 
established. Myosin I, V and VI are better characterised and are involved in membrane 
traffic (Reck-Peterson et al. 2000). Myosin I plays a significant role in cell motility and 
signal transduction, myosin V is the primary motor involved in vesicle transport 
(myosin XI in plants) and myosin VI performs a structural role within the cell 
(Hirokawa and Takemura 2003).
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1.4.1.2 Myosin Va
There are three distinct isoforms of myosin V in mammals: myosin Va, myosin Vb and 
myosin Vc (Reck-Peterson et al. 2000; Mercer et al. 1991; Rodriguez and Cheney 
2002; Reck-Peterson, 2000). Myosin Va was the first member to be discovered and, 
based on amino acid homology with this isoform, it is thought that the structure of 
myosin Vb and myosin Vc are similar to that of myosin Va (Rodriguez and Cheney 
2002; Zhao et al. 1996)
Myosin Va is present in the majority of, if not all, eukaryotes (excluding plants) (Reck- 
Peterson et al. 2000). It plays an important role in the trafficking of membranous cargo, 
such as secretory vesicles and melanosomes, which is the most studied system for 
investigating myosin V-mediated transport (Karcher et al. 2002). Rogers et al. have also 
shown that phosphorylation of the myosin Va motor domain during the transport of 
melanosomes can result in the dissociation o f the motor from the vesicle (although the 
ATPase activity is unaffected) (Rogers et al. 1999). Furthermore, it has been 
demonstrated that the small GTPase Rab27a is required for the connection of myosin 
Va to melanosomes, which can also bind to kinesin-1 (see Section 1.4.2.2) 
simultaneously (Hume et al. 2002; Cao et al. 2004; Seabra and Coudrier 2004). 
Additionally, myosin Va is implicated involved in the transport of an inositol 
triphosphate receptor-containing compartment in neurons (Takagishi et al. 1996). Thus, 
myosin Va appears to have the ability to switch tracks from microtubules to actin 
filaments (Wilson et al. 2000; Lionne et al. 2001; Seabra and Coudrier 2004).
The class V myosins are dimeric molecules and as well as containing a cargo-binding 
tail and conserved motor domain, they also possess a conserved -100 residue C- 
terminal domain, called the dilute (DIL) domain (high-lighted in purple in Figure 1.8). 
Myosin Va is encoded by the dilute locus in rats and mice and in dilute-null animals, 
functional myosin V is absent (Dekker-Ohno et al. 1993; Mercer et al. 1991). This 
results in the subsequent loss of coat colour due to defects that occur during the 
transport of the pigment granules within melanosomes (reviewed in Vale 2003; Wu et 
al. 1997; Silvers 1979; Dekker-Ohno et al. 1996). In addition, a direct interaction has 
also been demonstrated between myosin V and the mouse ubiquitous kinesin heavy 
chain (KhcU) (Huang et al. 1999). One can envisage that this enables vesicles to rapidly
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switch between microtubule and actin networks, which is indicative of these motors 
being co-ordinated in some manner.
1.4.2 Microtubule-based T ransport
The microtubule motor proteins, dynein and kinesin, are required for mitosis and 
trafficking of many sub-cellular organelles such as mitochondria and endosomes 
(Murray and Wolkoff 2003). Traffic travelling on microtubules that are intended for the 
cell centre or apical domains (minus-end) use cytoplasmic dynein, while traffic destined 
for the plasma membrane (plus end) generally move by kinesins (Figure 1.9). However, 
some members of the kinesin-14 family are able to generate minus end-directed 
movement in polarized epithelial cells and neurons (reviewed in Leopold and Pfister 
2006).
Nucleus ITO
J» Kinesin 
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Mitochondria
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Figure 1.9: Organisation of microtubules within a eukaryotic cell and its associated 
motor proteins. Within interphase fibroblast-type cells, the microtubules nucleate from the 
microtubule organising centre (MTOC; green) and radiate towards the cell periphery with their 
fast-growing plus-ends. The motor proteins kinesin and dynein utilize microtubules to transport 
various cargoes. Kinesins generally move towards the plus-ends of microtubules (towards the 
plasma membrane), while dyneins generally move towards the minus-ends. (Figure reproduced 
from Mallik and Gross 2004).
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1.4.2.1 Dynein
There are two main classes of dynein: cytoplasmic and axonemal. The axonemal 
dyneins generate sliding forces between adjacent axonemal microtubule doublets and 
produce the beating movement for cilia and flagella (Hirokawa and Takemura 2003). 
Cytoplasmic dynein (DYNC1 or 2) is a large (l-2MDa), Y-shaped, protein complex that 
is composed of two heavy chains (DYNC1HI and 2: 530 KDa), two intermediate chains 
(DYNC1I1 and DYNC1I2; 70-80 KDa), four light intermediate chains (DYNC1LI1 and 
DYNC1LI2; 50-60 KDa) and three families of light chains (7-14 KDa) (Figure 1.10) 
(King et al. 2003; Pfister et al. 2005; Pfister et al. 2006; Greber and Way 2006). The 
head domain of DYNC1H1 is centrally located, and rotates causing the microtubule- 
binding arm to move in a 15nm powerstroke. Dyneins are composed of a hexamer of 
AAA domains (ATPases Associated with cell Activities) that bind and release proteins 
in an ATP-dependent manner (Murray and Wolkoff 2003). Unlike kinesin and myosin, 
which contain single ATP-binding sites within their motor domains, dynein possesses 
multiple ATP-binding sites within each head (Mocz and Gibbons 1996; Mocz et al. 
1998; Gibbons et al. 1991). Therefore, dynein can be regulated in one o f three ways: via 
the motor domain itself, through controlling the number of dynein motors that function 
together or through the regulation of accessory proteins, such as the dynactin complex 
(which is described later) (Hirokawa 1998; reviewed in Mallik and Gross 2004).
Figure 1.10: The structure of cytoplasmic dynein. Cytoplasmic dynein is linked to cargo 
membranes indirectly via interactions with ankyrin, spectrin, Arp1-actin filament, dynamitin, 
p150Glued and the 74KDa intermediate chain (Reproduced from Hirokawa et al. 1998).
Dyneins are expressed in the majority of eukaryotic cells and are involved in cell
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division, the perinuclear localisation of several organelles around the MTOC and
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vesicle trafficking (reviewed in Hirokawa and Takemura 2003; Dohner and Sodeik 
2005). Cytoplasmic dynein is associated with both intermediate and light chains and 
pl50Glucd binds directly to the dynein-intermediate chains (Paschal et al. 1993; Boylan 
et al. 2000).
Numerous binding partners for the dynein light chains have been identified by yeast 
two-hybrid screens, GST pull-downs and co-immunoprecipitation experiments (Herzig 
et al. 2000: reviewed in Vallee et al. 2004; Lo et al. 2005; Lo et al. 2006). The 
cytoplasmic dynein light chains have been grouped into the following three families, 
based on their sequence homology: (i) LC7/Roadblock (DYNLRB1 and DYNLRB12), 
(ii) Tctex (DYNLT1 and DYNLT3) and (iii) LC8/PIN (DYNLL1 and DYNLL 2). The 
dynein light chains of the latter family, LC8/PIN bind to neuronal nitric oxide synthase 
(NOS), so they are also referred to as PIN: ‘protein inhibitor of nitric oxide synthase’ 
(Jaffrey and Snyder 1996). In addition, it is important to note that LC8/PIN is also a 
subunit of myosin V, which is involved in vesicular traffic (Espindola et al. 2000).
Dynein light chain proteins are components of both microtubule-based and actin-based 
motors that connect the complexes to their cargoes. Although DYNLL I and DYNLL2 
share 93% sequence identity, they bind and localise to the dynein- and myosin-V motor 
proteins respectively, in vivo. The DYNLL2 is found exclusively as a component o f the 
myosin V motor complex (Day et al. 2004). Within vertebrates myosin Va is able to 
bind to the same LC8 light chain that is found in cytoplasmic dynein and enzymes of 
nitric oxide (NO) (reviewed in Vale 2003). However, these subunits are suspected to 
perform a structural role rather than being involved in the cargo binding stage. NO is 
implicated in a wide variety of physiological roles, such as apoptosis and neuronal 
development (Alderton et al. 2001). PIN is a lOKDa protein that has been identified as 
a light chain o f both myosin V and dynein, in addition to interacting with and inhibiting 
NOS I. The activity of this enzyme is dependent upon its dimerization and PIN has also 
been shown to destabilise this dimer (Jaffrey and Snyder 1996).
Mutational analysis of the dynein light chains has established that amino acid residue 41 
plays a critical role in determining the specific interactions of dynein light chains 1 and 
2 with their respective motors. It was shown that the substitution of His-41 in dynein
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light chain 1 with tyrosine (residue 41 in dynein light chain 2) diverts dynein light chain 
I away from the dynein towards the myosin V motor complex. Similarly, the 
complementary mutation in dynein light chain 2 changed its association to the dynein 
motor. However, the direct target for their binding at these locations is currently 
unknown (Day et al. 2004).
In order for cytoplasmic dynein to stimulate the majority of transport processes, it must 
bind to a cofactor called dynactin (Karki and Holzbaur 1999; Murray and Wolkoff
2003). Dynactin is also a large multi-subunit complex that includes: p l50Glucd, 
dynamitin and actin-related protein 1 (ARP1) (Holleran et al. 1998). It is well 
established that dynactin is required for dynein to attach to membranes including, Golgi 
membranes, early and late secretory vesicles but dynactin alone is not sufficient to bind 
to these membranes (reviewed in Schroer 2004). There is also some evidence to suggest 
that non-erythroid spectrin is needed to anchor dynactin, and therefore dynein, to the 
membrane (Holleran et al. 2001). Also, if one of the subunits of dynactin, dynamitin 
(p50), is over-expressed, the dynactin complex becomes disrupted and can consequently 
inhibit processes that are driven by dynein (reviewed in Murray and Wolkoff 2003).
I.4.2.2 Kinesin
The kinesin superfamily is a diverse collection of microtubule-associated motor proteins 
that bind to and transport various cellular cargoes towards the plus end of microtubules 
(anterograde transport) (reviewed in Hirokawa and Takemura 2003). However, recent 
studies have shown that some kinesins are also required for the accurate segregation of 
chromosomes. These motors bind to microtubule spindles and move directionally in an 
ATP-dependent fashion to facilitate chromosome segregation during cell division 
(reviewed in Vale 2003).
There are fourteen classes of kinesin, in human and mouse, although they can be 
classified into three principle groups depending on whether the motor domain is 
positioned at the N-terminus (Kin-N or N-type), an internal or middle position (Kin-I or 
M-type), or at the C-terminus (Kin-C or C-type) (Mandelkow and Mandelkow 2002). 
Eleven classes are N-kinesin proteins, two are C-kinesin and one is an M-kinesin. N- 
type kinesins include the well-characterised kinesin-1 (previously known as
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conventional kinesin, KIF5) (Hirokawa and Takemura 2003). M-type kinesins are not 
considered to function as motor proteins but instead regulate microtubule dynamics by 
destabilising the plus-ends of microtubules. Most C-type kinesins act during mitosis 
although they have also been implicated in membrane transport within neuronal 
dendrites and polarized epithelial cells (Hanlon et al. 1997).
Each member of the kinesin superfamily is characteristically defined by the presence of 
a -360 amino acid, microtubule-binding motor domain (Miki et al. 2005). This region is 
folded into a core that possesses an overall structural fold that is similar to that of 
myosins and G proteins (Hirokawa et al. 1989. It is this well-conserved region that 
binds to microtubules and contains the catalytic pocket that is required for ATP 
hydrolysis, which subsequently generates force and movement along the microtubules 
(Hirokawa et al. 1989; Woehlke et al. 1997; Nitta et al. 2004; Miki et al. 2005).
The first family member of the kinesin superfamily to be identified was kinesin-1 (Vale 
et al. 1985). It was discovered in squid axons, as a factor that utilises energy from ATP- 
hydrolysis in order to move organelles and vesicles along microtubules (Vale et al. 
1985). Kinesin-1 is abundant in virtually all cell types throughout development and is 
present in the majority, if not all, multicellular organisms, including yeast. 
(http://www.proweb.org/kinesin/Kinesin.htmn.
Kinesin-1 is a heterotetramer composed of two 120KDa kinesin heavy chains (KHC) 
and two 64KDa kinesin light chains (KEC) (Figure 1.11). KHC has three domains: an 
NH2 terminal motor domain, containing the ATP and microtubule-binding sites (the 
motor functions as an enzyme to hydrolyze a single ATP molecule per step during 
motion); a central coiled coil stalk domain for dimerization and the CC^H-terminal 
globular domain that binds currently unknown factors (Mallik and Gross 2004). The 
KLC contains an NH2-terminal a-helical domain that binds to the KHC stalk, while the 
C-terminal contains 6 tetratricopeptide repeat (TPR) motifs. The TPR is a degenerate 34 
amino acid motif that is highly conserved across species and is involved in numerous
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Figure 1.11: A schematic illustration of kinesin-1. The heavy chains (red) and light chains 
(green) are shown, together with known cargo binding domains (CBD; black boxes) and 
domains involved in regulating motor activity (white boxes). NB: The amino acid residues in 
parentheses are referenced to the mouse ubiquitous isoform. (Figure reproduced from Schnapp
2003).
protein-protein interactions (Gindhart and Goldstein 1996; reviewed in Vale 2003). The 
TPR repeats of KLC act to attach the kinesin to the intracellular cargo that is to be 
moved by the motor (reviewed in Mandelkow and Mandelkow 2002). However, 
although most interactions are thought to occur via the KLC, cargo recruitment is not 
limited to it, as interactions can also take place with the heavy chain, e.g. the integral 
ER membrane protein kinectin (Kumar et al. 1995). Furthermore, as kinesin is a 
phosphoprotein in vivo, its activity may be regulated through phosphorylation of both 
the heavy and light chains, by specific kinases and phosphatases, and also through 
proteins interacting with kinesin (Hollenbeck 1993; Morfini et al. 2002a; Haimo 1995; 
Sato-Yoshitake et al. 1992; Matthies et al. 1993; Gross et al. 2002).
Kinesin-1 is capable of binding and transporting a wide variety of cargo. It can interact 
with several different proteins via its TPR motifs, including the c-Jun NH2-terminal 
kinase (JNK) scaffold protein Sunday driver (SYD; Bowman et al. 2000, Cavalli et al. 
2005), the amyloid precursor protein (APP; Kamal et al. 2000), the glutamate receptor
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interacting protein (GRIP; Setou et al. 2002) and the JNK-interacting proteins (JIP), 
JIPl and JIP2 (Verhey et al. 2001). Also, a yeast two-hybrid screen for proteins 
interacting with JNK discovered that the SYD protein is homologous to mammalian 
JIP3 (Ito et al. 1999). However, if kinesin-1 is not bound to cargo, its globular tail 
domain can fold back onto its head region in a manner that can block the ATPase 
activity (see Figure 1.11) (Woehlke and Schliwa 2000a, 2000b; Coy et al. 1999). 
Furthermore, this self-inhibition of kinesin-1 has also been suggested to occur when it is 
complexed with the myosin V motor protein (Langford 2002).
A variety of kinesins have the ability to transport different types o f cargo depending on 
the cell-type or localisation, e.g. kinesin-2 (KIF3) can transport membrane vesicles in 
the axon but moves macromolecular complexes within cilia. Also, some cargoes are 
moved by more than one type of motor protein, creating a high-level of plasticity to 
cytoplasmic transport, e.g. mitochondria can be transported by both kinesin-1 (KIF5) 
and kinesin-3 (K IFlBa) (Hirokawa and Takemura 2003). Many cargoes can also co­
ordinate multiple motor receptors and can move bidirectionally along microtubules (see 
Table 7.1; Schnapp 2003; Leopold and Pfister 2006). However, kinesins do not always 
require receptors in order to bind to membranes, e.g. kinesin KIK1A contains a 
pleckstrin domain that is able to bind directly to phospholipids (Klopfenstein et al. 
2002; Klopfenstein and Vale 2004). Some KIFs are also able to utilise the GTP-binding 
protein Rab (Ras superfamily) to connect them to their cargo (Jordens et al. 2005). For 
example, the kinesin-like protein rabkinesin-6 associates with the GTP-bound form of 
Rab6 (Echard et al. 1998). These proteins are normally located specifically to either the 
TGN, endosome or recycling endosome but over-expression of rabkinesin-6 results in 
the dispersion of vesicles from the Golgi to the plasma membrane (Karcher et al. 2002). 
While we have greatly enhanced our knowledge in recent years, there are still a number 
of fundamental motor-related questions that remain unanswered and need to be 
addressed. For example: (i) the nature of the cargo that many of the motors transport 
still remains to be established; (ii) the specific functions o f some of the motors are 
currently unknown; and (iii) the molecular basis of motor protein recruitment is 
currently unclear.
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1.5 Intracellular Protein Transport
All eukaryotic cells contain a host of different membrane-bound organelles and 
vesicles. Each possesses a unique complement of proteins, lipids and co-factors to 
create the optimal micro-environment for them to perform their specialised functions 
and transport cargo from one place to another. The maintenance and regulation o f these 
structures, together with the transport of proteins to specific destinations, requires a 
complex shuttling of vesicular traffic between the different compartments (Figure 1.12). 
This active and directed cytoplasmic transport is essential for the cargo to reach their 
desired location at the correct time, as the viscous nature o f the cytoplasm renders 
movement by free diffusion alone an incredibly inefficient mode o f transport (Luby- 
Phelps 2000: Lukacs et al. 2000). The focus of this section is on vesicle transport, so 
vesicle formation, biogenesis, targeting and fusion will not be addressed.
1.5.1 The Secretory Pathway
The secretory pathway defines the intracellular route by which newly synthesized 
proteins (as well as carbohydrates and lipids) travel to reach their final destination. En 
route they encounter a series of functionally distinct compartments that sort, deliver, 
regulate and post-translationally modify secretory proteins in transit (Stephens et al.
2000) (Figure 1.12). Each compartment is in constant communication and the 
membrane-flow between these organelles proceeds via transport vesicles that bud off 
from a donor compartment (‘vesicle budding’) and are targeted to a specific acceptor 
compartment (‘vesicle targeting’). Upon arrival, they fuse and release their contents. 
This process forms the basis of the ‘vesicular transport hypothesis’ that was originally 
postulated by Palade in 1975 (Palade 1975). The constant flux o f membrane-flow 
during organisation is in steady-state, whereby the rate o f anterograde transport is 
predicted to equal the rate of retrograde vesicle transport (Lippincott-Schwartz 2004; 
Mistilli 2001). It has long been established that microtubules serve as highways along 
which vesicles of both the secretory and endocytic pathways are transported through a 
cell (Freed and Lebowitz 1970). For example, it has been shown that depolymerisation 
of microtubules with the drug nocodazole reduces the protein secretion from lactating 
mammary epithelial cells (Rennison et al. 1992). Subsequent pulse-labelling 
experiments (prior to nocodazole treatment) determined that the major effect of 
nocodazole was on an early step in the secretory pathway and that microtubules
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Figure 1.12: Intracellular compartments and transport pathways of a eukaryotic cell. The
scheme encompasses the secretory, lysosomal and endocytic pathways. The arrows signify the 
transport phases between compartments. The transfer of cargo between organelles is mediated 
by protein-coated vesicles that capture cargo, bud from a donor membrane, and then deliver 
their contents by fusing with a recipient organelle or membrane. The three principle protein 
complexes that coat transport vesicles and mediate vesicle formation are indicated by colours: 
COP-II (blue) is associated with vesicles budding from the ER that are destined for the Golgi 
apparatus; COP-1 (red), is involved in retrograde transport from the Golgi apparatus to the ER 
and clathrin (yellow) mediate transport from the TGN to endosomes and lysosomes. Green 
arrows indicate the anterograde transport flow, while the purple arrows represent retrograde 
transport. (Figure modified from Bonifacino and Glick 2004).
normally facilitate vesicle transport to the plasma membrane (Rennison et al. 1992). 
Vesicular traffic is highly organised and the overall direction in which the secretory 
pathway transports cargo is anterograde, i.e. towards the plasma membrane (green 
arrows in Figure 1.12). Counter-balancing the flow of material in the retrograde 
direction ensures maintenance of the correct organelle positioning, surface area of 
previous compartments and allows reutilisation of the transport machinery required for 
the anterograde transport (purple arrows in Figure 1.12) (Pelham 1995).
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1.5.2 Organelles o f the Secretory Pathways
Newly synthesized proteins that are destined for the secretory pathway begin their 
journey in the endoplasmic reticulum (ER). The ER is an extensive labyrinth of tubules 
and cistemae that is continuous with the nuclear envelope and extends throughout the 
entire cytoplasm. Here, proteins become inserted into the membrane or translocated into 
the lumen, folded and assembled correctly. Several post-translational modifications, 
including N-linked glycosylation and the attachment of GPI-anchors also take place 
with this membrane compartment (Dejgaard et al. 2004). Prior to exiting the ER, an 
essential quality control step ensures that all of the proteins are correctly folded, 
modified as required and that any misfolded or unassembled proteins are retained, 
translocated to the cytosol and degraded via the ubiquitin-proteosome machinery 
(Plemper et al. 1997). Appropriately processed proteins are then concentrated within 
secretory vesicles and further sorted by the ER-Golgi intermediate compartment 
(ERGIC) as they are transported to the Golgi apparatus (named after its discoverer, 
Camillo Golgi) in tubular vesicular carriers (TVCs) (Kreis 1992: reviewed in Watson 
and Stephens 2005). They enter the system via the cis-Golgi network (CGN), which 
assists in the recycling of proteins and lipids back to the ER. The Golgi apparatus 
usually resides in the vicinity of the nucleus and close to the centrosome (MTOC). It is 
composed of a connected series of flattened membrane cistemae, bound on either side 
by the extensive tubulovesicular networks of the CGN and the trans-Golgi network 
(TGN) (Mellman and Simons 1992). As the proteins are transported through the Golgi 
stack (from cis to trans), the majority of the post-translational modification and 
processing events occur. These include: O-linked glycosylation, trimming o f N-linked 
glycosylation residues, sulphation, proteolytic processing and phosphorylation in an 
ordered sequence of enzyme-catalyzed reactions (Clausen and Bennett 1996; Komfeld 
and Komfeld 1985; Silbert 1996; Schnabel et al. 1989).
For regulated secretion, vesicles that bud from the TGN undergo maturation events and 
become secretory granules that fuse with the cell surface upon appropriate stimulation. 
The TGN also receives and sorts endocytosed material from the plasma membrane 
(Komfeld and Mellman 1989). Vesicles that are derived from the plasma membrane via 
endocytosis are sorted by early recycling endosomes, where proteins are either recycled 
back to the cell surface or delivered to the late endosomes. Late endosomes possess the
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principle role of mediating the traffic derived from the early endosome and the TGN to 
the lysosomes, which act as a degradative compartment for macromolecules.
1.5.3 Vesicle Transport
In order for different vesicles or organelles to reach their desired destinations within a 
cell, they acquire, retain and display a unique set of proteins on their cell surface 
(Blobel et al. 1979). This guarantees that cargo destined for different locations are 
separated into the appropriate transport vesicles and also so that they can easily be 
distinguished and separated from any resident proteins within an organelle. Different 
classes of transport vesicle, defined by their coat proteins, are responsible for mediating 
the discrete transport steps. For example, COPII-coated vesicles export cargo from the 
ER to the ERGIC (Figure 1.12, blue arrows; Barlowe et al. 1994; Liu and Lippincott- 
Schwartz 2005), COPI-coated vesicles shuttle between the ER and the Golgi apparatus 
and within the Golgi apparatus (Figure 1.12, red arrows; Orci et al. 1997), and clathrin- 
coated vesicles mediate transport from the TGN to endosomes and lysosomes, as well 
as the uptake of endosomes at the plasma membrane (Figure 1.12, yellow arrows; Le 
Borgne and Hoflack 1998). O f particular interest it has recently been shown that COPII 
can directly interact with dynactin to allow association with microtubules as they exit 
the ER (Watson et al. 2005). However, the majority o f motor-protein receptors that are 
utilised and the specific motors responsible for mediating these different movements 
still remain to be established.
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1.6 Use of Pathogens to Study Intracellular Transport
A variety of intracellular pathogens can enter a host cytoplasm during infection and 
exploit its cytoskeleton to allow them to move both intra- and intercellularly (Table 1.1) 
(reviewed in Gouin et a l 2005; Dohner and Sodeik 2005; Greber and Way 2006; Marsh 
and Helenius 2006). Viruses are obligate parasites and, in order for them to spread from 
one cell to another, they have evolved mechanisms to use the same transport strategies 
as vesicles during membrane trafficking. For example, many intracellular viruses are 
dependent upon the proteins of the host nucleus in order to replicate their genomes, e.g. 
human immunodeficiency virus (HIV), so they need a means by which they can move 
from the plasma membrane to their site of replication rapidly and efficiently. Other 
viruses, such as vaccinia virus, replicate within the cytoplasm o f the cell and therefore 
need to be able to move to specific regions within the cell in order to concentrate the 
proteins and membranes that are required for their assembly and maturation. Also, 
viruses that are not able to induce cell lysis need to be transported away from their 
replication sites in order to spread infection to adjacent cells. Therefore, viruses employ 
two alternative strategies for intracellular transport, either by hijacking the cytoplasmic 
membrane traffic or via direct interaction of the viral components with the cytoskeletal 
machinery (reviewed in Dohner and Sodeik 2005; Marsh and Helenius 2006; Henry et 
al. 2006).
As with vesicular membrane traffic, microtubules are the cytoskeletal element of choice 
for directed, long-range retrograde and anterograde transport of viral particles, as 
diffusion alone is also an ineffective method for transporting virions. For example, 
based on calculations by Sodeik it would take -22.8 hours for vaccinia IEV particle to 
diffuse ~40pm through the cytoplasm to the plasma membrane, in comparison to 8-16 
seconds when this transport is assisted by microtubules (Sodeik 2000).
Invading pathogens do not solely manipulate the microtubule network in order to 
facilitate their transport. The motility of viruses, such as vaccinia virus, bacteria such as 
Listeria monocytogenes and Shigella jlexneri also provide some o f the most well- 
characterised examples of pathogens that manipulate the actin cytoskeleton to aid their 
spread. They are all capable of manipulating similar signalling networks to induce actin 
polymerisation and nucleate bundles of ‘actin (comet-like) tails’ behind them, which
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Virus family 
Examples
Genome Morphology
Diameter
Cytosolic structure Mode of entry Mode of Exit Site of replication
Rhabdoviridae
Rabies virus 
Mokola virus
ss (-) RNA 
-12 kb
Envelope 
75x180 nm2
Internal ribo- 
nuceloprotein core
Endocytosis 
Fusion with 
endosomal membrane
Budding from the 
plasma membrane
Cytosol
Picornaviridae
Poliovirus
ss (+) RNA 
-8  kb
No envelope 
30nm
Genome Fusion pore at plasma 
or endosomal 
membrane
Cell lysis Cytosol, on small 
vesicles
Herpesviridae
HSV1
PRV
ds DNA 
120-230 kb
Envelope 
150-200 nm
Icosahedral capsid Fusion at plasma 
membrane
Exocytosis Nucleus
Retroviridae
HIV-1
ss (+) RNA dimer 
2x7-13 kb
Envelope 
80-130 nm
Internal nucleocapsid, 
reverse transcription 
complex
Fusion at plasma 
membrane, 
endocytosis possible
Budding from the 
plasma membrane
Cytosolic reverse 
transcription, 
nuclear transcription
Adenoviridae
Ad2, Ad5
dsDNA 
36-38 kb
No envelope 
70-100 nm
Icosahedral capsid Endocytosis, lysis Budding from the 
plasma membrane
Nucleus
Parvoviridae
CPV
AAV
ssDNA
(+) or (-) 
5 kb
No envelope 18- 
26 nm
Icosahedral capsid? Endocytosis, fusion 
pore?
Budding from the 
plasma membrane
Nucleus
Poxviridae
Vaccinia virus
dsDNA 
130-300 kb
Envelope 
2 infectious forms: 
IMV 200x300 nm2
Complex cores, IMV, 
IEV
Unclear, different for 
IMV or EEV
Budding from the 
plasma membrane; 
cell lysis
Perinuclear viral 
factories
Baculoviridae
AcMNPV
dsDNA 
90-160 kb
Envelope 
30-60x300 nm2
Rod-shaped
nucelocapsid
Endocytosis, 
membrane fusion
Budding from the 
plasma membrane; 
cell lysis
Nucleus
Table 1.1: Viruses that use the cytoskeleton. (Adapted from Dohner and Sodeik 2005). Key: ds =  double-stranded; ss = single-stranded.
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propel them forwards and enhance their spread of infection (see Section 1.9.3.2; Gouin 
et al. 2005; Cudmore et al. 1997). Although the entry and exit o f many viruses into and 
out of a host cell is dependent upon the actin cytoskeleton, this system is unable to 
transport the virus to the cell periphery as efficiently as microtubules (see Section 
1.9.3.1; Rietdorf et al. 2001).
The poxvirus, vaccinia virus is a good model system to dissect both the mechanisms of 
microtubule-based motility and actin polymerisation at the plasma membrane, as well as 
the regulation of motor function. Vaccinia virus can easily be manipulated, whereby 
genes of interest can be deleted, over-expressed or tagged with a marker protein. 
Additionally, the specific viral proteins are only present in cells that are infected, as 
opposed to vesicles that can also be detected in uninfected host cells. These properties 
are taken advantage of in this study and the following sections introduce the Poxviridae 
family, before providing a detailed description of vaccinia virus, its life-cycle and its 
use in this research.
1.7 Poxviridae
The Poxviridae family is comprised of large, complex DNA viruses that replicate 
exclusively in the cytoplasm of their host cell. Poxviridae are classified into two 
subfamilies: Entomopoxvirinae (insect poxviruses) and Chordopoxvirinae (vertebrate 
poxviruses) depending on the type of host organism. Chordopoxvirinae are further 
subdivided into eight genera: Orthopoxvirus, Parapoxvirus, Avipoxvirus,
Capripoxvirus, Leporipoxvirus, Suipoxvirus, Molluscipoxvirus and Yatapoxvirus, 
depending on their genetic make-up, their host, host-range and antigenic properties 
(Figure 1.13) (Fenner 1989; Moss 1996).
The most notorious Orthopoxvirus (OPV) member is variola virus, the causative agent 
of smallpox. Smallpox was a severe, highly contagious human disease that was spread 
through respiratory transmission. It was fatal in up to 30% of cases and was responsible 
for 300-500 million deaths during the 20th century fhttp://www.who.int/crs/en). It 
preferentially attacked skin cells, causing characteristic pimples associated with the 
disease, which grew into infectious pustules that protruded from the skin, particularly 
on the face, arms and legs (Moss 1996).
63
Chapter 1 Introduction
Family Subfam ily G enus H ost ca tegory:
example/species-type
Entomopoxvirinae 
(poxviruses of insects; 
invertebrates)
Entomopoxvirus A melolontha virus
Entomopoxvirus B amsacta moorei virus
Entomopoxvirus C chironomus luridus 
virus
Poxviridae
(poxviruses)
Chordopoxvirinae 
(poxviruses of 
vertebrates)
Orthopoxvirus 
Parapoxvirus 
Avipoxvirus 
Capripoxvirus
vaccinia virus 
orf virus 
fowlpox virus 
sheeppox virus
Leporipoxvirus
Suipoxvirus
Molluscipoxvirus
myxoma virus 
swinepox virus 
molluscum 
contagiosum virus 
Yaba monkeypox 
virus
Yatapoxvirus
Figure 1.13: Outline of the Poxviridae family tree. The classification of vaccinia virus is high­
lighted in red.
The incidence of smallpox decreased dramatically following the introduction and 
administration of the related cowpox virus as a vaccine*, by Edward Jenner in 1798. (* 
derived from ‘vacca\ the Latin word for cow) (Jenner 1799). This method of 
vaccination was quickly confirmed to be highly successful and, as early as 1805, 
worldwide vaccination laws were enforced. The last official case of naturally occurring 
smallpox was recorded in Somalia in 1977 and since then the only known outbreak was 
due to a laboratory accident in Birmingham, England in 1978 which killed one person. 
The World Health Assembly officially certified the eradication of smallpox on May 8th 
1980 (WHO 1980; Moss 1996).
The virus strain used to create the vaccine is the related OPV, vaccinia virus. The WHO 
smallpox vaccination programme used various vaccinia virus strains (including Lister 
(UK) and New York Board of Health (USA)) and numerous strains of this virus 
currently being used for research purposes have been derived from the New York Board 
of Health strain, including Western Reserve (WR) and Copenhagen (COP) strains. The 
sequences of the vaccinia virus strains WR and COP are identical except for some small 
transpositions and deletions mainly near the ends of the genome (Moss 1996).
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Since the eradication of smallpox and the rapidly increasing advances in molecular 
biology, the interest in vaccinia virus has developed significantly. In particular, since 
the terrorist attacks of 1 Ith September 2001 and the subsequent anthrax scares, there has 
been increasing concern and ongoing discussions about the potential use of smallpox as 
a bio-terrorist weapon. However, although variola virus presents the most obvious 
threat, other poxviruses also have the potential to be used as biological weapons. 
Camelpox virus presents a particularly dangerous threat, as it is the most closely related 
to variola virus. Any genetic modification that deletes those genes that are present in 
camelpox but absent in smallpox is, therefore, unwise and could be highly dangerous 
(Gubser and Smith 2002).
In 1999, the WHO declared that all remaining batches o f variola virus were to be 
destroyed by the end of 2002. However, destruction o f the last two official smallpox 
virus stocks, held at the Russian Vector Laboratory and United States Centres for 
Disease Control, have now been postponed indefinitely to enable valuable research to 
be completed (Black 2002). Vaccination of populations against smallpox has not been 
conducted since its eradication, with the exception of specific high-risk groups, such as 
specialist research scientists and military personnel. However, governments have 
considered whether the vaccine should be available for widespread use and new 
vaccines are currently being developed as a contingency for the protection o f all 
civilians (Harrison et al. 2004). Ironically, by retaining virus stocks and researching 
better defences there is also the potential danger that new developments could become 
available to those who support bio-terrorism. In addition to the threat of bio-terrorism, 
the retention of adequate stocks of vaccinia virus as a vaccine can be justified in further 
ways. Theoretically, it is possible that a smallpox-like virus could re-emerge in nature 
as a result of the many OPV that exist in animal species. Therefore, as the likelihood of 
an OPV emerging or re-emerging increases, the percentage o f the world population that 
is immunologically naive for OPV also increases. In addition, the parallel increase in 
immunosuppression (e.g. due to acquired immune deficiency syndrome, AIDS) 
increases the chances of OPVs jumping species and adapting to humans (Wolfs et al. 
2002).
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1.8 Vaccinia Virus
Vaccinia virus (VV) is the prototype member of the poxvirus family and, unlike variola 
virus that only infects humans, the original host and exact origin of ‘vaccinia virus’ 
(after -200 years of amplification in different hosts) is unknown (Baxby 1977). 
Vaccinia virus is a large (~19l,000bp), double-stranded DNA virus, encoding 273 
genes that replicates exclusively in the cytoplasm of the host cell. It was the first animal 
virus ever to be seen by light microscopy, due to the large size of its virions (Buist 
1886). When viewed by cryoelectron microscopy the vaccinia virions were seen to be 
smooth, rounded and brick-shaped, with dimensions of ~360nm x ~270nm x ~250nm 
(Miner and Hruby 1990; Cyrklaff et al. 2005). Vaccinia virus particles consist of a 
central core containing the viral genome, encapsidated by several membranes derived 
from different intracellular compartments from the host. They also contain proteins 
encoded by the viral genome, as well as host-derived proteins and was the first animal 
virus to be purified to an extent that allowed analysis o f its chemical composition 
(protein, 90%, lipid, 5% and DNA, 3.2%) (Zwartouw 1964).
Vaccinia virus has the capability to infect and replicate in a variety of different cell lines 
of mammalian origin. However, although this has been well characterised in vitro, little 
is known about the ability of vaccinia virus to infect cells in vivo or how it affects the 
cellular architecture (Sanchez-Puig et al. 2004). Epithelial cells are highly susceptible to 
vaccinia virus infection and are commonly used for research purposes. For example, 
HeLa cells - human epithelial cells (derived from a fatal cervical carcinoma transformed 
by human papillomavirus 18 (HPV18); Henrietta Lacks, 1951) and BSC-1 cells - 
epithelial cells of African green monkey kidney origin, are used in this thesis. In 
addition, although there is limited knowledge about the tropism in human leukocyte 
populations, studies have shown that various cell-types within leukocyte populations 
exhibit a broad range of susceptibility to infection with vaccinia virus. For example, 
infection of fresh human peripheral blood lymphocytes (PBL) preparations with 
vaccinia virus has revealed that monocytes were the most susceptible cell-type to 
infection (as measured by viral gene expression), followed by B-cells and natural killer 
(NK) cells. In contrast, infection rates were very low for T-cells. (Sanchez-Puig et al. 
2004; Nahlik et al. 2003). These findings may have important implications for our
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understanding of poxvirus pathogenesis and also in the development of new poxvirus- 
based vaccines (Chahroudi et al. 2005).
The genomes of the following vaccinia virus strains have all been fully sequenced: 
Western Reserve (WR), Copenhagen (COP), modified virus Ankara (MVA), Acambis 
3000 Modified Virus Ankara and Tian Tan (Baroudy et al. 2002; Baroudy and Smith 
2002; Goebel et al. 1990; Antoine et al. 1998). These strains of vaccinia virus are listed 
in Table 1.2, together with the other poxvirus genomes whose sequences have also been 
established (two are members of the Entomopoxvirinae subfamily, while the remaining 
viruses that are listed belong to the Chordopoxvirinae subfamily) (Upton et al. 2003; 
http://www.poxvirus.org).
The vaccinia virus genome is linear, with its ends being connected by AT-rich, 
incompletely paired hairpin loops that form a continuous, covalent polynucleotide chain 
(Figure 1.14; Baroudy et a l 1982).
INVERTED REPETITION INVERTED REPETITION
TERMINAL -C l r - , - - , , ~Ep— TERMINAL
LOOP 20 40 60 80 100 120 140 160 180 LOOP
KILOBASE PAIRS
TANDEM REPEATS
70 bp 70 bp 54 bp
q m i i i i i n "  m u y i u n i i j j i u i i  , • r   ............
2 125 bp 4 6 8 10
KILOBASE PAIRS
Figure 1.14: The structural properties of the vaccinia virus genome. The linear, double­
stranded DNA molecule is illustrated (top), together with an enlarged image of the inverted 
terminal repeat regions (bottom). There is great sequence variability at the ends of the genomes 
but a ~100kb region in the centre that is highly conserved (Figure reproduced from Moss 1996).
Sequence comparisons between the different vaccinia virus strains revealed that there is 
great sequence variability at the ends of the genomes but a highly conserved central 
region (~l00kb), which encodes numerous genes essential for virus replication. Ninety 
of these genes are identified as being conserved within all of the sequenced poxviruses. 
There are forty-one conserved genes in all Chordopoxviruses and, upon comparison of
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Genome Strain Abbreviation GenBank 
Accession No.
Reference
C h ordopoxviru ses
Vaccinia virus WR VV-WR AY243312 Baroudy e t al. 2002; 
Baroudy and Smith 
2002
Copenhagen W-Cop M35027 Goebel e t al. 1990
Modified Vaccinia Virus 
Ankara
W-MVA U98484 Antoine e t al. 1998
Acambis 3000 Modified 
Virus Ankara
W-MVA3000 AY603355 Unpublished
Tian Tan W-Tan AF095689 Unpublished
Variola major virus Bangladesh-1975 VAR-Bang L225579 Massung e t al. 1994
India-1967 VAR-Ind NC_001611 Schelkunov e t al. 
1996a, 1996b
Variola minor virus Garcia-1966 VAR-Gar NC_000900 Schelkunov e t al. 
2000
Bovine popular 
stomatitis virus
BV-AR02 BV-AR02 NC_005337 Delhon e t al. 2004
Camelpox virus Kazakhstan M-96 CMLV AF438165 Afonso e t al. 2002
CMS CMLV-CMS AY009089 Gubser and Smith 
2002
Canarypox virus Wheatley C93 CPV-C93 NC 005309 Tulman e t al. 2004
Cowpox virus Brighton Red CPV AF482758 Pickup e t al. 1982
GRI-90 CPV-GRI90 X94355 Safronov e t al. 
1996; Shchelkunov 
e ta l. 1998
Ectromelia virus Moscow EVM AF012825 Mossman e t al. 
1995; Wall I 1997
Naval (unpublished) EVM-N None Unpublished
Fowlpox virus Virulent challenge virus FPV-V AF198100 Afonso e t al. 2000
Isolate HP-438 Munich FPV-M AJ581527 Laidlaw and Skinner 
2004
Goatpox virus G20-LKV GPV-LKV AY077836 Tulman et al. 2002a
Pellor GPV AY077835 Tulman e t al. 2002b
Lumpy skin d isease  
virus
Neethling 2490 LSDV NC 003027 Tulman e t al. 2001
Neethling vaccine LW 
1959
LSD V-1959 AF409138 Kara e t al. 2003a
Neethling Warmbaths 
LW
LSDV-WB AF409137 Kara e t al. 2003b
Molluscum contagiosum  
virus
Subtype 1 MCV U60315 Senkevich e t al. 
1997
Monkeypox virus Zaire MPV AF380138 Schelkunov e t al. 
2001
Myxoma virus Lausanne MYX NC 001132.2 Cameron e t al. 1999
Orf virus IA28 OV-IA28 AY386263 Delhon e t al. 2004
SA00 OV-SA00 NC 005336 Delhon e t al. 2004
Rabbitpox virus Utrecht RPV None Unpublished
Sheeppox virus Turkey; TU-V02127 ShPV NC 004002 Tulman e ta l. 2002
A ShPV-A AY077833 Tulman e t al. 2002
NISKHI ShPV-NISKHI AY077834 Tulman e t al. 2002
Shope rabbit fibroma 
virus
Kasza SFV AF170722 Wilier e t al. 1999
Swinepox virus Nebraska 17077-99 SPV AF410153 Afonso e t al. 2002
Yaba m onkey tumour 
virus
Roswell Park-Yohn YMTV NC_005179 Brunetti ef al. 2003
Yaba-like d isease virus Smith YLDV NC 002642 Lee e t al. 2001
E ntom opoxviru ses
Melanoplus sanguinipes Tucson MsEPV NC 001993 Afonso e t at. 1999
Amsacta moorei Moyer AmEPV NC 002520 
AF250284
Bawden e t al. 2000
Table 1.2: Sequenced poxvirus genomes. Information was compiled from Upton et al. 2003 
and htto://www.Doxvirus.org.
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the conserved orthologs, the majority of the genes appear to be involved in 
morphogenesis rather than in RNA and DNA synthesis. There are also twenty-four 
highly conserved genes that, at present, do not have an assigned function and require 
further characterisation (Upton et al. 2003; Da Silva and Upton 2005)
The identical, hypervariable inverted terminal repetitions (ITR) (10-I2,000bp) that are 
positioned at either end of the genome contain blocks o f short tandem repeats as well as 
deletions, transpositions and mutations that can render some genes inactive (Garon et al. 
1978). These genes are largely non-essential for virus replication in cell culture and do 
not appear to encode proteins that affect virus virulence and/or the host range. As the 
genes are packed incredibly tightly together, leaving very little or no space between 
adjacent open reading frames (ORFs), some genes actually overlap or even contain 
another full or partial ORF, e.g. C18L (7856-7077bp) & C20L (7132-6821 bp) (Goebel 
et al. 1990; http://www.poxvirus.org). Therefore, the promotor of one gene often resides 
in the ORF of another.
The expression of vaccinia virus genes is tightly controlled and classified as being 
either early, intermediate or late. Expression of each class of gene occurs in temporal 
succession, where the transcription of each class is dependent upon the prior expression 
of genes within the preceding class (see Figure 1.16; reviewed in Broyles 2003).
• Early genes represent approximately half o f the vaccinia virus genome and encode 
proteins responsible for a wide range of functions, e.g. host interactions, 
immunomodulators and proteins responsible for viral DNA replication (Smith and 
Law 2004). Early expression begins at 30 minutes post-infection and accumulates 
until it reaches its maximum expression at 1-2 hours, prior to virus particle assembly 
and DNA replication.
• Intermediate genes are expressed once DNA replication begins at 100 minutes post­
infection. They encode a number of proteins involved in DNA replication and are 
required for late gene expression, such as late transcription factors. At present, only 
seven intermediate genes have been identified (AIL, A2L, G8R, I8R, I3L, K2L), 
although others are predicted to exist (http://athena.bioc.uvic.ca: Viral 
Bioinformatics Resource Center, Canada).
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• Late genes are expressed between 140 minutes post-infection and 48 hours post­
infection (hpi). They encode many structural proteins that are essential for the 
generation of new virus particles, as well as enzymes that are packaged into new 
virions in order to initiate subsequent infection (Smith and Law 2004). The majority 
of these genes are located in the highly conserved central region of the genome.
The vaccinia virus genome is divided into 16 fragments, based on restriction digestion 
with the restriction endonuclease Hindlll. Restriction maps of the resultant DNA 
fragments are numbered alphabetically in decreasing size, A—»P, following the 
nomenclature of De Filippes (Figure 1.15; DeFilippes 1982). Each ORF is named by 
using the letter of the Hindlll fragment followed by the ORF number within the 
fragment (numbered sequentially from the 5’ end), followed by the letter L (left) or R 
(right), which indicates the ORF direction. For example, F12L refers to the twelfth ORF 
within the sixth largest DNA fragment that is transcribed from left to right. The ORFs 
of other genomes are based on a similar idea and homologies to vaccinia virus, although 
their gene numbers do not always agree and can prove problematic when making cross­
comparisons, e.g. the A36R gene in vaccinia virus corresponds to the A39R gene in 
variola virus (http://www.poxvirus.org).
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Figure 1.15: Hindlll restriction map of the vaccinia virus genome. The resultant DNA 
fragments are numbered alphabetically in decreasing size order. The sizes of each fragment 
and the number of coding regions that initiate within the boundaries are indicated below the 
map. (NB: The smallest ORF, i.e. P, is not indicated but resides between ORFs E and O). 
(DeFilippes 1982; Goebel et al. 1990).
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1.9 L ife -cy c le  o f  V a c c in ia  V iru s
For the vaccinia virus life-cycle to commence it must first enter the cell, be transported 
to its replication site and then travel to the plasma membrane again to exit the cell. The 
life-cycle of any virus is comprised of the following general phases: (1) virus 
adsorption, (2) viral cell entry, (3) viral protein synthesis, (4) viral replication, (5) virus 
particle assembly and maturation, (6) viral egress and (7) viral release (Dohner and 
Sodeik 2005) (Figure 1.16).
©
TGN
early e n d o so m e s
Nucleus
Virus factory
Figure 1.16: An overview of vaccinia virus morphogenesis. The vaccinia virus life-cycle is 
composed of the following stages: (1) virus adsorption, (2) viral cell entry, (3) viral protein 
synthesis, (4) viral replication, (5) virus particle assembly and maturation, (6) viral egress and 
(7) viral release. Key: IV = immature virus, IMV = intracellular mature virus, IEV = intracellular 
enveloped virus, CEV = cell-associated enveloped virus, EEV = extracellular enveloped virus, 
MT = microtubule(s), TGN = trans Golgi network. (Figure adapted from Smith et al. 2002).
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Initially, upon infection with vaccinia virus, cell rounding occurs as a result of dramatic 
cytoskeletal rearrangements and the cytoplasmic redistribution o f mitochondria and late 
endosomes (Schepis et al. 2006). However, this redistribution may be a consequence of 
the cytoskeletal remodelling, rather than being a primary cause upon infection. And, it 
is the microtubules that are primarily responsible for this early phenotype (Ploubidou et 
al. 2000; Schepis et al. 2006). During these early stages the microtubules retract and 
then regrow later during infection. Also, mitochondria and intermediate filaments 
collapse early during infection and (partially) regain their normal cytoplasmic 
distribution later, which suggests that the transport on microtubules is initially impaired 
and then restored (Ferreira et al. 1994). It has also been reported that the early processes 
of cell rounding coincide with the microtubule-dependent, perinuclear accumulation of 
the cytoplasmic viral factories (Schepis et al. 2006). In addition, the actin cytoskeleton 
is also dramatically modified both early and late during infection.
1.9.1 Viral Adsorption and Viral Cell Entry
The viral life-cycle begins with the attachment of virions to the cell surface, penetration 
of the plasma membrane and fusion of the viral membrane (Smith et al. 2002). 
However, the entry mechanisms of vaccinia virus are not clearly understood (and will 
only briefly be addressed) and is complicated further by the existence of two 
structurally different and infectious forms of the virus: intracellular mature virion 
(IMV) and extracellular enveloped virus (EEV) that appear to interact with different 
types of cellular receptors (Boulter and Appleyard 1973; Vanderplasschen and Smith
1997). IMV and EEV possess different numbers of encasing membranes, so their entry 
mechanisms must be different, unless the membranes are removed.
Several mechanisms have been proposed by which IMV and EEV can enter a host cell 
(Figure 1.17; reviewed in Smith et al. 2003; Moss 2006). The two principle mechanisms 
involve either direct fusion of the virion with the plasma membrane or internalisation to 
reach endosomes, where low-pH fusion occurs; both of which are poorly understood 
(Krinjnse Locker et al. 2000; Vanderplasschen et al. 1997; Vanderplasschen et al.
1998). The first mechanism claims that entry of IMV results from the virus binding to 
the host cell plasma membrane. Although the cell receptors are unknown, several IMV
72
Chapter 1 Introduction
(A) (B) (C)
EEVIMV.
a
a acore
a
a O
CD
Figure 1.17: Possible IMV and EEV entry mechanisms. (A) Bound IMV enters by 
endocytosis after which the IMV surface membrane fuses with the vesicular membrane to 
release a core into the cytosol. (B) Bound IMV fuses with the plasma membrane releasing a 
core into the cytosol. (C) IMV uncoats outside the cell and the core somehow crosses the 
plasma membrane. (D) Bound EEV fuses with the plasma membrane. The IMV within the 
cytosol then loses its membrane to release the core. (E) EEV is endocytosed and the outer EEV 
membrane is destroyed within an acidified vesicle releasing an IMV. The IMV then fuses with 
the vesicle membrane releasing the core into the cytosol. (Reproduced from Smith et al. 2003).
surface proteins have been implicated in binding to glycosaminoglycans (GAGs) on the 
cell surface: A27L, D8R, LIR and H3L (Chung et al. 1998; Maa et al. 1990; Hsiao et 
al. 1998; Ichihashi 1994; Ichihashi 1996; Ravanello and Hruby 1994; Wolffe et al. 
1995; Lin et al. 2000). Further research by Carter et al. established that binding of IMV 
to GAGs is cell-type specific and is not essential for entry of IMV particles (Carter et 
al. 2005). Binding to the plasma membrane induces actin polymerisation, their 
subsequent fusion, drawing the viral core into the cell and incorporating IMV surface 
antigen into the plasma membrane. Electron micrographs have also been published that 
show membrane continuity between the IMV membrane and plasma membrane 
(Armstrong et al. 1973; Chang and Metz 1976; Carter et al. 2005). This membrane 
continuity has recently been confirmed by using tilt-series analysis to orientate 
membranes perpendicularly to the beam of the electron microscope (Carter et al. 2005). 
Their results are consistent with the hypothesis that a single lipid membrane surrounds 
IMV and enters the cell by fusion (Carter et al. 2005). Heuser has recently strengthened
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this hypothesis, as only a single fracture plane could be identified when employing 
deep-etch electron microscopy (Heuser 2005).
The second mechanism concerns the entry of EEV, which possesses an additional 
membrane cistema (i.e. two lipid bilayers) to IMV. Therefore, in order for EEV to gain 
entry into the cytosol it must first shed these extra membranes. It has been proposed that 
this event occurs after acidification of virions in intracellular vesicles (Ichihashi 1971; 
Vanderplasschen et al. 1998) or by shedding EEV membranes at the cell surface (Law 
et al. 2006; Krinjse-Locker et al. 2000). EEV do not induce actin polymerisation, are 
able to uncoat outside the cell without fusion to the plasma membrane and introduce the 
viral core through the plasma membrane at the points of contact between the virus and 
the plasma membrane (Krinjnse-Locker et al. 2000). Therefore, if EEV loose a 
membrane it becomes an IMV, which implies that it is only IMV that enter the cell. 
Surprisingly, neither the IMV nor EEV viral antigens are detected in the plasma 
membrane after fusion and only appear to be present on the cores within the cytoplasm 
(Vanderplasschen et al. 1997; Vanderplasschen et al. 1998; Krinjnse-Locker 2000b). A 
recent study by Law et al. supports this model as they have demonstrated by immuno- 
electron microscopy that EEV ruptures and sheds its outer membrane via a ligand- 
dependent nonfusogenic mechanism, enabling fusion of the IMV membrane with the 
plasma membrane (Law et al. 2006). The B5R and A34R proteins were identified as 
ligands on EEV and GAGs were recognised as ligands on the cell surface that are 
responsible for disrupting the outer membrane (Law et al. 2006). Nevertheless, by 
whatever mechanism the virus gains entry into the cytosol it appears to release an 
identical core into the cytoplasm, which is then transported on microtubules from the 
cell periphery to the site of replication in the central region of the cell (Carter et al. 
2003; Schramm and Krijnse-Locker 2005; Moss, 2006).
Enveloped viruses gain entry into a host cell via the attachment o f viral particles to 
receptors that are present on the cell surface (reviewed in Marsh and Helenius 2006). In 
the case of vaccinia virus, the epidermal growth factor receptor (EGF-R) was originally 
implicated in this entry process (Twardzik et al. 1985; Marsh and Eppstein 1987). The 
vaccinia virus growth factor (VGF) is a secretory viral protein that is made once the cell 
becomes infected and can therefore affect the EGF-R (Blomquist et al. 1984). VGF
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contains a region of forty amino acids that shares 33% sequence identity to EGF and is 
capable of binding to cellular EGF-R (Blomquist et al. 1984). However, EGF-R is now 
considered to be an unlikely candidate as the virus has since been shown to infect cells 
that lack the EGF-R and the receptor failed to influence viral adsorption and/or 
penetration (Stroobant et al. 1985; Hugin and Hauser 1994).
VGF and IMV-specific membrane proteins: D8L and A27L have also been suggested to 
play a role in the attachment of viral particles to the plasma membrane, i.e. it aids the 
spread of the virus but is not involved in the initial entry event (Maa et a l  1990; 
Sanderson et al. 2000). A recent report has strengthened the involvement o f A21L and 
L5R, as experiments using conditional lethal mutants demonstrated that this gene is 
essential for viral fusion and entry (Townsley and Senkevich 2005a; Townsley and 
Senkevich 2005b). Furthermore, new data from Senkevich et al. identified eight 
vaccinia virus membrane proteins that form a stable entry-fusion complex (Senkevich et 
al. 2005). A21, A28, H2 and L5 were originally shown to be involved in the entry 
process by using a reverse genetics approach, i.e. characterising the phenotypes of 
conditional-lethal mutants (Senkevich et al. 2005; Townsley et al. 2005a; Townsley et 
al. 2005b). Subsequent immunoaffinity purification, followed by mass spectrometry 
demonstrated that these four proteins together with A 16, G3, G9 and J5 form a stable 
complex. All eight proteins are conserved in all poxviruses, suggesting that the principal 
entry mechanism was established early in their evolution, prior to the division into the 
Chordopoxvirinae and Entomopoxvirinae subfamilies (Senkevich et al. 2005).
1.9.2 An Overview o f Virus Morphogenesis
Vaccinia virus infection has a profound effect on many host cell processes, including: 
cell motility, re-organisation of the actin and microtubule cytoskeletons, prevention of 
apoptosis, destruction of the centrosome and modulation of nuclear function. A 
summary of the cellular changes that occur during vaccinia virus infection are outlined 
in Figure 1.18. Vaccinia virus has evolved strategies so that it can hijack and manipulate 
the cells cytoskeleton in order to promote its own replication and dissemination, by 
forming a variety of morphologically distinct virions. This makes the virus a good tool 
to study host cell biology and dissect the mechanisms involved in controlling 
cytoskeletal dynamics.
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Figure 1.18: Summary o f the cellular changes in morphology and the cytoskeleton that 
occur during the course o f vaccinia virus infection. The red  line defines the times post­
infection. The arrows above the line indicate the approximate start and duration o f particular 
stages during morphogenesis. Below the line, the cellular changes that occur during the viral 
life-cycle are outlined; the arrows indicate the approximate time-duration o f each cellular 
change. (Adapted from Schepis et al. 2006).
1.9.2.1 Viral Protein Synthesis and Replication
Entry of IMV and EEV delivers the DNA-containing viral cores into the cytoplasm. 
These cores have been shown by immunofluorescence to align with microtubules and 
by electron microscopy to reside close to the cytosolic side o f the ER (Mallardo et al.
2001). Although it is currently unclear how the binding of cores to microtubules is 
mediated, the core protein L4R has been implicated in this process, at least in vitro 
(Ploubidou et al. 2000). Carter et al. have suggested that these incoming cores are 
transported on microtubules to the viral factories located in the perinuclear region of the 
cell, while Schramm et al. have presented data that suggests the cores utilise 
microtubules in order to reach sites of disassembly and DNA-release, which, 
conversely, occurs in the cell periphery (Carter et al. 2003; Schramm and Krijnse- 
Locker 2005). Therefore, imaging of GFP-labelled viral cores moving along 
microtubules is still required to confirm how they move.
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Approximately 100 mRNAs are made and transcribed inside the viral cores, within 20 
minutes of the virus entering the cell (Moss 1996). And, upon initiation of DNA 
replication, rough ER (rER) cistemae are recruited to the sites o f replication, encasing it 
to create a cytosolic subcompartment (also termed ‘mini-nuclei’ due to its 
morphological similarity to the nucleus), which facilitates viral DNA synthesis 
(Tolonen et al. 2001; Schramm and Krijnse-Locker 2005). Early proteins are known to 
induce the uncoating of the core and release of parental DNA for translation, in an ATP- 
dependent manner; the parental DNA is associated with the early proteins 13L, E8R, 
B1R and H5R (Mallardo et al 2002; Kates and Beeson 1970; Joklik 1964; Schramm, 
and Krijnse-Locker 2005). Viral factories provide a centre for the replication of the 
genome and for the recruitment of structural proteins to the site o f virus assembly. The 
first structures to materialise in these specialised perinuclear viral factories (or 
inclusions) are crescent-shaped structures containing many viral proteins and host- 
derived lipids. However, the source from which these membranes and lipids are derived 
is unknown. These structures develop into the non-infectious immature virus (IV) 
particles that acquire their infectivity to become IMV particles, during condensation and 
insertion of the viral core and proteolytic cleavage of capsid proteins (Moss et al. 1973). 
To date, the process by which infectivity is acquired by a virus particle has not been 
fully established but it is made apparent by the cleavage of several structural proteins, 
together with a simultaneous change in particle morphology (Katz et al. 1970; Moss and 
Rosenblum 1973; Yeh et al. 2000).
During the initial stages of vaccinia virus infection, the establishment of viral factories, 
its assembly at the MTOC and morphogenesis involves important participation by both 
microtubules and the dynein-dynactin complex. They are needed to (i) keep the IMV 
anchored in the vicinity of the TGN, (ii) maintain the integrity and organisation of the 
TGN, (iii) facilitate the movement o f IMVs from their site o f assembly in the virus 
factory towards the TGN, where they become wrapped to form IEV. However, 
microtubules are not required for the assembly of IMV (Sanderson et al. 2000; 
Ploubidou et al. 2000; Schramm and Krijnse-Locker 2005).
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1.9.2.2 Virus Particle Assembly and Maturation
IMV particles represent the majority o f infectious progeny from each infected cell and 
are incredibly robust (reviewed in Smith and Law 2004). They are resistant to freezing, 
thawing and physical forces, which permits the virus to survive for prolonged periods of 
time outside of a host. Although these properties are ideal to enhance the spread of 
infection to new hosts, IMV are inadequately adapted to spread infection within a host, 
due to the viral particles being easily neutralised in vitro by the antibody generated 
against inactivated IMV particles (reviewed in Smith and Law 2004).
Once IMV have assembled they are transported out of the viral factories on the 
microtubule network (Sanderson et al. 2000). The accumulation of vaccinia close to the 
MTOC requires the activity of the dynein-dynactin complex, as overexpression of 
p50/dynamitin inhibits the anchoring o f virus particles close the centrosome, although 
the viral proteins responsible are currently unknown (Ploubidou et al. 2000). Dynein is 
needed for the vesicular traffic of the membrane-bound viral proteins required to make 
the virus, rather than to enable movement of virus particles per se. This directed 
trafficking of IMV is also known to be dependent upon the A27L protein, as viruses in 
which this gene has been deleted fail to accumulate at the centrosome and are unable to 
reach their wrapping site to form IEV particles (Sanderson et al. 2000). A27L is 
exposed on the surface of IMV particles but requires the A17L protein to facilitate its 
binding (Rodriguez et al. 1993).
The general structure of biological membranes consists of lipid and protein molecules, 
whereby the lipid molecules are arranged as a continuous double layer (i.e. a single 
lipid-bilayer) (Singer 1972). However, there is still unresolved controversy concerning 
the number and origin of the membranes that form viral crescents. There are two 
discrete types of vaccinia virus membrane involved in virus assembly: the ‘primary 
membrane’ and the ‘secondary or wrapping membrane’ (which is described later in 
Sections 1.9.2.3 and 1.9.2.4). The ‘primary membrane’, contains non-glycosylated 
proteins and represents the viral membrane that forms crescents and surrounds IV and 
IMV. Conflicting studies have proposed that this membrane consists of either a single 
lipid-bilayer (Dales and Mosbach 1968; Heuser 2005) or a tightly apposed pair of
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membranes, derived from host cell membranes (i.e. double lipid-bilayer) (Sodeik et al. 
1993; Griffiths et al. 2001; Risco et al. 2002).
In 1968, Dale et al. proposed that viral crescents were synthesized de novo by a unique 
viral mechanism and that they were composed of a single lipid-bilayer that was not 
continuous with cellar membranes (Dales and Mosbach 1968). However, this model 
was disfavoured as it contradicts dogma stating that all membranes grow from existing 
membranes and are closed upon themselves (Hollinshead et al. 1999; Smith et al.
2002). Subsequent research proposed an alternative model, whereby the primary 
membrane is derived from and is continuous with the ERGIC compartment (Griffiths et 
al. 2001a; Griffiths et al. 2001b; Sodeik et al. 1993; Ichihashi et al. 1971; Hiller and 
Weber 1985). Husain et al. have produced electron micrographs showing that viral 
membrane proteins are co-translationally inserted into the ER before being transported 
to the ERGIC (the tubules of which form the viral crescent membranes), where they 
accumulate and are retained (Husain et al. 2003). However, this model is not consistent 
with the findings that resident proteins of the ERGIC are not detected in purified IMV 
particles (Krauss 2002). Furthermore, experiments have shown that IMV formation is 
not inhibited if the COPII-mediated transport of membrane proteins from the ER to 
ERGIC is blocked (Husain and Moss, 2003). And, as poxviruses encode their own 
transcription machinery, DNA replication apparatus and their own disulfide bond 
pathway, it is possible that viral crescents could be derived directly from the ER via a 
novel mechanism (Moss 1994; Traktman 1996; Senkevich 2002; Husain and Moss 
2003; Schramm et al. 2005).
During viral infection, the TGN becomes loaded with viral proteins and some studies 
claim that this is the origin of the wrapping membranes that encase IMV, to form IEV. 
Alternatively, it has been proposed that the wrapping membranes are derived from early 
endosomes and the TGN (Tooze et al. 1993; van Eijl et al. 2002; Husain and Moss,
2003). Research by Hollinshead et al. supports a model in which only a single lipid- 
bilayer membrane exists around IMV and where no continuity is seen between the viral 
lipid crescents or IV particles and the cellular membrane cistemae (Hollinshead et al. 
1999; Heuser 2005). The single membrane model would simplify virus re-entry 
mechanism, although a more satisfying explanation is needed to explain how a single
79
Chapter 1 Introduction
membrane with ‘free ends’ is generated in the cytoplasm. Other studies propose that 
IMV particles possess two or more membranes (Risco et al. 2002; Griffiths et al. 2001). 
This model is difficult to conceive during viral entry, as the multiple membranes 
encasing the virus must be shed by some mechanism in order for it to release its viral 
core into the cytoplasm (Smith et al. 2002). Griffiths et al. argue that the virus 
membranes are derived from the ERGIC and, therefore, the viral membrane proteins 
would inevitably be cisternal rather than a single lipid-bilayer (Sodiek et al. 2003; 
Griffiths et al. 2001). They have produced electron micrographs that clearly 
demonstrate a black/white banding pattern that distinguishes the membrane boundaries, 
as well as claiming that the membrane thickness calculated is too great for a single­
bilayer. In addition, they also proposed that the ultrastructure o f IMV is highly complex, 
consisting of one continuous, interwoven, folded membrane cistema. This model 
contains two distinct cytoplasmic compartments that are physically separated. One fold 
enclosing the genome and the inner-membrane cisternal domain is always in direct 
continuity with the crescent cistema. Irrespective of which model proves to be true, the 
resultant IEV particles possess two more double-membranes than IMV, which is 
required for efficient spread of infection.
One reason for the controversial interpretations of the vaccinia vims structure stems 
from the use of different sample preparations and visualisation techniques. However, 
employing cryo-electron tomography has the ability to obtain unique three-dimensional 
(3D) views of vaccinia virus-infected cells at different stages of the life-cycle, while 
removing potential artefacts derived from sample preparation. Dubochet et al. first used 
this technique to examine vaccinia vims in 1994. They showed that the virions appeared 
uniform and subsequent research has produced evidence to support the presence of two- 
membranes surrounding IMV particles (Dubochet et al. 1994; Roos et al. 1996; 
Cyrklaff, et al. 2005; Risco et al. 2002).
1.9.2.3 IMV-specific Vaccinia Virus Proteins
Proteins that are IMV-specific are divided into core proteins and envelope proteins, 
which can be separated biochemically by a combination o f detergent (usually NP-40) 
and reducing agents (usually DTT or pME) (Holowczak 1972; Jenson et al. 1996). 2D 
gel electrophoresis of purified IMV particles resolved approximately 100 different
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polypeptides, with only fourteen of these being identified as viral core or IMV-specific 
membrane proteins (One and Ichihashi 1981; Jensen et al. 1996). O f these, six structural 
proteins of the viral cores were identified, two of which are also associated with IMV 
membranes; eight other IMV-specific membrane proteins are also known (Table 1.3).
Localisation Viral Proteins
Viral core A3L, A4L, A10L, A30L, D2L, D3L, E11L, F17R, G7L, ML, I3L, L4R
IMV membranes A2.5, (A4L), A9L, A10L, A13L, A14L, A17L, A21L, A25L, A26L, 
A27L, A28L, D8L, D13L, E8R, E10R, F9R, (G4L), H2L, H3L, I2L, 
I5L, J1R, L1R, L5R
IEV/EEV membranes A33R, A34R, A36R, A56R, B5R, F12L, F13L
Table 1.3: Summary of the known vaccinia virus core, IMV and IEV/EEV membrane 
proteins. The proteins shown in blue show the revised viral core and IMV membrane proteins 
identified by Chung et al. 2006. However, the proteins written inside brackets were not 
recognised in this recent analysis but had been previously been identified (Oie and Ichihashi 
1981; Jensen et al. 1996).
Recent data from Chung et al. extends these previous findings and provides the first 
comprehensive structural analysis of the IMV proteome (Chung et al. 2006). They 
identified 75 viral proteins and 23 IMV-associated host proteins in purified IMV, by 
using gel-free liquid chromatography and tandem mass spectroscopy (Chung et al. 
2006). Of the viral proteins that were identified, 22 are membrane proteins, 12 are core 
proteins, 24 are enzymes, 3 are viral transcription factors, 4 are proteins that interact 
with host proteins and 10 are novel viral proteins present in IMV (see blue proteins in 
Table 1.3 for revised version). The host-proteins associated with IMV particles were 
divided into several categories for analysis, including cytoskeletal proteins (actin, 
tubulin and myosin-9 (myosin heavy chain, non-muscle Ha) and protein 
transport/vesicular trafficking proteins (ADP ribosylation factors 1/3 and 4, Rab7, 
RablO and ubiquitin). 7 of the 23 host proteins identified (including ADP ribosylation 
factor 4 and RablO) have been shown to uniquely associate with vaccinia virus and not 
with other viruses (Chung et al. 2006). The identified Rab proteins are o f particular 
interest, due to their reported utilisation by particular kinesins in binding them to their 
cargo (Jordens et al. 2005).
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The ‘secondary or wrapping membrane’ consists of a single membrane cistema (i.e. 2 
lipid-bilayers), contains glycoproteins, is derived from virus-modified TGN and/or 
endosomes and represents the viral membrane that delimits IEV. The term ‘envelope’ is 
also used to refer to the outer membrane of extracellular virions (Schmelz et al. 1994; 
Husain and Moss 2003a).
1.9.2.4 IEV Movement to the Plasma Membrane and Viral Release
The IEV are subsequently transported to the plasma membrane via microtubules. Seven 
vaccinia virus proteins are currently known to be associated with the membranes o f IEV 
particles. They are: F12L, F13L, A33R, A34R, A36R, A56R and B5R (see Sections
1.9.3.2 and 1.9.4.1 for details). Once at the plasma membrane, the outer membrane of 
IEV fuses with it, exposing CEV on the cell surface (which possess one extra 
membrane than IMV and one less than IEV). CEV particles induce a localised 
signalling cascade that nucleates an actin tail, which aids the release and spread o f the 
vims into adjacent cells (see Section 1.9.3.2 for details) (van Eijl et al. 2000; 
Hollinshead et al. 2001; Ward and Moss 2001; Frischknecht et al. 1999b; Rietdorf et al. 
2001 ).
1.9.2.5 IEV- specific Vaccinia Virus Proteins
All IEV specific proteins are localised to the Golgi apparatus, which is consistent with 
the wrapping of IMVs with the TGN. However, unlike the IMV membrane proteins, the 
majority of integral IEV membrane-specific proteins are glycosylated (all but A36R, 
F13L and F12L). With the exception of F12L and F13L, all known IEV proteins are 
integrated transmembrane proteins, containing a single membrane-spanning region (see 
Table 1.4 and Figure 1.19).
Interestingly, research from Brum et al. has suggested that an eighth protein, called 
K2L, may also be present on IEV (Brum et al. 2003). It is a glycoprotein, demonstrating 
an association between the EEV envelope, via an interaction with the A56R protein, and 
the Cowpox orthologue of the vaccinia vims K2L protein, which possess sequence 
similarity to serine protease inhibitors (serpins) (Boursnell et al. 1988). As this thesis 
primarily focuses on the transport of IEV, the IEV proteins are introduced in greater 
depth below and their details are summarised in Tables 1.4, Table 1.5 and Figure 1.20.
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Lumen
Cytoplasm
(complex)
Figure 1.19: Topology of integral membrane proteins. Simple proteins with only one 
membrane-spanning segment are made in one of three ways. Class I: possess an amino- 
terminal cleavable signal peptide (SP) and an internal apolar stop-transfer sequence (ST). This 
yields a topology with the amino terminus of the protein translocated across the membrane. 
Class II: have an amino-terminal or internal, uncleaved signal peptide (USP). This results in a 
non-translocated amino-terminus. Class III: contain an amino-terminal start-stop transfer 
sequence (SST). This results in a translocated amino terminus. Complex membrane proteins 
with more than one membrane-spanning segment in the final structure can have their amino 
and carboxyl termini on the same or opposite sides of the membrane, and they can be either 
translocated or remain non-translocated (Class IV). (Figure taken from von Heijne and Gavel 
1988).
NOTE:
• Type la membrane proteins p o sse s s  an N-terminal, non-translocated signal peptide which is cleaved after 
translocation of the polypeptide, releasing its N-terminus into the lumen of the ER. In addition to the signal peptide, 
these proteins have an internal hydrophobic stop-transfer sequence.
• Type II membrane proteins display an uncleavable N-terminal or internal signal peptide. Their N-terminus is not 
translocated but remains in the cytoplasm.
•  Type lb or III membrane proteins include an N-terminal start-stop-transfer sequence, which m ediates translocation 
of the N-terminus of the polypeptide into the ER lumen.
1.9.2.5.1 A33R
The A33R gene encodes a 185 amino acid, type II integral membrane protein that 
possesses a single transmembrane domain and is highly conserved in poxviruses (Roper 
et al. 1998). Only 31 amino acids are exposed on the surface o f IEV (Roper et al. 1996). 
It has been demonstrated that the A33R protein can undergo post-translational 
modification by both phosphorylation and palmitoylation, as well as forming 
disulphide-bonded homodimers (Payne 1992; Roper et al. 1996; Grosenbach et al. 
2000). The gene product can exist as different isoforms that display different patterns of 
N- and O-glycosylation (see Figure 5.1C), resulting in a range of molecular weights 
between 23 and 28KDa (Payne 1992; Roper et al. 1996).
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Figure 1.20: (A) Schematic illustrating the localisation and topology of vaccinia virus 
proteins in IMV, IEV, CEV and EEV. F12L and A36R are only present on IEV particles, while 
A36R also becomes concentrated beneath the CEV particle on the plasma membrane. A33R, 
A34R, A56R and B5R are exposed on the CEV/EEV and F13L is located between the EEV 
outer envelope and the IMV surface. (B) An enlarged image of the location of lEV-specific 
proteins and their association with the wrapping membrane. Y112 and Y124 of A36R, which 
become phosphorylated during actin tail formation, are high-lighted, together with its 
kinesin/A33R binding site. The cytoplasmic and luminal faces of the outer IEV membrane, as 
well as the positions of the N and C-termini of A33R, A34R, A36R, A56R, B5R, F12L and F13L 
are indicated. (Figure A is reproduced from Smith et al. 2002 and B is adapted from Ward 
2005).
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PROTEIN PROPERTY A33R A34R A36R A56R B5R F12L F13L
Predicted polypeptide 
length (aa)
185 168 221 314 317 635 372
Predicted cytoplasmic 
tail (aa)
31 12 195 15 14 635 373
Predicted KDa 20.5 19.6 25.1 34.7 35.1 73.3 41.8
Apparent SDS-PAGE 
(KDa)
23-25 24-28 43-50
85/89 
68 (late)
42
65-70 37
Membrane topology 
association
Type II Type II Type lb Type 1 Type 1
Peripheral/
Membrane
associated?
Peripheral
Membrane
associated
Expression Early & late Late Early & late Early & late Early & late Early & late Late
Glycosylation I N & 0 N - N & O N N .
Phosphorylation Serine
[threonine]
- Serine & tyrosine Yes - ? -
Acylated Yes - Yes Yes* Yes ? Yes
Sulphated - - - Yes - ? -
Palmitoylated? Yes** - Yes** Yes** Yes** 7 Yes**
Similarity 1 C-type lectin­
like domain
1 1g-like domain 
& 2 tandem 
repeats
4 SCR domains Phospholipases
Interactions & 
associations Forms dimers 
A36R
A36R
B5R
A33R
A34R
F13L 
Forms 220KDa 
complex with 
unknown 
partners.
A34R
A36R
F13L
7 B5R
Role in IEV assembly? Yes Yes No No Yes No Yes
Role in IEV egress? No No Yes No No Yes No
Role in actin tail 
formation?
No No Yes No No No No
Role in EEV formation? Yes Yes Yes No Yes No Yes
Table 1.4: Summary of the properties of IEV proteins. * In Copenhagen strain of vaccinia virus, ** Grosenbach et al. 2000. Key: aa = amino acid(s); ? = 
Not known. (Adapted from Smith et al. 2002).
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DELETION VIRUS
PROPERTY AA33R AA34R AA36R AA56R AB5R AF12L AF13L
Plaque size Tiny Small Small Syncytial, 
normal size
Small Tiny Tiny
IMV Normal Normal Normal Normal Normal Normal Normal
IEV Yes Yes Yes No Few Yes Very few**-3o CEV Yes Reduced Yes Yes Few No Few
c
O♦3(0
E
EEV t  3-fold 125-fold, 5-fold 
I  specific 
infectivity
I  5-fold Normal I  5- to 10-fold I  7-fold 1 10-fold
o
LL Virus- 
tipped 
actin tails
No No No Yes No Very few Very few
Virulence ? Attenuated Attenuated Normal,
intranasal,
attenuated,
intracranial
Attenuated Attenuated Attenuated
Table 1.5 Summary of the phenotypes associated with vaccinia virus when various genes encoding the IEV proteins are deleted from the 
genome. The upward arrows (1) indicate an increase in value, while the downward arrows represent a decrease in value. (Adapted from Smith et al. 
2002).
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In cells that have been infected with wild-type vaccinia virus, A33R is localised to the 
Golgi apparatus, the TGN-derived membranes and the two outer membranes of IEV 
particles (Schmelz et al. 1994; Roper et al. 1996). However, when cells are infected 
with a virus strain in which A33R has been deleted, AA33R, IMV assembly proceeds 
normally but many of the IMV are only partially wrapped by a membrane cistema and 
the presence of completely wrapped IEV particles are scarce (Roper et al. 1996; Roper 
et al. 1998).
1.9.2.5.2 A34R
The A34R gene encodes a highly conserved, 168 amino acid, type II integral membrane 
protein, with a cytoplasmic tail of only 1 2  amino acids and a luminal domain that is 
homologous to a number of C-type lectins (McIntosh and Smith 1996). This domain 
aids the association of CEV with the cell surface (Blasco et al. 1993; Drickamer and 
Taylor 1998). There are several different N-glycosylated A34R variants of molecular 
weights between 22 and 24 KDa.
The A34R protein is involved in the assembly and organisation of IEV particles and can 
be seen localised to the Golgi apparatus, endosomes and the plasma membrane in 
vaccinia-infected cells (Rottger et al. 1999). Deletion of A34R from the genome 
(AA34R) creates a severely attenuated mutant strain (McIntosh and Smith 1996). 
Neither IMV formation nor infectivity of IMV is impaired by its absence and although 
IEV assembly is reduced there is no affect on the production of EEV (Wolffe et al. 
1997).
1.9.2.5.3 A36R
The A36R gene encodes a 221 amino acid, type lb protein, with a 195-amino-acid 
cytoplasmic domain exposed on the surface of IEV particles (Rottger et al. 1999). It is 
also highly conserved in poxviruses (van Eijl et al. 2000). It is important to note that 
despite the predicted molecular weight of A36R being 25KDa, by SDS-PAGE it 
migrates at a position twice the predicted weight of the amino acid sequence, i.e. at ~45- 
50KDa. However, as the electrophoretic mobility o f A36R remains the same when 
subjected to various reducing conditions, the 45-50KDa protein could correspond to an 
A36R monomer or, more likely, a very stable dimer. A36R is heavily serine-
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phosphorylated, which could account for this. However, the proportion, specific sites 
and roles of A36R phosphorylation is currently unclear.
In vaccinia virus-infected cells, despite A36R being absent from CEV particles, it does 
concentrate beneath CEV to induce actin tail formation (van Eijl et al. 2000). In the 
absence of A36R (AA36R), there is a significant reduction of EEV released from 
infected cells and a noticeable decrease in virulence (Parkinson and Smith 1994). 
However, the formation of IEV particles does not appear to be impaired (Sanderson et 
al. 1998; Wolffe et al. 1998).
1.9.2.5.4 A56R
A56R is an 89KDa, conserved type I membrane protein that contains a signal peptide 
and a transmembrane domain followed by a short cytoplasmic tail and encodes the viral 
hemagglutinin (HA) (Payne and Kristenson 1979). A56R is able to be post- 
translationally modified by sulphation, phosphorylation and both N- and O- 
glycosylation (Payne 1992). It is able to interact non-covalently with F13L and has been 
shown to form a disulphide-bonded complex (~220KDa) that incorporates several 
precursor proteins of lower molecular weight (Oie et al. 1990; Payne 1992).
In cells infected with wild-type vaccinia virus, A56R localises to the Golgi apparatus, 
the ER, endosomes, the plasma membrane and to the outer membranes of IEV and EEV 
particles (Schmelz et al. 1994). Additionally, AA56R infected cells do not impair IEV 
assembly and are still able to egress to the plasma membrane (Sanderson et al. 1998).
1.9.2.5.5 B5R
B5R is a 42KDa, type I integral membrane protein that is highly conserved in various 
strains of vaccinia virus and other poxviruses (Engelstad et al. 1993). It only has a short, 
14 amino acid tail, exposed in the cytoplasm and has the capacity to be both N- 
glycosylated and palmitoylated (Isaacs et al. 1992; reviewed in Smith et al. 2002). The 
larger luminal domain contains four short consensus repeat (SCR) domains, each 60 
amino acids in length. These domains are found in multiple adjacent copies, connected 
in a head-to-tail fashion by 2-12 amino acid linkers, in over 40 human proteins 
(Lehtinen et al. 2004). Each of the neighbouring SCR domains can interact with each
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other via the interdomain contact region. SCR domains are characteristic o f complement 
control proteins that are involved in modulating the host inflammatory response 
(Takahashi-Nishimaki et al. 1991; Engelstad et al. 1992).
In vaccinia virus-infected cells, B5R localises to the Golgi apparatus, the plasma 
membrane and both sides of the wrapping membranes for IEV and EEV particles 
(Isaacs et al. 1992; Smith et al. 2002). In AB5R-infected cells, IEV formation is 
inhibited, the number of EEV released from infected cells is reduced considerably and it 
is extremely attenuated (See Table 1.5) (Wolffe et al. 1993). The cytoplasmic tail, and 
thus SCR domains, of B5R is not essential for IEV formation, the recruitment of B5R to 
the outer membrane of IEV particles, or infectivity (Lorenzo et al. 1998; Mathew et al. 
2001; Herrera et al. 1998). Upon deletion of the luminal domain (i.e. the 4 SCRs) 
normal wrapping of IMV occur and the virus particles are still able to reach the plasma 
membrane but they are unable to produce actin tails (Rodger and Smith 2002). 
Moreover, this phenotype is seen with a recombinant virus that only expresses SCR 
domains 1-3 (Herrera et al. 1998). However, in cells infected with a recombinant virus 
containing only the SCR domain 4, CEV are able to induce actin tails (Newsome et al. 
2004).
1.9.2.5.6 F12L
The vaccinia virus gene F12L encodes a 65kDa protein that is highly conserved in 
Chordopoxvirinae (Zhang et al. 2000). The protein is synthesized early and late during 
infection and is important for plaque formation (which is thought to be indicative of 
efficient viral spread), EEV production and virulence. It does not contain a predicted 
transmembrane domain and it is unknown if the protein is subjected to any form of 
modification. F12L is not modified by glycosylation and no signal sequence was found, 
despite a computer search identifying 6  potential sites of attachment for N-linked 
carbohydrate (van Eijl et al. 2002).
In vaccinia virus-infected cells, F12L is located exclusively on IEV particles (Zhang et 
al. 2000; van Eijl et al. 2002). In AF12L-infected cells, IEV particles are still made but 
they are unable to be transported effectively to the cell surface and have been shown by 
electron microscopy to cluster at the viral factories (Zhang et al. 2000; van Eijl et al.
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2002). In addition, the EEV levels were reduced, the plaque size was small, there was a 
99.5% reduction in actin tail formation and the virus was highly attenuated (Zhang et al. 
2000; van Eijl et al. 2002).
1.9.2.5.7 F13L
F13L is a 373 amino acid protein (37KDa) that is conserved in poxviruses and lacks a 
transmembrane domain (Roper et al. 1998). However, it is membrane-associated and 
can undergo acylation via palmytic or oleic acids that become covalently bound to 
cysteine 185 and 186 (Grosenbach et al. 1997). If either o f these anchoring acylation 
sites becomes mutated or hydroxylamine is used to cleave the palmitoyl residues, F13L 
is no longer able to associate with IEV or TGN membranes. F13L is required for IEV 
formation, which is regulated by its phospholipase activity; F13L contains variant HKD 
(His-Lys-Asp) motifs that are conserved in the phospholipase and phospholipid 
synthase families (Husain and Moss 2001; Husain and Moss 2002).
In vaccinia-infected cells, F13L localises to Golgi apparatus, IEV particles and to the 
luminal surface o f the outer EEV, where it is the most abundant component (Hiller and 
Weber 1985; Hirt et al. 1986). However, in AF13L-infected cells, the assembly of IEV 
particles and the release of EEV is severely impaired (Blasco et al. 1991; Blasco et al. 
1992; Borrego et al. 1999).
1.9.2.6 Summary of IEV-Vaccinia Virus Proteins Interactions
At the outset of this project, the following interactions between the IEV proteins had 
already been established: F13L and A56R; F13L and B5R; A33R and A33R; A33R and 
A36R; A33R and B5R; A34R and A36R; A34R and B5R; A36R and A36R; A36R and 
B5R (Figure 1.21; Table 1.6, green boxes) (Rottger et al. 1999; Wolffe et al. 2001; Oie 
and Ichihashi 1981). However, during the course of this research an additional 
interaction was elucidated: A36R and kinesin-1 (TPR) (Table 1.3, blue boxes). Other 
interactions between these IEV proteins are likely to exist and those that mediate the 
interaction of IMV and IEV with microtubules and IMV with the wrapping membranes 
remain to be elucidated (Smith et al. 2002).
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Table 1.6: Established interactions between IEV vaccinia virus proteins and kinesin-1. An
interaction is indicated by a tick, V, and no interaction by a cross, X. The interactions that were 
established at the initiation of this thesis are shown in green, while those interactions that were 
discovered during the course of this research are shown in blue.
1 = Ward and Moss 2004; 2 -  Oie and Ichihashi 1981; 3 = Payne 1992; 4 -  Rottger et al. 1999; 
5 = Ward et al. 2003; 6 = Smith et al. 2002.
Figure 1.21: Schematic representation of the established interactions between vaccinia 
virus IEV proteins. Direct interactions have been established between: F13L and A56R, F13L 
and B5R, A33R and A33R, A33R and A36R, A33R and B5R, A34R and A36R, A34R and B5R, 
B5R and A36R, [A36R and A36R].
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1.9.3 Cytoskeletal Transport of Vaccinia Virus
1.9.3.1 Microtubule-based Transport in Vaccinia Virus
It was originally thought that vaccinia virus used actin-based motility to promote the 
spread of its viral particles through the cytoplasm, from their site of assembly to the 
plasma membrane. However, vaccinia virus particles are able to reach the cell periphery 
in the absence o f actin-based motility, suggesting that the particles can also move on 
microtubules (Wolffe et al. 1997; Sanderson et al. 1998; Rottger et al. 1999). This was 
confirmed by subsequent analysis using video and confocal microscopy, which 
demonstrated that actin tail formation only takes place at the plasma membrane and that 
the viral spread through the cytoplasm is a microtubule-, kinesin-1 and A36R-dependent 
process (Hollinshead et al. 2001; Rietdorf et al. 2001; Ward and Moss 2001; Geada et 
al. 2 0 0 1 ).
Transport of vaccinia virus along microtubules usually occurs over long distances, at an 
average speed o f 60pm/min, and can even switch from one microtubule to another 
(Rietdorf et al. 2001). The motility of the faster-moving IEV particles are comparable to 
that observed with the microtubule-based motility of secretory vesicles during 
membrane trafficking (Lippincott-Schwartz et al. 2000; Geada et al. 2001). Rietdorf et 
al. also showed that virions in which A36R has been deleted from the genome (AA36R) 
are unable to egress to the cell surface and form CEV, which implicates this protein in 
both microtubule-mediated IEV movement and actin tail formation at the plasma 
membrane. However, Herrero-Martinez et al. have recently presented conflicting data 
claiming that IEV particles are able to move to the plasma membrane in the absence of 
the A36R protein (Herrero-Martinez et al. 2005). Further analysis by Rietdorf et al., 
using a mutation series determined that residues 71-100 of A36R are required for this 
movement on microtubules (Rietdorf et al. 2001). This region overlaps with that 
required for A36R to bind to the A33R protein (Ward et al. 2003). Moreover, in the 
absence of A33R, A36R does not reach IEV and localises exclusively to the Golgi 
membrane. However, in a AA36R background, A33R is still localised to IEV, thus it 
has been suggested that A33R guides A36R to the IEV membrane, which then travel to 
the plasma membrane along microtubules (Wolffe et al. 2001).
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The movement of IEV on microtubules was also shown to involve the TPR domain of 
the kinesin light chain, directly associating this microtubule motor with IEV transport. 
The recruitment of kinesin-1 to IEV, via the TPR, is reminiscent of that seen with APP, 
SYD and JIP, all o f which bind directly to the TPR domain of KLC (Goldstein 2001; 
Bowman et al. 2000; Verhey et al. 2001; Inomata et al. 2003). Immunofluorescence 
studies have also revealed that at low levels of GFP-KLC2-TPR expression, recruitment 
to IEVs was observed, together with inhibition o f IEV accumulation in the cell 
periphery. Furthermore, A36R-dependent recruitment of kinesin-1 and actin tail 
formation is mutually exclusive, as virus particles are never associated with both 
kinesin-1 and an actin tail (Rietdorf et al. 2001). Although the viral spread can be 
inhibited with the expression of dominant-negatives, it is not known how GFP-TPR 
inhibits at low expression levels. Surprisingly, even though GFP-TPR is recruited to the 
virus at low levels, this is not observed at high levels nor is the viral factory labelled.
Another IEV protein, F12L is also important for IEV movement and has also been 
implicated in interacting with microtubules, although the mode of interaction between 
F12L, IEVs and microtubules is not understood. In cells infected with the AF12L virus, 
IEV are made but fail to move away from the MTOC to the cell surface (Zhang et al. 
2000; van Eijl et al. 2002). No direct interaction has been demonstrated between F12L 
and microtubules but it may occur indirectly, i.e. via interactions with other proteins 
(Zhang et al. 2000; van Eijl et al. 2002). It is possible that F12L and A36R (together 
with other proteins) may be part of a viral protein complex that interacts with kinesin- 1 
(Herrero-Martinez et al. 2005; Ward and Moss 2004; Rietdorf et al. 2001; Newsome et 
al. 2004).
However, in March 2004, Ward et al. identified a direct interaction in vitro between 
kinesin light chain and A36R using yeast two-hybrid and GST pull-down assays (Ward 
et al. 2004). The binding site on A36R for kinesin-1 lies in the same region as that 
required for binding to A33R. The binding of A36R was shown to be mutually 
exclusive to either A33R or kinesin-1, suggesting that A33R competes with kinesin-1 
for binding to A36R. It was also demonstrated that there was no direct interaction 
between F12L and kinesin-1 by yeast two-hybrid (Ward and Moss 2004). How these 
proteins interact to form a complex and the molecular basis of how this complex
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recruits motor proteins in order to regulate the movement of IEVs to the cell periphery 
remains to be established. This phase of the life-cycle is the focus of my thesis.
1.9.3.2 Actin-based M otility of Vaccinia Virus
Upon the arrival of IEV particles at the cell surface, it is thought that the outer 
membrane of the IEV particle fuses with the plasma membrane to expose an enveloped 
virion on the cell surface, so-called cell-associated enveloped virus (CEV) (reviewed in 
Smith and Law 2004; Blasco et al. 1992). This process is reminiscent of that seen 
during the process of exocytosis of intracellular vesicles. Vaccinia virus then utilises 
actin-based motility to enhance its propulsion away from the host and facilitate its 
intercellular spread (Rietdorf et al. 2001). Actin polymerisation is restricted to beneath 
CEV particles and the average speed via actin tail movement is calculated at 
2 .8 pm/min, which is approximately twenty times slower than virion transport along 
microtubules (Cudmore et al. 1995). After the virion has fused with the plasma 
membrane, it is thought that CEV induce a localised outside-in signalling cascade that 
results in the activation of Src at the plasma membrane and the subsequent formation of 
an actin tail beneath these particles (Newsome et al. 2004). This mechanism therefore 
explains why actin tails are only formed at the plasma membrane. The signalling 
cascade is known to involve the SCR4 domain of B5R but how it is involved directly is 
currently unknown.
As a result of actin tail formation at the plasma membrane, CEV are released and are 
responsible for viral cell-to-cell spread, while extracellular enveloped virus (EEV) are 
also formed, spreading the infection over longer distances (Blasco and Moss 1991, 
1992; Payne 1980; Cudmore et al. 1995; Cudmore et al. 1996). It should also be 
emphasised that as EEVs are derived from IEVs, some of these proteins are present on 
the EEV membranes but with reverse topology (i.e. with the lumen now occurring on 
the outside). Vaccinia virus strains that are unable to form actin tails exhibit a small- 
plaque phenotype on confluent cell monolayers, suggesting that actin-based motility of 
the virus is required for efficient cell-to-cell spread (Sanderson et al. 1998; Wolffe et al. 
1997; Wolffe et al. 1998). Actin-based motility of vaccinia virus is dependent upon a 
signalling cascade involving Src-family and Abl-family kinases (Frischknecht et al. 
1999; Newsome et al. 2004; Reeves et al. 2005). When IEV particles fuse with the
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plasma membrane, the cytoplasmic domain of A36R remains exposed in the cytoplasm 
beneath CEV to the host-machinery required to nucleate an actin tail (Rietdorf et al.
2001). Actin tail formation proceeds in a manner analogous to signalling cascades that 
activate receptor-tyrosine kinases. It involves phosphorylation o f tyrosine 112 and 132 
of A36R, although T y rll2  plays the more important role (Frischknecht et al. 1999; 
Scaplehom et al. 2002). Recombinant viruses containing substitutions from Tyrl 12 and 
Tyrl32 to phenylalanine (Phe) residues demonstrated that while Tyrl 12 is essential, 
T yrl32 plays an auxiliary role to generate actin tails more efficiently (Scaplehom et al.
2002). However, when both tyrosine residues are mutated (referred to as YdF vims), 
actin tail formation is completely ablated, although Src is still activated (Frischknecht et 
al. 1999; Newsome et al. 2004). In addition, expression o f dominant negative kinase- 
dead Src in vaccinia virus-infected cells inhibits the phosphorylation of Y112 and actin 
tail formation (Frischknecht et al. 1999). This release o f CEV from the cell requires 
Abl- but not Src-family tyrosine kinases and can be blocked by an Abl-family kinase 
inhibitor (Gleevec; STI-571; Imatinib) that is used to treat chronic myelogenous 
leukaemia in humans (Reeves et al. 2005; Newsome et al. 2006; Baselga 2006).
The YdF vims exhibits a significant defect in cell-to-cell spread, as measured using 
plaque assay in confluent monolayers (Ward and Moss 2001). This deficiency has been 
attributed to the inability of this vims to form actin tails. However, although A36R-YdF 
plaques are significantly smaller than those formed by the WR vims, plaques formed by 
A36R-Y112F and A36R-Y132F vimses are intermediate in size (Dr. Niki Scaplehom, 
personal communication; Scaplehom et al. 2002). Therefore, in addition to actin tail 
formation being important for viral transmission, these plaque sizes suggest that sites 
Y112 and Y132 on A36R may also play important roles in cell-to-cell spread of the 
vims.
Src-mediated tyrosine phosphorylation o f A36R (Tyrl 12 and T y rl32) induces a cascade 
of events that results in the generation o f binding sites for the SH2 (Src homology 2) 
domains o f the adapter proteins Nek and Grb2, respectively (Frischknecht et al. 1999; 
Scaplehom et al. 2002). It has recently been determined that the recmitment of Src is 
dependent upon its myristoylation, as well as an interaction with A36R at a site 
immediately upstream of Y 112 and Y132 (Newsome et al. 2006). Furthermore, the Src-
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and Abl-family kinases have both been shown to support actin motility, while the Src- 
family kinases can also mediate the release of virions from microtubules (Newsome et 
al. 2004; Newsome et al. 2006; Reeves et al. 2005). Newsome et al. demonstrated that 
multiple Src-family kinases are able to induced actin polymerization by using cell lines 
deficient in the Src family kinases: Src, Fyn and Yes (Newsome et al. 2006). Src, Fyn 
and Yes all exhibit unique specificities towards Y112 and Y132 in in vitro 
phosphorylation assays, while the Abl-family kinases: Abl and Arg, which are also 
capable of phosphorylating A36R in vitro, are recruited to actin tails (Newsome et al. 
2006; Reeves et al. 2005). In addition, the Abl-family kinases are required for 
mediating the efficient release of infectious EEV, although it is currently unknown how 
they are involved (Reeves et al. 2005). The advantage of vaccinia virus utilising 
multiple kinases to directly phosphorylate A36R, is that it ensures that it the virus is 
disseminated efficiently, as it broadens the range of cells that are susceptible to 
infection.
Phosphorylated-A36R interacts directly with Nek (via Tyrl 12), which is recruited as 
part of a tripartite complex containing the WASP-interacting protein (WIP) and N- 
WASP (Frischknecht et al. 1999; Zettl and Way 2002; reviewed in Munter et al. 2006). 
The recruitment of Grb2 is dependent upon the proline rich domain of N-WASP, which 
increases the efficiency of actin tail formation and stabilises the complex. Therefore, the 
prior recruitment of N-WASP, by Nek, is required for the association o f Grb2, as well 
as phosphorylation of Tyrl 32 (Scaplehom et al. 2002). Using cells derived from knock­
out mice that are deficient in N-WASP (AN-WASP) and in which WIP and Nek are not 
detected on the vims, it was demonstrated that N-WASP is essential for actin tail 
formation. The direct interaction of N-WASP (via its WA domain) with the Arp2/3 
complex, triggers its activation and ultimately nucleates actin tails (Figure 1.22A) 
(Frischknecht et al. 1999a; Frischknecht et al. 1999b; Moreau et al. 2000; Zhang et al. 
2000; Snapper et al. 2001; Scaplehom et al. 2002; reviewed in Frischknecht and Way 
2001; reviewed in Munter et al. 2006).
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Figure 1.22: Schematic models of proteins involved in vaccinia virus, Listeria, Shigella 
and EPEC actin based motility. Listeria is capable of directly recruiting and activating the 
Arp2/3 complex, whereas vaccinia virus, Shigella and EPEC achieve Arp2/3 activation by 
recruiting N-WASP indirectly via intermediate binding partners. (A) Phosphorylated (P) A36R of 
vaccinia recruits N-WASP indirectly via Nek, Grb2 and WIP. N-WASP activates the Arp2/3 
complex locally on the viral surface. (B) Shigella achieves N-WASP recruitment through direct 
interaction of the glycine-rich repeats o f IcsA with N- WASP. (C) Listeria uses ActA to directly 
recruit and activate the Arp2/3 complex. (D) EPEC surface protein Tir needs to be 
phosphorylated on Tyr474 in order to directly recruit Nek. EPEC pedestal formation is 
dependent on N-WASP and it was hypothesised that the Rho GTPase Chp is recruits N-WASP 
to EPEC. Possible interactions are indicated by '?'. Arrows or overlapping proteins indicate 
where interactions have been demonstrated experimentally. Abbreviations for domains in the 
respective proteins as follows: PolyPro, proline-rich regions; ABS, actin-binding sequence; A, 
acidic region; V, verprolin homology; C, connecting region; WH1, Wiskott-Aldrich homology I 
domain; CRIB, Cd42/Rac interactive binding motif; WBD, WASP-binding domain; SH2, 
phosphotyrosine-binding Src-homology 2 domain; SH3, polyproline-binding Src-homology 3 
domain. (Figures adapted from Frischknecht and Way 2001 and Hayward et al. 2006).
97
Chapter 1_____
A
B
C
c-Src
c-Fyn
c-Yes
c-Abl
c-Arg
Y112 Y132 A36R
Grb2
SH2
WIP
N-WASP
Cdc42
SH3SH3
VVBD NBD E U H S I B
WHI VCA_ |
Arp2/3
Complex
•2
&
•2»
-c
CO
Glycine rich repeats"!,csA
lCCdc42]
N-WASP
WIP 
NcK
w h i 2 3 5 2 3  v  c a
WBD NBD ggO TshfrlW
Arp2/3 
Complex
1 /  ^
SH2]SH3SH3SH3
ActA
N-temn
C-AblIntimin
Y474
Z E H 2 3  r v c a
Actin' /
N-WASP
Arp2/3
Complex
Introduction
98
Chapter I Introduction
Vaccinia virus actin tails are reminiscent of those produced by several other pathogens, 
including the intracellular bacteria Shigella flexneri and Listeria monocytogenes; both 
of which can to induce actin tails to propel them through the cytoplasm (reviewed in 
Cossart 2000; Kocks et al. 1992; Welch et al. 1998; reviewed in Pizarro-Cerda and 
Cossart 2006a, 2006b; Frischknecht and Way 2001). It is known that the signalling 
cascade responsible for the formation of actin tails is dependent upon the surface 
proteins IscA and IscA respectively, for Shigella and Listeria (Figure 1.22B+C 
respectively) (Bemardini et al. 1989; Kocks et al. 1992). In addition, the RickA protein 
of Rickettsia conorii has also been reported to activate the Arp2/3 complex (Gouin et al. 
2004). In contrast to the fore-mentioned pathogens, enteropathogenic E.coli (EPEC) 
induces actin polymerisation from outside o f the cell that it has adhered to. Actin 
polymerisation is subsequently stimulated at the plasma membrane beneath its site of 
attachment, forming a structure referred to as a ‘pedestal’ (Campellone and Leong
2003). The formation of these pedestals is dependent upon the surface protein, intimin 
and the translocated intimin receptor (Tir) (Kenny 1999) (Figure 1.22D) (reviewed in 
Hayward et al. 2006).
As a consequence of vaccinia virus actin tail formation, the CEV is released and either 
driven towards adjacent cells or into the extracellular space as EEV. This final stage 
completes the viral life-cycle and prepares the virus for the re-infection of neighbouring 
(CEV) and distant cells (EEV) (see Figure 1.16).
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1.10 Aims and Objectives
Both the actin and microtubule cytoskeletons play vital roles in the vaccinia virus life­
cycle. During cytoskeletal transport, microtubules are considered to be of utmost 
importance in facilitating the spread of infection. Whilst the key vaccinia virus proteins 
involved in microtubule-based transport of IEV particles have been identified, their 
exact mechanistic relationship to each other and to kinesin- 1  is yet to be fully 
established (Figures 1.23 and 1.24). The molecular basis of kinesin-1 recruitment is also 
still unknown. Therefore, the overall objective and aims of the research described 
within this thesis were:
• To identify the relationships between the vaccinia virus proteins F12L,
A36R, A33R and kinesin-1 during microtubule-based transport.
To determine whether phosphorylation of A33 R plays a role in viral transport.
- To elucidate the involvement of F12L in viral egress.
- To investigate the mechanisms underlying the recruitment of kinesin-1 to IEV
particles.
To investigate whether myosin Va plays a role in viral egress.
P lasm a m em brane
A36R
F12L
Figure 1.23: Depiction of an IEV particle, illustrating the known binding relationships 
between the viral proteins F12L, A33R, A36R and kinesin-1. Direct interactions occur (i) 
between the cytoplasmic domain of A33R and amino acids 91-111 of A36R and (ii) between 
kinesin-1 and amino acids 81-111 of A36R. The interaction partners of F12L are currently 
unknown.
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Figure 1.24: Schematic representations of the vaccinia virus proteins F12L, A33R and 
A36R. (A) F12L is a 635 amino acid protein. Two putative myristoylation sites are indicated (*). 
(B) A33R is a 558 amino acid protein. (C) A36R is a 221 amino acid protein. The N and C- 
terminals are shown and regions of known interest have been labelled. Key: TM =  
transmembrane domain; OPV =  orthopoxviruses. (Adapted from Smith et al. 2003; not to scale).
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MATERIALS AND METHODS
102
Chapter 2 M aterials and Methods
2.1 Buffers and Solutions
All of the laboratory chemicals and reagents described in this chapter were o f analytical 
grade and purchased from Sigma-AIdrich (Dorset, UK), unless otherwise stated. The 
details o f additional suppliers and distributors are provided in Section 2.13.
The in-house Cancer Research UK Central Services supplied a variety of general 
materials and solutions, as well as autoclaved glassware and pipettes. These solutions 
are listed below together with their recipes. In addition, solutions that were used for 
molecular biology techniques are outlined in Section 2.4.1 and any buffers that were 
used specifically for one method are described in the relevant section. All of the buffers 
and solutions were prepared using deionised water, purified by a NANOpure 
Diamond™ reverse osmosis system (Triple Red Ltd).
2.1.1 General Buffers 
Phosphate Buffered Saline A (PBSA)
8 g Sodium chloride, NaCl
0.25g Potassium chloride, KC1
l.43g Sodium phosphate dibasic, Na2 HPC>4
0.25g Potassium phosphate monobasic, KH2PO4, pH 7.2
The reagents were dissolved in I litre o f  distilled water and the p H  was adjusted to pH
7.2 before the solution was autoclaved.
Tris/EDTA (TE) Buffer. p H 8.0
1.21g Trizma Base 
0.37g EDTA (pH 8.0)
The reagents were dissolved in I litre o f  distilled water and the p H  was adjusted to pH
8.0 with hydrochloric acid (HCl).
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2.1.2 Cell Culture Media
M aterials and Methods
Trypsin Solution ; 0.25% in Tris Saline 
Tris Saline (TS)
8 g NaCl
2 ml 19% (w/v) KC1 solution
O.lg Na2H2P 0 4
lg D-Glucose
3g Trizma Base
1.5ml 1% (w/v) Phenol red solution
0.06g Penicillin
O.lg Streptomycin
The Tris Saline reagents were dissolved in 200ml o f  distilled water and the pH  was 
adjusted to pH  7.7 with HCl. To this solution 0.06g penicillin and O.lg streptomycin 
was added.
Trypsin
2.5g Trypsin (Difco 1:250) was dissolved in 200ml o f  distilled water, assisted by 
bubbling air through the solution and the p H  was adjusted to p H  7.7 using HCl. The 
200ml containing the dissolved trypsin was mixed with 200ml o f  Tris Saline solution 
and the fina l volume was made up to I litre with distilled water. The solution was then 
sterilised by filtration using a 0.22 pm filter (Millipore) and stored at -20°C.
Versene Solution
8 g NaCl 
0.2g KC1 
I.15g Na2H P04 
0.2g KH2P 0 4 , pH 7.2
0.2g Ethyldiaminotetraacetic acid disodium (EDTA) salt 
1.5ml 1% (w/v) Phenol red solution
The reagents were dissolved in I litre o f  distilled water and the p H  was adjusted to pH
7.2 before the solution was autoclaved. The media was stored at room temperature.
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Glutamine Solution
A stock solution (0.24M) was prepared by dissolving 35.05g o f  L-Glutamine in I litre o f  
distilled water, at 37°C. The solution was sterilised by fdtration using a 0.22pm filter  
and stored at -20°C. For use, the solution was diluted I in 60 times in the appropriate 
medium (making the fina l concentration 4mM).
Minimal Essential M edium (MEM)
9.68g MEM powder
3.7g Sodium bicarbonate (NaHCC^)
0.06g Penicillin 
O.lg Streptomycin
The reagents were dissolved in 10 litres o f  distilled water and the pH  was adjusted to 
pH  7.0 with carbon dioxide (CO2). (N.B: The M EM  powder used in the above
formulation is supplied by ICNFlow Cat.#10-I21-24).
2.1.3 Bacteriological Media
Luria-Bertani (LB) Medium
lOg Bacto-tryptone 
5g Bacto-yeast extract 
lOg NaCl
The reagents were dissolved in I litre o f  distilled water and the pH  was adjusted to p H
7.0 using NaOH, before the solution was autoclaved.
LB Agar
I5g o f  Bacto-agar were dissolved in I litre o f  LB medium, before the solution was 
autoclaved.
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2.2 Cell culture
2.2.1 Materials and Solutions
All tissue culture media and solutions were supplied by the in-house Cancer Research 
UK Cell Services, as described in Section 2.1, with the exception o f those listed below.
D ulbecco’s MEM tDM EM )
D M EM  containing lOOOg/l glucose was purchasedfrom Sigma (Cat. HD5546). 
DMEM was supplemented with glutamine.
Foetal Calf Serum (FCS)
Purchasedfrom PAA Laboratories (Cat. HA 15-041).
Penicillin G Sodium
100 units/ml.
lOOjug/ml streptomycin sulphate, from  a lOOx stock (Invitrogen, Cat. H15140-122).
2.2.2 General Cell Culture Conditions and M aintenance
HeLa cells (obtained from Dr. Sally Cudmore - EMBL, Heidelberg, Germany) were 
grown and maintained in minimal essential medium (MEM), supplemented with 
I0%(v/v) foetal calf serum (FCS), I00pg/ml penicillin, 100p.g/ml streptomycin and 
2mM L-glutamine. In this chapter, this composition is referred to as ‘complete 
medium’, while ‘serum-free medium’ refers to the same medium without the addition of 
FCS. The cells were grown as monolayers at 37°C, in humidified air containing 5% 
CO2 and were passaged every 2-3 days or when the cells were 60-80% confluent; cells 
were not usually allowed to grow until 100% confluency. Once the cells reached 
approximately 40 passages, or looked unhealthy, new stocks were thawed from liquid 
nitrogen.
When the cells were -80%  confluent, they were washed once in pre-warmed PBS 
(37°C) and incubated with a 1:4 trypsin:versene mix for approximately 2 minutes to 
detach the cells. The resuspended cells were then diluted with complete medium to 
inactivate the trypsin and the cells were seeded into new flasks or dishes at the 
appropriate densities.
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For immunofluorescence analysis, cells were seeded onto 11 mm round, untreated, 
autoclaved coverslips and grown to 60-70% confluency. For biochemical analysis by 
western blotting, cells were grown to - 1 0 0 % confluency to ensure that there were 
enough surviving cells after infection with vaccinia virus (see Section 2.3.2).
2.2.3 Cell Storage and Recovery
To generate frozen stocks of cells, a 10cm diameter tissue culture dish containing cells 
at -70%  confluency were trypsinised and collected by centrifugation at 250rcf (relative 
centrifugal force) for 5 min at 4°C. The medium was then aspirated and the pellet was 
resuspended in 1ml freezing mix before being aliquoted into a cryovial and stored at -  
80°C for 24 hours. The cells were subsequently transferred to liquid nitrogen.
Frozen aliquots of cells were thawed by dilution (1 in 10) in complete medium and 
collected by centrifugation at 250rcf for 5min at 4°C. The medium was then aspirated to 
remove residual dimethyl sulfoxide (DMSO) and the cells were resuspended in 
complete medium before seeding them into new dishes (one vial per lOcm-diameter 
dish).
Freezing Mix
10% Dimethyl sulfoxide (DMSO)
90% FCS (Heat-inactivated at 55 °C fo r  30 min and allowed to cool to R T  before use) 
The mixture was sterilised by filtration using a 50ml Steriflip filte r  (Millipore).
2.2.4 Transfection
Three different transfection methods were employed during my studies, depending on 
the assay being performed.
2.2.4.1 Calcium Phosphate-based Transfection
Uninfected cells were transfected with the CMV-based expression vectors (CB6 , 
Section 2.4.2) using a calcium phosphate-based method, in order to express proteins in 
FleLa cells, prior to infection with vaccinia virus. The reaction volumes o f the required 
transfection reagents used are shown in Table 2.1. For example, to transfect a 3.5 cm 
well, cells were passaged on the day o f transfection and allowed to adhere for at least 4
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hours. 1 jag plasmid DNA was incubated in 50pl 0.25M CaCl2 for 20 min at room 
temperature, before it was added, drop-wise, to 50pl HBS. Following incubation for a 
further 10-15 min at room temperature, the transfection mixture was added to 1.5 ml 
complete medium that was covering the cells and the cells were left to grow at 37°C, 
5 % C 0 2. 12-24 hours post-transfection, the cells were washed twice with phosphate 
buffered saline (PBS), and cells were allowed to recover in complete medium until 
required (between 2 and 4 hours). For infection experiments, transfected cells were 
infected 2-4 hours post recovery with vaccinia virus (see Section 2.3.2).
Table 2.1: Calcium phosphate-based transfection method. Reaction volumes of DNA, 
CaCI2, HBS and medium required for transfection of different sized cell culture dishes.________
Dish size Concentration 
of DNA
Volume of 
distilled water
Volume of 
10xCaCI2
Volume of HBS that 
DNA-CaCI2 mixture is 
added to
3.5 cm 1 44 nl 5 ul 50 ul
6 cm 2ug 133 ul 15 ul 150 ul
10 cm 5ug 445 ul 50 ul 500 ul
HBS
280mM NaCl 
lOmM KCl 
l.5mM Na2H P 0 4 
12mM Glucose
50mM HEPES (Gibco), pH 7.05
2.2.4.2 Lipofectin-based Transfection
The Lipofectin-based method was employed to transfect vaccinia virus-infected cells, 
using the pE/L vector system (Section 2.4.2) when the cells were approximately 70% 
confluent. As vaccinia virus encodes for its’ own transcription machinery and replicates 
in the cytoplasm, the pE/L vector DNA does not have to enter the nucleus and is 
efficiently transcribed in the cytoplasm of the cell. The reaction volumes of the 
required transfection reagents used are shown in Table 2.2. For example, for a 3.5 cm 
dish, l OjlxI lipofectin was diluted in 450pl serum-free medium and incubated for 40 min, 
at room temperature (RT). In parallel, 4pg plasmid DNA was also diluted in 450pl 
serum-free medium. The DNA- and lipofectin-containing solutions were then mixed 
together and incubated for a further 15 min, at RT. This solution was then added to the
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PBSA-washed, vaccinia-infected cells. The duration of transfection was selected 
according to the level of expression required. Typically, to evaluate the localisation of 
GFP-tagged proteins and to rescue actin-tail formation, cells were transfected 4 hours 
post infection (hpi) and subsequently fixed 4 hours later ( 8  hpi) before being processed 
by immunofluorescence analysis.
Table 2.2: Lipofectin-based transfection method. Reaction volumes of DNA, Lipofectin and 
medium required for transfection of different sized cell culture dishes. ____________________
Dish size 
(diameter)
Concentration 
of DNA
Volume of 
transfection medium 
added to DNA
Volume of 
Lipofectin
Volume of 
transfection medium 
added to Lipofectin
3.5 cm 4 M9 450 |il 10 ul 450 ul
6 cm 8 u9 750 ul 20 ul 750 ul
10 cm 20 ug 1.5 ml 50 ul 1.5 ml
2.2.4.3 Effectene-based Transfection
The Effectene-based method was also used to transfect vaccinia virus-infected cells 
using the pE/L vector system (Section 2.4.2) but was employed for experiments that 
were performed on a large scale, i.e. in 1 0 cm or 15cm diameter dishes (e.g. for 
immunoprecipitation experiments, see Section 2.7.4). The Effectene transfection 
reagent is a unique non-liposomal lipid formulation capable of achieving high 
transfection efficiencies quickly and efficiently, with the advantage o f  requiring 
significantly less DNA than alternative methods. The reaction volumes o f the required 
transfection reagents are shown in Table 2.3. For example, to transfect a 15cm dish, 
4.5pg DNA was diluted with Buffer EC (to a total volume o f 675pl) before 36pl 
Enhancer was added. The mixture was then vortexed for I sec, incubated at RT for 2- 
5min and then spun down in a table-top microfiige. I35pl Effectene was then added to 
the mixture, pipetted up and down 5 times and incubated at RT for a further 5-10 min. 
While the complex was forming the cells were washed in PBS and replaced with 
15.75ml complete medium. 6.75ml of complete medium was then added to the tube 
containing the transfection complex, mixed by pipetting and immediately added, drop- 
wise, to the dishes.
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Table 2.3: Effectene-based transfection method. Reaction volumes of DNA, Effectene and 
medium required for transfection of different sized cell culture dishes.___________ __________
Dish size 
(diameter)
Concentration 
of DNA
Enhancer Final 
volume of 
DNA in 
Buffer EC
Volume of 
Effectene 
reagent
Volume of 
medium 
added to 
cells
Volume of 
medium to 
add to 
complexes
10 cm 2 U9 16 ul 300 ul 60 ul 7 ml 3 ml
15 cm 4.5 u9 36 ul 750 ul 135 ul 15.75 ml 6.75 ml
2.3 Vaccinia Virus
2.3.1 Viruses
The wild type vaccinia virus strain used in this study is the Western Reserve strain 
(referred to as WR) and all o f the viruses used in this thesis are detailed below in Table
2.4.
Table 2.4: Vaccinia virus strains used in this thesis. (With the exception of the WR and
A36R-YdF virus strains, these were generous gifts from the named researchers).____________
Vaccinia virus 
strain
Source Reference
WR
A36R-YdF Generated by Anna Holmstrdm. Rietdorf et al. 2001
AF12L Prof. Geoffrey Smith, Imperial College, 
London
Zhang et al. 2000
AA36R Prof. Geoffrey Smith, Imperial College, 
London
Parkinson and Smith 1994
AA33R Bernard Moss, NIH, Bethesda, USA Roper et al. 1998
AB5R Geoffrey Smith, Imperial College, London Engelstad and Smith 1993
AA34R Geoffrey Smith, Imperial College, London McIntosh and Smith 1996 
Wollfe etal. 1997
vRB12 (F13L) Rafael Blasco, Madrid, Spain. Blasco and Moss 1991
2.3.2 Infection
Cells were seeded in complete medium, at least 12 hours before infection. Prior to 
infection, lOOpl aliquots of post-nuclear supernatant (see Section 2.3.3) were incubated 
with lOpl 2.5mg/ml trypsin solution and 90pl PBS A for 25min at 37 °C, to reduce viral 
aggregation. The viral aliquots were then made up to 1ml with serum free medium and 
frozen at -20°C. It was possible to freeze-thaw the virus repeatedly without noticeable 
effects on infectivity. Prior to infection, cells were washed once in PBS A. For a 3.5 cm 
dish at -70%  confluency, 1ml serum free medium was mixed with 8.4 x 105 infectious 
units o f trypsinised virus and added to the washed cells, to give a multiplicity of 
infection (MOI) of 1. (A MOI of I is defined as the viral dose required to infect 100% 
of the cells available). The infections were incubated at 37°C for 1 hour before the 
media was removed by aspiration, and replaced with complete medium for as long as
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was required. The infections proceeded for 8  hours before fixation or lysis, unless 
otherwise stated (see Sections 2.5.1 and 2.6, respectively).
2.3.3 Virus Stock Preparation
Viral stocks were prepared from 10-20 175cm Falcon flasks (Becton Dickinson) 
containing HeLa cells grown to -80%  for the day of infection. The flasks were infected 
with seed virus (see below) at a MOI o f 0.05 in 5ml serum free medium per flask and 
incubated for 1 hour at 37°C. The flasks were agitated regularly to redistribute the virus. 
Each flask was supplemented with 20ml of a complete : serum free medium mix, to 
give a final serum concentration of 5%. The infections were allowed to proceed for 3-5 
days before being harvested.
To obtain seed virus, one of the flasks was scraped in the infection medium and 
transferred to a 50ml Falcon tube. The infected cells were pelleted by centrifugation at 
250rcf for 5min at 4°C and the medium was subsequently aspirated, leaving 1-2 ml in 
the tube. The infected cells were then resuspended in this medium by trituration and 
transferred in 500(l i 1 aliquots to screw-cap eppendorfs, before performing three freeze- 
thaw cycles between -80°C and 37°C. The seed virus was stored at -80°C and used to 
generate new stocks.
To obtain post-nuclear supernatant (PNS), medium from the remaining flasks was 
removed by aspiration. The cells were then scraped in 10ml PBS A per flask and 
pelleted by centrifugation at 250rcf for 5 min at 4°C. The supernatant was aspirated and 
the cell pellet was resuspended in 1.5 - 3ml ice-cold virus buffer. The suspension was 
then triturated ten times using a 21/22 gauge needle (Becton Dickingson) and the nuclei 
and membranes were pelleted by centrifugation at 2500rcf for 5 min at 4°C. The 
supernatant was retained and the pellet was resuspended in 1 - 2  ml ice-cold virus buffer 
by mild trituration using a P I000 Gilson pipette. The suspension was then re-pelleted by 
centrifugation at 2500rcf for 5 min at 4°C. The supernatant was combined with that of 
the previous step, mixed and divided into lOOpl aliquots, which were stored at -80°C.
2.3.4 Titring Virus Stocks
To determine the viral titre, HeLa cells were infected with a range o f virus volumes and 
the infection was analysed after 8  hours by immunofluorescence. The samples were
111
Chapter 2 M aterials and Methods
stained, examined and quantified for viral DNA, late viral protein synthesis (using the 
viral protein A27L as a marker), and actin tails, where appropriate. The viral titres are 
measured in plaque-forming units per ml (pfii/ml), even though the titrations were not 
calculated using a plaque assay (on the basis that 1 pfu is sufficient to infect an 
individual cell). All o f the experiments, unless otherwise stated, were performed by the 
addition o f MOI 1-2 of virus to ensure complete infection.
Virus Buffer
lOmM Tris.HCl, pH 9.0 
lOmM KC1
3mM Magnesium acetate
N.B: The buffer was used ice-cold and was sterilised by filtration using a 0.22 pm filter.
2.4 M olecular Biology
2.4.1 M aterials and Solutions
Standard molecular biology procedures were performed as described in (Sambrook 
1989), including polymerase chain reactions (PCR), restriction enzyme digestion, 
ligation reactions and agarose gel electrophoresis, and are briefly described in this next 
section. The list o f solutions supplied by Cancer Research UK is described in Section 
2.1. Additional materials and solutions that were used to perform molecular biology 
techniques are listed below and any buffers that were used specifically for one method 
are described in the relevant section.
50x Tris-borate (TBE) Buffer
10.8g Trizm aBase 
5.48g Boric Acid 
0.93g EDTA
The reagents were dissolved in 1 litre with distilled water and the p H  was adjusted to 
pH  8.0.
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Ethidium Bromide
The stock solution was made to lOmg/ml and was used at 0.5jug/ml.
lOx DNA Loading Buffer
0.25%(w/v) Bromophenol Blue 
30%(v/v) Glycerol
lOx dNTPs (Amersham Pharmacia Biotech)
2mM dATP 
2mM dCTP 
2mM dGTP 
2mM dTTP
2.4.2 DNA Constructs
The plasmid DNA constructs that have been used in this thesis are listed below in 
Tables 2.5, 2.6 and 2.7, together with details on how the new plasmids were 
constructed. In general, the vectors described in this thesis belong to three categories:
• The CB6  vector contains a CMV promoter that is able to drive protein 
expression in tissue culture cells (Reckmann et al. 1997).
• The pE/L vector contains a constitutive early/late poxviral promotor that is able 
to drive protein expression in vaccinia virus infected cells (Frischknecht et al. 
1999).
• The pMW172 vector is a gene transcription, T7-based expression vector used to 
express proteins in E.coli (Way et al. 1990).
Each vector is available with several different affinity tags, including green fluorescent 
protein (GFP), 6 -Histidine (His), glutathione-S-transferase (GST), haemagluttinin (HA), 
vesicular stomatitis virus glycoprotein (VSVG) and ZIP (see Section 2.7.3), at either the 
5’ or 3’ end o f the insert. In all cases, a Not I site separates the tag from the insert and 
all new constructs were verified by sequencing.
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New constructs were generated by either subcloning DNA fragments that already 
existed and had been confirmed by sequencing, or by amplifying new sequences via 
PCR. In the majority of cases, subcloning was performed using Notl and EcoRl 
enzymes to release the insert from the vector. For example, constructs with N-terminal 
tags were cloned into an in-frame Notl restriction site downstream  o f the tag, whereas 
for C-terminally tagged constructs, inserts were cloned into Notl site upstream o f tag. 
There are no internal Notl or EcoRl sites within any of the clones used in this thesis.
Table 2.5 : pMW E.coli expression constructs used in this thesis.
Construct Cloning sites Source
5’site 3’site
HIS-F12L Notl EcoRl This Thesis
HIS-GFP-F12L Notl EcoRl This Thesis
GST-F12L Notl EcoRl This Thesis
HIS-G F P-cy to A36 R Notl EcoRl MW
HIS-cytoA36R Notl EcoRl MW
HIS-GFP-A36R63-100 Notl EcoRl MW
HIS-TPR Notl EcoRl MW
GST-TPR Notl EcoRl MW
Table 2.6: pE/L DNA constructs used in this thesis
Construct Cloning sites Primers used 
(see Tables 2.8 + 2.9)
Source
5’site 3’site
VSVG-A33R Notl EcoRl - SR
GFP-A33R Notl EcoRl - SR
VSVG-A33R S12A Notl EcoRl A33R-3 + A33R-4 This Thesis
VSVG-A33R S15A Notl EcoRl A33R-5 + A33R-6 This Thesis
VSVG-A33R S12+15A Notl EcoRl A33R-7 + A33R-8 This Thesis
GFP-A33R S12A Notl EcoRl A33R-3 + A33R-4 This Thesis
GFP-A33R S15A Notl EcoRl A33R-5 + A33R-6 This Thesis
GFP-A33R-S12+15A Notl EcoRl A33R-7 + A33R-8 This Thesis
VSVG-A33R-S12+15D Notl EcoRl A33R-9 +A33R-10 This Thesis
N-GFP - - - MW
GFP-F12L Notl EcoRl F12L-1 + F12L-2 This Thesis
F12L-GFP Bgl II Notl F12L-3 + F12L-4 This Thesis
GFP-F12L (0-470) Notl EcoRl F12L-1 + F12L-7 This Thesis
GFP-F12L (0-216) Notl EcoRl F12L-1 + F12L-6 This Thesis
GFP-F12L (217-635) Notl EcoRl F12L-5 + F12L-2 This Thesis
GFP-F12L (471-635) Notl EcoRl F12L-8 + F12L-2 This Thesis
GFP-F12L (217-470) Notl EcoRl F12L-5 + F12L-7 This Thesis
F12L-G124A EcoRl Notl F12L-21 + F12L-22 This Thesis
F12L-G546A EcoRl Notl F12L-23 + F12L-24 This Thesis
F12L-G124+546A EcoRl Notl (F12L-21 + F12L-22) 
&(F12L-23 + F12L-24)
This Thesis
HIS-F12L Notl EcoRl - This Thesis
HA-F12L Notl EcoRl - This Thesis
ZIP-F12L Notl EcoRl - This Thesis
F12L-ZIP EcoRl Notl - This Thesis
Table 2.6 - Continued: pE/L DNA constructs used in this thesis
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Construct Cloning sites Primers used 
(see Tables 2.8 + 2.9)
Source
5’site 3’site
GST-F12L Notl EcoRl - This Thesis
F12L-YFP EcoRl Notl - This Thesis
HA-TPR Notl EcoRl - MW
HIS-TPR Notl EcoRl - MW
ZIP-TPR Notl EcoRl - This Thesis
GFP-TPR Notl EcoRl - MW
GST-TPR Notl EcoRl - MW
A36R-HIS EcoRl Notl - MW
A36R-GFP EcoRl Notl - MW
F13L-GFP EcoRl Notl - FF
HIS-NCK Notl EcoRl - FF
GFP-NCK Notl EcoRl - FF
ZIP-NCK Notl EcoRl - NS
A3L-GFP EcoRl Not - RA
GFP-LC8/DLC1 Notl EcoRl - WS
GFP-LC8/DLC2 Notl EcoRl - WS
Table 2.7: CB6 DNA constructs used in this thesis
Construct Cloning sites Primers used Source
5’site 3’site (see Table 2.8)
GFP-F12L Notl EcoRl F12L-1 + F12L-2 This Thesis
F12L-GFP EcoRl Notl F12L-3 + F12L-4 This Thesis
pCMV-myc dynamitin/p50 EcoRl Notl - TS
PEGFP-LC8/DLC1 EcoRl Notl - WS
Note: SR=Sabine Rottqer. MW=Michael Nay; FF = Freddy Frischknecht; NS=Niki Scaplehorn;
RA-Ruta Almedom, TS= Trina Schroer; WS=Walter Steffan.
2.4.3 Plasmid DNA Preparation
A single colony was picked and grown overnight at 37°C in 5ml LB containing the 
correct selective antibiotic. From this overnight culture, the bacteria were pelleted in a 
Beckman Coulter centrifuge (J6-M1) at 3000rpm for lOmin at 4°C before being 
processed using a Qiagen biorobot 8000 or the QIAprep Spin Miniprep Kit (Qiagen), 
according to the manufacturer’s instructions. For larger-scale DNA purifications, the 
5ml pre-culture was added to 100ml LB with antibiotic and grown overnight at 37°C 
prior to processing with the QIAfilter Plasmid Midi Kit (Qiagen).
The DNA concentration and purity was assessed using an Ultraspec 3100 pro 
UV/visible spectrophotometer (Amersham Pharmacia Biotech), which measures the 
optical density (O D ) at 260nm. An O D 26o of 1 equals a DNA concentration of 50pg/ml 
and a ratio o f O D 26o/OD28, which measures the DNA versus the protein concentration, 
that equals 1.8 was considered to be acceptable DNA quality. Alternatively, DNA
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concentration was measured using the Nanodrop® ND-1000 spectrophotometer v3.1.0 
(Nanodrop® Technologies).
2.4.4 Construction of DNA Plasmids - Subcloning
2.4.4.1 Restriction Enzyme Digestion and Agarose Gel Electrophoresis
DNA (l-5pg) was digested in 50pl reactions or lOpl reactions for PCR-colony screens, 
(see Section 2.4.7.1) containing an excess of restriction enzyme (all purchased from 
New England Biolabs), together with the appropriate enzyme buffer and BSA if 
recommended, supplied by the manufacturer. The digests, or PCR products, were 
separated on a 0.8 - 1.5% agarose gel. The gel was made by mixing ultra pure agarose 
(Invitrogen) with lx  TBE buffer, microwaving it at high power for ~2 minutes until the 
agarose dissolved and then adding ethidium bromide (5 pi/100ml). The gel was cast into 
a mould assembled within the gel tank apparatus (with appropriate combs; Cambridge 
Electrophoresis Ltd) and allowed to set. When ready, the samples were mixed with 5 pi 
DNA loading buffer prior to loading them into the gel. The DNA was electrophoresed 
at 120V/120mA/12W. A I kb DNA ladder (Invitrogen) was run alongside the samples to 
determine the fragment size. The DNA bands were visualised under UV light and 
photographed using the Genestore System (Syngene).
2.4.4.2 Purification of DNA from Agarose
The bands were excised and purified using a Qiagen QIAquick® Gel Extraction kit, 
following the manufacturer’s instructions. Briefly, the gel slice containing the fragment 
of interest was solubilised and applied to the reservoir of a silica-gel membrane column. 
During centrifugation, the DNA becomes attached to the silica membrane whilst 
agarose and other impurities pass through the column. The bound DNA was eluted in 
30pl distilled water and vacuum dried in a DNA Speed Vac® 110 (Savant Instruments 
Inc.). The DNA was then resuspended in an appropriate volume o f TE buffer.
2.4.4.3 Ligation
Ligation reactions were set up between digested vector DNA (l00-500ng) and an excess 
of purified insert DNA in a lOpl reaction volume, using 200 units T4 DNA ligase (New 
England Biolabs). The reaction was incubated for at least 30 min at room temperature. 
5 pi of the ligation reaction was used to transform chemically competent E. coli and the
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resulting colonies were then screened by polymerase chain reaction (PCR, see Section 
2.4.7.1).
2.4.5 Preparation o f Chemically Com petent Cells
Chemically competent E.coli (strains DH5a, XL 10 or BL21(DE3); Stratagene) were 
prepared in the following way. 500 ml Luria-Bertani (LB) medium was inoculated with 
2 ml of an over-night culture of bacteria, and incubated with shaking at 37°C until the 
OD600 reached 0.5. The culture was then incubated on ice for 30 min and centrifuged in 
a Beckman Coulter centrifuge (J6-M1) at 2500rpm for I2min, at 4C. The resulting 
pellet was resuspended in 20ml RF1 buffer and incubated on ice for a further 15min. 
Finally, the suspension was centrifuged at 2500rpm for 9min at 4°C, before the pellet 
was resuspended in 7ml buffer RF2. Aliquots o f competent bacteria were then stored at 
-80°C.
RF1 Buffer
12g Rubidium chloride. RbCl 
9g Manganese chloride, MnCh
2.94g Potassium acetate 
150g Glycerol, pH 5.8
The reagents were dissolved in 900ml o f  distilled water and the p H  was adjusted to 
pH5.8 with acetic acid, before the volume was made up to 1 litre. The buffer was 
subsequently filtered  through a 0.22 pm filter and stored at 4°C.
RF2 Buffer
2.09g MOPS 
l.2g RbCl
1 lg Calcium chloride, CaCb
I50g Glycerol, pH 6.8
The reagents were dissolved in 900ml o f  distilled water and the pH  was adjusted to pH  
6.8 with sodium hydroxide, before the volume was made up to o I litre. The buffer was 
subsequently filtered  through a 0.22pm filter and stored at 4°C.
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2.4.6 Transformation o f E.coli
Chemically competent E.coli (prepared as described in 2.4.5) were thawed on ice in 
50pl aliquots and incubated with plasmid DNA (either 5pl of a ligation reaction or 50ng 
of plasmid DNA) for 5-10 min on ice. The cells were then plated onto an LB-agar 
plates containing selective antibiotic, which had been preheated to 42°C. All o f the 
plasmids described in this thesis confer ampicillin resistance, except for pEGFP- 
LC8/DLC1 and pCMV-myc-dynamitin/p50, which confer kanamycin resistance. 
Ampicillin and kanamycin were used at final concentrations of lOOpg/ml and 30pg/ml 
respectively.
2.4.7 Polymerase Chain Reaction
Polymerase chain reaction (PCR) was used to amplify cDNA for subcloning and also 
for the production o f mutant constructs, by site-directed mutagenesis. Primers were 
designed to incorporate the desired region of the gene sequence, with some primers also 
incorporating restriction sites.
2.4.7.1 Colony-screen PCR
The resulting colonies from ligation and transformation reactions were screened for the 
correct sized-insert by PCR colony-screen using insert or vector primers 5’ and 3 ’ o f the 
insert. For each 25pl PCR reaction, 10 pmole/pl o f each vector primer, lx PCR buffer, 
6.25nmol dNTP mix and 1.25 units Taq polymerase (Cancer Research UK) were 
inoculated with a single colony on a toothpick, before transferring the toothpick to a 
3ml LB culture containing the appropriate antibiotic. The reactions were performed 
using an Applied Biosystems GeneAmp PCR machine, using the standard conditions 
outlined below.
96°C 4 minutes
Denaturation: 96°C 15 seconds ]
Annealing : 60°C 15 seconds  ^ 30 cycles
Extension: 72°C 1 minute * }
72°C 1 minute
4°C oo
* Extension time: I min/kb o f  plasmid length
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2.4.7.2 Gene Amplification using Standard PCR
Genes were amplified from vaccinia virus genomic DNA or from a HeLa cDNA library 
(made by Dr. James Sutherland) using the following lOOjal PCR reaction mixture, ljul 
o f DNA template (either vaccinia genomic DNA, HeLa cell cDNA library or pre­
existing DNA constructs containing the gene of interest) was mixed with: 40pmol o f 
each primer, lx Taqplus Precision DNA polymerase buffer (Stratagene), 25nmol dNTP 
mix and 5 units Taqplus Precision DNA polymerase (Stratagene). The reaction was 
performed on an Applied Biosystems GeneAmp PCR machine using standard 
conditions.
2.4.8 Oligonucleotides
2.4.8.1 Oligonucleotides used for Standard PCR
The oligonucleotides used in this study were made by either the Cancer Research UK 
Oligonucleotide Service or by Sigma-Aldrich. The oligonucleotides were supplied with 
-O H  groups at both the 5 ’ and 3’ ends and the melting temperatures (Tm) were 
calculated (by the suppliers) using a formula based on a published calculation (Baldino 
et al. 1989). The oligonucleotides were used as primers for PCR amplification and the 
subsequent generation of the constructs described in Section 2.4.2 (Tables 2.6 and 2.7), 
or for DNA sequencing. The oligonucleotides used in this thesis are listed in Table 2.8.
2.4.8.2 Oligonucleotides used for Mutagenic PCR
Point mutations were introduced into the plasmid constructs using the QuikChange™ 
Site-Directed Mutagenesis Kit (Stratagene), according to the manufacturer’s 
recommendations. The oligonucleotides used to generate the mutant constructs were 
designed to incorporate the desired mutation flanked by 15-20 nucleotides o f wild-type 
sequence and are detailed in Table 2.9.
2.4.9 DNA Sequencing
Sequencing was used to verify sequences and to check that clones made by site-directed 
mutagenesis were correct. Oligonucleotide primers corresponding to the ends of the 
vector were used to sequence the start and the end o f the cloned insert and also to 
confirm that the insert was cloned in frame with the open reading frame. For long 
inserts, primers were designed at intervals of 300-500 base pairs. DNA sequencing
119
Chapter 2________________________________________________________________ Materials an d  Methods
Table 2.8 : List of oligonucleotides used in this thesis for standard PCR reactions.
Code
name
Description Oligonucleotide Sequence
F12L-1 Not-F12L For aaaaacaaccqcqqcggcatgttaaacagggtacaaatcttga
F12L-2 F12L-R1 Rev cccqaattcattataattttaccatctgactcatg
F12L-3 Bgl(ll)-F12L For ooaaqatctatqttaaacagggtacaaatcttga
F12L-4 F12L-Not Rev aoooqcqqccqcqccgcctaattttaccatctgactcatggat
F12L-5 Not217F12L For ooooqcqqccqcqqcqgcttagatcaaacacatataaaaacc
F12L-6 F12L216R1 Rev cccqaattcatcacqaqgaagaaattcgcaccca
F12L-7 F12L470-R1 Rev cccqaattcatcaqqqacgtcctgcagggtattgttt
F12L-8 Not471F12L For ooooqcqqccqccaactacgttaaaaatgqtacaaaag
F12L-9 F12L-301 For ccgttgatcgatattatacga
F12L-10 F12L-601 For attaaatacatatctagagat
F12L-11 F12L-901 For tgtggatggaaaatctataat
F12L-12 F12L-1201 For gaagacatgttcttaactagt
F12L-13 F12L-1500 For tcacgatgattgacaatactac
F12L-14 F12L-1801 For gaaaccatagatccggtgtat
F12L-15 F12L-321 Rev cgactatcgaatatcctgctc
F12L-16 F12L-601 Rev gatagatgattcgataaatag
F12L-17 F12L-899 Rev taacaatagtattgtaaagat
F12L-18 F12L-1201 Rev attatcagtaatagctccata
F12L-19 F12L-1501 Rev ttcattaatttctgatatgga
F12L-20 F12L-1701 Rev ttgtgcaatgagtcgtcaatc
F12L-25 Hindlll/LAfor qqqaaqcttataqaqqaqttaagatcaqacttctagttq
F12L-26 GFPCterm/BamH 1 /RAfor actctcggcatggacgaqctqtacaaqtaaqqatccaaaqtoaaaa
acaatattattttatcgtt
F12L-27 F12LCterm/Notl/GFPNtermrev cccggtqaacaqctcctcqcccttqctcatqcqqccocctaattttacc
atctgactcatggattcatt
F12L-28 RA/Notlrev tttqcqqccqctctaatacaqcatctaacttqatqtcaqqa
A33R-11 Notl/A33RNterfor aaaqqcqqccqcatqatgacaccaqaaaacqacqaaq
A33R-12 EcoRl/RArev cccqaattctaatctttataaaaaatactaaaca
A33R-13 Kpnl/LAfor aaaqqtacctaatatqatttqqccaaatgtatcc
A33R-14 LA/Kpnlrev aaaqqtaccgataataaatgttatttatgtcacg
DLC2-1 Not1-ggcggc-LC8-DLC2 For qcqqccqcoacqqctctgaccggaaqqcaqtqatcaaqaacqca
DLC2-2 EcoRl-ggcggc-LC8-DLC2 Rev qaattcaocqqcctagcctgacttgaaqaqqaqqattqcaac
m21l-1 Not-m21l-For qqcqqcqcqqccqc atgattaaactattaqqactattacacqac
m211-2 EcoRlm21l-Rev pqcQoc qaattcttatcqtagtttgacgacqttcqacaqaaa
m21l-3 EcoRl-m21l-For oocoocqaattc atqattaaactattaqqactattacacqac
m211-4 Not-m21l-For qqcqqc  qcqqccqctcgtaqtttgacqacqttcqacagaaactc
NOTE:
The ‘Description’ explains which gene region the oligonucleotide corresponds to by indicating 
the position number of the first amino acid, with the name of the restriction site either introduced 
5’ (written in front of the name, e.g.Not217F12L) or 3’ (written afterwards, e.g. F12L216R1). No 
number refers to either the beginning (e.g.Not-F12L) or end (e.g. F12L-R1) of a gene sequence 
and For (forward) and Rev (reverse) explains the reading-direction of the primer.
• Bold, underlined letters indicate bases that have been used to introduce a restriction site 
for cloning purposes. (Abbreviations: Not=Not1; R1-EcoRl).
• Italic letters indicate bases that have been introduced as linker sequences between a 
restriction site enzyme and the desired sequence to be amplified, to ensure efficient 
digestion of the resulting PCR product.
Oligonucleotides F12L-9 to F12L-20 are sequencing primers used to verify the constructs.
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reactions were prepared with 200ng plasmid template (or l-50ng o f gel-purified PCR 
product), 3.2pmol oligonucleotide primer and 8 j l x 1 BigDye® Terminator v3.l reaction 
mix (Applied Biosystems), in a final volume of 20pl. This method uses the PCR 
reaction to incorporate dye-labelled dNTPs into the DNA to be sequenced.
Table 2.9: List of oligonucleotides used in this thesis for mutagenic PCR reactions
Code
name
Description Mutagenic Oligonucleotide Sequence (5’-3’)
F12L-21 F12LG124A For ggctttagaacaatacgCtatcgagaatacagattccatatca
F12L-22 F12LG124A Rev tgatatggaatctgtattctcgataGcgtattgttctaaagcc
F12L-23 F12L G546A For ccagaacttaaaaacgCtttactggatagtatcaagatgatttat
F12L-24 F12L G546A Rev ataaatcatcttgatactatccagtaaaGcgtttttaagttctgg
A33R-3 A33RS12A For gacgaagagcagacaGctgtgttctccgctactgtttacgga
A33R-4 A33RS12A Rev tccgtaaacagtagcggagaacacagCtgtctgctcttcgtc
A33R-5 A33RS15A For gacgaagagcagacatctgtgttcGccgctactgtttacgga
A33R-6 A33RS15A Rev tccgtaaacagtagcggCgaacacagatgtctgctcttcgtc
A33R-7 A33R S12+15A For gacgaagagcagacaGctgtgttcGccgctactgtttacgga
A33R-8 A33R S12+15A Rev tccgtaaacagtagcggCgaacacagCtgtctgctcttcgtc
A33R-9 A33R S12+15D For gacgaagagcagacaGAT gtgttcGAT gctactgtttacgga
A33R-10 A33R S12+15D Rev tccgtaaacagtagcAT CgaacacAT Ctgtctgctcttcgtc
NOTE:
The ‘Description’ provides details of the gene name, together with the amino acid number to be 
mutated, flanked by the amino acid substitution. E.g. F12L G124A indicates that amino acid 
number 124 of the gene F12L is mutated from a glycine (G) to an alanine (A).
•  Capital letters indicate bases that have been altered in order to introduce point mutations.
The sequencing reaction was then carried out in a 3730 DNA Analyser (Applied 
Biosystems) using the following standard sequencing conditions:
96°C 1 minute
96°C 10 seconds ]
50°C 5 seconds } 25 cycles
60°C 4 minutes J
60°C 1 minute
4°C oo
Unincorporated dye terminators were removed from the sequencing reactions using the 
DyeEx™ 2.0 Spin Kits (Qiagen) and the pellet was vacuum-dried in a Speed Vac 
microcentrifuge. The subsequent stages were performed by Cancer Research UK staff 
in the Equipment Park and the samples were analysed using a 3730 DNA Analyzer 
(Applied Biosystems). The DNA o f interest is run through a gel where the dye-labelled
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terminators are monitored passing through a laser beam. The information is 
automatically entered onto a computer and processed. The fidelity o f the sequence data 
was analysed using Seqman software (DNAstar, Madison, WI, USA) and compared 
with sequence data downloaded from the National Centre for Biotechnology 
Information (NCBI) or gene sequences within the laboratory.
2.5 Im m unofluorescence
2.5.1 Fixation
At the appropriate time-point for an experiment, cells were washed once in PBS A and 
subjected to one o f four standard fixation methods (depending on the antibody to be 
used). The first, and most frequently used, method in this thesis is treatment with 3% 
paraformaldehyde (PFA; Merck) (PFA-fixation) made up in lx  CB, followed by 
permeabilisation with 0.1% Triton-XlOO. However, some epitopes of proteins may not 
be exposed during this fixation and require a different method to be detected. The 
second procedure (P-T fixation) fixed and extracted the cells at the same time, using 3% 
PFA in lx CB containing 0.1% Triton X-100. This reduced the background and 
enhanced the ability to see some localisations. In the third method, cells were fixed with 
ice-cold methanol (MeOH fixation) and in the fourth method with 3% PFA in lx CB, 
followed by ice-cold methanol treatment (P-M fixation). The details for each fixation 
method are described below in Table 2.10.
2.5.2 Labelling and Mounting
After the cells had been fixed and permeablised, the coverslips were incubated for 15- 
30min in immunofluorescence (IF)-blocking buffer, to reduce any non-specific antibody 
binding sites (Frischknecht et al. 1999; Moreau et al. 2000). The coverslips were then 
labelled with primary antibody (see Table 2.11) diluted in IF-blocking buffer for 30min 
(up to 1 hour) and washed three times in PBSA. They were then incubated in the 
appropriate secondary antibodies and/or Alexa-568-phalloidin (which labels F-actin; 
Molecular Probes) (see Table 2.12), diluted in IF-blocking buffer, for 20 min (up to I 
hour). The cells were then washed a further three times in PBSA and, if required, were 
incubated for 10-30 sec in 4',6-diamidine-2’-phenylidole dihydrochloride (DAPI; 
Roche) solution. The coverslips were then washed once in distilled water and mounted 
onto slides in 200mg/ml MOWIOL (Calbiochem) mixed with 1/10 of p-
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phenylendiamine immediately prior to use. This mounting medium prevents bleaching 
of the conjugated fluorophore on the secondary antibody. The slides were dried for 
~30min at 37°C before being examined.
Table 2.10: Fixation methods used for immunofluorescence experiments
Method
no.
Fixation
Method
Description
1 PFA -Pre-washed cells were incubated with 3% paraformaldehyde (PFA) 
dissolved in 1 x cytoskeletal buffer (CB) for 10min at room temperature. 
-The cells were then washed in PBSA, and permeabilised, for 2min at 
room temperature, with 0.1% Triton X-100 dissolved in CB.
-The cells were then washed a further 3 times with PBSA.
2 P-T -Pre-washed cells were fixed for 10 min at room
temperature in 3% PFA/CB containing 0.1% Triton X-100, --The cells
were then washed 3 times in PBSA.
3 MeOH -Pre-washed cells were fixed for 10 min at -20°C in 
ice-cold methanol.
-The cells were then rapidly rehydrated, by washing five times in PBSA 
at room temperature.
4 P-M -Pre- washed cells were fixed for 5 min in 3% PFA in CB.
-The cells were then washed in PBSA, and fixed for a further 30sec at -  
20°C in ice-cold methanol.
-The cells were then rapidly rehydrated, by washing five times in PBSA 
at room temperature.
2.5.3 M icroscopy and Image Processing
The cells were visualised using a Zeiss Axioplan-2 microscope (Oberkochen, 
Germany), and the images were captured using a Photometries Coolsnap HQ cooled 
CCD camera and Metamorph software (Universal Imaging Corporation). Initially, the 
images were recorded in a 12-bit format, before being converted to an 8-bit RGB 
overlay file and adjusted using Metamorph. All subsequent image processing was 
performed using Adobe Photoshop and Adobe Illustrator (Adobe Systems 
Incorporated).
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Table 2.11: Primary antibodies used for immunofluorescence analysis
Antibody Specificity Species Fixation Dilution Origin
cx-A33R A33R Rabbit MeOH, PFA 1; 100 SR
a-A33R-12 A33R-12 Rabbit MeOH, PFA 1:200 This thesis
a-A33R-15 A33R-15 Rabbit MeOH, PFA 1:200 This thesis
a-A33R-12+15 A33R-12+15 Rabbit MeOH, PFA 1:200 This thesis
a-A36R (5215G) A36R Rabbit All 1:300 SR
a-A36R-Y132P A36R-Y132P Rabbit All 1:200 NS
a-A36R-Y 112P A36R-Y112P Rabbit All 1:200 NS
a-A27L (P14) A27L Mouse All 1:400 Dr. Mariano 
Esteban
a-B5R B5R Rat All 1:500 Dr. Gerhardt 
Hiller
a-F13L F13L Rabbit All 1:50 MW
a-A17L A17L Rabbit PFA 1:300 Dr. Jacomine 
Krijnse-Locker
Alexa568-
phallodin
Actin Stain PFA, P-T 1:800 Molecular
Probes
a-HA 16B12 HA Mouse PFA 1:500 BAbCo
PY69 Phospho-
tyrosine
Mouse PFA 1:100 Cancer 
Research UK
DAPI DNA Stain All 1 mg/ml Sigma
a-kinesin (H2) Kinesin 
heavy chain
Mouse All 1:100 Chemicon
a-kinesin (L2) Kinesin light 
chain
Mouse All 1:100 Chemicon
a-Gamma-tubulin
(GTU88)
Gamma-
tubulin
Rabbit MeOH, PFA, 
P-M, P-T
1:2500 Sigma
a-alpha-tubulin Alpha-tubulin Mouse MeOH 1:150 Amersham
AC74 (actin) Actin Mouse MeOH, P-M. 
P-T
1:400 Sigma
a-VSV-G (P5D4) VSV-G Mouse All 1:100 Cancer 
Research UK
a-Myosin Va 
(LE-16)
Myosin Va Rabbit PFA 1:100 Sigma
a-Myosin Va 
(LF-18)
Myosin Va Rabbit PFA 1:100 Sigma
a-Myosin-Va
(Cambridge)
Myosin Va Rabbit PFA 1:100 John Kendrick- 
Jones, 
Cambridge
Table 2.12: Secondary antibodies used for immunofluorescence analysis
Antigen Species raised in Label Dilution Origin
Rabbit Donkey FITC 1 400 Jackson ImmunoResearch
Mouse Goat Alexa488 1 400 Molecular Probes
Rat Goat Alexa488 1 400 Molecular Probes
Rabbit Donkey Texas Red 1 300 Jackson ImmunoResearch
Mouse Goat Alexa568 1 300 Molecular Probes
Rat Donkey Texas Red 1 300 Jackson ImmunoResearch
Rabbit Donkey AMCA 1 100 Jackson ImmunoResearch
Mouse Goat Alexa350 1 100 Molecular Probes
Rat Goat Alexa350 1 100 Molecular Probes
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2.5.4 Quantification of Actin Tail Formation
The quantification of actin tail formation was performed as described previously 
(Frischknecht et al. 1999; Moreau et al. 2000). In brief, for each experiment the 
presence of at least one actin tail was scored in transfected versus untransfected cells. A 
minimum of 100 cells were counted per coverslip and all experiments show the 
standard deviations from the mean (obtained from at least three independent 
experiments). The number of actin tails varies between cells, so not all untransfected- 
but-infected cells exhibit actin tails. Therefore, the data in this thesis has been 
normalised to the number of infected cells that were not transfected but showed actin 
tails.
Extracellular labelling of the viral protein B5R, in non-permeablised cells, also provides 
a good, quantifiable measure for the successful completion o f the vaccinia viral life­
cycle. Therefore, cells positive for extracellular B5R were scored and quantified in the 
same way as described for actin tails above.
IQx Cvtoskeletal Buffer (CB)
lOmM Mes pH 6.1 
150mM NaCl 
5mM EGTA 
5mM MgCl2 
5mM Glucose
The reagents were dissolved in distilled water.
Immunofluorescence Blocking Buffer
1% BSA 
2% FCS
The reagents were dissolved in Ix  Cytoskeletal Buffer.
4 \  6“ diamidine-2-phenvlindole dihvdrochloride (DAPO
1 mg/ml DAP I
Made up in distilled water.
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M OW IOL
2.4g MOWIOL and 6g glycerol was mixed with 6ml o f  distilled water and incubated fo r  
at least 2 hours at room temperature. 12ml o f  200mM Tris-HCl, pH8.5 was then added 
and the solution was mixed at 60°C fo r  lOmin, before being centrifuged at 5000rpm for  
5min (to remove any precipitates). Aliquots were then stored at -20°C .
3% Paraformaldehyde in lx  CB
15g paraformaldehyde was carefully added to 500ml pre-warmed (~55°C) lx CB. The 
solution was heated and stirred with the addition o f  NaOH, until it was completely 
dissolved. The solution was then cooled to RT and the pH  was adjusted to pH 8.8 before 
being passed through a 0.45pm fd te r  (Millipore). Aliquots were then stored at -20°C.
2.6 Protein Biochemistry
2.6.1 Preparation of Cell Extracts
2.6.1.1 Preparation of W hole Cell Extracts
Whole cell extracts were prepared by directly adding and scraping HeLa cells, pre­
washed with PBSA, in preheated (95°C) protein sample buffer. Typically, 350pl of the 
protein sample buffer was used for a confluent 10 cm dish. The lysed samples were 
transferred to an eppendorf and subsequently denatured at 95°C for 5 min, followed by 
vortexing before being stored at -20°C. These samples were subsequently subjected to 
SDS-PAGE and western blot analysis.
2.6.1.2 Preparation of Soluble Cell Extracts
Soluble protein extracts from HeLa cells were prepared by scraping PBSA-washed cells 
in lysis buffer. All of the steps were performed on ice and at 4°C until the protein 
sample buffer was added. Typically, 350pl lysis buffer was used to scrape cells in a 
10cm dish, before the lysate was transferred to an eppendorf and incubated on a rotating 
wheel at 4°C for 15min. The lysates were then clarified by a final centrifugation step at 
I6,000rcf for 5 min at 4°C and the supernatant (crude extract) was retained and 
subsequently incubated with resin in pull-down experiments.
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Protein Sample Buffer
50% Glycerol 
3% SDS 
50mM Tris.HCl pH 6.8 
2% (3-Mercaptoethanol 
+ Solid Bromophenol Blue
Lysis Buffer
25mM Tris-HCl, pH7.5 
1% Triton X -100
0.5% Nonidet P40 
lOOmM NaCl
lx Protease Inhibitors (Complete EDTA-freeprotease inhibitor tablets, Roche)
2.6.2 M easurement of Protein Concentration
The protein concentration of lp l of sample was estimated by using the Biorad Protein 
Assay Reagent Kit (Biorad), according to the manufacturer’s instructions. A standard 
calibration curve was prepared by making a series o f dilutions of a 1 mg/ml BSA 
solution (New England Biosciences). The optical density (OD) was measured at 595nm 
using an Ultraspec 3100pro UV/visible spectrophotometer and the protein concentration 
was determined from the BSA standard curve.
2.6.3 Isolation o f M embrane-containiqg Fractions
Cells, grown to confluency in a 10cm diameter dish, were infected with an appropriate 
vaccinia virus strain for 8 hours (see Section 2.3.2), and washed with PBS A before 
being scraped in I ml PBSA. The lysate was transferred to an eppendorf and centrifuged 
in a minifuge at 13,000rpm for 5min at 4°C. The pellet was then washed with 1ml of 
HEPES lysis buffer and centrifuged at 13,000rpm for a further 5min at 4°C. The 
supernatant was removed (an aliquot was retained for analysis; ‘total extract') and the 
pellet was resuspended in 500pl HEPES lysis buffer, prior to incubation on ice for 
30min. The sample was then centrifuged at 5000rpm for 5min at 4°C, and the 
supernatant was removed (an aliquot was retained for analysis -nuclear extract) and 
transferred to an ultra Micro fuge® Tube (Beckman Coulter™). The sample was
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centrifuged at 50,000rpm for I hour at 4°C in an Optima™MAX ultra centrifuge 
(Beckman Coulter™) and the supernatant was extracted (an aliquot was kept for 
analysis-so/w6/e extract). The pellet was then washed once with 1ml PBS A and 
centrifuged for a final time at 13,000rpm for 5min at 4°C. The supernatant was 
removed and the pellet (membrane extract) was resuspended in an equal volume of 
protein sample buffer before being denatured at 95°C for 5min. The samples were then 
analysed by SDS-PAGE and western blotting (see Section 2.8.1 and 2.8.2, 
respectively).
HEPES Lysis Buffer
lOmM HEPES (Gibco)
lx Protease Inhibitors (Complete EDTA-free protease inhibitor tablets, Roche)
2.6.4 Treatm ent o f Cells with Phosphatase Inhibitors
Cells, grown to confluency in a 10cm dish, were infected with an appropriate vaccinia 
virus strain for 8 hours (see Section 2.3.2). The cells were then washed with PBS A and 
scraped, on ice, in 200pl phosphorylation lysis buffer, with or without the presence of 
ImM sodium orthovanadate (Na3V 03). The addition o f Na3V 0 3 to the sample blocks 
tyrosine phosphatase activity and thus preserves the phosphorylation state o f the 
proteins in the cell extract. The lysates were incubated on a rotating wheel at 4°C for 1 
hour and subsequently centrifuged at 13,000rpm for lOmin at 4°C. The supernatant was 
retained and divided into two lOOpl aliquots. To one of the lOOpl samples, 25pl of 
protein sample buffer was added and denatured at 95°C for 5min. To the second lOOpl 
sample, I pi lambda protein phosphatase (A.PP), lOpl >.PP buffer and lOjul MnCl2 were 
added and incubated at 30°C for 1 hour. Finally, 25pl of protein sample buffer was 
added and the sample was denatured at 95°C for 5min. All of the samples were stored at 
-20°C. 20pl of each sample was analysed by SDS-PAGE and western blotting (see 
Sections 2.8.1 and 2.8.2, respectively).
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PhosDhorvlation Lvsis Buffer
200ml PBSA
200pl 10% Triton-X 100
lx Phosphatase inhibitors
lx Protease Inhibitors
+/- ImM Sodium ortho vanadate, Na3VC>3
2.7 Pull-down Assays
In all of the pull-down experiments described in this section, a sample of the total lysate 
was retained and mixed with 0.5 volumes o f protein sample buffer, to represent the total 
protein input.
2.7.1 Ni-NTA Pull-down Experiments
The Ni-NTA resin (with or without pre-bound protein extract, see Section 2.9) was 
washed three times in lysis buffer prior to incubation with the lysate. Imidazole (pH 8.0) 
was added to the lysates, to a final concentration o f 50mM, to reduce the background 
binding of positively charged amino acids to the Ni-resin. The pull-down reactions were 
incubated for 1 -2 hours (or overnight) on a rotating wheel at 4°C and then centrifuged at 
lOOrcf for lmin at 4°C. The resins were then washed five times in the Ni-washing 
buffer before adding protein sample buffer and denaturating the sample at 95°C for 
5min. The samples were stored at -20°C and analysed by SDS-PAGE and western 
blotting (Section 2.8.1 and 2.8.2).
Ni-washing buffer
PBSA, containing: l50m M N aCl 
0.1% Tween-20 
50mM Imidazole, pH8.0
2.7.2 ZIP Pull-down Experiments
Peptides corresponding to the novel coiled-coil pair, ZIP (Figure 2.1) (Arndt et al.
2000) were coupled to resin SulphoLink® (see Section 2.10.1) by Dr. Niki Scaplehom,
and were subsequently used for pull-down experiments. The ZIP resin (with or without
pre-bound protein extract see Section 2.9) was washed three times in the appropriate
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lysis buffer prior to incubation with the lysate samples. The pull-down reactions were 
incubated for 1-2 hours (or overnight) on a rotating wheel, at 4°C and then centrifuged 
at lOOrcf for lmin at 4°C. An aliquot of the supematent was retained for analysis o f the 
sample that did not bind to the beads. The resins were then washed five times in ZIP- 
washing buffer before finally adding protein sample buffer (equal to the volume of 
beads used) and denaturating the sample at 95°C for 5min. The samples were stored at -  
20°C and analysed by SDS-PAGE and western blotting (Section 2.8.1 and 2.8.2, 
respectively).
ZIP-washing Buffer
lOmM Tris, pH 7.5
150mM NaCl
1% CHAPS
2mM Na3V 0 3
lx Phosphatase inhibitors
The reagents were diluted in distilled water and chilled on ice.
WINZIPA
GATCTACCATGACCGTGGCCCAGCTGGAGGAGAAGGTGAAGACCCTGCGCGCCCAGAACTAC...  
ATGGTACT GGCACCGGGTCGACCT CCTCTT CCACTTCTGGG ACGCGCGGGT CTT GATG 
M T V A Q L E  E K V K T L  R A Q N Y
.. GAGCTGAAGAGCCGCGTGCAGCGCCTGCGCGAGCAGGTGGCCCAGCTGGGCGGC 
. . .  CTCGACTTCTCGGCGCACGTCGCGGACGCGCTCGTCCACCGGGTCGACCCGCCGCCGG 
E L K S R  V Q R  L R  E Q V A Q  L G G
W1NZ1PB
GATCTACCATGTCCGTGGACGAGCTGCAGGCCGAGGTGGACCAGCTGCAGGACGAGAACTAC . . 
AT GGTACAGGC ACCT GCTCG ACGTCCGGCT CC ACCTGGTCGACGTCCTGCT CTT GAT G . . .  
M S  V D E L Q A  E V D  Q L Q D E N Y
. GCCCTGAAGACCAAGGTGGCCCAGCTGCGCAAGAAGGTGGAGAAGCTGGGCGGC 
CGGGACTT CTGGTTCCACCGGGTCG ACGCGTT CTT CCACCTCTT CGACCCGCCGCCGG 
A L K T  K V A  Q L R K K V E K L G G
Figure 2.1: Peptide sequences of WINZIPA and WINZIPB
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2.7.3 Anti-GFP im m unoprecipitation (IP) from vaccinia-infected cells
HeLa cells were grown to confluency in 10cm or 15cm diameter dishes, one for each 
sample, infected with appropriate vaccinia virus (see Section 2.3.1) and transfected with 
appropriate DNA constructs, using the Effectene reagent (Qiagen) (see Section 2.2.4.3). 
Approximately 18 hpi, the cells were scraped in their own complete medium, 
transferred to a 50ml falcon tube and centrifuged at 1200 rpm for 5 min at 4°C in a 
581 OR Centrifuge (Eppendorf). After the medium was aspirated, the pellet was lysed in 
lml of IP-lysis buffer on ice and incubated on a rotating wheel at 4°C for 30min. The 
samples were then centrifuged at 13,000rpm for 5min at 4°C and the resulting 
supematent were transferred to a new tube. lOOjul of this sample was retained and 50pl 
of protein sample buffer was added and denatured at 95°C for 5min {‘total extract’). To 
the remaining 900pil either lpg  anti-GFP (4E12;Cancer Research UK) monoclonal 
antibody or Ipg anti-HA (12CA5; Cancer Research UK) monoclonal antibody, as a 
control, was added and incubated on a rotating wheel at 4°C for 2 hours. Following the 
incubation, lOOjul o f 20% UltraLink Immobilized Protein G (Pierce) solution (pre­
washed in PBS) was added to each IP experiment and rotated for a further I hour at 
4°C. The samples were then centrifuged in a minifuge at 2000rpm for 30sec at 4°C. 
lOOpl of the supernatant was removed and 50p.l o f protein sample buffer was added 
prior to denaturation at 95°C for 5min {‘not bound sam ple’). The remaining supernatant 
was then aspirated and the pellet was washed 3 times in lml o f IP wash buffer. After the 
final aspiration, 60p.l o f protein sample buffer was added and the samples were 
denatured at 95°C for 5min {‘boundsample ’). The samples were then analysed by SDS- 
PAGE and western blotting (see Sections 2.8.1 and 2.8.2, respectively).
IP Lvsis Buffer {N.B: This buffer was made up with distilled water and chilled on ice).
25mM Tris-HCl, pH 7.5
1% Triton X-100
0.5% Nonidet-P40
lOOmM NaCl
1 X Protease inhibitors
ImM Sodium orthovanadate
lOmM Sodium fluoride
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IP  W ash Buffer (N.B: This buffer was chilled on ice). 
PBSA containing: 0.1 % Tween-20
!50mM NaCl
2.8 Protein Analysis
2.8.1 SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE)
Proteins were separated according to their size using SDS-PAGE (Laemmli 1970). 
Samples were prepared by the addition of Protein Sample Buffer (see Section 2.6.1.2), 
which contained: SDS (sodium dodecyl sulphate), (3-mercaptoethanol ((3ME), 
bromophenol blue, glycerol and Tris-glycine (pH 6.8). SDS is an ionic detergent that 
binds to the majority of proteins at a constant ratio o f 1.4gm SDS/gm protein. However, 
as some proteins do not bind at this ratio, this is one reason why some proteins migrate 
anomalously, e.g. tubulin. SDS has a very hydrophobic end (dodecyl part), which 
interacts with hydrophobic amino acids within proteins, and a highly charged region 
(the sulphate group). PME is a reducing agent that prevents oxidation of cysteine 
residues and disrupts disulfide bonds within and between molecules, resulting in an 
extended monomeric form. Bromophenol blue is a dye that enables the samples to be 
visualised as it is loaded into the well(s) and as it migrates through the gel. As glycerol 
is denser than water, it ensures that the sample falls to the bottom of the well, rather 
than being dispersed into the surrounding buffer. Tris-HCl acts as a buffer, and is a 
source of chloride ions.
After addition of the Protein Sample Buffer, samples were denatured at 95°C for 5 min. 
This results in the protein adopting a linear structure and enables it to bind to SDS. SDS 
imparts a negative charge to all the proteins within the sample, swamping the inherent 
charge of the proteins and providing every protein with the same charge-to-mass ratio. 
Therefore, as a result of the proteins possessing the same charge-to-mass ratio and the 
sieving properties of the gel, mobility becomes a function o f molecular weight.
Laemmli gels are composed o f two different gels, each cast at a different pH: a stacker 
gel (pH 6.8) and a resolving gel (pH 8.8); the running buffer is a different pH again. 
Both gels contain pores that are formed by acrylamide molecules linked together by 
bisacrylamide in a lattice-like structure. This process o f polymerisation is accelerated in
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the presence of free radicals, therefore, TEMED and ammonium persulfate are added, as 
TEMED causes the production o f free radicals from ammonium persulphate. The ratio 
o f acrylamide and bisacrylamide determines how large the pores will be, which 
influences how fast proteins move through the gel. Thus a large protein will move faster 
through a gel containing a small amount of acrylamide/bisacrylamide (as it has larger 
pores) compared to one containing a high amount of acrylamide/bisacrylamide (because 
it has smaller pores).
Acrylamide resolving gels were prepared as described in Table 2.13, using a Cambridge 
Electrophoresis gel system and, unless otherwise stated, all resolving gels made were 
10%. Cast resolving gels were overlaid with water-saturated butanol and allowed to 
polymerise. The butanol was subsequently washed out and the stacking gel was poured, 
into which a comb was placed to generate wells. Pre-stained broad-range molecular 
weight markers (Biorad) or unstained low-range molecular weight markers (Biorad) 
were loaded adjacent to the samples to allow the estimation o f apparent molecular 
weights and to orientate the samples. The gels were run in lx  SDS-running buffer at 
250V for 90 min or until the necessary degree of separation had been achieved. In 
addition, some experiments were performed using NuPAGE® Novex 4-12% Bis-Tris 
pre-cast gels (Invitrogen), with lx  MES running buffer at 200V.
The SDS-Running buffer enables an electric current to be conducted through the gel. It 
contains glycine, which is a weak acid, and can exist in one o f two forms: an uncharged 
zwitterion, or a charged glycinate anion (negative charge). At low pH it is protonated 
and therefore uncharged, while at a higher pH it is negatively charged. Upon application 
of a current, the proteins (in Protein Sample Buffer) become trapped in the ‘migrating 
front’ as it progresses through the stacking gel. The glycine ions in the SDS-Running 
buffer migrate from the cathode towards the anode, via the sample and the stacking gel. 
As the stacking gel possesses a low pH, the ions lose some o f their charge as they reach 
it, reducing the rate of migration. Concurrently, the mobile chloride ions (negative 
charge) in the sample and stacking gel also move towards the anode, creating a narrow 
zone of very low conductance (i.e. high electrical resistance) within the gel. In 
accordance with Ohms Law (that states the ‘potential difference (voltage) across an 
ideal conductor is proportional to the current through it’; V=IR, where: V = potential
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difference between two points, I = current and R = resistance), the majority of the 
voltage passing through the gel is concentrated in this small region. The high field 
strength makes the negatively charged proteins move forward, in a tight band. The 
effect of this moving zone of high voltage is that all the proteins reach the resolving gel 
at approximately the same time, so that migration of the proteins is truly a function of 
molecular size. When the ions hit the resolving gel, the pH increases and the glycine 
becomes deprotonated (and therefore more negatively charged). The mobility of the 
glycine increases and mobility of the proteins decreases (due to the sieving properties of 
the gel). The result is that the glycine moves passed the proteins and the proteins are no 
longer in a narrow zone of very high resistance.
Following SDS-PAGE, gels were stained with either Coomassie solution, proceeded by 
destaining (to visualise the proteins) in first high-destain and then low-destain, or 
transferred to nitrocellulose membrane and used for western blotting (see Section 2.8.2).
Table 2.13: Composition of resolving and stacking gels for SDS-PAGE analysis.
All resolving gels made were 10%, unless otherwise stated.
Solution Percentage of resolving gel Stacking
gel7.5% 10% 12.5% 15%
40% (w/v) acrylamide / 
0.8%(w/v) bisacrylamide 
(37.5:1)
4.7ml 6.25ml 7.8ml 9.4ml 2.25ml
0.5M Tris-HCI (pH6.8) (Biorad) - - - - 6.9ml
1.5M Tris-HCI (pH8.8) (Biorad) 6.3ml 6.3ml 6.3ml 6.3ml -
10%(w/v) SDS (Biorad) 0.25ml 0.25ml 0.25ml 0.25ml 0.25ml
100% TEMED (Sigma) 20 pi 20pl 20pl 20pl 20pl
Distilled water 13.7ml 12.2ml 10.6ml 9ml 15.7ml
Bromophenol blue - - - - +
10%(w/v) ammonium 
persulphate (100mg/ml) 
(Sigma)
75pl 55pl 42pl 0.2ml
2.8.2 W estern Blotting
After electrophoresis, six pieces o f Whatman 3mm paper and one piece o f nitrocellulose 
membrane (Schleicher and Schuell) were cut to the size of the gel and, together with the 
SDS gels, they were soaked in transfer buffer. Three pieces of Whatman paper, 
followed by the membrane, the gel (so the membrane is at the anode side o f the gel) and 
another three pieces of Whatman paper, were assembled in a Pharmacia semi-dry 
blotting apparatus. Bubbles were removed by gently rolling the stack with a disposable 
plastic pipette. Proteins were then transferred for 1 hour at 150mA per gel. For the
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experiments that used the pre-cast gels from Invitrogen, the proteins were transferred 
for 1.5 hours, as the gels were of a greater thickness (1mm as opposed to 0.5mm).
The membranes were then incubated briefly with Ponceau S solution, washed with 
distilled water and then scanned to visualise the total protein transferred. The blots 
were then blocked in western-blocking buffer for 30min at room temperature (on a 
rocker) before being incubated with primary antibody (see Table 2.14), diluted in 
western-blocking buffer, for 1 hour at room temperature or overnight at 4°C. 
Subsequently, the blots were washed briefly 3 times, and then 3 times for 10 min in 
western-blocking buffer, and then incubated for ~45min in western-blocking buffer 
containing the appropriate secondary antibody coupled to horseradish peroxidase (HRP) 
(Jackson Immunno Research) (see Table 2.15). The membranes were then washed 
briefly 3 times, and then 3 times for 10 min in PBST buffer, to ensure the removal of 
milk (from the western-blocking buffer), before developing using ECL reagent 
according to the manufacturer’s instructions (Amersham Biosciences). The membrane 
was then exposed to Hyperfilm-ECL (Amersham Biosciences) and developed on an 
IGP Compact2 automated developer (IPG (UK) Limited).
lOx SDS Running Buffer
lOg SDS
30g Trizma Base
144g Glycine (Merck)
The reagents were dissolved in I litre o f  distilled water.
20x IVIES Running Buffer (for pre-cast gels: Invitrogen)
MES 97.6g (1M)
Tris Base 60.6g (IM )
SDS lO.Og (69.3mM)
EDTA 3.0g (20.5mM)
The reagents are dissolved in 500ml o f  distilled water and the lx  working solution 
should be pH  7.3.
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lOx Transfer Buffer
14.4g Glycine 
3g Trizma base, pH 8.8
The reagents were dissolved in 1 litre o f  distilled water. The lx  working solution was 
made up to contain 10%(v/v) methanol.
Coomassie Solution
0.5% Coomassie Brilliant Blue 
50% Methanol, MeOH 
10% Acetic acid
High-Destain
50% MeOH 
10% Acetic acid
Low-Destain
5% MeOH 
10% Acetic acid
Ponceau S solution
2%(w/v) Ponceau S
30%(v/v) Trichloroacetic acid
W estern-Blocking Buffer
PBSA containing 0.1 %(v/v) Tween-20 and 5% fat-free dried milk powder.
PBST Buffer
PBSA containing 0. l%(v/v) Tween-20
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Table 2.14: Primary antibodies used for Western Blotting
Antibody Specificity Species 
raised in
Dilution Origin
cx-F12L F12L Rabbit 1:1000 This Thesis
a-A36R (5215G) A36R Rabbit 1:5000 Dr. Sabine Rottger
a-A33R A33R Rabbit 1:2500 Dr. Sabine Rottger
ct-A33R-12 A33R-12 Rabbit 1:1000 This Thesis
a-A33R-15 A33R-15 Rabbit 1:1000 This Thesis
a-A33R-12+15 A33R-12+15 Rabbit 1:1000 This Thesis
a-GFP GFP Rabbit 1:5000 Santa Cruz
a-His 6xHis tag Mouse 1:3000 Sigma
a-Nck Nek Rabbit 1:2000 Upstate Biotech
a-Grb2 Grb2 Mouse 1:5000 Transduction Lab
cx-4G10 Phosphotyrosine Mouse 1:1000 Upstate Biotech
a-alpha-tubulin Alpha-tubulin Mouse 1:1000 Sigma
a-Kif5B Kinesin Rabbit 1:10,000 Dr. Larry Goldstein
a-Bak Bak Rabbit 1:1000 Upstate Biotech
Table 2.15: Secondary antibodies used for Western Blotting
Antigen Species raised in Label Dilution Origin
Rabbit Goat HRP 1:3000 Jackson ImmunoResearch
Mouse Goat HRP 1:3000 Jackson ImmunoResearch
Rat Goat HRP 1:3000 Jackson ImmunoResearch
2.8.3 Membrane Stripping
To strip the nitrocellulose membrane of primary antibody, the blot was incubated in the 
following stripping buffer 3 times for 15 min, at 50°C, with gentle agitation. The 
membrane was then washed briefly with distilled water and blocked for ~30minutes 
with western-blocking buffer, before proceeding normally with the primary antibody.
M embrane Stripping Buffer
41.35ml Distilled water
3.125ml Tris, pH 8.0 (1M)
400jnl P-mercaptoethanol (100% stock solution)
2ml 10% SDS
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2.8.4 Isoelectric Focusing and Two-dimensional SDS-PAGE
Confluent 10cm diameter tissue culture dishes (~ lx l0 7) were washed with PBSA but 
before lysis they were rinsed briefly with a low-salt isotonic solution, as the high salt in 
any residual PBS will interfere with the first dimension separation. The cells were then 
scraped in 300pl of 2D-lysis buffer and left at room temperature for 30min to allow full 
denaturation of the sample. The lysate was centrifuged at I3,000rpm in a microfuge for 
10 min at 4°C. The supematent was removed and diluted 1:4 in rehydration buffer (in 
order to reduce the concentration of the charged particles (i.e. Tris, salts) to below 
lOmM) before pipetting exactly I25pl into the ceramic strip holder. If the volume is too 
little, the strip will not hydrate completely and will bum at the electrodes and if the 
volume used is too great, the current will flow through the buffer rather than the strip. In 
both of these cases focusing will be incomplete. The lysate was separated in the first 
dimension by isoelectric focusing (IEF) using 7cm Immobiline™DryStrip gels pH3-10 
or pH4-7 (Amersham Biosciences), using an IPGphor™ Isoelectric Focusing System 
(Amersham Biosciences) according to the manufacturer’s protocol. Following IEF and 
before subjecting the strips to SDS-PAGE (second dimension), they were incubated, 
with gentle agitation, for 15min in Equilibration Solution 1 (a reducing buffer), 
followed by 15 min in Equilibration Solution 2 (an alkylating buffer). The strips were 
then positioned in the well of a NuPAGE Novex 4-12% Bis-Tris IEF Zoom gel 
(Invitrogen), adjacent to a well containing pre-stained SDS-PAGE marker (Biorad). The 
gel was run at 200V/150mA/24W in lx  MES running buffer. After completion of the 
second dimension, standard western blotting procedures were followed, as described in 
Section 2.8.2.
Low-Salt Isotonic Wash Solution
0.12g Trizma Base 
8.56g Sucrose
The reagents were dissolved in 100ml o f  distilled water and the p H  was adjusted to 
pH7.0 with HCl.
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2D Lvsis Buffer
7M Urea 
2M Thiourea 
4% CHAPS 
40mM Tris base 
Immediately prior to lysis add:
Dithiothreitol (DTT): lOmg per lml lysis buffer (~65mM)
Immobilised pH gradient (IPG) buffer*: lOjal per lml 2D-lysis buffer (1%)
Protease inhibitors lOpl/ml (Amersham Biosciences)
Nuclease lOpl/ml (Amersham Biosciences)
*N.B: The IPG buffer chosen must correspond to the p H  range o f  the strips to be run o f  
the strips to be run.
Rehvdration Buffer
8M Urea
2% 3[3-Cholamidopropyl)dimethylammonio]-propanesulfonicacid (CHAPS)
5% Glycerol
+ Bromophenol Blue
Immediately prior to rehydration add:
DTT: lOmg per lm l (~65mM)
IPG buffer: 5pl per lml (0.5%)
Equilibration Solution 1
50mM Tris-HCI, pH8.8
6M Urea
30%(v/v) Glycerol
2%(w/v) SDS
+ Bromophenol Blue
1% DTT (lOmg/ml)
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Equilibration Solution 2
50mM Tris-HCI, pH8.8
6M Urea
30%(v/v) Glycerol
2%(w/v) SDS
+ Bromophenol Blue
2.5% Iodoacetamide (IAA) (25mg/ml)
2.9 Protein Expression and Purification
2.9.1 Protein Expression
All pMW172 clones (see Table 2.5) were transformed into chemically competent BL21 
(DE3) E. coli. Single colonies were used to inoculate a 5 ml LB-ampicillin starter 
culture, which was incubated during the day with vigorous shaking at 37°C. I ml o f this 
starter culture was then used to inoculate 1 litre o f LB+ampicillin, which were then 
incubated overnight with vigorous shaking at 30°C. Induction was not necessary using 
the pMW172 vector. Prior to centrifugation o f the cultures, a sample (lm l) was 
removed in order to check the expression levels by SDS-PAGE. The cultures were then 
pelleted by centrifugation at 2000rcf and the supematent was discarded. The pellets 
were frozen at -20°C, in aliquots equivalent to 500 ml culture.
The pellets were thawed at room temperature, and thoroughly resuspended in bacterial 
lysis buffer before adding 3mg lysozyrpe. The lysate was then incubated at room 
temperature for 30min, before adding 9.6jnl 1M MgCl2, 0.96pl MnCl2 and 0.4pl 10 
mg/ml DNase I per ml o f lysate. The lysate was then incubated for a further 30 min at 
room temperature, prior to centrifugation at I2,000rcf for 15 min at 4°C. The bacterial 
soluble fraction (supernatant) was retained and stored at 4°C.
2.9.2 Purification o f  proteins on Ni-NTA resin
For the purification o f His-tagged proteins on nickel resin, imidazole (pH 8.0) was also 
added to the soluble fraction to make a final concentration of 50mM. Ni-NTA resin, 
prewashed in bacterial lysis buffer, was added to the soluble fraction and incubated on a 
rotating wheel for 30min at room temperature. The resin was centrifuged at lOOrcf and
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washed five times in bacterial Ni-washing buffer (containing 500mM NaCl to reduce 
the amount of non-specific binding that occurs). The resin was stored as a 1:1 slurry in 
resin storage buffer.
Bacterial Lysis Buffer
50mM Tris-HCI, pH8.0 
ImM EDTA 
25% Sucrose 
0.1% Tween-20
lx Protease Inhibitors (Complete EDTA-freeprotease inhibitor tablets, Roche)
Bacterial Ni-wash Buffer
PBSA containing : 150 mM NaCl,
1% Tween-20 
50 mM imidazole
Resin Storage Buffer
PBSA containing : 150 mM NaCl
0.1% Tween-20
2.10 Peptides
The Protein and Peptide Chemistry Laboratory, at Cancer Research UK, synthesized all 
of the peptides used in this thesis and they are described in Table 2.16. The sequences 
of all peptides were confirmed by mass spectrometry. A cysteine was added to each 
peptide to allow for covalent coupling to SulfoLink® resin (Pierce). The SulfoLink® 
resin is 6% cross-linked agarose, which reacts with free sulfhydryl groups (SH) in a 
covalent manner. Two glycine residues were also added after the cysteine residue, in 
order to provide the coupled peptides with a flexible linkage when bound to the resin.
2.10.1 Coupling Peptides to Sulpholink® Resin
Peptides were coupled to SulfoLink® resin according to the manufacturer’s 
instructions. In brief, 2-5 mg peptide was dissolved in 2ml coupling buffer and bound to 
200-500pl resin for 45 min at room temperature. As each peptide possesses unique
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characteristics in terms of hydrophobicity and amino acid composition, there is no ideal 
solvent to solubilize all peptides. Therefore, if a peptide was found to have poor 
solubility, a small volume of DMSO (200pl) was added. The resin was blocked in 
coupling buffer containing 8 mg/ml L-cysteine.HCl for 45min and then washed 4 times 
in SulfoLink® wash solution before washing 3 times in distilled water containing 
0.05% sodium azide. Resins were stored in distilled water containing 0.05% sodium 
azide at 4°C.
In order to determine that the peptide had bound successfully to the resin, an aliquot of 
the ‘wash’ was compared with a retained aliquot o f original starting material. The 
samples were mixed with Ellman’s Reagent (Pierce), according to the manufacturers 
instructions and their respective absorbance was measured at 280nm. Ellman’s Reagent 
is a simple, sensitive, colorimetric method that can reliably determine the content of 
free sulfhydryls in peptides and proteins. The coupling efficiency of the peptide can 
then be calculated by inserting the resultant absorbance measurements for the pre­
starting material) and post-binding (‘wash’) samples, into the following equation: 
Percentage (%) coupling efficiency = 100 x [I -  (A2soPost /  A28oP^e)].
Table 2.16: Peptides used in this thesis. Peptide No. 1-5 were used to generate polyclonal 
antibodies (see Section 2.11.)______________ _____________________________________
No. Peptide Name Peptide Sequence
1 F12L-614C h 2n -c g g k e l y v s s s y k d in e s m s q m v k -c o 2h
2 F12L-N19 h 2n -m l n r v q il m k t a n n y e t ie g g c -c o 2h
3 A33R-PSer12 h 2n -c e e q t s v f s a -c o 2h
4 A33R-PSer15 h 2n -c t s v f s a t v y -c o 2h
5 A33R-PSer12+15 h 2n -c e e q t s v f s a t v y -c o 2h
6 A33R-3/34 h 2n -t p e n d e e q t s v f s a t v y g d k iq g k n k r k r v ig c -c o 2h
7 A33R-3/34 PSer12 h 2n -t p e n d e £q t s v f s a t v y g d k iq g k n k r k r v ig c -c o 2h
8 A33R-3/34 PSer15 h 2n -t p e n d e e q t s v f s a t v y g d k iq g k n k r k r v ig c -c o 2h
9 A33R-3/34 Pser12+15 h 2n -t p e n d e e q t s v f s a t v y g d k iq g k n k r k r v ig c -c o 2h
SulfoLink® Coupling Buffer (Pierce)
50mM Tris base
5mM EDTA-Na, pH8.5
SulfoLink® Wash Solution (Pierce) 
1.0M NaCl
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2.10.2 Peptide Pull-down Experiments
Peptide resins were washed in bacterial lysis buffer before being added to the soluble 
fractions, which had previously been complemented with 1M Na3VC>3 , pH 8.0 (to give a 
final concentration of 1 mM) and NaCl (to give a final concentration of 150mM). The 
samples was then incubated on a rotating wheel at room temperature for 30min and the 
resins were centrifuged at lOOrcf for lm in at 4°C. The resin pellet was then washed in 
peptide-pull-down washing buffer before adding an equal volume of protein sample 
buffer and denaturation at 95°C, to elute the bound proteins.
Peptide Pull-down W ashing Buffer
PBSA containing: 150 mM NaCl,
1% Tween- 20
+/- 1 mM Sodium ortho vanadate
2.10.3 Peptide Inhibition o f Antibodies
For peptide competition experiments, the peptides were dissolved in coupling buffer to 
make 1 mg/ml solutions. This solution was then added to immunofluorescence-blocking 
buffer at a dilution of 1:100, prior to the addition of the primary antibody.
2.11 G eneration o f Polyclonal Antibodies
2.11.1 Antibody Peptides and Generation of Bleeds
To generate polyclonal antibodies, each peptide (Table 2.16, peptide no. 1-5) was 
coupled to maleimide activated keyhole ljmpet haemocyanin (KLH, Pierce), according 
to the manufacturer’s instructions. In brief, 2mg peptide was dissolved in 500pl sterile 
distilled water. KLH was dissolved in 230jnl sterile distilled water, and the two 
solutions were mixed and incubated for 2 hours at room temperature. The peptide-KLH 
conjugates were isolated by applying the mixture to a D-Salt Dextran desalting column 
(Pierce), and eluting in 0.5ml aliquots of sterile PBSA. The conjugate-containing 
aliquots were identified by measurement of OD280, pooled, and quantified using the 
Biorad protein assay reagent.
Rabbits (two per peptide) were initially injected, subcutaneously, with 200pg
immunogen in 1.2ml PBSA. They were then boosted five more times with lOOpg
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immunogen in 1.2 ml PBSA on day 14, 28, 42, 56 and 70 after the primary 
immunisation. The bleeds were taken 35, 49 and 63 days post immunisation, with a 
terminal bleed taken on day 77 to measure the antibody response. (The peptides were 
administered to the rabbits at Harlan Sera-Lab).
2.11.2 Affinity Purification of Antibodies
Sulfolink(D-peptide resins were prepared as described previously (section 2.10) in the 
2ml column format. The columns were washed first with triethylamine (TEA) buffer, 
followed by PBSA, then with glycine buffer, followed by PBSA. The bleeds were 
diluted 1:1 in PBSA and clarified, first by centrifugation at 12,000 ref, then by filtration 
through a 0.45 pm filter (Millipore). The bleeds were passed through the column twice, 
to bind the antibody, and then washed with column wash buffer, before a final wash in 
PBSA. The antibody was eluted using I ml aliquots of the glycine buffer, and then 
neutralised (immediately) using IM Tris-HCI, pH 8.8. Measuring the samples at OD280 
identified the antibody-containing fractions. The positive fractions were then tested for 
specificity, by western blotting and immunofluorescence analysis, and any fractions that 
had identical specificity were pooled together and diluted 1:1 with glycerol. Aliquots 
were subsequently stored at -20°C.
TEA Buffer
lOOmM Triethylamine (TEA), pH 11.5
Glycine Buffer
lOOmM Glycine, pH 2.5
Column W ash Buffer
PBSA containing 250 mM NaCl
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2.12 G eneration o f a Recom binant Virus
2.12.1 Construction of Targeting Vectors
To construct suitable targeting vectors for F12L and A33R recombinant viruses 
containing a fluorescent protein tag, the following strategies were employed (Figure 
2 .2).
2.12.1.1 F12L Targeting Vector
A primer set was designed to amplify F12L plus 300bp upstream (referred to as left- 
arm, LA-F12L) and another set to amplify 300bp downstream of the gene (right-arm, 
RA), from viral genomic DNA (see Table 2.8, primers F12L 25-28). The LA-F12L was 
initially cloned into the vector CB6-GFP, with a fluorescent protein tag at the C- 
terminus, whereas the RA was cloned into the vector pBS KSII (Invitrogen). The LA- 
F12L-GFP fragment was subsequently excised from the CB6 vector and cloned into the 
pBS-F12L-RA vector, to form pBS-LA-F12L ORF-GFP-RA.
2.12.1.2 A33R Targeting Vector
A primer set was designed to amplify A33R plus 300bp downstream (referred to as 
right-arm, A33R-RA) and another set to amplify 300bp upstream of the gene (left-arm, 
LA), from viral genomic DNA (see Table 2.8, primers A33R 11-14). The A33R-RA 
was initially cloned into the vector pE/L-GFP, with a fluorescent protein tag at the N- 
terminus, whereas the LA was cloned into the vector pBS KSII. The GFP-A33R-RA 
fragment was subsequently excised from the pE/Lvector and cloned into the pBS-LA- 
A33R construct, to form pBS-LA-GFP-A33R ORF-RA.
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Figure 2.2: Cloning strategy employed to generate fluorescently-tagged recombinant 
vaccinia virus constructs for (A) F12L and (B) A33R. The ORF region plus 300bp up-stream 
and 300bp down-stream were amplified from viral genomic DNA fused with a fluorescently 
labelled protein, e.g. GFP.
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2.13 Suppliers and Distributors
Adobe Systems Incorporated San Jose, California, USA
Amersham Biosciences UK Limited Buckinghamshire, UK
BAbCo (Berkley Antibody Company) Richmond, California, USA
Beckman Coulter™ Buckinghamshire, UK
Beckton Dickinson Oxfordshire, UK
Biosource International California, USA
Bio-Rad Laboratories Inc. Hertfordshire, UK
Cambridge Electrophoresis Ltd Cambridgeshire, UK
Carl Zeiss Ltd. Hertfordshire, UK
Eppendorf UK Limited Cambridgeshire, UK
Gibco BRL/Life Technologies Paisley, UK
Harlan Sera-Lab Leicestershire, UK
Invitrogen Paisley, UK
IPG (UK) Limited Essex, UK
Jackson Immunno Research Baltimore, USA
Merck and Co. Inc. New Jersey, USA
Millipore Watford, UK
Molecular Probes Leiden, Netherlands
New England Biolabs (NEB) New York, USA
Pierce Biotechnology Rockford, USA
Qiagen Ltd West Sussex, UK
Roche Hertfordshire, UK
Savant Instruments Inc. Holbrook, NY, USA
Schleicher & Schuell Dassel, Germany
Sigma Chemical Co. Dorset, UK
Stratagene La Jolla, CA, USA
Syngene Cambridge, UK
Triple Red Ltd Buckinghamshire
Universal Imaging Corporation Marlow, UK
Upstate Biotech Dundee, UK
Zeiss Oberkochen, Germany
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3.1 Introduction
A33R is one protein member of a large viral complex that is present on IEV particles, 
which travel from the perinuclear viral factories to the plasma membrane along 
microtubules. Several interactions between these other viral proteins have already been 
established (see Section 1.9.3.3), including the well-characterised A36R protein. A33R 
is known to interact with A36R, which is required for viral movement (Wolffe et al. 
2001; Ward et al. 2003). Therefore, A33R was considered a worthy candidate to 
investigate further. Also, the presence of a short (31 amino acid) A3 3 R-tail protruding 
from the surface of IEV particles, into the cytoplasm raises the possibility that it may 
contribute to the micro tubule-dependent transport o f these virions.
Both A33R and A36R can be post-translationally modified by phosphorylation, while 
A33R can also be palmitoylated (Frischknecht et al. 1999a; Frischknecht et al. 1999b; 
Wolffe et al. 2001; Grosenbach et al. 2000) and can form disulphide-bonded 
homodimers (Payne 1992; Roper et al. 1996). They are both required to make IEV and 
the important role of A36R tyrosine phosphorylation, which recruits signalling 
molecules that mediate actin tail formation, is well established (Frischknecht et al. 
1999a) (see Section 1.9.3.2 for details). When cells are infected with vaccinia virus in 
which the A33R gene has been deleted (AA33R), IMV assembly proceeds in the normal 
manner but there is a severe defect in the membrane-wrapping stage, which results in 
the absence of IEV formation (Roper et al. 1998) (Figure 3.1A+B). Therefore, it is 
difficult to know whether it is involved in microtubule movement. Furthermore, in the 
absence of A33R (AA33R), A36R is not recruited to IEV and it localises exclusively to 
the Golgi membrane, whereas in a AA36R background, A33R is still localised to IEV 
(Figure 3.1C+D, respectively) (Wolffe et al. 2001). Therefore, it has been suggested 
that A33R acts as a chaperone and guides A36R to the IEV particles.
Previous experiments have demonstrated that a direct interaction exists between the 
cytoplasmic domains o f the A36R and A33R proteins, forming a non-covalent complex 
(Ward et al. 2003). They mapped the interaction site o f A36R to amino acids 91-111, 
using the yeast two-hybrid system and confirmed their findings by constructing 
recombinant viruses that contained truncated versions o f the A36R and A33R proteins.
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Figure 3.1: A33R is required for the formation of A36R-positive virus particles. HeLa cells 
infected with either: WR (A+B), AA33R (C) or AA36R (D) vaccinia virus at 1 pfu per cell were 
fixed and permeabilised at 8 hpi. (A.i) Cells stained with A33R (green), B5R (red) and A27L 
(blue) demonstrate that A33R is localised to the Golgi apparatus and TGN (*) as well as IEV, 
CEV and EEV in WR-infected cells. An enlarged region of the cell is shown in (A.ii) to 
emphasize the viral localisation; the white arrows indicate particles positive for B5R, A33R and 
A27L, while the open-arrows high-light those particles only positive for B5R and A33R. (B) 
Localisation of A36R (green) and A27L (red) in WR-infected cells; an enlargement o f the co­
localisation is shown in (B.ii), high-lighted by white arrows. (C) Localisation o f A36R (green), 
B5R (red) and A27L (blue) in AA33R-infected cells. A36R localises to IEV particles and the TGN 
in the WR background but fails to reach IEV and localises exclusively to the Golgi apparatus (*) 
when A33R is deleted from the vaccinia virus genome. (D) Cells infected with AA36R-infected 
virus, probed with A33R (green) and B5R (red). Despite the failure of A36R to be recruited to 
IEV in the absence o f A33R, A33R is still able to localise to IEV particles in the absence of 
A36R. Scale bar = 10pm in (Ai), (Bi), (C) and (D); scale bar = 2.5pm in (Ail) and 2,um (Bii).
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More specifically, they made and analysed five recombinant viruses that contained 
B5R-GFP as an internal marker for IEV. Four of them had the full-length A36R gene 
replaced with C-terminal truncations o f A36R: two of the truncations included residues 
91 to 111, while in the other two viruses these residues were absent. The fifth 
recombinant virus contained a version o f the A33R gene in which the majority of its 
cytoplasmic tail had been deleted (A33RA5-4o). The A36R mutants that lacked residues 
91-111 and the A33R mutant that had its cytoplasmic tail deleted did not make actin 
tails, formed small plaques on cell monolayers (similar to that seen with the AA36R 
mutant) and were only capable o f producing short, sporadic, intracellular movements 
when analysed by video microscopy. These results established that these regions are 
necessary for an interaction between the A36R and A33R proteins and confirmed that 
A33R is required for the incorporation o f the A36R protein into the outer membrane of 
IEV particles (Ward et al. 2003). However, the A33R interaction site on the A36R 
protein could also overlap with potential binding sites of additional, as yet unknown, 
proteins necessary for microtubular movement and/or the formation o f actin tails (Ward 
et al. 2003).
Phosphorylation is one o f the most important regulatory events in eukaryotes and 
involves the addition of a phosphate (P O 4 ) group to a protein, catalyzed by various 
specific protein kinases (Pawson and Scott 2005). Conversely, phosphatases act to 
dephosphorylate a protein and, as a result, many enzymes and receptors are switched 
‘on’ or ‘o f f  by phosphorylation and dephosphorylation. Within a protein, 
phosphorylation can take place on several amino acids, with the most common 
phosphorylation event occurring on serine residues (Ser, S), followed by threonine (Thr, 
T) and tyrosine (Tyr, Y) residues. This is true for the A33R and A36R proteins, as 2- 
dimensional (2D) phosphoamino-acid analysis demonstrated that both are 
predominantly phosphorylated on serine residues (Wolffe et al. 2001). Although A36R 
can also be phosphorylated on tyrosine residues there is no evidence for tyrosine 
phosphorylation o f A33R. Interestingly, serine phosphorylation of A33R and A36R has 
been shown to occur independently o f each other and does not require virus assembly 
(Wolffe et al. 2001). Since A33R is a transmembrane protein, serine phosphorylation is 
limited to its cytoplasmic tail, which is the region defined to mediate binding to A36R. 
However, the identity o f the serine residues that undergo phosphorylation and the exact 
role of A33R serine phosphorylation remains to be established. Therefore, I set out to
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examine if serine phosphorylation of A33R modulates the ability of the protein to bind 
and/or recruit A36R and/or microtubuie-based transport.
3.2 Generation o f phosphospecific antibodies against A33R
There are only two serine residues exposed on the cytoplasmic tail of A33R: S e ri2 and 
Seri5. S eri2 is predicted to be the most likely candidate for phosphorylation, using the 
Netphos software (www.cbs.dtu.dk/services/NetPhos: Technical University of
Denmark). It is important to note that this programme also predicted phosphorylation 
sites on the cytoplasmic tail at threonine residues 3, 11 and 17 and tyrosine residue 19 
(Figure 3.2A). However, as there is no evidence for A33R being phosphorylated on 
tyrosine residues and only trace amounts on threonine residues, these sites were ignored 
(Wolffe et al. 2001). And, based on the assumption that these serine residues are 
phosphorylated we set out to raise phosphospecific antibodies. Therefore, to test the 
hypothesis that S eri2 and Seri5 are phosphorylated, rabbits were immunized with 
phosphopeptides corresponding to the regions surrounding these two serine residues, 
either individually or in combination: Serl2, Serl5 or Serl2 and Serl5 (Figure 3.2B). 
Short peptides were designed to ensure that the phosphorylated serine is immuno­
dominant within the sequence: the Seri2 peptide spans A33R amino acid residues 8-16; 
the Seri5 peptide spans residues 11-19; and the S eri2+ 15 peptide spans residues 8-19. 
Peptide-KLH conjugates were isolated, injected into rabbits (two per antigen) using the 
maleimide-activated KLH approach (see Section 2.11.1) and the resulting bleeds were 
analysed by western blot and immunofluorescence microscopy.
A33R phosphopeptides were prepared by solid-phase peptide synthesis, in Cancer 
Research UK’s Peptide Synthesis Laboratory, whereby the protected amino acids are 
added sequentially to an insoluble support by a linker. A cysteine residue was added to 
the N-terminal o f each peptide sequence to permit efficient conjugation of the peptide to 
the carrier protein KLH via the sulpho bond (-SH group) on the cysteine residue, using 
the Sulfo-SMCC linker (Sulfosuccinimidyl 4-[N-maleimidomethyl]cyclohexane-l- 
carboxylate) (Pierce). Coupling the peptide to a larger carrier molecule, i.e. KLH, acts 
as an adjuvant to induce a strong antibody response and presents multiple epitopes, thus 
improving the immuno-genetic efficiency. Also, if the resultant antibody is going to be
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Figure 3.2: Generation of A33R phosphospecific antibodies. (A) Prediction results for sites 
of phosphorylation on the A33R protein (generated using NetPhos software, Technical 
University of Denmark; www.cbs.dtu.dk/services/NetPhos). The potential residues identified 
include: serine residues 12, 15; threonine residues 3, 11, 17; tyrosine residues 19, which all 
reside on the exposed cytoplasmic tail that is accessible for possible interactions. The red line 
divides those residues exposed on the cytoplasmic tail (above the line) from the rest of the 
protein. The scores have an output range o f 0.000 -  1.000, with a significant threshold value of 
0.500. Those residues labelled with a star (*) are above this threshold and thus possess a 
greater probability of being phosphorylated (Aii). Note that residues that are not predicted to be 
phosphorylated, as a result o f the output score being below the threshold (0.500) or because 
the residue is not Ser, Thr or Tyr, is represented by a dot (.). Those residues that have 
generated a predicted score above the threshold are indicated by ‘S ’, ‘T  or ‘Y’, respectively. For 
example, A33R Ser 12 has a score o f 0.861, which indicates a highly likely site of 
phosphorylation; whereas Ser15 has a score of 0.029, indicating that the confidence for this 
being a true site of phosphorylation is quite low. (B) Phosphopeptides used to generate 
phosphospecific antibodies against A33R: A33R-PSer 12, A33R-PSer15, A33R-PSer12+15. The 
serine (S) residues that have been phosphorylated are indicated in red and the additional N- 
terminal cysteine residue (blue) was added to allow optimal conjugation of the peptide o f the 
carrier protein KLH.
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Ai PHOSPHORYLATION PREDICTIONS
Threonine
N a m e Pos Context Score Pred
Sequence 3 --MMTPEND 0.749 T*
Sequence 11 DEEQTSVFS 0 883 *T*
79 _ass iiiatfflgiffl
Sequence 71 EAAITDAAV 0.060 .
Sequence 83 AASSTHRKV 0 858 ‘T*
Sequence 91 VASSTTOYD 0 023
Sequence 92 ASSTTQYDH 0.350
Sequence 127 KANCTAESS 0.026
Sequence 132 AESSTLPNK 0.021 .
Sequence 142 OVLITWLID 0 010
Sequence 151 YVEDTWGSD 0 754 *T* 
Sequence 160 GNPITKTTS 0.015
Sequence 162 PITKTTSDY 0 426
Sequence 163 ITKTTSDYQ 0.152
Sequence 183 FCVKTMN-- 0.012
Tyrosine
Name Pos Context Score Pred
104 CNGLYYQGS 0 417
105 NGLYYQGSC 0.109 
110 QGSCYILHS 0 062 
116 LHSOYQLFS 0 043 
147 WLIOYVEDT 0321 
166 TTSOYQOSD 0.942 *Y* 
178 EVRKYFCVK 0323
Sequence
Sequence
Sequence
Sequence
Sequence
Sequence
Sequence
Serine
Name Pos Context Score Pred
Sequence 12 EEQTSVFSA 0 861 *S* 
15 TSVFSATVY 0 <MB ii W ffllW .
Sequence 44 SMVISLLSM 0 009
Sequence 47 ISLLSMITM 0 035 .
Sequence 52 MITMSAFU 0.007
Sequence 64 NQCMSANEA 0.145
Sequence 81 VAAASSTHR 0.185
Sequence 82 AAASSTHRK 0.471
Sequence 89 RKVASSTTQ 0.081
Sequence 90 KVASSTTQY 0.991 *S*
Sequence 99 DHKESCNGL 0.058
Sequence 108 YYQGSCYIL 0.003
Sequence 114 YILHSDYQL 0 079 .
Sequence 120 YQLFSDAKA 0.011 - 
Sequence 130 CTAESSTLP 0.006
Sequence 131 TAESSTLPN 0032
Sequence 137 LPNKSDVLI 0.100 .
Sequence 154 OTWGSDGNP 0.062
Sequence 164 TKTTSDYQD 0.965 *S*
Sequence 169 DYQDSDVSQ 0.588 ‘S*
Sequence 172 DSDVSQEVR 0 954 *S*
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c o
cd
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 I____
Sarin*
T h r e o n i n e
Tyrosine
T h re sh o ld
— I—
A33R sequence position (amino acids)
Bi
A33R-PSer12 
A33R-PSer15 
A33R-PSer12+15
h2n-CEEQTSVFSA-co2h
H2N-CTSVFSATVY-CO2H
H2N-CEEQTSVFSATVY-CO2H
A33R
IEV
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subjected to affinity purification, this terminal cysteine residue enables straightforward 
immobilization of the peptide on the SulphoLink® affinity matrix (Pierce).
3.3 Characterisation o f A 33R  anti-sera
SDS-PAGE and western blot analyses were performed on whole cell (total protein) 
extracts prepared from HeLa cells infected with equal titres o f WR and AA33R vaccinia 
viruses. Unfortunately, none of the bleeds tested (Ser 12 peptide [rabbit #1 and #2], 
Seri 5 peptide [rabbit #3 and #4], Ser 12+15 peptides [rabbit #5 and #6]) recognised a 
unique band between 23 and 28kDa in the WR background when compared against the 
control AA33R or uninfected backgrounds (Figure 3.3). Initially, it appeared as though 
rabbit #6 (Ser 12+15) detected a band in the correct range but this band was apparent in 
both the WR and AA33R backgrounds. Therefore, these sera were not suitable for 
further biochemical analysis. Although, perhaps these antibodies have a weak or low 
affinity, which suggests that purification might be necessary.
However, although the antibodies failed to reproducibly detect a single band by western 
blotting, investigation continued with immunofluorescence testing. The denaturing 
conditions that the samples are subjected to for SDS-PAGE unfolds the protein, 
potentially disrupting the 3D epitopes. Nevertheless, as the epitopes are presented 
differently on cells prepared for immunofluorescence studies (see Section 2.5), i.e. in 
their native conformation, analysis was performed by immunofluorescence for 
completeness.
For immunofluorescence analysis, the bleeds were tested on WR-infected HeLa cells, 
using a range of different fixation conditions. The ideal fixation condition would have 
the capacity to stabilize all structures within the cell in their native conformation, while 
allowing complete access o f antibodies to their epitopes. Unfortunately, this ideal 
fixation condition does not always exist, so a compromise is attained between these 
conflicting requirements that is dependent upon the type and the location of the specific 
antigens. Some antibodies detect a precise localisation with one fixation but not another, 
so it was essential to test the antibodies with a range of different fixation methods to 
establish the best one (see Section 2.5.1). All o f the antibodies were tested on cells fixed 
by PFA, P-T, MeOH and P-M (see Table 2.10). Both antibodies raised against the
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Figure 3.3: Western blot analysis o f A33R phosphospecific antibodies. Example of 
western blots achieved upon testing the phosphospecific antibodies raised against the A33R- 
PSer12 (rabbits 1&2), A33R-PSer15 (rabbits 3&4) and A33R-PerS12+15 (rabbits 5+6) peptides. 
The anti-sera used in this figure was obtained from Bleed #2, used at a dilution of 1:1000, and 
was tested on HeLa whole cell extracts infected with either WR or AA33R virus. A33R typically 
runs at -~23-28KDa. The antibodies behaved the same in both the WR and AA33R viral 
backgrounds for Bleed #1, 2, 3 and the terminal bleed. Therefore, no A33R-specific antibodies 
were generated that were suitable for western blot detection.
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A33R-PSerl2 peptide worked well in all four fixation conditions but it was felt clearer 
and cleaner results were achieved when cells were fixed with either PFA or MeOH. 
Likewise, the antibodies raised against the A33R-PSerl5 and A33R-PSerl2+15 
peptides performed best on PFA or MeOFl treated cells.
The sera from rabbits inoculated with the Ser 12 peptides, the S eri5 peptides and the 
Ser 12+15 peptides all stained virus particles that were associated with actin tails (Figure 
3.4). However, in order to determine the specificity of these antibodies, the first step 
was to label WR and AA33R-infected HeLa cells with a wild-type A33R antibody, 
together with the PSerl2, PSerl5 and PSerl2+15 antibodies (Figure 3.5). The 
A33R:PSerl2 antibody is the only one that demonstrated co-localisation with A33R in 
WR-infected cells, as shown by a strong TGN signal and co-localisation of virus 
particles in the cell periphery. This peripheral signal appears to be specific, as the 
background staining produced by the antibody is also seen when tested in the AA33R 
background and can therefore be disregarded (Figure 3.5A). As it could be predicted 
that extended analysis may reveal one o f the following staining patterns: (i) negative 
TGN and positive IEV signals, (ii) positive TGN and IEV signals, (iii) negative TGN 
and IEV signals together with a positive CEV signal, it should be investigated further.
The Netphos software also identified Ser 12 as the residue most likely to be 
phosphorylated, with a significant prediction score of 0.861, compared to 0.029 for 
S eri5 (Figure 3.2. The legend provides details about interpretation o f the scores). 
Therefore the analysis reported herein refers to the A33R-PSerl2 antibody. For 
comparison, the A36R tyrosine residues 112 and 132, which are known to undergo 
phosphorylation, produce scores o f 0.97 and 0.95 respectively, with the Netphos 
software (Figure 3.6). In addition, the other two tyrosine residues that are recognised by 
the programme, 158 and 200, give scores o f 0.963 and 0.970, respectively, while two 
randomly selected non-phosphorylated serine residues 91 and 169 produce scores of 
0.102 and 0.002, respectively.
The staining pattern o f the A33R-PSerl2 antibody appears to be specific to Ser 12 of 
A33R, as the labelling o f virus particles was ablated by peptide competition using the 
Ser 12 phosphorylated antigenic peptides (Figure 3.7A+B). Importantly, incubation of
158
Chapter 3 Is There A Role For A33R. Phosphorylation In Viral Egress?
A
Antibody Fixation Condition
Peptide Rabbit P-M MeOH PFA P-T
PSer12 1 V vvv
2 V v w vv V
PSer15 3 X V V X
4 X V vv X
PSer12+15 5 vv vv V
6 X V X
A33R
Figure 3.4: Immunofluorescence activity of A33R phosphospecific antibodies. (A) Results 
table comparing the different phosphospecific A33R antibodies by immunofluorscence in P-M, 
MeOH, PFA and P-T fixation conditions (see Table 2.10). The efficiency of each antibody was 
graded on a scale of 1 to 3 ticks (W), with VVV demonstrating the clarity of the localisation and a 
cross (X) indicates that the antibody did not work. The most efficient methods were MeOH and 
PFA (high-lighted by the red box). (B) HeLa cells were infected with the WR vaccinia virus, 
fixed at 8 h.p.i and labelled with alexa phalloidin (red), B5R (blue) and the A33R antibodies 
(green). The A33R antibody used in each panel is detailed on the left-handside, i.e. (i) wild-type 
A33R, (ii) A33R-PSer12, (Hi) A33R-PSer15 and (iv) A33R-PSer12+15. For each A33R antibody, 
co-localisation is evident with viral particles that are associated with actin tails. Scale bar = 
10pm and 1.25pm in the enlarged images.
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Figure 3.5: Localisation of the A33R phosphospecific antibodies. The (A) A33R:PSer12,
(B) A33R:PSer15 and (C) A33R:PSer12+15 antibodies (red) were co-labelled with wild-type 
anti-A33R (green) on HeLa cells infected with either WR orAA33R virus. Scale bar = 10pm.
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Sequence *  200 HSDOYLNKQ 0.978 »Y* Sequence 119 VAGSTLLIN 0.024 Sequence *  60 KSTDSESCW 0.997 »s*
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Sequence *  144 NETETVKVL 0.923 *T* Sequence 94 SFAGSLIWD 0.102
Sequence 1S2 INEDTKQNP 0.120 Sequence 101 WDNESNVMA 0.089
Sequence 169 NYNKTSICS 0.025 Sequence 107 VMAPSTEHI 0.510 •s*
Sequence 180 NPFITELNN 0.034 Sequence 114 HIYDSVAGS 0.257
Sequence 118 SVAGSTLLI 0.010 .
Sequence 159 NPNYSSNPF 0.014
Sequence 160 PNYSSNPFV 0.002
Sequence 170 YNKTSICSK 0.070
Sequence 173 TSICSKSNP 0.583 •s*
Sequence 175 ICSKSNPFI 0.029
Sequence 187 NNKFSENNP 0.223
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Figure 3.6: Prediction results for sites of phosphorylation on the A36R protein (generated 
using NetPhos software, Technical University of Denmark; www. cbs. dtu. dkJservices/NetPhos). 
The potential residues identified include: 12 serine residues, 2 threonine residues and 4 tyrosine 
residues. The red line divides those residues exposed on the cytoplasmic tail (below the line) 
from the rest of the protein. The scores have an output range of 0.000 -  1.000, with a significant 
threshold value of 0.500. Those residues labelled with a red star (*) are above this threshold 
with a value >0.900 and thus possess a greater probability of being phosphorylated. Tyrosine 
residues 112 and 132, labelled with a green star (*), are known to be phosphorylated. Note that 
residues that are not predicted to be phosphorylated, as a result o f the output score being below 
the threshold (0.500) or because the residue is not Ser, Thr or Tyr, is represented by a dot (.). 
Those residues that have generated a predicted score above the threshold are indicated by ‘S’, 
T  or ‘Y’, respectively. For example, A33R Ser12 has a score o f 0.861, which indicates a highly 
likely site of phosphorylation, whereas Ser15 has a score of 0.029, indicating that the 
confidence for this being a true site o f phosphorylation is quite low.
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Figure 3.7: Peptide competition experiments with the A33R-PSer12 antibody. WR-infected 
HeLa cells were fixed 8 hpi with 3% PFA and permeabilised with 0.1% Triton X-100 before co­
labelling with A33R-PSer12 (green), alexa phalloidin 568 (red) and B5R (blue). The A33R- 
PSer12 antibody alone is shown in (A), the antibody incubated with the A33R-PSer12 
phosphopeptide is shown in (B) and the antibody plus the addition of unphosphorylated A33R 
peptide is shown in (C). The antibody labels virus particles and can clearly be seen associated 
with actin tails in (A) and (C) but absent in (B). The loss of antibody signal during peptide 
competition with the PSer12 peptide but not with the unphosphorylated form is indicative of the 
antibody being phosphospecific. Scale bar = 10pm in (Ai, Bi, Ci) and 1.5pm in (Aii, Bii, Cii)
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the antibodies with the unphosphorylated form of this peptide did not inhibit the 
staining of virus particles (Figure 3.7C). These results suggest that: (i) Ser 12 of A33R is 
phosphorylated when recruited to virus particles, or possibly even prior to recruitment 
(this is highly likely as the TGN has a positive signal) and (ii) the antibody that has 
been generated is specific for this site. Although it was demonstrated that the Ser 12 
antibody was blocked by the Ser 12 peptide, its specificity was not additionally analysed 
by the incubation o f the antibody with the Seri 5 and S eri2+15 peptides. Nevertheless, 
to confirm the specificity o f the A33R-PSerl2 antibody, it was subsequently tested on 
uninfected, WR-infected and AA33R-infected HeLa cells (Figure 3.8A,B,C 
respectively). The AA33R-infected cells were additionally transfected with each of the 
serine-to-alanine mutant constructs (Figure 3.8D,E,F,G respectively). Upon analysis, 
the results suggest that the antibody generated is indeed site-specific. In these images 
the antibody has a high background staining, possibly due to the antibody concentration 
not being dilute enough or as a result o f cross-reactivity with A33R (regardless of its 
phosphorylation status), so it was difficult to draw definitive conclusions. In spite of 
this, no signal was detected in the uninfected or AA33R backgrounds, as expected 
(Figure 3.8A+C), whereas the antibody does co-localise with A33R in WR-infected 
cells (Figure 3.8B). Co-localisation was also seen with transfection of the wild-type 
A33R and A33R:S15A (Figures 3.8D and F, respectively), but this was not evident with 
the A33R:S12A or A33R:S12+15A mutants (Figure 3.8E and G, respectively). 
Unfortunately, due to time constraints, it was not possible to analyse the A33R:S12D 
mutant in the same manner.
Immunofluorescence stainings with the A33R-PSerl2 antibody recognised A33R- 
positive virus particles in WR virus-infected cells (Figure 3.9A). The A33R-PSerl2 
antibody also labelled the TGN, although with variable intensities, and co-localised on 
IEV with kinesin (Figure 3.9B+C). Irrespective of the fixation method used the same 
localisation patterns were observed, although PFA-only or MeOH-only produced the 
best results (See Figure 3.4A). However, despite this co-localisation, kinesin-positive 
particles could also be identified independently o f the A33R-PSerl2 antibody labelling 
(Figure 3.9Bi, open-arrow). This could implicate the event of A33R phosphorylation as 
a prerequisite for the loading and/or unloading o f kinesin-1.
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Figure 3.8: Demonstration of the specificity of the A33R:PSer12 antibody. The antibody 
was tested on HeLa cells that were either (A) uninfected or infected with (B) WR virus or (C-G) 
AA33R. Cells infected with AA33R were additionally transfected with (D) pE/L-VSVG-A33R, (E) 
pE/L- VSVG-A33R.S12A, (F) pE/L-VSVG-A33R:S15A and (G) pE/L-A33R:S12+15A. Cells in (A)-
(C) were co-stained with A33R:PSer12 (red), A33R (green) and A27L (blue), while those in (D)- 
(G) were co-labelled with A33R:PSer12 (red), VSVG (green) and A27L (blue). This data 
indicates that the antibody is specific as it recognises wild-type A33R (B) and only co-localises 
with the pE/L-VSVG-A33R and pE/L-VSVG-A33R.S15A constructs. Co-localisation is exhibited 
in B, D and F. Scale bar = 10pm.
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Figure 3.9: A33R-PSer12 co-localises with A33R-positive and kinesin-positive particles.
HeLa cells were infected with either WR (A) or YdF vaccinia virus (B+C) and fixed 8 hpi. (A) Co­
labelling with A33R-PSer12 (red) and wild-type A33R (green) demonstrates clear co-localisation 
between the antibodies, as indicated by the resultant yellow colour. (B) Co-staining with A33R- 
PSer12 (green), kinesin (red) and B5R (blue) also displays co-localisation. However, kinesin- 
positive particles are also detected independently of the A33R-PSer12 antibody, as indicated by 
the open-arrow in (Bi). Scale bar = 10pm in the whole cell images of (A), (B) and (C), while in 
the enlargements, the scale bars = 1.5pm in (A) and 2 pm in (B) and (C).
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3.4 M utations introduced into the A33R protein do not affect actin 
tail form ation
In parallel, to investigate the effect o f phosphorylation on the function of the A33R 
protein, Serl2, Serl5 and Serl2+15 were mutated to aspartic acid (D) to mimic the 
effects o f phosphorylation or to nonphosphorylatable alanine (A), using Quikchange™ 
PCR reactions (Figure 3.10A and Figure 3.11 A, respectively; see Section 2.4.8.2). 
These constructs were additionally tagged at the N-terminus with the viral 
transmembrane protein vesicular stomatitis virus glycoprotein (VSV-G), to facilitate 
their localisation in transfected cells. The VSV-G tag, YTDIEMNRLGK, corresponds 
to amino acids 501-511 o f VSV-G and the anti-VSV-G antibody recognises and reacts 
specifically with the VSV-G tag sequence on the VSV-G tagged fusion proteins (Kreis 
1986). An advantage of utilising this viral epitope as a tag, in addition to its small size, 
is the reduced risk of the same epitope being present in cellular proteins and, thus, the 
possibility of the antibody cross-reacting with cellular material. Tagged-versions of the 
A33R protein(s) were made and utilised in order to confirm, unequivocally, the results 
seen using the AA33R virus and A33R antibodies.
In order to assess the role of these putative serine phosphorylation sites, cells that were 
infected with the AA33R virus were also transfected with each of the mutant constructs 
at 4 hpi. Cells infected with AA33R virus cannot make IEV particles but this defect can 
be rescued upon transfection with wild-type A33R (Figure 3.12A+B). The mutants were 
assayed in the same way and actin tail formation was used as a read-out for effective 
virus formation and egress, i.e. complete life-cycle. A positive result was scored if a cell 
contained at least one actin tail.
Immunofluorescence analysis demonstrated that all three constructs possessing the 
serine-to-alanine mutation: A33R-S12A, A33R-S15A and A33R-S12+15A, are 
incorporated into virus particles that are able to egress to the periphery of the cell and 
generate actin tails. This proved true for the constructs tagged at the N-terminus with 
either VSV-G or GFP (Figure 3.10B+C). Subsequently, a quantitative analysis of actin 
tail-associated, VSV-G positive viral particles present in cells, showed that there was no 
significant reduction in the percentage o f cells that can make tails in the absence of 
phosphorylated.
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Figure 3.10: Mutation of putative A33R serine phosphorylation sites to alanine residues 
does not appear to alter its function. (A) DNA sequence of A33R high-lighting the serine-to- 
alanine substitutions that were introduced by Quikchange™ PCR reaction. (B) Wild-type A33R 
and A33R-S12A, A33R-S15A, A33R-S12+15A mutant constructs were transfected into AA33R- 
infected HeLa cells, fixed and permeablised 8 hpi and labelled with VSVG (green), alexa- 
phalloidin 568 (red) and A27L (blue). (D) The same mutant constructs were also made and 
analysed with a GFP tag, to ensure that the tag did not impair their function. The GFP- 
constructs were transfected into AA33R-ihfected HeLa cells and co-stained for actin (red) and 
B5R (blue). The wild-type and all of the mutants are capable of rescuing the wild-type 
phenotype. The number cells possessing VSVG-tagged A33R virus particles associated with 
actin tails were scored and their corresponding percentages calculated (C). A positive result 
was scored for cells containing at least one actin tail. The graph demonstrates that there is no 
significant difference between the wild-type and mutant A33R constructs. Scale bars = 10pm 
and 1.5 pm in the enlarged images.
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Figure 3.11: Introduction of an A33R:S12+15D phosphomimetic mutation appears to 
behave as wild-type A33R. (A) Sequence of A33R high-lighting the serine [S] to aspartic acid
[D] amino acid substitutions that were introduced by Quikchange™ PCR reaction. pEL-VSVG- 
A33R:S12+15D was transfected into AA33R-infected HeLa cells, fixed and permeablised 8 hpi. 
Cells were and labelled with alexa-phalloidin 568 (red), VSVG (green) in (B) and with A33R 
(green) and VSVG (red) in (C). The mutant construct is still recruited to actin tails and exhibits 
co-localisation with wild-type A33R. Scale bars = -2[im in (B) and (C).
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Figure 3.12: Rescue o f the AA33R virus. Panels A, B and C show HeLa cells infected with 
AA33R, transfected with either pEL-GFP-A33R (A) or pEL-VSVG-A33R (B+C) and fixed at 8hpi. 
Co-labelling with alexa-phalloidin 568 (A+B) or A33R (C) (red) and VSVG (green; B+C) 
demonstrates that both constructs are capable of rescuing the wild-type phenotype as they 
recognise virus particles associated with actin tails (A+B). As this was the first time the VSVG 
tag had been used as a marker in this study, co-staining was performed with an A33R antibody 
(red) to verify the localisation (C). Comparison with the wild-type situation demonstrates that the 
VSVG-tag labels viral particles upon transfection of the pEL-VSVG-A33R construct into WR- 
infected cells (D). Cells were labelled with B5R (red), VSVG (green) and A27L (blue). Taken 
together, this data indicates that the constructs are functional. Scale bar = 10pm in (Ai, Bi, Ci) 
and 1.5pm in (Aii, Bii, Cii, D).
MergeVSVG-A33R
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A33R (Figure 3.9Bii). Wild-type behaviour was also observed upon transfection of the 
construct containing the aspartic acid phospho-mimetic substitutions (Figure 3.11). 
However, this does not preclude a role for these serine sites in the life-cycle of the virus 
and a different assay may be required to determine their role. This is discussed in 
Chapter 7.
Over-expression in the AA33R background demonstrates co-localisation with a few 
viral particles, although the antibody appears to more strongly co-localise with A33R on 
larger structures clustered towards the cell periphery. Although not confirmed, these 
structures are reminiscent of endosomes or a collection of virus particles (i.e. the small 
dots seen in the cell periphery by immunofluorescence) and Chapter 7 considers future 
evaluations to determine their true nature.
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3.5 Sum m ary
Antibodies directed against the two cytoplasmic A33R serine phosphorylation sites 
(Seri2 and S eri5) were generated and used to examine the potential effect of A33R 
phosphorylation on viral egress. The antibodies failed to detect a specific signal by 
western blotting but proved to label virus particles associated with actin tails by 
immunofluorescence analysis. The A33R-PSerl2 antibody, but not the A33R-PSerl5 or 
the A33R-PSerl2+15 ones, co-localised with wild-type A33R positive and kinesin- 
positive particles. Furthermore, peptide competition experiments with the A33R-PSerl2 
antibody and unphosphorylated peptide were indicative of its specificity.
A33R mutant constructs in which Serl2, Serl5 and Serl2+15 were altered to non- 
phosphorylatable alanine residues demonstrate that there was no significant reduction in 
the percentage of cells that can make tails in the absence of A33R phosphorylation. 
Also, substitution of the serine residues for aspartic acid, which is thought to mimic the 
constitutively phosphorylated state, demonstrated that they also appear to behave as 
wild-type A33R. The specificity of the A33R-PSerl2 antibody was strengthened upon 
labelling AA33R-infected cells that over-expressed the various serine-to-alanine 
mutants, as the antibody only showed co-localisation with the wild-type and 
A33R:S15A constructs. The mutant A33R constructs demonstrated that they are 
capable o f nucleating actin tails, indicating that they must be able to move to the cell 
surface. And, as this transport occurs on microtubules, the A33R-mutants must also be 
able to recruit A36R into IEV.
In conclusion, at this elementary level, no effect on viral transport was observed upon 
phosphorylation of A33R and more detailed analysis is required (discussed in Chapter 
7). An antibody was also generated that was specific for the PSerl2 site on A33R.
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Chapter 4 Characterisation o f  FI 2L
4.1 Introduction
While our knowledge and understanding o f vaccinia virus egress has developed 
significantly, the molecular basis by which kinesin-1 is recruited to IEV is currently 
unknown (Rietdorf et al. 2001). In addition to the A36R protein being essential for actin 
tail formation, our laboratory has shown that it is also required for the movement of IEV 
particles on microtubules, as virions in which A36R has been deleted (AA36R) do not 
egress to the cell surface and form CEV (Rietdorf et al. 2001; Ward and Moss 2001). 
However, in contrast to these findings, studies performed by other groups have reported 
that IE Vs in the AA36R mutant virus are capable o f moving to the cell surface and EEV 
particles are also detected (Herrero-Martinez et al. 2005).
The involvement of another IEV protein, F12L, has also been implicated in viral egress 
to the cell periphery and in viral association with microtubules (Zhang et al. 2000; van 
Eijl et al. 2002). However, the mode of interaction o f F12L with microtubules, motor 
proteins and IEV is not understood. And, as IE Vs are transported along microtubules, 
the detection of F12L positive particles on microtubules does not demonstrate that F12L 
actually binds microtubules directly (Zhang et al. 2000; van Eijl et al. 2002). In cells 
infected with the AF12L virus, the viral factories remain visible, IV and IMV particles 
are present and IEV particles still form normally, although they fail to be distributed to 
the cell surface. Instead they cluster together in the vicinity o f the viral factories and no 
CEV are detectable on the cell surface (Herrero-Martinez et al. 2005; van Eijl et al. 
2002).
Upon treatment o f infected cells with Ni-isonicotinoyl-N2-3-methyl-4- 
chlorobenzoylhydrazine (IMCBH), IEV formation is blocked and both F12L and B5R 
cluster in cellular processes near the cell periphery. In infected cells, F12L has been 
shown to co-localise with endosomes that are also located in this region (van Eijl et al. 
2002). This can be reasoned by the fact that in the absence of IEV formation, the IEV 
membrane proteins are able to reach the cell periphery via the secretory pathway, 
therefore F12L would also be transported via this system.
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The AF12L virus that was used throughout this study lacks 1207bp (63%) of the F12L 
ORF (Zhang et al. 2000). AF12L virus produces a small plaque phenotype that is 
indicative of an inability to reach the cell periphery and produce actin tails, and hence 
there is a reduction in the virulence o f the virus.
F12L and A36R are likely to be members o f a larger viral complex, together with other 
IEV proteins that constitute the surface o f virus particles. New tools have been 
developed to promote the investigation into how F12L is recruited to IEV and its 
relationship with other viral proteins and kinesin-1. However, during the course of this 
study, another group identified a direct interaction between KLC and A36R using yeast 
two-hybrid analysis and GST pull-down assays (Ward and Moss 2004). The TPR 
domain of the KLC was used as bait to test for interactions with the cytoplasmic regions 
of the A33R, A34R, A36R, B5R and F12L proteins by yeast two-hybrid testing. Initial 
experiments only produced a positive interaction between TPR and A36R and upon 
further testing with a series o f A36R truncations, it was defined that residues 81-111 of 
A36R were sufficient for interaction with TPR.
Residues 91-111 of A36R are required for its interaction with the cytoplasmic tail o f 
A33R and yeast three-hybrid analysis demonstrated that this binding of the A36R 
protein is mutually exclusive to either A33R or kinesin-1. This suggests that A33R 
competes with kinesin-1 for binding to A36R. The same investigation also reported that 
no direct interaction was detected between F12L and kinesin-1 by yeast two-hybrid 
analysis (Ward and Moss 2004). However, it is clear that F12L plays a significant role 
in viral egress but the mechanisms underlying its involvement is currently unclear. 
Therefore the objective o f this chapter is to confirm previous findings from Zhang et al. 
(2000) and van Eijl et al (2002), and to extend the characterisation of F12L by 
generating a range o f new tools, including a F12L antibody and GFP-F12L fusion 
constructs (additional tools were generated and are described in Chapter 5).
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4.2 G eneration of F12L anti-sera
Production of an antibody against F12L was considered a valuable tool to extend the 
characterisation of this protein, as there were no antibodies available against F12L at the 
time when this study was initiated. Rabbits were injected with peptides corresponding 
to either the N- or C-terminus of F12L and the resultant bleeds were subsequently tested 
for reactivity against F12L (either endogenous-F12L or tagged-F!2L expressed in 
E.coli, or infected HeLa cells) by both western blot and immunofluorescence analysis 
(Figure 4.1). The F12L614C peptide spans residues 614-634, i.e. from amino acid 
number 614 to the end of the protein at the C-terminus, hence the adopted nomenclature 
‘F12L614C’ and, in the same respect, the F12LN19 peptide spans residues 1-19 at the 
N-terminus (Figure 4.1 A). Following the same procedure that was described for 
generating the A33R phosphospecific antibodies (see Section 3.2), both peptides were 
conjugated to the carrier protein KLH by the addition of a cysteine residue at the N- 
terminus.
4.3 Characterisation of F12L anti-sera
SDS-PAGE and western blot analysis was performed on whole cell extracts prepared 
from WR-infected or uninfected HeLa cells. The anti-sera raised against the C-terminus 
of the protein (rabbit #7 and #8) detected a band at the correct size for F12L (~65KDa) 
in cells infected with wild-type (WR) virus (Figure 4.2A). Anti-sera from rabbit #8 was 
cleaner and identified fewer non-specific bands. In contrast, the anti-sera raised against 
the N-terminus of the F12L protein (rabbit #5 and #6) failed to detect a specific band 
corresponding to the size o f F 12L.
An affinity-purified antibody was subsequently isolated from the pooled anti-sera (1 ,2 , 
3 and terminal bleeds) of rabbit #8 (see Section 2.11.2). The fractions eluted with 
glycine (pH 2.5) and triethylamine (TEA, pH 11.5) during the purification process (10 
fractions for each) were analysed further to determine which ones displayed the greatest 
affinity, to allow the most efficient pooling of the fractions. The fractions were tested on 
WR-infected HeLa cell lysates expressing both GFP-F12L (~92.5KDa) and the 
endogenous F12L (~65KDa), which were clearly detected in the glycine fractions 3-7 
and the TEA fractions 4-8 (Figure 4.2B). A higher band, approximately ~120KDa, is
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F12L N19 H2N - CMLNRVQILHKTANNYETIE - C02H
F12L614C H2N - CKELYVSSSYKDINESMSQMVK - C02H
0 635
B F12L full length N ----------------------------------------------------------- C
F12LN19 0 — 19
F12L614C 614— 634
C
N-terminal Peptide C-terminal Peptide
Rabbit 5 Rabbit 6 Rabbit 7 Rabbit 8
Bleed 1 - - V vv
2 - - a/ aN
3 - - V a/a/
4 - - a/ VaI
Figure 4.1: Generation of an F12L antibody. (A) Peptide sequences used to raise F12L 
antibodies against the N-terminus (F12LN19) and the C-terminus (F12L614), together with their 
location within the F12L protein (B). (C) Final results table comparing the performance of the 
different F12L antibodies by immunofluorescence and western blot analysis.
(Key: - = no signal, V = good signal, VV = very good signal).
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P ep tid e : N C N C
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A ntibody: R abb it 8 a G F P R abb it 8 a G F P
Elution: G lycine TEA
Fraction  No: 3 4 5 6 7  5  4 5  6 7 8  6
Figure 4.2: F12L antibody testing by western blot analysis. (A) Western blots of F12L bleed 
#3 and the terminal bleed derived from rabbit #5 and #6 (N-terminal peptide) and from rabbit #7 
and #8 (C-terminal peptide). The anti-sera were tested on whole cell lysates, infected with WR 
vaccinia virus. Antibody raised against the C-terminus detects a band at the correct size for 
F12L (indicated by the blue arrow) that was absent in uninfected cell lysates. Antibody raised 
against the N-terminus failed to detect a band. (B) Glycine fractions 3-7 and TEA fractions 4-8 
from rabbit #8 were subsequently tested on WR-infected cell lysates that had been transfected 
with pE/L-GFP-F12L. Endogenous F12L (blue arrow) and GFP-F12L (green arrow) were 
detected in all of the fractions. The fractions were also probed with anti-GFP as a control, 
although only a weak signal was detected; glycine fraction #5 and TEA fraction #6 are shown as 
representative examples.
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also detected by the F12L antibody but not by the GFP antibody. This suggests that 
there may be some cross-reactivity with the F12L antibody or it may recognise a higher 
complex to which GFP-F12L cannot be recruited. Flowever, the ~l20KDa band is 
present in non-infected cells, therefore, any cross-reaction would be with a non-virus 
band. The glycine and TEA fractions were subsequently pooled together (separately) 
and re-tested on the following cell extracts: (i) uninfected, (ii) infected, (iii) infected and 
over-expressing GFP-F12L and (iv) infected and over-expressing F13L-GFP (as a 
negative control) (Figure 4.3). The pooled glycine fractions and TEA fractions detected 
no signal in the non-infected cells but recognised bands of the correct size in all of the 
infected samples.
The resultant affinity purified antibody raised against the C-terminus (rabbit #8) was 
used for the subsequent work presented in this thesis and even after the affinity- 
purification stage, two non-specific bands were still detected above (~95KDa) and 
below (~45KDa) the ~65KDa F12L protein. Investigation of the peptide sequences 
failed to reveal any homologies with host proteins that could account for these spurious 
bands. However, in spite of this, it remains clear that the antibody detects F12L, as 
although these additional bands are recognised in the AF12L background and non- 
infected cells, the genuine F12L signal is not (Figure 4.4).
For immunofluorescence analysis, the bleeds were tested on WR-infected HeLa cells, 
using a range of fixation methods (see Section 2.5.1). Initial analysis revealed 
promising results with rabbit #6 (C-terminal peptide) and rabbit #7 (N-terminal 
peptide). Both rabbits detected clean, precise signals that co-localised with IEV 
particles in all fixation conditions tested, although optimal staining was achieved with 
either PFA or MeOH. However, no clear localisation was detected with the bleeds 
derived from rabbit #5 (N-terminal) or rabbit #8 (C-terminal). Unfortunately, the 
specificity o f the positive bleeds rapidly deteriorated and therefore, an alternative 
strategy for visualising F12L localisation in cells was necessary (Figure 4.5 shows an 
example o f the F12L staining before the antibody stopped working).
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Blot: F12L: G lycine Fractions 3-7 F12L: TEA Fractions 4-8 Anti-GFP
Un Un G FP- F13L- 
F12L G FP 
Non W R WR WR
Un Un G FP- F13L- 
F12L G FP  
Non WR WR W R
Un Un G FP- F13L- 
F12L G FP 
Non W R WR WR
Transfection:
Infection:
F12L -»  66
F13L-GFP
Figure 4.3: Testing pooled F12L glycine and TEA fractions, from rabbit #8, by western 
blot analysis. Western blots of non-infected (Non) and WR-infected whole cell lysates probed 
with pooled F12L glycine fractions (#3-7) (A) and pooled F12L TEA fractions (#4-8) (B) from 
rabbit #8; anti-GFP was used as a control (C). The WR-infected samples were either 
untransfected (Un), or transfected with pE/L-GFP-F12L or pE/L-F13L-GFP. The glycine and 
TEA fractions identify a band at the correct size for endogenous F12L in the WR-infected 
samples (blue arrow) in (A) and (B), in addition to a band corresponding to the correct size for 
GFP-F12L in the sample transfected with GFP-F12L (green arrow). F13L-GFP was used as a 
positive control (F13L is ~37KDa; F13L-GFP is ~64.5KDa; red arrow).
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Blot:
Anti-F12L Anti-GFP
Transfection: Un Un Un GFP-F12L GFP-F12L
Infection: Non 2 F12L WR WR WR
<— GFP-F12L
Figure 4.4: Western blot showing the size of viral F12L. Western blot analysis reveals the 
correct size of viral F12L (~65KDa; blue arrow) and GFP-F12L (~95KDa; green arrow), using an 
affinity purified anti-F12L antibody and anti-GFP antibody. Whole cell lysates were prepared 
from untransfected (Un) HeLa cells that were either non-infected (Non) or infected with AF12L 
or WR vaccinia virus. In addition, a WR sample was prepared that was transfected with pEL- 
GFP-F12L.
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A27L MergeF13L-GFP
Figure 4.5: F12L antibody testing by immunofluorescence. YdF-infected HeLa cells were 
transfected with pE/L-F13L-GFP (green) and fixed with 3% PFA 8 hpi. Cells were permeablised 
and labelled with A27L (blue) and F12L anti-sera (red) from rabbit #6 (A) and rabbit #7 (B). In 
this figure anti-sera from bleed #3 is used as a representative example. Scale bar = 10pm in 
(Ai), (Bi); 2pm in (Aii) and 1.5pm in (Bii).
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4.4 F12L is expressed from  2-4 hpi
The F12L protein has been reported to be expressed both early and late during infection, 
even though it does not posses the late transcriptional start motif, TAAAT, near the 5’ 
end of the open reading frame (ORF) (Zhang et al. 2000). It was shown that the level of 
F12L was severely reduced, but was still detectable, in infected cell lysates that had 
been treated with cytosine arabinoside. This drug has the capacity to inhibit virus DNA 
replication and therefore the expression of intermediate and late virus proteins (Zhang et 
al. 2000). This indicates that the F12L protein is expressed early and it remains 
expressed, or perhaps the protein is not degraded effectively, so once it becomes 
expressed it remains detectable within the cell. Further western blotting experiments 
were performed that support this characterisation, as expression o f F12L can be strongly 
detected from 4 hpi (and weakly at I and 2 hpi) in whole cell lysates infected with the 
WR virus and remains detectable for at least 12 hpi (Figure 4.6).
4.5 F12L Localisation
4.5.1 F12L tagged with GFP localises to IEV particles on microtubules
GFP-tagged F12L is recruited to IEV particles, which was identified by co-staining for 
a known IEV marker B5R (Figure 4.7A). GFP-tagged F12L also labels a subset of 
A27L positive particles, which are a mixture of both IMV and IEV (Figure 4.7B). This 
data is consistent with previous findings suggesting that F12L is located on IEV (Zhang 
et al. 2000; van Eijl et al. 2002). They also observed that F12L does not label the viral 
factory (site of IEV assembly), in contrast to B5R labelling. F12L is not exposed on the 
cell surface nor associated with CEV particles and electron microscopy confirmed that 
F12L is located solely on IEV particles, primarily around the outside of the particle, 
rather than between the wrapping membranes (van Eijl et al. 2002). And, as F12L is not 
an integral membrane protein, this suggests that it is recruited to mature virus particles. 
When these results are considered together with the fact that B5R is also present on 
CEV, it explains why F12L only labels a subset of B5R positive particles. Therefore, 
F12L resides exclusively on IEV particles while B5R is present on IEV and CEV (van 
Eijl et al. 2002). Co-staining with alpha-tubulin also reinforce previous confocal 
microscopy analysis claiming that IE Vs that have recruited F12L are associated with 
microtubules (Figure 4.8).
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102.4
anti-F12L
anti-A36R
anti-Tubulin
0 1 8 10 12 hours
Figure 4.6: Timecourse of F12L expression. Western blot analysis, of whole cell lysates from 
HeLa cells infected with the WR virus, demonstrating the expression of F12L over a 12 hour 
duration. Blots were probed with anti-F12L (A) and the control antibodies: anti-A36R, (B) and 
anti-tubulin (C). The F12L protein is expressed between 2 and 4 hpi, while A36R can be seen 
expressed from 6-8 hpi.
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Figure 4.7: F12L is located in IEV particles. Immunofluorescence analysis of WR-infected 
cells 8hpi reveals that GFP-F12L and F12L-GFP (green) are recruited to B5R positive IEV 
particles (red (A); solid arrows) and to a subset of A27L positive particles (blue (B); open 
arrows). A27L positive particles represent both IMV and IEV. Scale bar = 1.5pm.
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A Merge
Figure 4.8: F12L localises to virus particles associated with microtubules. (A) WR-infected 
HeLa cells were transfected with pE/L-GFP-F12L (green) 4 hpi and fixed 8 hpi, prior to staining 
with anti-a-tubulin (red). An enlargement of a selected region of the cell is shown in (B). Scale 
bar = 10pm.
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4.5.2 GFP-F12L and F12L-GFP rescue viral egress of AF12L
In order to facilitate the localisation studies of F12L, constructs were generated (with 
both pE/L and CB6 promotors; see Section 2.4.2) in which the F12L protein was tagged 
at either the N or C-terminus with GFP (termed GFP-F12L and F12L-GFP, 
respectively). These were shown by western blotting to be the correct size when 
expressed in infected HeLa cells, i.e. ~92.5KDa (Figure 4.4). In uninfected cells, both 
GFP-F12L and F12L-GFP adopt a diffuse localisation (Figure 4.9).
ot-Tubulirv
Figure 4.9: Immunofluorescence localisation of F12L in uninfected cells. HeLa cells were 
transfected with (A) CB6-GFP-F12L and (B) CB6-F12L-GFP (green) and co-stained with anti-a- 
tubulin (red). Both constructs exhibit a non-specific, diffuse localisation in uninfected cells. Scale 
bar = 10pm.
Expression of GFP-F12L or F12L-GFP rescued the transport of IEV to the cell surface 
in cells infected with the AF12L virus (Figure 4.10). This indicates that the GFP-tag 
does not appear to compromise the function of F12L. To verify this, a F12L plasmid 
was also constructed in which the relatively large GFP-tag (~27.5KDa) was replaced 
with the smaller HA-tag (~lK D a; 9 amino acids). Upon expression of this clone in 
AF12L-infected cells, HA-F12L was also recruited to IEV particles and was able to 
rescue the microtubule-based movement, based on actin tail formation (i.e. the ‘wild- 
type’ phenotype). The ‘wild-type’ phenotype refers to the ability of vaccinia virus to 
complete its life-cycle, which is evident by the formation of actin tails, or by staining 
for extracellular virus with the B5R antibody prior to permeabilisation (Figure 
4.10A+B). van Eijl et al. calculated that the number of actin tails produced in AF12L-
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Figure 4.10: Rescue of the AF12L virus. (A) AF12L-infected HeLa cells were transfected with 
either pE/L-F12L-GFP (Ai+Bi) or pE/L-GFP-F12L (Aii+Bii) (green). In (A), unpermeabilised cells 
were co-stained with B5R (red) and DAPI (blue), while in (B) cells were permeablised and co­
stained with alexa-phalloidin 568 (red) and DAPI (blue). (C) Quantitation of extracellular B5R 
particles (A) or actin tail formation (B) in AF12L-infected HeLa cells, transfected with either 
GFP-F12L or F12L-GFP. A positive result was scored when a transfected cell exhibited either 
extracellular B5R (A) or at least one actin tail (B). The data shown represents the results 
accumulated from three separate experiments, counting a minimum of 100 cells per condition. 
The standard deviations are indicated by error bars. (D) Rescue of AF12L with HA-F12L. 
AF12L-infected HeLa cells were transfected with pE/L-HA-F12L 4 hpi and fixed 8 hpi, prior to 
staining with HA (red), A36R (green) and B5R (blue). Arrows high-light the co-localisation 
observed. Scale bar = 10pm in (A), (D) and 1.5pm in (B).
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infected cells was reduced by 99.5% and on the rare occasion that a tail was observed, it 
appeared thicker than those normally detected in WR-infected cells (van Eijl et al. 
2002). Positioning the GFP-tag at either the N- or C-terminus enabled the viral life­
cycle to be rescued, although it appeared that the rescue efficiency was significantly 
more efficient when the construct was tagged at the C-terminus. For example, when 
tagged at the C-terminus, the rescue efficiencies were 77% and 75%, compared to 63% 
and 66% for the N-terminus, when analysed> by extracellular B5R staining and actin 
tails, respectively (Figure 4 .10C). However, T-test calculations confirmed that there is 
no significant difference between the readings produced when the constructs are tagged 
at either the N- or the C-terminus.
4.5.3 Localisation of other IEV proteins in the AF12L background
The localisation of the IEV proteins A33R, A34R, A36R, B5R and F13L in vaccinia 
virus-infected cells is already well documented (see Section 1.9.2.5 and Table 1.4). In 
WR-infected HeLa cells, they are all capable of labelling virus particles that associate 
with actin tails, in addition to labelling the TGN (Figure 4 .1 la  and Figure 4.11b). 
Various interactions between these proteins have already been verified (see Table 1.6), 
although these have not been extensively investigated in the context o f the F12L 
protein. Therefore, characterisation of F12L continued with the examination of these 
IEV proteins in HeLa cells infected with the AF12L virus, with the aim of determining 
whether F12L has an effect on the recruitment of viral proteins and the transport of 
virus particles.
Despite the inability of the AF12L virus to produce IEV that egress to the cell surface, 
the viral proteins analysed do not appear to be mis-localised by the absence o f the F12L 
protein (Figure 4.12). Virus particles can be visualised, although their egress appears to 
be restricted, as they do not reach the cell periphery. This data represents preliminary 
results and localisation of these IEV proteins should also be performed with another 
viral marker to acquire more informative data. Nevertheless, current findings suggest 
that: (i) F12L is recruited after IEV assembly; (ii) the presence of F12L correlates with 
kinesin-1 (with the majority not being located on microtubules) and (iii) F12L needs to 
be studied dynamically in order for real insight to be gained.
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Figure 4.11a: Localisation of IEV proteins in WR-infected cells. Immunofluorescence 
sum m ary of the localisation the IE V  proteins (A) A33R, (B) A 36R, (C ) B5R, (D ) A 34R  and (E) 
F13L (green) in HeLa cells fixed a t 8  hpi and co-labelled with alexa phalloidin 568  (red) and  
D A P I (blue). All o f the IE V  m arker antibodies recognise D A P I virus particles associated with 
actin tails and label the Golgi apparatus and  TGN. For additional localisations for each protein 
see Section 1.9.2.5. Enlargem ents o f the selected regions are shown in Figure 4.11b. Scale bar 
= 10g m .
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PI
Figure 4.11b: Enlarged images from Figure 4.11a, showing the localisation of IEV 
proteins in WR-infected cells. Immunofluorescence summary o f the localisation the IE V  
proteins (A) A33R, (B) A36R, (C) B5R, (D) A 34R  and (E) F13L (green) in HeLa cells fixed at 
8hpi and co-labelled with alexa phalloidin 568 (red) and D A PI (blue). Scale bar = 2.5pm.
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Figure 4.12: Localisation of IEV proteins in AF12L-infected cells. Immunofluorescence 
demonstrating the localisation o f the IE V  proteins (A) A 33R, (B) A 36R , (C) B5R, (D) A 34R  and  
(E) F13L (green) in HeLa cells infected with AF12L and fixed at 8hpi. The cells were co-labelled  
with alexa phalloidin 568 (red) and  D A P I (blue). Scale bar = 10pm.
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4.5.4 Over-expression of GFP-tagged F12L constructs in different viral 
backgrounds
Due to the vital role that F12L appears to play in the egress o f vaccinia virus particles to 
the cell periphery on microtubules, the localisation of F12L was examined in the 
absence o f other IEV proteins, i.e. in AA33R, AA34R, AA36R, AB5R and AF13L viral 
backgrounds (see Table 1.5).
When GFP-tagged F12L was transfected into the fore-mentioned viral backgrounds, the 
F12L protein appears to behave as would be assumed in each o f the viral backgrounds 
tested (Figure 4.13). The staining is largely cytoplasmic with a bright, localised signal 
in the centre of the cell that is probably unfolded protein being degraded by proteosome. 
The AA33R, AA34R, AB5R, AF13L all possess defects in IEV formation, which is 
consistent with the immunofluorescence data produced, showing that F12L is not seen 
on virus particles in the cell periphery (as is normally observed with the wild-type 
virus). Within the AA36R background IEV particles seem to form, although their 
movement appears to be restricted and it was not established if F12L was definitely 
located on these virions. Due to time restrictions, this analysis also represents 
preliminary data and requires attention in order to establish the precise localisations and 
behaviour of F12L in the absence o f these other viral proteins. Thus, in these 
experiments it is not clear whether the GFP-F12L signal is definitely associated with 
IEV in the AA36R background. If this recruitment proves not to be true, it would 
suggest that IEV assembly and the presence of A36R are required before F12L is 
recruited. Recent research by Herrero-Martinez et al. has demonstrated that in the 
absence of F12L, IEV particles are formed but the production o f CEV is inhibited by 
>99%, while in the absence of A36R they were produced at -60%  of the wild-type 
levels (Herrero-Martinez et al. 2005). Their data, accrued from immunofluorescence, 
drug-treatments and time-lapse microscopy demonstrated that IEV were able to move to 
the cell periphery on microtubules in AA36R-infected cells, implying that at least one 
other protein must be involved in attaching IEV to their motor proteins, possibly F12L? 
(Herrero-Martinez et al. 2005).
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Figure 4.13: Localisation of F12L in various vaccinia virus deletion backgrounds.
Immunofluorescence of the localisation pE /L-G FP-F12L (green) in H eLa cells infected with (A) 
AA33R, (B) AA36R, (C) AB5R, (D) A A 34R  and (E) AF13L viruses. Cells were fixed at 8hpi. and  
co-labelled with alexa phalloidin 568 (red). The merged image is also stained with D API (blue). 
Scale bar = 10pm.
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4.5.5 Co-localisation of F12L and kinesin
As both F12L and kinesin-1 are required for the transport of IEV particles to the cell 
surface, F12L may be involved in recruiting kinesin-1 to the virus, either via a direct or 
an indirect interaction with another protein. The initial approach to address this question 
was to label YdF-infected HeLa cells that had been transfected with GFP-tagged F12L, 
with kinesin. Both the N- and C-terminally-tagged F12L constructs showed convincing 
co-localisation with kinesin-1 positive particles (Figure 4.14). It is also clear that IEV 
can simultaneously be associated with both F12L and kinesin because the two co- 
localise on A36R positive virus particles. However, while it appears that all of the 
F12L-positive virions are accompanied by a positive labelling for kinesin-1, IEV 
particles have been detected that are kinesin-1-positive but lack a signal for F12L 
(Figure 4.14B open arrow). This suggests that the virus may be able to recruit kinesin in 
the absence of F12L but is unable move. Therefore, perhaps F12L is required to activate 
the motor?
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Kinesin
Figure 4.14: Co-localisation of F12L and kinesin. Immunofluorescence showing the co­
localisation of GFP-F12L (A+C) and F12L-GFP (B+D) (green) with kinesin-1 (red) in YdF 
vaccinia virus-infected HeLa cells. The blocked-arrows high-light the co-localisation between 
F12L and kinesin-1 and the open-arrows indicate kinesin-1 positive particles that are F12L- 
negative. Co-localisation is also observed with A36R (blue). Scale bar = 2pm in (A), (B) and 
2.5pm in (C), (D).
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4.6 Sum m ary
A new antibody was generated to aid the detection of the IEV protein F12L. Although 
anti-sera were raised against both the N- and C-termini o f the protein, only the anti-sera 
raised against the C-terminus produced positive results when analysed by western 
blotting. The anti-serum identifies a band at the correct size for F12L (~65KDa) and 
GFP-tagged F12L (~92.5KDa) in cells infected with WR vaccinia virus. It also 
correctly detects no signal in uninfected cells and cells that are infected with the AF12L 
virus (although it does also detect two non-specific bands). The anti-sera was 
subsequently affinity-purified, which increased its specificity. Unfortunately, neither the 
serum nor the affinity purified antibody works for immunofluorescence analysis. The 
affinity purified F12L antibody was used to confirm previous reports that the protein is 
expressed early and late in infection. Western blot timecourse experiments support this 
expression pattern as F12L is detected from 2-4 hpi (and weakly from 1-2 hpi). As none 
of the antibodies proved suitable for detecting F12L by immunofluorescence, GFP- 
tagged F12L constructs were generated. They were shown to rescue viral egress in 
AFl2L-infected cells when tagged at either the N- or the C-terminus, although the latter 
exhibits a greater rescue efficiency. GFP-tagged F12L is localised to IEV particles, 
identified by co-staining with B5R and A27L. F12L also associates with microtubules 
and clear co-localisation was observed between F12L and kinesin.
Localisation of the IEV proteins A33R, A36R, A34R, B5R, and F13L does not appear 
to be altered when examined in the AF12L background, which implies that F12L does 
not play a critical role in the assembly o f IEV and/or the recruitment or transport of 
these viral proteins and particles. In addition, upon transfection o f GFP-F12L into viral 
backgrounds, in which various different IEV genes had been deleted, the F12L protein 
appears to function as would be assumed in these viral backgrounds. F12L adopts a 
predominantly cytoplasmic localisation with a lack o f IEV particles in the cell 
periphery. In the absence o f IEV formation, they accumulate in the vicinity of the viral 
factories. As the majority o f IEV proteins are involved in IEV formation, this 
preliminary data set is not very informative. My data confirms that F12L is associated 
with IEV during viral egress but how it is recruited to IEV particles still remains to be 
established.
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Chapter 5
MODIFICATIONS, DELETIONS AND INTERACTION
ANALYSIS OF F12L
2 0 0
5.1 Introduction
Sequence analysis of F12L, which is highly conserved in poxvirus genomes (Table 5 .1), 
reveals a complete absence of predicted domains, including a transmembrane domain. 
F12L also lacks any recognised motifs, with the exception o f two putative 
myristoylation sites located at amino acid positions G124 and G546 (Smith et al. 2003). 
To gain more insight into the mechanisms underlying IEV recruitment and the potential 
regions involved in viral egress, a structure-function, deletion analysis approach was 
used. It is possible that F12L contains regions that are required for its recruitment and 
additional regions that are required for viral egress. For example, F12L could be 
recruited via a protein that is already incorporated into IEV particles, such as A36R or 
A33R, which could subsequently become modified. Therefore, it is possible that one 
region of F12L could bind to an IEV protein and another region could be responsible 
for interacting with kinesin-1 in, for example, a tripartite complex.
Virus Strain Amino acid identity 
with 
W -F12L (%)
Similarity with 
W -F12L (%)
Vaccinia virus (VV) -  Western Reserve (WR) 100 100
Vaccinia virus -  Copenhagen (COP) 99 100
Rabbitpox virus 99 100
Vaccinia virus Modified Ankara strain (MVA) 99 100
Vaccinia virus strain Tian Tan 99 99
Cowpox virus 98 99
Camelpox virus 97 98
Monkeypox virus 97 99
Cowpox virus 97 98
Variola major virus 96 97
Ectromelia virus 97 98
Variola minor virus 96 97
Swinepox virus 39 59
Yaba-like disease virus 37 57
Sheeppox virus 37 58
Lumpy skin disease virus 37 57
Goatpox virus 37 57
Myxoma virus 36 57
Rabbit fibroma virus 35 56
Shope fibroma virus 34 55
Molluscum contagiosum virus 27 50
Fowlpox virus 27 45
Table 5.1: Comparison of the amino acid identity and similarity (length) of vaccinia virus 
F12L (WR strain) with orthologs present in other sequenced Chordopoxviruses. The data 
was retrieved and compiled from www.Doxvirus.ora. E.g. The F12L ORF (1908bp) in vaccinia 
virus WR possesses 16 nucleotide changes from the Copenhagen sequence (99% identity) 
(Zhang et al. 2000).
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Once viral proteins have been expressed, it is essential that they reach their desired 
location at the correct time in order for correct assembly, maturation and egress of the 
virions to occur (Martin et al. 1997). Post-translational modification events, such as 
phosphorylation, proteolysis, glycosylation, prenylation, myristoylation and fatty 
acylation all participate in trafficking proteins to their proper locations within the cell. 
The distinct nature of each lipid modification determines the strength o f the membrane 
interaction o f the modified protein, as well as the specificity of membrane targeting.
Many proteins are modified by the addition of carbohydrates, i.e. glycosylation, and the 
resultant glycoproteins are classified as either N-linked or O-linked, depending on the 
attachment site o f the carbohydrate side chain (Figure 5.1C). The protein component is 
synthesised from polyribosomes bound to the endoplasmic reticulum (ER), while 
processing of the carbohydrate moiety occurs co-translationally in the lumen of the ER 
and continues in the Golgi apparatus for N-linked glycoproteins (King 2004). In N- 
linked glycoproteins, the carbohydrate is attached to the nitrogen atom in the side chain 
of asparagines residues, whereas in O-linked glycoproteins, the oxygen atom in the side 
chain of serine or threonine residues is the site of carbohydrate attachment (reviewed in 
Medzihradszky 2005; Peter-Katalinic 2005). The sugars directly attached to these 
positions are usually either N-acetylglucosamine or N-acetylgalactosamine, 
respectively.
The principle forms of fatty acylation include the attachment of the 16-carbon palmitate 
to internal cysteine residues and/or modification of the N-terminal glycine of proteins 
by N-myristoylation (Resh 2004; Martin et al. 1997). In both cases, a saturated fatty 
acid is transferred to the protein, catalyzed by specific enzymes. Lipids can also be 
attached to side chains of cysteine, serine and threonine residues via prenylation. In this 
modification, specific types of lipids (i.e. prenyl groups) are attached to the sulphur 
atoms in the side chains of cysteine residues located near the C-terminus of the 
polypeptide chains.
Palmitoylation is a reversible, post-translational event, whereby attachment of the 
palmitate group to a protein (via an ester or thioester bond to a serine, threonine or 
cysteine residue), is catalyzed by palmitoyl acyl transferase (PAT) (Figure 5.1 A; lozzo
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Figure 5.1: Schematic representations of palmitoylation, myristoylation and the linkage 
of carbohydrate side chains to glycoproteins. (A) Palmitoylation: palmitate (a 16-carbon fatty 
acid) is added to the side chain o f an internal cysteine residue. (B) Addition of a fatty acid by N- 
myristoylation: the initiating methionine is removed, leaving glycine at the N-terminus o f the 
polypeptide chain; myristic acid (a 14-carbon fatty acid) is then added. (C) Linkage of 
carbohydrate side chains to glycoproteins: the carbohydrate chains of N-linked glycoproteins 
are attached to asparagines residues, while those o f O-linked glycoproteins are attached to 
either serine (shown) or threonine residues. The sugars joined to the amino acids are usually 
either N-acetylglucosamine (N-linked) or N-acetylgalactoseamine (O-linked). (Reproduced from 
Cooper 2000).
et al. 1990). The mechanisms underlying palmitoylation are not clearly understood at 
present, although in the majority o f proteins palmitic acid is esterified to the free thiol of 
cysteine residues. Cysteine residues that reside in the vicinity of membrane-interacting 
domains (i.e. transmembrane domains or membrane-associated domains in non-integral 
membrane proteins) appear to be the site o f preference for palmitoylation, possibly due 
to their accessibility to PAT. Indeed, the majority o f palmitoylated cysteine residues are 
located within ten residues either side o f the transmembrane domain (see Bijlmakers 
and Marsh 2002 for review). Within cytosolic proteins, palmitate is attached either close 
to myristic acid or prenyl groups, or in the absence o f other acylations (Bijlmakers and 
Marsh 2002). Palmitoylation plays a variety of roles that include: 
activation/deactivation o f a protein and the promotion of membrane interactions of 
peripheral membrane proteins, facilitating the association of cytosolic proteins with 
membranes and mediating protein trafficking (Grosenbach et al. 1997; reviewed in 
Bijlmakers and Marsh 2002).
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Myristoylation is generally a co-translational, irreversible protein modification that is 
often necessary, although not sufficient, for membrane binding of the modified protein 
(reviewed in Resh 1999). Conventionally, it involves the covalent attachment of the 14- 
carbon myristate to an exposed N-terminal glycine residue (once the initiator residue 
methionine has been removed), via an amide linkage. This modification is executed by 
N-myristoyltransferases (NMTs) of the eukaryotic host and are capable of stabilizing 
protein-membrane and protein-protein interactions (Maurer-Stroh and Eisenhaber 2004) 
(Figure 5.IB). N-myristoylation can also occur post-translationally, as is the case with 
gelsolin, cytoskeletal actin and the pro-apoptotic protein BID, where proteolytic 
cleavage by caspases reveals hidden myristoylation motifs (Sakurai and Utsumi 2006; 
Utsumi et al. 2003; Zha et al. 2000).
At least six vaccinia virus proteins are known to be palmitoylated, including the IEV 
proteins A33R, A36R, A56R, B5R and F13L (Child and Hruby 1992; Smith et ai.
2002). While, time-course studies using vaccinia virus-infected cells labelled with 
myristic acid have also demonstrated that five late proteins are also myristoylated. They 
are: E7R (l7KDa), L1R (25KDa), A16L (36KDa), G9R (38KDa) and a 92KDa protein 
that was subsequently shown to be the type A-inclusion protein encoded by WR, and 
confirmed (by FIPLC) to be myristoylated (Martin et al. 1997; Martin et al. 1999). 
Myristoylated proteins may be membrane-bound (e.g. L1R), associated with other 
proteins or free in the cytoplasm.
Despite the identification of 6 potential attachment sites for N-linked carbohydrate by 
computer analysis, it was discovered that F12L is not modified by glycosylation (or 
contains very little carbohydrate) and no signal sequence was found (Zhang et al. 2000). 
This was deduced after the presence of tunicamycin and monensin (drugs that inhibit 
the addition of N- or O-linked carbohydrate, respectively) failed to affect the size of 
F12L when analysed by SDS-PAGE (Zhang et al. 2000). Taking into account the 
topology of F12L, i.e. all o f its mass resides within the cytosol, the protein would be 
denied access to the enzymes located within the vesicles that attach to carbohydrate. 
Therefore, F12L may behave in a similar manner to that of the IEV protein F13L, which 
is heavily modified by myristoylation and palmitoylation.
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The aims of this chapter are to determine which regions o f F12L are required for viral 
transport, investigate its interaction capabilities with A36R, A33R and/or kinesin-l, and 
to explore whether F12L is subjected to any form of post-translational modification that 
may influence or mediate its interaction potential, or recruitment, with the other 
proteins.
5.2 Does F12L undergo post-translational m odification?
5.2.1 F12L phosphorylation was not detected by 1-D SDS-PAGE analysis
Protein post-translational modifications often act as a trigger or a switch for specific 
cellular events to occur. Therefore, as F12L is only present on IEV moving to the cell 
periphery it is possible that it could act as a switch for the recruitment and release that 
follows kinesin-l. Therefore, the potential for F12L to become modified was 
investigated.
In order to address whether the F12L protein is subjected to any form of post- 
translational modification, initial investigation focused on identifying possible 
phosphorylation events. The Netphos software (Technical University of Denmark; 
www.cbs.dtu.dk/services/NetPhos) predicted that F12L has 11 tyrosine, 5 threonine and 
31 serine residues that could potentially be phosphorylated (Figure 5.2). These key 
residues are distributed along the entire length of the protein and the following residues 
generated highly significant scores (>0.900): Tyrosine 203, 324 and 472; Serine 74, 94, 
110, 139,163, 215, 360, 373, 396, 398, 455, 612, 621 (see Figure 5.2).
Cell lysates (from WR, AF12L and AA33R-infected HeLa cells) were incubated and 
prepared in the presence of either: (i) lambda protein phosphatase (>-PP), which removes 
phosphate(s) from serine, threonine and tyrosine residues; (ii) sodium orthovanadate, 
which maintains the phosphorylated state by inhibiting tyrosine phosphatase activity 
only and (iii) ‘nothing’, to use as a comparable control sample. The samples were then 
analysed by SDS-PAGE and western blotting (Figure 5.3). As the A36R protein is 
unmistakably phosphorylated, it was used as a positive control to clarify that the 
experiment had been conducted correctly. As expected, dephosphorylation of A36R was 
inferred in the WR, AF12L and AA33R backgrounds, as demonstrated by the presence 
of a single intense band in the presence of A.PP, while an additional (upper) band is
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OVERLEAF
Figure 5.2: Prediction results for sites of phosphorylation on the F12L protein (generated 
using NetPhos software, Technical University of Denmark; 
www.cbs. dtu.dk/services/NetPhos). The potential residues identified include: 11 tyrosine 
residues, 5 threonine residues and 31 serine residues. The scores have an output range of 
0.000 -  1.000, with a significant threshold value of 0.500. Those residues labelled with a star (*) 
are above this threshold and thus possess a greater probability of being phosphorylated. Note 
that residues that are not predicted to be phosphorylated, as a result of the output score being 
below the threshold (0.500) or because the residue is not Ser, Thr or Tyr, is represented by a 
dot (.). Those residues that have generated a predicted score above the threshold are indicated 
by ‘S ’, 'T  or ‘Y\ respectively. For example, F12L Ser74 has a score of 0.993, which indicates a 
highly likely site of phosphorylation, whereas Ser256 has a score of 0.527. The latter score is 
only just above the threshold value (0.500), indicating that the confidence for this being a true 
site o f phosphorylation is quite low.
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PHOSPHORYLATION PREDICTIONS
Tyrosine Threonine Serine
Name Pos Context Score Pred
V
Name Pos Context Score Pred
V
Name Pos Context Score Pred
V
Sequence 15 TANNYETIE 0441 Sequence 11 ILMKTANNY 0 015 Sequence 49 DNIDSIMSM 0022
Sequence 24 ILRNYLRLY 0 010 Sequence 17 NNYETIEIL 0 058 Sequence 52 DSIMSMMNI 0 705 'S '
Sequence 28 YLRLYIILA 0.089 Sequence 57 MMNITRLEV 0 057 Sequence 73 TKLRSSPPI 0 042 .
Sequence 43 GILIYDDNI 0 068 . Sequence 65 VK3LTTHCT 0.179 •  Sequence 74 KLRSSPPIP 0 993 'S ’
Sequence 92 OHESYYSPK 0 885 'Y' Sequence 66 K3LTTHCTK 0 363 Sequence 80 PIPMSRLFM 0 077
Sequence 93 HESYYSPKT 0 703 ‘Y‘ Sequence 69 TTHCTKLRS 0 055 Sequence 91 IDHESYYSP 0 764 'S '
Sequence 100 KTSDYPUD 0 489 Sequence 97 YSPKTSDYP 0 333 •  Sequence 94 ESYYSPKTS 0 992 ’S '
Sequence 123 ALEQYGIEN 0 241 Sequence 128 GIENTDStS 0.064 Sequence 98 SPKTSDYPL 0 739 'S '
Sequence 146 GLACYRFVK 0 009 Sequence 166 FSRCTIVOS 0 861 T* *  Sequence 110 IRKRSHEQG 0 998 ‘S*
Sequence 154 KFNDYRKQM 0 041 Sequence 188 KNLETYTRP 0 025 Sequence 130 ENTDSISEI 0 863 ‘S '
Sequence 159 RKQMYRKFS 0 085 Sequence 190 LETYTRPEI 0 038 Sequence 132 TDSISEINE 0 202
Sequence 180 IGHHYIWIK 0 159 Sequence 220 SLDQTHIKT 0 404 *  Sequence 139 NEWLSSKGL 0 961 ‘S '
Sequence 189 NLETYTRPE 0 661 *Y* Sequence 224 THIKT1AVS 0100 Sequence 140 EWLSSKGLA 0 015
*  Sequence 203 FDIKYISRD 0 904 *Y* Sequence 234 YGAfTONGP 0101 *  Sequence 163 YRKFSRCTI 0 971 'S ‘
Sequence 230 AVSVYGAIT 0 057 Sequence 245 YMISTYPGN 0184 Sequence 170 TIVOSMIIG 0 017
Sequence 241 GPIPYMIST 0 118 Sequence 250 YPGNTFVNF 0546 *T Sequence 205 IKYISRDEL 0 835 'S '
Sequence 246 MISTYPGNT 0 026 Sequence 273 KDIMTSTRT 0 485 Sequence 214 WVRISSSLD 0046
Sequence 283 H.VGYMSNL 0.101 Sequence 275 IMTSTRTII 0 024 *  Sequence 215 VRISSSLDQ 0 923 'S '
Sequence 296 LLTVYWPNN 0.023 . Sequence 277 TSTRT18.V 0.036 Sequence 216 RISSSLDQT 0.168 .
Sequence 306 GWKIYNNTL 0 091 Sequence 294 IPLLTVYWP 0 412 Sequence 228 TIAVSVYGA 0 910 'S '
•  Sequence 324 WMDAYKFSC 0.906 'Y' Sequence 309 IYNNTLISS 0 033 Sequence 244 PYMISTYPG 0 007
Sequence 335 SLQOYCYHW 0 218 Sequence 380 EAFETQSGA 0620 ‘T Sequence 256 VNFNSVKNU 0 527 ‘S '
Sequence 337 QOYCYHWGS 0 046 Sequence 406 DMFLTSVIN 0 446 Sequence 274 DIMTSTRTI 0 486
Sequence 375 LKSLYEAFE 0 292 Sequence 416 VSENTGMGM 0 252 Sequence 285 VGYMSNLFD 0007
Sequence 421 GMGMYYPTN 0 072 Sequence 424 MYYPTNDIP 0021 Sequence 312 NTLISSDGA 0.177
Sequence 422 MGMYYPTND 0 035 Sequence 477 VKNGTKGKL 0 110 Sequence 313 TLISSDGAR 0 019
Sequence 440 ICLDYIIVN 0829 'Y' Sequence 489 LCKVTVPTN 0 006 Sequence 327 AYKFSCGLS 0 005 .
Sequence 451 ESNKYRIKS 0 700 'Y' Sequence 492 VTVPTNOHI 0 028 Sequence 331 SCGLSLQDY 0 836 ‘S '
Sequence 465 SSKQYPAGR 0.152 . Sequence 506 DODNTTTFI 0 015 Sequence 341 YHWGSKPES 0320
*  Sequence 472 GRPNYVKNG 0 921 ‘Y‘ Sequence 507 DONTTTFrr 0  246 Sequence 345 SKPESRPFD 0 902 'S '
Sequence 482 KGKLYIALC 0 129 Sequence 508 DNTTTFITV 0 056 Sequence 354 LIKKSDAKR 0.009
Sequence 500 IPWYHDDD 0 073 Sequence 511 TTFITVLTS 0 009 *  Sequence 360 AKRNSKSLV 0935 ‘S '
Sequence 528 IRAGYSIVE 0084 . Sequence 514 ITVLTSVDI 0647 T* Sequence 382 RNSKSLVKE 0 565 ‘S '
Sequence 555 IKMIYDLNA 0 112 Sequence 520 VDIETAIRA 0 073 Sequence 367 LVKESMASL 0 612 'S ’
Sequence 585 ISLFYTFAI 0.016 . Sequence 561 LNAVTTNNL 0015 . Sequence 370 ESMASLKSL 0 972 'S '
Sequence 591 FAISYCRAF 0 056 Sequence 562 NAVTTNNLL 0 124 *  Sequence 373 ASLKSLYEA 0 989 ‘S '
Sequence 597 RAFIYSIME 0482 Sequence 586 SLFYTFAIS 0 007 Sequence 382 FETQSGALE 0 006
Sequence 607 IDPVYISQF 0 267 Sequence 602 SIMETIDPV 0 591 ‘T* Sequence 390 EVLMSPCRM 0 840 ‘S '
Sequence 613 SQFSYKELY 0 804 *Y* *  Sequence 396 CRMFSFSRI 0 949 'S '
Sequence 617 YKELYVSSS 0 984 *Y" *  Sequence 398 MFSFSRIED 0.978 ‘S '
Sequence 622 VSSSYKDIN 0935 *Y* Sequence 407 MFLTSVINR 0 192
Sequence 413 INRVSENTG 0 231
Sequence 429 NDIPSLF1E 0 048
Sequence 434 LFIESSKX 0130
Sequence 435 FIESSICLD 0 004
Sequence 448 NNQESNKYR 0 085
*  Sequence 455 YRIKSVLDI 0.994 ‘S '
Sequence 461 LOIISSKQY 0 159
Sequence 482 DIISSKQYP 0 005
Sequence 515 TVLTSVDIE 0 208
Sequence 527 RAGYSIVEL 0 758 'S '
Sequence 550 GLLDSIKMI 0 258
Sequence 578 NFNNSSIIS 0 110
Sequence 579 FNNSSIISL 0.013 .
Sequence 582 SSIISLFYT 0 018
Sequence 590 TFAISYCRA 0839 'S*
Sequence 598 AFIYSIMET 0662 ‘S '
Sequence 609 PVYISQFSY 0116
*  Sequence 612 ISQFSYKEL 0 996 ‘S '
Sequence 619 ELYVSSSYK 0498
Sequence 620 IYVSSSYKD 0014
•  Sequence 621 YVSSSYKDI 0995 'S '
Sequence 628 DINESMSOM 0 678 ‘S '
Sequence 630 NESMSQMVK 0.705 'S '
N e t P h o s  2 . 0 s  p r e d i c t e d  p h o s p h o r y l a t i o n  s i t e *  i n  S e q u e n c e
J------------------------------1__________________I__________________I_________________ I_______________
S e r  m e  
T h r e o n i n e
T y r o s i n e
T
4 3 0130 200 3 0 0 5 0 0 6 0 0
F12L sequence position (amino acids)
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Figure 5.3: Phosphorylation of F12L is not detected by 1D SDS-PAGE analysis. Western 
blot of whole cell lysates treated with nothing (-), lambda protein phosphatase, aPP (P) and 
sodium orthovanadate (V). (A) WR and AF12L lysates probed with anti-F12L antibody; (B) WR, 
AF12L and AA33R lysates probed with anti-A36R antibody. Arrows indicate the bands 
corresponding to F12L (green), A36R (blue) and phosphorylated A36R (PO4A3 6 R; red).
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present in the non- and sodium orthovanadate-treated samples (Figure 5.3B). However, 
there was no evidence of F12L phosphorylation in the WR background, as only a single 
band was detected at the same (correct) size in all of the samples (Figure 5.3A). This 
band was confirmed as F12L due to its absence when the experiment was performed in 
the AF12L background.
5.2.2 2D-analysis indicates that F12L is post-translationally modified
l-D SDS-PAGE analysis is suitable for identifying large modifications that occur to a 
protein but if they are not detected, this does not mean that the protein is not altered in 
some respect. This method is only informative where a change in mass is apparent; the 
modification may be small, e.g. a phosphate group but the change in mass may be large. 
Therefore, to reduce the possibility that F12L is modified in a manner that does not alter 
its size, 2D gel electrophoresis was adopted as a more sensitive method to detect a 
modification, as an answer had not been resolved by 1D analysis. The advantage o f this 
technique is that it has the capacity to separate proteins by two independent properties: 
in the first-dimension (isoelectric focusing, IEF) according to their isoelectric point (pi) 
and in the second-dimension (SDS-PAGE) according to their molecular weight (Mr, 
relative molecular weight). Each resultant spot identified by western blot analysis 
corresponds to a single protein species within the sample. The pi of a protein refers to 
the specific pH at which the net charge of a protein is zero. Proteins become positively 
charged at values below their pi and negatively charged at pH values above their pi.
F12L has a predicted pi value of 5.76 or 6.03, as calculated by 
http://ca.expasav.org/ch2d and http://www.poxvirus.org. respectively. As the affinity- 
purified F12L antibody recognizes two minor, non-specific bands, in addition to the 
~65KDa protein, whole-cell-samples were prepared from HeLa cells infected with 
either WR or AF12L vaccinia virus (as described in Section 2.8.4). This enabled the 
irrelevant spots to be identified and, upon comparison, eliminated from the analysis.
Following IEF of the samples on IPG 3-10 strips (i.e. strips that cover a range from pi 
3.0 to pi 10.0) the proteins were separated on a 4-12% bis-acrylamide gel and visualised 
by western blotting, using F12L and A36R (positive control) antibodies. The F12L 
antibody identified a protein smear of the correct size and approximate pi value, in the
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Figure 5.4: 2D gel analysis indicates that F12L undergoes some form of post- 
translational modification event (pi 3.0 -  pi 10.0). 2D gels o f whole cell lysates infected with
(A) WR and (B) AF12L, run on Immobiline™ Dry Strip gels - p i 3.0-10.0 and probed with anti- 
F I 2L (Ai, Bi) and anti-A36R (Aiii, Biii) antibodies. Enlargements o f the selected area (red box) 
are shown in (Aii) and (Bii) and a p i scale bar is shown in (Aii).
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WR-infected sample (Figure 5.4Ai) and was absent in the AF12L-infected samples 
(Figure 5.4Bi). Upon closer inspection of the smear, a more prominent protein spot of 
the expected size and pi value was detected (~pl 5.8), together with at least one slightly 
more acidic spot (~pl 5.4) (Figure 5.3Aii). Measurement of these spots against the pi 3- 
10 ruler, calculated that these spots cover the pi range of -5 .8  to -5 .4  (Figure 5.4Aiii, 
Biii). A36R has a pi value of 4.53 (Copenhagen strain; www.poxvirus.org) and as the 
protein can be phosphorylated it was a suitable control for this experiment. In both the 
WR-infected and AF12L-infected samples, the A36R signal produced signals that were 
in agreement with its pi value, as a predominant spot was seen at ~pl 4.5, together with 
minor signals at ~pl 3 and ~pl 5.5.
In order to visualise these results with greater resolution, the samples were run on an 
IPG strip with a narrower pi range, o f 4.0-7.0, in order to expand the scale (Figure 5.5). 
Unfortunately, determining the nature of these spots did not become clearer at this 
higher level of resolution, as a streaking pattern of incompletely focused spots was 
observed, which interfered with their interpretation. This pattern is indicative of several 
possible events that should be considered and then addressed. Streaking can occur: (i) if 
the samples are not completely solubilized prior to loading; (ii) the sample is poorly 
soluble in the rehydration buffer; (iii) if there are non-protein or ionic 
impurities/detergent interfering with the sample; (iv) if too much sample is loaded, or 
(v) if the focusing time is not optimal. When the F12L protein was analysed by 2D gel 
analysis software, available at http://prometheus.brc.mcw.edu/promost.website. it 
predicted results that were consistent with the above findings and indicates that the 
results produced could be due to various combinations of phosphorylation events.
Although it is not possible to form conclusive results from this 2D analysis, the 
experiments are strongly indicative that F12L is subjected to some form of post- 
translational event. If time had allowed, further analysis would have been conducted to 
determine the nature o f this modification. This is discussed in Chapter 7.
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Figure 5.5: 2D gel analysis indicates that F12L undergoes some form of post- 
translational modification event (pi 4.0 -  7.0). 2D gels of whole cell lysates infected with: (A) 
WR and (B) HF12L, run on Immobiline™ Dry Strip gels -  p i 4.0 -  7.0 and probed with anti-F12L 
(Ai, Bi) and anti-A36R (Aii, Bii) antibodies. Enlargements of the selected area (red box) are 
shown in (Aiii) and (Bin) and the dashed blue circles high-light bands that are due to loading.
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5.2.3 F12L is present in both m em brane and soluble fractions
In order to test whether F12L associates with the membrane or soluble (cytoplasmic) 
fraction, a membrane-pelleting assay was performed (see Section 2.6.3). Non-nuclear, 
soluble and membrane fractions were isolated from uninfected and infected (WR, YdF, 
AF12L) FleLa cells by various centrifugation steps and analysed by SDS-PAGE and 
western blotting using the F12L antibody (Figure 5.6). To confirm that the procedure 
had been executed correctly, an antibody against the membrane protein A36R was used 
as a positive control and uninfected and AF12L backgrounds provided negative controls 
for comparison. The results clearly showed that A36R is detected in the membrane 
fraction(s) only and is absent from the soluble fractions, as expected. It was determined 
that F12L is present in both the membrane and the soluble fractions, which indicates 
that F12L possesses the potential to become associated with membranes. This result 
may not be highly significant, as the fact that F12L associates with IEV membranes 
must be taken into consideration.
However, although the levels of F12L residing in the membrane and soluble fractions 
appear to be equal, the relative proportions are difficult to ascertain without comparison 
with an appropriate loading control, e.g. a-tubulin  or another IEV marker. The results 
presented are reproducible although, ideally, additional control antibodies against: (i) a 
cytoplasmic (soluble), non-viral protein; (iv) a membrane protein that translocates to a 
different cellular compartment and (iii) an IMV protein, would have provided 
conclusive evidence to support this finding. Furthermore, F13L, would be an ideal 
control as, like F12L, it is an lEV-associated cytoplasmic protein, used together with a 
soluble viral protein as a negative control. As the data stands, it cannot be ruled out that 
the membrane fraction was not contaminated with cytoplasm or that the membrane 
pellet contains IEV. However, using IMBCH to inhibit virus assembly could 
circumvent this issue. In spite o f this, the results suggest that F12L is present in both 
cellular fractions.
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Figure 5.6: F12L is present in both the membrane and soluble fractions. Cell lysate 
samples were prepared (as described in Section 2.6.3) to obtain the non-nuclear (N), the 
soluble (S) and the membrane fractions (M) from uninfected (Un), YdF-, WR- and AF12L- 
infected HeLa cells. The samples were subjected to SDS-PAGE and western blotting and 
probed for anti-F12L (A) and anti-A36R (B). The membrane protein A36R is detected in the 
membrane fraction but absent from the soluble, while F12L is present in both the membrane 
and soluble fractions.
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5.2.4 M utation of putative F12L m yristoylation sites does not block IEV egress
2D gel analysis suggests that the F12L protein is subjected to some form of 
modification. And, although very little has been discovered about the structure of F12L, 
two putative myristolyation sites have been identified at positions 124 and 546 using the 
programme http://ca.expasv.org/prosite (Figure 5.7A). It is important to note that it had 
previously been claimed that these sites existed at positions 129 and 551 (Smith et al,
2003). However, upon examination of the sequence it became evident that this 
information had been inaccurately reported, as these residues correspond to aspartic 
acid (D) and isoleucine (I), respectively, which are not known myristoylated (Figure 
5.7B). In addition, it was not reported how these particular sites were identified, nor the 
viral strain within which they were found. It is possible that alteration of the putative 
myristoylation sites (G124 and G546) may change its behaviour, localisation or mediate 
membrane-association and, ultimately, affect the function of F12L. However, 
proteolytic processing would need to occur in order to expose an internal glycine at the 
N-terminus of the protein, which seems unlikely.
Therefore, pEL-GFP-F12L constructs were generated in which amino acids G124 and 
G546 were mutated from glycine to alanine (G 124+546A) residues by Quikchange™ 
PCR reaction. Upon transfection into the AF12L background, co-localisation with DAPI 
positive particles was visualized (Figure 5.7Ci), as well as with the viral markers B5R 
and A27L (Figure 5.7Cii). Virus particles can clearly be seen in the cell periphery, 
suggesting that mutation o f these potential myristoylation sites does not effect F12L 
recruitment to IEV and their subsequent movement to the cell periphery. However, this 
approach does not actually identify whether F12L is actually myristolyated. Therefore, 
further analyses, that time did not allow, are required and are discussed in Chapter 7.
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Figure 5.7: Mutation of putative F12L myristoylation sites. (A) Location of putative 
myristoylation sites within the F12L protein. (B) Sequence of F12L high-lighting the mutational 
changes that were introduced by QuikChange™ PCR to modify the potential sites of 
myristoylation (G124A and G546A). (C) Immunofluorescence of AF12L-infected HeLa cells, 
transfected with pE/L-GFP-F12L:G124+546A (green) and fixed 8hpi. Cells were co-labelled with 
DAPI (blue) in (Ci) and with B5R (red) and A27L (blue) in (Cii). Arrows high-light the co­
localisation.
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5.3 Deletion analysis o f F12L
In order to determine which regions o f F12L are required for its recruitment to IEV and 
which regions are necessary for IEV egress, F12L deletion mutants were generated, 
tagged with GFP at the N-terminus (Figure 5.8A). In the absence of structural 
information arbitrary deletion constructs were made, by dividing the protein into thirds. 
DNA sequencing and western blot analysis verified the construction o f these deletion 
clones. Whole cell lysates from WR- and AF12L-infected HeLa cells that had been 
transfected with each construct demonstrated that each deletion mutant was the correct 
predicted size (Figure 5.8Bi+ii; Table 5.2). Unfortunately, the sequence analysis 
predictions failed to reveal any significant information about the secondary structure of 
the protein.
F12L deletion 
construct 
(amino acids)
Predicted size of 
protein 
(KDa)
Predicted size of 
GFP-tagged 
construct (KDa)
Observed sized of 
GFP-tagged construct 
(KDa)
F12L 0-635 (full-length) -  73.3 (65) -92.5 -90-95
F12L 0-470 -5 4 .2 -8 1 .7 -80
F12L 0-216 -2 4 .9 -5 2 .4 -50
F12L 217-635 -4 8 .2 -7 5 .7 -75
F12L 471-635 -  18.9 -4 6 .4 -45
F12L 217-470 -2 9 .2 -  56.7 -55
Table 5.2: Predicted size of pEL-GFP-F12L deletion constructs, in kilodaltons (KDa).
Calculations were obtained by multiplying the number o f amino acid residues present in the 
construct by the average size o f an amino acid (110Da). [Note: the number in brackets refers to 
the apparent size by SDS-PAGE],
Examination o f the localisation o f these mutants in HeLa cells infected with WR 
vaccinia virus suggested that none o f the mutant proteins associated with IEV particles 
(Figure 5.9a and Figure 5.9b). However, in the same cells GFP-F12L negative IEV 
particles can be detected by staining with B5R, demonstrating that normal IEV 
formation is not compromised. Despite this, data accrued for the F12L deletion mutants 
showed that there are no dominant-negative effects and none of the characterized 
mutants associate with IEV. Instead, they adopt a particulate, reasonably confined, 
perinuclear localisation, as well as a diffuse cytoplasmic pattern (see GFP panels in 
Figure 5.9). Under some circumstances, misfolded proteins may escape the quality 
control systems that promote correct folding and eliminate faulty proteins, and when 
they accumulate in sufficient quantity, these misfolded proteins are prone to aggregation
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Figure 5.8: Generation of F12L deletion mutants. (A) Schematic representation o f the F12L 
expression constructs used to attempt to rescue the dispersion of AF12L virus to the cell 
periphery. The numbers represent the range o f amino acids present within each F12L construct.
(B) Western blot analysis o f F12L deletion constructs; N-terminally tagged with GFP, together 
with the full-length F12L protein, which was tagged with GFP at either the N- (GF) or the C- 
terminus (FG). The constructs were transfected into HeLa cells infected with either WR virus (A) 
or AF12L virus (B). All o f the constructs were shown to be the correct size: GFP-F12L 0-470 
(81.7KDa), GFP-F12L 0-216 (52.4KDa), GFP-F12L 217-635 (75.7KDa), GFP-F12L 471-635 
(46.4KDa), GFP-F12L (56.7KDa), GFP-F12L and F12L-GFP (92.5KDa). Loading controls were 
performed with the host protein, Grb2, and the viral protein, A36R.
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Figure 5.9a: Localisation of F12L deletion constructs in WR-infected cells. HeLa cells were infected 
with WR and transfected (4hpi) with pE/L-GFP-F12L deletion constructs (green) that contained the 
following amino acids: (A) 0-635, i.e. full-length, (B) 0-470, (C) 0-216, (D) 217-635, (E) 471-635, (F) 217- 
470. Cells were fixed at 8hpi and co-stained with B5R (red). Upon comparison of the deletion constructs 
with the full-length protein, none of the mutants appear to travel to the cell periphery despite B5R-positive 
particles being detected. Scale bar = 10pm.
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5 .9  b :
Enlargement of the GFP-F12L deletion constructs in WR-infected cells from a selected 
region from Figure 5.8a. HeLa cells were infected with WR and transfected (4hpi) with pE/L- 
GFP-F12L deletion constructs (green) that contained the following amino acids: (A) 0-635, i.e. 
full-length, (B) 0-470, (C) 0-216, (D) 217-635, (E) 471-635, (F) 217-470. Cells were fixed at 8hpi 
and co-stained with B5R (red). Upon comparison o f the deletion constructs with the full-length 
protein, none of the mutants appear to travel to the cell periphery, despite B5R-positive particles 
(red) being detected in the cell periphery. Scale bar 2-jum.
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around the centrosome (Johnston et al. 1998). Therefore, these particulate structures are 
likely to be sites of protein degradation or mis-folded proteins, i.e. unfolded GFP-F12L.
When the mutants are compared with the expression o f the full-length F12L protein (0- 
635aa), the wild-type situation defines discrete IEV particles that are able to egress to 
the cell periphery (Figure 5.9aA, 5.9bA). It is also possible that the endogenous viral 
F12L is preferentially recruited to IEV, thus preventing the association of the mutants 
with the viral particles. Completely folded protein may be required for optimal 
association of F12L with its binding site on the virus particle. Therefore, to avoid the 
possible competition with the endogenous F12L protein, the mutants were subsequently 
expressed in HeLa cells infected with the AF12L virus (Figure 5.10a and Figure 5.10b). 
Similarly to that seen in the WR-infected cells, the deletion constructs were not 
recruited to IEV, therefore, wild-type F12L appears to block the recruitment of 
potentially weaker binding mutants.
Taking this information into consideration, together with the fact that there are no 
identified domains within F12L, it is likely that the protein acts as a single-folded 
domain and any deletion disrupts the structure so that it is non-functional. Also, the lack 
of a folded structure would explain the deficiency in rescue and the lack of dominant- 
negative effects observed when transfected into AFl2L-infected cells.
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Figure 5.10a: Localisation of F12L deletion constructs in \F12L-infected cells. HeLa cells 
were infected with AF12L and transfected (4hpi) with pE/L-GFP-F12L deletion constructs 
(green) that contained the following amino acids: (A) 0-635, i.e. full-length, (B) 0-470, (C) 
0-216, (D) 217-635, (E) 471-635, (F) 217-470. Cells were co-stained with B5R (red). Upon 
comparison of the deletion constructs with the full-length protein, none of the mutants 
appear to travel to the cell periphery. Scale bar = 10pm.
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Figure 5.10b: Enlargement of the GFP-F12L deletion constructs in AF12L-infected cells 
from a selected region from Figure 5.9a. HeLa cells were infected with AF12L and 
transfected (4hpi) with pE/L-GFP-F12L deletion constructs (green) that contained the following 
amino acids: (A) 0-635, i.e. full-length, (B) 0-470, (C) 0-216, (D) 217-635, (E) 471-635, (F) 217- 
470. Cells were co-stained with B5R (red). Upon comparison of the deletion constructs with the 
full-length protein, none of the mutants appear to travel to the cell periphery. Scale bar 2pm.
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5.4 F12L Interactions
As explained in Section 1.9.2.6 (and Table 1.6) a number of interactions between 
vaccinia IEV proteins have already been determined. In this section, several different 
approaches have been implemented to gain a greater understanding of how F12L is 
recruited to IEV through its possible interaction with other IEV proteins.
5.4.1 F12L does not appear to interact directly with kinesin-l
In addition to confirming the co-localisation of F12L and kinesin-l by 
immunofluorescence (Figure 4.14), it was also attempted to demonstrate their direct 
binding by performing in vitro pull-down assays. The vector of choice to express 
proteins in E.coli was the gene transcription, T7-based expression vector pMW172 
(Way et al. 1990) (see Sections 2.4.2 and 2.9). F12L was subcloned into this vector, 
containing either a His or GST tag that ultimately enabled the protein to be purified on 
Ni-NTA-resin or GST-resin, respectively, in pull-down experiments. However, due to 
the high background obtained with the GST tag, work proceeded only using the His- 
tagged version (Figure 5.11). F12L (His-tagged, GST-tagged or no tag) repeatedly 
demonstrated poor solubility when expressed in E.coli and proved difficult to work 
with, despite extensively testing a range of salt and detergent conditions. Therefore an 
alternative approach o f over-expressing constructs in infected HeLa cells was conducted 
in parallel to obtain material for pull-downs. In these subsequent experiments, as an 
interaction between F12L and kinesin-l was being investigated, the TPR domain of 
KLC was over-expressed and either immobilized on Ni-NTA beads, or beads that were 
coupled to ZIP peptide (see Section 2.7.2). Simultaneously, the converse experiment 
was also performed, in which HIS-F12L was immobilized on beads and used as the bait 
for kinesin-l, from HeLa cell lysates. However, no positive interaction was visualised 
between F12L and TPR, in addition to F12L failing to pull-down endogenous kinesin-l 
when purified on either Ni-NTA or ZIP resin (Figure 5.12a and Figure 5.12b). 
Unfortunately, it was not possible to perform all the required controls in some of these 
experiments. Therefore, in order to validate these results, further work is necessary 
utilising the appropriate tools. This is discussed in Chapter 7.
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Figure 5.11: Generation and expression of pMW-His-F12L constructs in E.coli. (A) Bands 
of the correct size were identified for His-F12L clones, when probed with anti-His (top panels; 
Ai, Bi) and anti-F12L (bottom panels; Aii, Bii) antibodies. Clone #3 was selected for use and its 
expression levels are shown in (B). Whole extract (W), soluble extract (S) and sample bound to 
Ni-NTA beads (B) are shown. F12L exhibits poor solubility.
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Figure 5.12a: F12L pull-down experiments using HeLa cell extracts over-expressing (A) 
His-tagged or (B) ZIP-tagged pE/L constructs. Cell lysates were prepared from YdF-infected 
HeLa cells (see Section 2.6.1) that were transfected with pE/L-His-F12L, pE/L-A36R-His and 
pE/L-His-Nck (control). Extracts (Ex) were then bound (B) to Ni-NTA (see Section 2.7.1) and 
analysed by SDS-PAGE and western blotting. The membrane was probed with anti-F12L and 
anti-Kif5B antibodies. Identification o f F12L being pulled down in the ‘bound lane' of His-F12L 
confirms that the experiment was conducted correctly. F12L was not detected in either the 
A36R or Nek ‘bound sample' lanes. Similarly, Kif5B was not pulled down in any of the samples.
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Figure 5.12b: F12L pull-down experiments using HeLa cell extracts over-expressing ZIP- 
tagged pE/L constructs. Cell lysates were prepared as described in Section 2.6.1. HeLa cells 
were infected with YdF and transfected with pE/L-ZIP-F12L, pEL-ZIP-TPR and pE/L-ZIP-Nck 
(control). In addition, an uninfected (Un) sample was also analysed. The extracts (Ex) were 
bound (B) to beads coupled with the ZIP peptide (see Section 2.7.2) and subjected to SDS- 
PAGE and western blotting. The resulting membranes were probed with (A) anti-F12L and anti- 
Kif5B, (B) anti-tubulin, (C) anti-Nck and (D) anti-A36R. F12L was not pulled down with ZIP-TPR 
(i), neither was Kif5B pulled down with ZIP-F12L. In addition, A36R was not detected in either 
the ZIP-F12L or the ZIP-TPR pull-down lanes.
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To date, no positive data has been acquired to show that F12L interacts with TPR in 
vitro. This is supported by the yeast two-hybrid experiments performed by Ward et al. 
(2004). It is plausible that during vaccinia virus infection F12L or kinesin-l, or both, 
become modified and it is this adaptation that is needed for the interaction to occur. 
Also, if an interaction does prove to exist, it may be part of a tripartite or more complex 
interaction.
5.4.2 Anti-GFP immunoprecipitation investigation into the interactions between 
F12L, A36R, A33R and kinesin-l
Alternative approaches were considered to address the interaction potential of F12L 
with A33R, A36R and kinesin-l. Yeast two-hybrid assays, or the use of purified 
proteins as bait in pull-downs may be unsuitable to demonstrate a protein interaction if 
the interaction is dependent on post-translational modifications, such as 
phosphorylation. However, immunoprecipitation (IP) of e.g. F12L or kinesin-l from 
cell extracts followed by probing of the immunoprecipitates for kinesin-l or F12L 
respectively, would circumvent this issue. Unfortunately, immunoprecipitation cannot 
demonstrate whether an interaction is actually direct. However, the technique is able to 
provide a rapid and simple means to separate specific proteins from whole cell lysates, 
thus allowing us to establish where other proteins co-purify and are therefore part of a 
complex.
Immunoprecipitation was chosen to explore the potential interactions between the 
F12L, A36R, A33R and TPR proteins, as this method had also consistently proven to be 
a successful tool within our laboratory. GFP-tagged versions of these constructs, 
together with a control-construct that only expressed GFP, were transfected into HeLa 
cells infected with either WR, YdF or AF12L vaccinia virus. The samples were then 
treated as described in Section 2.7.3 and analysed by SDS-PAGE and western blotting. 
The original WR-infected input-extract (total protein) was compared alongside the 
bound samples of Protein G beads obtained from either pre-incubating the samples with 
a GFP or a HA (control) antibody.
5.4.2.1 Identification of a putative interaction between F12L and A36R
Initial probing of the resultant western blot membranes with an anti-GFP antibody 
confirmed that the experiment had been successfully executed (Figure 5.13D). Bands
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corresponding to the correct size for each of the named constructs were detected in both 
the input extract (Ex) and the GFP-bound IP (GFP) lanes but was expectedly absent 
from the control HA-bound IP (HA) lanes. However, the expression of GFP-F12L is 
significantly weaker in comparison with the other samples. This is not simply a 
consequence o f less protein being loaded onto the gel as the loading control, for the host 
protein Bak, verified equal protein input levels (Figure 5.13E). The poor expression of 
F12L is a persistent issue and consideration.
When the samples were probed with F12L and Kif5B (kinesin) antibodies, kinesin-l 
was not pulled down in any o f the GFP-bound IP samples despite the fact that the direct 
interaction between A36R and kinesin-l has been published (Figure 5.13A; Ward and 
Moss, 2004). O f greater interest, however, is the identification of a band at the correct 
size for F12L being pulled down with the A36R-GFP bound sample (Figure 5.13A; 
solid red box). Nevertheless, it should be noted that the reverse situation is not 
observed, i.e. A36R is not detected when GFP-F12L is over-expressed (Figure 5.13B; 
dashed red box).
Upon closer examination, this band is clearly presented as a doublet and is visible at 
low exposure times. However, as the F12L and Kif5B antibodies were incubated 
together in this experiment the band cannot be eliminated from being a product of cross­
reactivity. It is important to note that all o f the antibodies used for western- 
blotting were anti-rabbit, to reduce the level of cross-reactivity and non-specific binding 
of the monoclonal antibodies used for the IP. Results from subsequent experiments that 
were performed in exactly the same manner addressed this issue and satisfactorily 
removed the suspicion of cross-reactivity with the kinesin antibody. Identical results 
were produced to those presented in Figure 5.13A, when the F12L antibody was 
incubated in isolation. The F12L antibody has, therefore, reproducibly detected the 
same doublet-band in IP-treated samples over-expressing A36R-GFP.
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Figure 5.13: Anti-GFP immunoprecipitation of F12L, A33R, A36R and kinesin-1 in WR- 
infected cells. WR-infected HeLa cells were transfected with the following GFP-tagged 
constructs: GFP alone, TPR, F12L, A36R and A33R, prior to immunoprecipitation and western 
blot analysis (see Sections 2.7.3 and 2.8.2). The resulting membranes were probed with (A) 
anti-F12L and anti-Kif5B, (B) anti-A36R and (C) anti-A33R antibodies, to investigate the 
interaction potential between these proteins. Anti-GFP (D) was used as a control antibody to 
assess the transfection efficiency and expression levels o f each construct, while anti-Bak (E) 
was included as a loading control. A summary table is also presented to clarify the 
immunoprecipitation results. Key: X = no interaction; V = interaction; X fV j = a known interaction 
that was not detected by this method. The significant (reciprocal) interactions are high-lighted 
with coloured boxes; solid lines denote an interaction, while boxes with dashed .lines indicate no 
interaction. The green boxes emphasise the known interaction between A33R and A36R 
(positive control). However, although endogenous A36R is detected in the GFP-A33R IP (solid 
green box), the reciprocal experiment does not clearly detect endogenous A33R in the A36R- 
GFP IP (dashed.green box). The red box outlines a putative interaction between F12L and 
A33R. Endogenous F12L is detected in the A36R-GFP IP (solid red box) but endogenous A36R 
is not detected in the GFP-F12L IP (dashed, red. box). The dashed, blue, boxes highlight no 
interaction between F12L and A33R. fProtein sizes: F12L=-~65KDa, Kif5B=~115KDa, A36R-43- 
50KDa, A33R=23-25KDa, GFP=~27.5KDa, Bak=23-24KDa. See Section 1.9.2.4 and Table 1.4].
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Figure 5.14: Anti-GFP immunoprecipitation of F12L, A33R, A36R and kinesin-1 in YdF- 
infected cells. YdF-infected HeLa cells were transfected with the following GFP-tagged 
constructs: GFP alone, TPR, F12L, A36R and A33R, prior to immunoprecipitation and western 
blot analysis (see Sections 2.7.3 and 2.8.2). The resulting membranes were probed with (A) 
anti-F12L and anti-Kif5B, (B) anti-A36R and (C) anti-A33R antibodies, to investigate the 
interaction potential between these proteins. Anti-GFP (D) was used as a control antibody to 
assess the transfection efficiency and expression levels o f each construct, while anti-Bak (E) 
was included as a loading control. A summary table is also presented to clarify the 
immunoprecipitation results. Key: X  -  no interaction; V = interaction; X(yl) = a known interaction 
that was not detected by this method. The significant (reciprocal) interactions are high-lighted 
with coloured boxes; solid lines denote an interaction, while boxes with dashed Jines indicate no 
interaction. The green boxes emphasise the known interaction between A33R and A36R 
(positive control). However, although endogenous A36R is clearly detected in the GFP-A33R IP 
(solid green box), the reciprocal experiment does not clearly detect endogenous A33R in the 
A36R-GFP IP (dashed_green box). The red box outlines a putative interaction between F12L 
and A33R. Endogenous F12L is detected in the A36R-GFP IP (solid red box) but endogenous 
A36R is not detected in the GFP-F12L IP (dashed red box). The dashed^ blue boxes highlight no 
interaction between F12L and A33R. fProtein sizes: F12L=~65KDa, Kif5B=~115KDa, A36R=43- 
50KDa, A33R=23-25KDa, GFP=~27.5KDa, Bak=23-24KDa. See Section 1.9.2.4 and Table 1.4].
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The known interaction between A36R and A33R was used as an internal positive 
control. Incubation with the A36R antibody correctly identified endogenous A36R 
being pulled-down with GFP-A33R (Figure 5.13B; solid green box), in addition to 
recognising A36R in the A36R-GFP lanes. Unfortunately, when the samples were 
probed for A33R the reciprocal interaction was not clearly detected with over-expressed 
A36R-GFP, despite the A33R antibody being capable of detecting GFP-A33R (Figure 
5.13C; dashedgreen ..box). However, the signal produced for endogenous A33R was 
also very weak and reciprocal immunoprecipitation experiments do not always produce 
positive results.
5.4.2.2 F12L and A33R do not interact by im m unoprecipitation
Another valuable finding is that F12L and A33R do not demonstrate signs of an 
interaction, either when GFP-F12L is over-expressed and probed for endogenous A33R, 
or when GFP-A33R is over-expressed and probed for endogenous F12L (Figure 5.13C 
and Figure 5 .13A, respectively; dashed..blue...boxes). This whole experiment was 
performed in parallel in cells infected with the YdF virus and exactly the same results 
were produced (Figure 5.14).
5.4.2.3 Introduction of a pre-clearing stage abolishes the putative interaction 
between FI2L and A36R
A pre-clearing stage can be incorporated into the immunoprecipitation procedure, 
whereby the samples are incubated with pre-washed beads prior to its incubation with 
the GFP (or HA) antibody and subsequent binding to Protein G/Protein A beads. The 
objective of this additional step is to reduce the level o f non-specific contaminants 
within the cell-lysate, by removing proteins that possess a high affinity for the Protein 
G/Protein A.
With the exception o f the additional pre-clearing step, the immunoprecipitation 
procedure was carried out identically to that described above. However, in order to 
determine whether the band being pulled down with GFP-A36R was indeed F12L, the 
experiment was also performed in the AF12L viral background (Figure 5.17). This 
provided the most suitable negative control to complement the samples infected with 
WR (Figure 5.15) and YdF-vaccinia virus (Figure 5.16).
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Figure 5.15: Anti-GFP immunoprecipitation of F12L, A33R, A36R and kinesin-1 in WR- 
infected cells after pre-clearing. WR-infected HeLa cells were transfected with the following 
GFP-tagged constructs: GFP alone, TPR, F12L, A36R and A33R, prior to immunoprecipitation 
and western blot analysis (see Sections 2.7.3 and 2.8.2). The resulting membranes were 
probed with (A) anti-F12L, (B) anti-A36R and (C) anti-A33R antibodies, to investigate the 
interaction potential between these proteins. Anti-GFP (D) was used as a control antibody to 
assess the transfection efficiency and expression levels of each construct, while anti-Bak (E) 
was included as a loading control. A summary table is also presented to clarify the 
immunoprecipitation results. Key: X  = no interaction; V = interaction; X('J) = a known interaction 
that was not detected by this method. The significant (reciprocal) interactions are high-lighted 
with coloured boxes; solid lines denote an interaction, while boxes with dashed Jines indicate no 
interaction. The green box emphasises the known interaction between A33R and A36R 
(positive control). However, although endogenous A36R is detected in the GFP-A33R IP (solid 
green box), the reciprocal experiment does not detect endogenous A33R in the A36R-GFP IP 
(dashed, green box). The dashed, red, boxes show that endogenous F12L is not detected in the 
A36R-GFP IP and that endogenous A36R is not detected in the GFP-F12L IP. The dashed, blue 
boxes highlight no interaction between F12L and A33R. fProtein sizes: F12L=~65KDa, 
A36R-43-50KDa, A33R=23-25KDa, GFP=~27.5KDa, Bak=23-24KDa. See Section 1.9.2.4 and 
Table 1.4].
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Figure 5.16: Anti-GFP immunoprecipitation of F12L, A33R, A36R and kinesin-1 in YdF- 
infected cells after pre-clearing. YdF-infected HeLa cells were transfected with the following 
GFP-tagged constructs: GFP alone, TPR, F12L, A36R and A33R, prior to immunoprecipitation 
and western blot analysis (see Sections 2.7.3 and 2.8.2). The resulting membranes were 
probed with (A) anti-F12L, (B) anti-A36R and (C) anti-A33R antibodies, to investigate the 
interaction potential between these proteins. Anti-GFP (D) was used as a control antibody to 
assess the transfection efficiency and expression levels of each construct, while anti-Bak (E) 
was included as a loading control. A summary table is also presented to clarify the 
immunoprecipitation results. Key: X  = no interaction; V = interaction; X(yl) = a known interaction 
that was not detected by this method. The significant (reciprocal) interactions are high-lighted 
with coloured boxes; solid lines denote an interaction, while boxes with dashed Jines indicate no 
interaction. The green box emphasises the known interaction between A33R and A36R 
(positive control). However, although endogenous A36R is detected in the GFP-A33R IP (solid 
green box), the reciprocal experiment does not detect endogenous A33R in the A36R-GFP IP 
(dashed green box). The dashed. red. boxes show that endogenous F12L is not detected in the 
A36R-GFP IP and that endogenous A36R is not detected in the GFP-F12L IP. The dashed, blue 
boxes highlight no interaction between F12L and A33R. fProtein sizes: F12L=-~65KDa, 
A36R=43-50KDa, A33R=23-25KDa, GFP=~27.5KDa, Bak=23-24KDa. See Section 1.9.2.4 and 
Table 1.4].
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Figure 5.17: Anti-GFP immunoprecipitation of F12L, A33R, A36R and kinesin-1 in AF12L- 
infected cells after ore-clearing. AF12L-infected HeLa cells were transfected with the 
following GFP-tagged constructs: GFP alone, TPR, F12L, A36R and A33R, prior to 
immunoprecipitation and western blot analysis (see Sections 2.7.3 and 2.8.2). The resulting 
membranes were probed with (A) anti-F12L, (B) anti-A36R and (C) anti-A33R antibodies, to 
investigate the interaction potential between these proteins. Anti-GFP (D) was used as a control 
antibody to assess the transfection efficiency and expression levels of each construct, while 
anti-Bak (E) was included as a loading control. A summary table is also presented to clarify the 
immunoprecipitation results. Key: X -  no interaction; V = interaction; X(d) = a known interaction 
that was not detected by this method. The significant (reciprocal) interactions are high-lighted 
with coloured boxes; solid lines denote an interaction, while boxes with dashed.lines indicate no 
interaction. The green box emphasises the known interaction between A33R and A36R 
(positive control). However, although endogenous A36R is detected in the GFP-A33R IP (solid 
green box), the reciprocal experiment does not detect endogenous A33R in the A36R-GFP IP 
(dashed, green box). The dashed. red. boxes show that endogenous F12L is not detected in the 
A36R-GFP IP and that endogenous A36R is not detected in the GFP-F12L IP. The dashed, blue 
boxes highlight no interaction between F12L and A33R. fProtein sizes: F12L=~65KDa, 
A36R=43-50KDa, A33R=23-25KDa, GFP=~27.5KDa, Bak=23-24KDa. See Section 1.9.2.4 and 
Table 1.4].
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The results after pre-clearing accurately reproduced the outcome achieved for the 
previous sets of immunoprecipitation experiments (i.e. without the pre-clearing stage), 
including the control antibodies, with one notable exception. Upon pre-clearing the 
samples, the F12L signal that was pulled-down with A36R-GFP failed to be detected 
(Figure 5.15A; dashed .red .box). As the principle o f pre-clearing is to remove non­
specific binding, it could be argued that the endogenous F12L signal disappears because 
there is, in fact, no interaction between these two proteins. Therefore, the signal seen in 
the non pre-cleared samples could be a spurious, non-specific band due to F12L 
possessing a high binding affinity for the resin. However, it can equally be argued that 
the F12L signal is no longer detected because F12L is washed off and/or essential 
interaction sites could be altered during the pre-clearing stage. This also proves that the 
band is not apparent as a result of cross-reactivity with A36R, as this band is absent 
from all other conditions.
5.4.2.4 The interaction between F12L and A36R is ambiguous
All of the IP experiments described in this section were repeated several times to 
validate the results. And, due to the ambiguity over the potential interaction between 
F12L and A36R this was examined more thoroughly. When samples infected with WR 
or YdF virus, and over-expressing A36R-GFP, were immunoprecipitated and analysed 
alongside each other, two bands were still recognised by the anti-F12L antibody 
(identified by arrows, < , in Figure 5.18; solid red boxes). However, upon comparison 
with the IP performed in AFl2L-infected cells, the upper band is not detected (Figure 
5.18; dashed, red..box). Therefore, as a band is clearly evident in the WR and YdF- 
infected samples that is absent from the AF12L sample, this is indicative of the lower 
band being a spurious, non-specific band or contaminant that can be disregarded, while 
the upper band is specific for F12L (Figure 5.18; solid red boxes, upper arrow). The 
various approaches that can be employed to verify this putative interaction between 
F12L and A36R are discussed in Chapter 7. The results from each immunoprecipitation 
experiment described above are summarised in tables beneath their respective figures 
(i.e. Figures 5.13 -  5.18).
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Figure 5.18: Immunoprecipitation of A36R-GFP in AF12L- WR- and YdF-infected cells.
AF12L, WR and YdF-infected HeLa cells were transfected with A36R-GFP, prior to 
immunoprecipitation and western blot analysis (see Sections 2.7.3 and 2.8.2). The resulting 
membranes were probed with (A) anti-F12L, (B) anti-A36R and (C) anti-GFP (control) 
antibodies. Kev: X  = no interaction; V  = interaction; X(^l) = a known interaction that was not 
detected by this method. The solid red boxes emphasise that endogenous F12L is detected in 
the A36R-GFP IP in both the WR- and YdF-infected backgrounds but not in the in AF12L- 
infected cells (dashed red box). I.e. in the former viral backgrounds, two bands are recognised 
by the anti-FI 2L antibody (identified by arrows, <), however, upon comparison with the IP 
performed in AF12L-infected cells the upper band is not detected. This confirms that the upper 
band is F12L and the lower band is a spurious, non-specific band or contaminant that can be 
disregarded. In addition, endogenous A33R failed to be detected in A36R-GFP IP. IProtein 
sizes: F12L=~65KDa, A36R=43-50KDa, A33R=23-25KDa, GFP=~27.5KDa. See Section
1.9.2.4 and Table 1.4].
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5.5 Sum m ary
• There is no evidence to suggest that the F12L protein is phosphorylated when 
subjected to ID SDS-PAGE. However, analysis by 2D gel electrophoresis indicates 
that F12L is modified in some manner, as a range of increasing acidic protein spots 
were identified from an original spot of the expected pi value for F12L. However, 
the nature of this modification remains unclear, although phosphorylation is highly 
likely.
• Mutation of two putative myristoylation sites does not appear to block the 
recruitment o f F12L to IEV. However, this study does not determine whether F12L 
is actually myristoylated.
• Construction of a series of F12L deletion mutants failed to identify a specific region 
o f the protein that was sufficient for IEV recruitment and viral egress to the cell 
periphery. Results are consistent with F12L being a single-folded domain, as any 
deletion introduced to the protein appears to disrupt its fold.
• No positive data has been acquired to show that F12L interacts with kinesin-l, in 
vitro.
• Immunoprecipitation experiments demonstrated that there is no apparent interaction 
between: (i) F12L and A33R, (ii) F12L and TPR, and (iii) A33R and TPR. 
However, a putative interaction has been detected between F12L and A36R, 
although the positive result was not obtained in reciprocal experiments.
238
Chapter 6 Does Myosin Va Plav a Role During the Vaccinia Virus Life-cvcle?
Chapter 6
DOES MYOSIN VA PLAY A ROLE DURING THE 
VACCINIA VIRUS LIFE-CYCLE?
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6.1 Introduction
The well-established motor protein, myosin Va, has been shown to interact directly with 
kinesin-l, by yeast and mammalian two-hybrid screens as well as by GST pull-down 
experiments in addition to its conventional role o f binding to actin fdaments (Huang et 
al. 1999). Myosin Va was shown to bind to the mouse ubiquitous kinesin heavy chain 
(KhcU) in a complex that also contains the kinesin light chain. Therefore, it has been 
suggested that cargo associated with such a complex is competent to switch between 
microtubule-based and actin-based transport (Huang et al. 1999). More recent studies 
have strengthened this evidence by reporting that myosin Va can bind directly to 
microtubules in vitro, via its tail region (Cao et al. 2004). Furthermore, research by 
Weber et al., has demonstrated that another member of the myosin superfamily, 
myosin-10, is able to directly link microtubules and actin within the meiotic Xenopus 
oocyte (Weber et al. 2004). This presents the interesting possibility that other myosins 
could behave in a similar manner and also bind with microtubules, either routinely or 
invoking this interaction in specific situations.
Immunolocalisation studies have shown that myosin Va can be localised to either the 
perinuclear region or the plasma membrane (Lionne et al. 2001). And, as a result, it has 
been proposed that a two-step transport system may be employed. Firstly, vesicles are 
transported on microtubules, by utilizing kinesin-l and upon arrival in the cell 
periphery, which has a low density of microtubules but is rich in actin, the vesicles 
switch preferences to use myosin Va to transport it through the subcortical actin 
network and to reach the plasma membrane (Lionne et al. 2001). These events all occur 
during vaccinia virus morphogenesis, as IEV particles also use microtubule-based 
transport to reach the cell periphery, at which point they switch to actin-based motility 
in order to exit the cell and spread infection. O f particular interest is what happens to 
the IEV particle once it reaches the end of the microtubules in the cell cortex, i.e. how 
does the virion actually reach the plasma membrane? Therefore, these considerations 
prompted an investigation into a putative role for myosin Va in vaccinia virus transport. 
In addition, recent experiments analysing the IMV proteome identified myosin Va as a 
host protein that can associate with IMV particles, thus strengthening the possibility of 
myosin Va being involved in viral transport (Chung et al. 2006).
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6.2 Localisation o f M yosin Va in vaccinia virus-infected cells
Three antibodies raised against myosin Va were used in this study:
• Myosin Va Clone LF-18 (Sigma).
• Myosin Va Clone LE-16 (Sigma).
• Myosin Va [Antibody #1] from J. Kendrick-Jones (Cambridge, UK) (Lionne
et al. 2001; Mercer et al. 1991). Note that this antibody is referred to as
‘Cambridge’.
Firstly, the myosin Va - clone LF-18 was tested by immunofluorescence and 
subsequently, in order to confirm its localisation, the two additional myosin Va 
antibodies were analysed.
6.2.1 Localisation o f myosin Va: clone LF-18
Anti-myosin Va (LF-18) was raised in rabbits using the synthetic peptide: 
RLRDRKDSPQLLMDAKHI. This sequence corresponds to amino acids 1782 -  1799 
(with an N-terminally added lysine) that are positioned near the C-terminus of chicken 
myosin Va (Espreafico et al. 1992). This antibody was used to localise myosin Va in 
both uninfected and vaccinia-infected cells. In uninfected HeLa cells, ‘myosin Va’ 
showed a non-specific, diffuse cytosolic staining pattern, regardless of the fixation 
condition used. Intriguingly, in cells infected with vaccinia virus it was observed that 
the antibody strikingly labelled DAPI-positive, perinuclear virus factories (Figure 6.1- 
Part I). This was confirmed by co-staining the cells with the phosphotyrosine antibody 
PY69 that is known to label the DNA factories (and the viral protein A17L) (Figure 
6. lA -Part I). Initially, the viral markers A27L and B5R were also used to gauge the 
localisation of myosin Va and to ensure that the cells were suitably infected but no co­
localisation was seen between either of these antibodies and myosin Va (Figure 6. IB+C 
-Part I). However, when cells were transfected with the IMV core protein A3L, tagged 
at the C-terminus with GFP, co-localisation was clearly apparent with the ‘myosin Va’ 
antibody (Figure 6.1D-Part I). At this point suspicions were raised as to the true nature 
o f this localisation. Does myosin Va really localise to viral factories or is the antibody 
cross-reacting with a viral protein? Analysis o f the peptide sequence that the antibody 
was raised against failed to reveal any significant homology to any vaccinia virus
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Figure 6.1 - Part I: Myosin Va (clone LF-18) localisation in vaccinia virus-infected HeLa 
cells. Cells were infected with wild-type vaccinia virus, fixed 8hpi and stained for myosin Va 
(LF-18; green), together with DAP! (blue) and PY69 (a marker for DNA viral factories), A27L 
and B5R (red). Scale bar = 10pm.
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protein (see Section 6.3.1). Furthermore, the antibody failed to detect a band o f the 
correct size (190KDa) by western blot analysis (Figure 6.1-Part II). This result was 
unexpected as: (i) it is in disagreement with the manufacturer’s claims and (ii) the 
peptide sequence from which the antibody was raised is conserved between chicken and 
human (as well as in other species; see Section 6.3.2).
<— Myosin Va 
(190KDa)
W R  Y d F  Un  
Infec t ion
Figure 6.1 - Part II: Myosin Va (clone LF-18) antibody fails to detect a band by western 
blot analysis. The antibody was tested on whole cell lysates from uninfected (Un) and vaccinia 
virus-infected (WR and YdF) HeLa cells. Myosin Va is expected to produce a band at 190KDa 
(red).
6.2.2 Myosin Va is detected on viral factories from 4 hpi
Further investigation into the localisation o f the reactive antigen was performed to 
determine how long it takes for a viral factory to acquire the ‘myosin Va’ signal. For 
example, are ‘myosin Va’-negative factories visible at early time-points after infection? 
Additionally, a time-course investigation could provide insight into the viral protein(s) 
that the antibody may be recognising. Subsequent analysis at different time points over 
the course of 8 hours revealed that myosin Va appears on the viral factories as early as 4 
hpi. (Figure 6.2A). Quantitation of the number of virus factory-positive cells that also 
showed myosin Va-positive staining of the viral factories, revealed that there is a clear 
correlation between the appearance of viral factories and the recruitment of myosin Va 
to the factory from the cytosolic pool. Interestingly, after 8 hours, by which time actin- 
tail-positive IEV particles have appeared in the cell periphery, ‘myosin Va’ was still 
localised to the factories (Figure 6.2B). This data, together with the fact that ‘myosin 
Va’ is not detected on IEV or CEV particles at this time-point, suggests that whilst
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Figure 6.2: Timecourse of myosin Va (LF-18) localisation in vaccinia virus-infected HeLa 
cells. (A) ‘Myosin Va’ localises to maturing viral factories in WR-infected HeLa cells. Cells were 
infected, fixed at the indicated times post-infection and probed with anti-myosin Va (LF-18, 
Sigma; green), PY69 (red) and DAP! (blue); Un = uninfected. (B) Determination of the time- 
point at which the myosin Va is located on DNA factories. DAPI positive cells were counted and 
the number with myosin Va localised to the factories were counted and their respective 
percentages calculated. ‘Myosin Va’ is located on DNA viral factories from 4hpi and by 5hpi 
-70% o f viral factories are by labelled with ‘myosin Va’. Scale bar = 10pm.
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‘myosin V a’ may be involved in the viral life-cycle at the factory stage, it does not 
appear to support a role for myosin Va in the microtubule-to-actin switch of virus 
transport (Figure 6.1-Part IC). This suggests that the epitope could be hidden on IEV 
particles but exposed on the DNA viral factories.
Time-course localisation experiments were also performed using HeLa cells infected 
with modified vaccinia virus Ankara (MVA), which lacks 45 known genes present in 
the wild-type (WR) virus (Figure 6.3; http://www.poxvirus.org). Therefore, the aim was 
to establish whether the localisation o f ‘myosin V a’ was altered in cells infected with 
this virus, as a means to identify potential genes that this myosin Va antibody (clone 
LF-18) could be co-Iocalising with. Upon analysis there appeared to be no difference in 
the formation o f the viral factories and ‘myosin Va’ could also be detected on them as 
early as 4 hpi. More importantly, the MVA virus provides an initial indication of which 
viral proteins could be cross-reacting with the antibody, as 45 candidate genes can be 
eliminated from the investigation.
6.2.3 The effect of different drugs on the localisation of myosin Va
2,3-Butanedione monoxime (BDM) is a well-characterised inhibitor of skeletal muscle 
myosin-II and studies have indicated that the drug also inhibits motility due to the 
activity o f non-muscle myosins II and V (Cramer and Mitchison 1995; Duran et al. 
2003; reviewed in Forer and Fabian 2005). This implies that this pharmacological 
inhibitor should be able to perturb the function of myosin Va in infected HeLa cells. 
Therefore, HeLa cells were treated with lOmM BDM (Calbiochem) at the beginning of 
the viral infection and fixed at 8 hpi. Preliminary experiments, co-labelled with PY69 
and viral markers, indicate that the antibody is localised in the same manner as the wild- 
type situation (Figure 6.4). However, contradictory information regarding the action of 
BDM has been reported. Ostap et al. claim that BDM only inhibits myosin-II and does 
not inhibit the ATPase activity o f other myosins, so it should not be considered as a 
general inhibitor of the myosin ATPase (Ostap 2002). As BDM inhibits the activity of 
ATPase and not the rest o f the molecule, recruitment is therefore likely to occur.
In parallel, the following drug-treatments were also applied to vaccinia-infected HeLa 
cells to investigate if they have any effect on myosin Va: (i) nocodazole, which
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Figure 6.3: Timecourse of myosin Va (clone LF-18) localisation in MVA-infected HeLa 
cells. Myosin Va localises to maturing viral factories in MVA-infected HeLa cells. Cells were 
infected, fixed at the indicated times post-infection and probed with anti-myosin Va (LF-18, 
Sigma; green), PY69 (red) and DAP! (blue). Myosin Va is located on DNA viral factories from 4 
hpi, the same time-point that was determined for WR-infected cells. Scale bar = 10pm.
A
B
Figure 6.4: BDM treatment appears to have no affect on ‘myosin Va’ (clone LF-18) 
localisation. HeLa cells infected with WR vaccinia virus were treated with 10mM BDM and 
fixed 8 hpi. Cells were co-la belled with myosin Va clone LF-18 (green), DAPI (blue) and (A) 
A27L or (B) PY69 (red). Scale bar = 10pm.
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destabilizes the microtubule cytoskeleton; (ii) cytochalasin D, which disrupts actin 
filaments and inhibits actin polymerization; (iii) geldanamycin A (GA), which inhibits 
the ATPase activity o f the heat shock protein (Hsp) Hsp90 (Hung et al. 2002); (iv) 
rifampicin, which destabilises nascent viral membranes, blocking virus assembly (IMV) 
and (v) DMSO, as a control. Upon staining the cells with myosin Va (clone LF-18), the 
antibody demonstrated the same specific co-localisation with the DNA viral factories as 
seen previously (and in the control sample) in all-but-one (GA) of the drug-treated cells. 
These results imply that nocodazole, cytochalasin D and rifampicin treatment have no 
effect on ‘myosin V a’.
Viral infection induces a cellular stress response, which often results in the expression 
of stress response proteins such as Hsp that facilitate protein folding, translocation and 
cell viability. However, the particular cellular response is determined by the infecting 
virus and the cell-type (Fink 1999). The myosin Va localisation that was the exception 
exhibits a non-specific, diffuse localisation throughout the cytoplasm and was seen in 
the presence o f GA, a benzoquinine ansamycin antibiotic from Streptomyces 
hygroscopius (Figure 6.5, panel D) (Whitesell et al. 1994). The B5R-labelling fails to 
detect any viral spread and is concentrated around the viral factories, which appear 
smaller and distorted when visualised with DAPI. However, it would have been more 
informative to use PY69 as a marker in addition to B5R. This result for GA-treated cells 
is not surprising, as Hung et al. demonstrated that Hsp90 is essential for vaccinia virus 
growth, however, the drug was included within this study to investigate whether there is 
an effect on the turnover or folding of viral proteins (Hung et al. 2002). Hung et al. also 
showed that GA strongly inhibits vaccinia growth in several cell lines by specifically 
binding to the ATP-binding pocket on Hsp90 and, thus, interfering with its chaperone 
function (Hung et al. 2002). The expression from early viral promoters was not affected 
by the GA treatment, although DNA replication and intermediate gene transcription are 
delayed and the expression from the viral late promoter is reduced. Vaccinia virus 
infection does not induce Hsp90 expression, although the intracellular distribution of 
Hsp90 is altered in virus-infected cells (Hung et al. 2002).
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Figure 6.5: The effect of various drug treatments on the localisation of ‘myosin Va’ (clone 
LF-18). HeLa cells were infected with WR vaccinia virus and treated with the following drugs: 
(B) nocodazole, (C) cytochalsin D, (D) geldanamycin A, (E) rifampicin and (F) DMSO as a 
control. Cells were co-la belled with myosin Va (LF-18; green), B5R (red) and DAPI (blue). The 
localisation of the myosin Va antibody in non-treated cells is also shown for comparison (A). 
Scale bar = 10pm.
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6.3 What is the true localisation of myosin Va?
6.3.1 Localisation of myosin Va: clone LE-16 and ‘C am bridge’
In order to confirm the localisation o f myosin Va seen with clone LF-18, two additional 
antibodies were examined: clone LE-16 (Sigma) and ‘Cambridge’ (Lionne et al. 2001). 
Unfortunately, immunofluorescence stainings using these antibodies did not reproduce 
the viral factory localisation observed with the LF-18 clone, in any of the fixation 
conditions. Clone LE-16 predominantly labels the nucleus (Figure 6.6A), while the 
‘Cambridge’ antibody diffusely stains the cells (Figure 6.6B). Both antibodies were 
used in conjunction with PY69, which reinforced the fact that there is no co-localisation 
with the viral factories. This additional data questions the validity of these findings. 
Moreover, neither the LE-16 clone nor the ‘Cambridge’ antibodies produced 
localisation patterns that would suggest a role for myosin Va in the cell cortex.
A
B
Figure 6.6: Immunofluorescence using alternative myosin Va antibodies demonstrates 
different localisation patterns to that of myosin Va (clone LF-18). HeLa cells were infected 
with WR vaccinia virus, fixed 8 hpi and co-labelled with PY69 (red), DAPI (blue) and myosin Va 
(green). The myosin Va antibodies analysed were (A) clone LE-16 from Sigma and (B) a kind 
gift, referred to as ‘Cambridge’, from J. Kendrick-Jones (Lionne et al. 2001). Scale bar = 10pm.
PY69 DAPI
PY69
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6.3.2 All three myosin Va clones are highly conserved amongst myosin Va’s
Analysis and comparison of myosin Va sequences used to raise clones LF-18, LE-16 
and Cambridge are presented in Table 6.1, Table 6.2 and Figure 6.7. The general 
structure o f myosin Va is composed o f a well-conserved N-terminal motor domain, 
preceding 6 IQ, calmodulin-binding motifs (which are the major calcium sensor and 
regulator for various interactions with cellular proteins) and the conserved DIL domain 
at the C-terminal (Dekker-Ohno et al. 1993; Mercer et al. 1991). The data shows that 
each antibody is raised against different regions of the protein. Clone LF-18 resides 
towards the C-terminus, after the DIL domain, whereas clone LE-16 is located within 
the DIL domain and ‘Cambridge’ spans 375 amino acids within the region between the 
IQ domains and the DIL domain.
Sequence alignments and homology studies revealed that all three myosin Va clones are 
highly conserved amongst myosin V a’s from various species and exhibit no significant 
homology with other sequences (Figure 6.7). Therefore, as the myosin Va peptide 
sequences are identical there should be no cross-reactivity between species. 
Furthermore, specific BLAST searches against viral genomes failed to identify any 
significant protein matches and only produced results against small fragments of the 
protein. In addition, a general homology search also failed to produce any highly 
significant matches, although the highest (non-myosin Va) identity match against LF-18 
and ‘Cambridge’ was myosin Vb, and against LE-16 it was myosin Vc (Table 6.3). 
Therefore, there is a possibility that these antibodies may cross-react with other myosin 
V’s. The potential involvement o f these myosin V isoforms in the vaccinia virus life­
cycle are discussed further in Chapter 7.
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Figure 6.7: Schematic of Myosin Va, indicating the position of clones LF-18, LE-16 and ‘Cambridge’. Each clone demonstrates a high level of 
conservation between Myosin Va’s of different species, as illustrated with LF-18 and LE-16. The region high-lighted in red corresponds to the antibody 
peptide. Cambridge* is also highly conserved, although its alignment is not shown in this Figure.
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Name Species Amino acid range Sequence (amino acids)
LE-16 Chicken 1705-1720 LRDKNLMNSGAKETLE
LF-18 Chicken 1782-1799 RLRDRKDSPQLLMDAKHI
CAMBRIDG
E
Mouse 987-1362 SLQEEIAKLRKDLEQTRSEKKSIEERADKYKQETDQLVSNLKEENTLLKQEKETLNHRIVEQAKEMTETMER
KLVEETKQLELDLNDERLRYQNLLNEFSRLEERYDDLKEEMTLMLNVPKPGHKRTDSTHSSNESEYTFSSE
FAETEDIAPRTEEPIEKKVPLDMSLFLKLQKRVTELEQEKQLMQDELDRKEEQVFRSKAKEEERPQIRGAEL
EYESLKRQELESENKKLKNELNELRKALSEKSAPEVTAPGAPAYRVLMEQLTSVSEELDVRKEEVLILRSQL
VSQKEAIQPKDDKNTMTDSTILLEDVQKMKDKGEIAQAYIGLKETNRLLESQLQSQKRSHENEAEALRGEIQ
SLKEENNRQQQLLAQNL
Table 6.1: Myosin Va peptide and construct sequences for the antibodies used in this thesis. (LF-18: Sigma anti-Myosin Va [Product No. M4812]; LE- 
16: Sigma anti-Myosin Va [Product No. M5062]; CAMBRIDGE: anti-Myosin Va ‘Antibody No. 1' from Lionne et al. 2000; Mercer et al. 1991).
Region of Myosin Va (amino acids)
Species Accession
No.
Full-length Motor (head) 
domain
6 x  IQ 
domains*
DIL domain LE-16
antibody peptide
LF-18
antibody peptide
CAMBRIDGE
antibody construct
Mouse NP 034994.1 1853 71-751 767-906 1685-1790 1728-1743 1805-1822 987-1362
Rat NP 071514.1 1828 71-751 767-906 1660-1765 1703-1718 1780-1797 987-1362
Chicken NP 990631.1 1829 71-752 768-907 1661-1766 1705-1720 1782-1799 988-1363
Human NP 000250.1 1855 71-751 767-906 1687-1792 1730-1745 1807-1824 987-1389
Dog XP 535487.2 1930 62-742 758-897 1676-1781 1805-1820 1882-1899 1064-1339
Cow XP 615219.2 1866 63-743 759-898 1677-1982 1741-1756 1818-1835 1000-1375
Pig BAE03307.1 1851 71-751 767-906 1684-1789 1726-1741 1803-1820 986-1385
Chimp XP 510412.1 1842 62-742 758-896 1674-1779 1717-1732 1793-1761 976-1376
Table 6.2: Analysis and comparison of the myosin Va sequences used to generate the antibodies tested in this thesis. Data was obtained, analysed 
and compiled from the National Center for Biotechnology Information (httpJ/www. ncbi. nlm.nih. aov/entrez/auerv. fcai?db=aene). Pfam 
(httoJ/pfam. wustl.edu/hmmsearch.shtml). The peptides in red indicate the species against which the antibody was raised. NOTE: *IQ domains = calmodulin- 
binding motifs; 6x21 aa with 2-3aa spacers. The full-length figures for Myosin Va ‘Cow’ and ‘Chimp’ were obtained from the complete genomes, respectively.
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Myosin Va
LE-16
antibody peptide
LF-18
antibody peptide
CAMBRIDGE
antibody construct
Species Highest
match
Identity to 
MyoVa
Highest
match
Identity to 
MyoVa
Highest
match
Identity to 
MyoVa
Mouse
Myosin
Vc
68%
Myosin
Vb
52%
Myosin
Vb
40%
Rat 81% - 40%
Chicken 75% - -
Human 81% 62% 42%
Dog 81% 56% 42%
Cow - - 42%
Pig - - -
Chimp 81% - -
Table 6.3: Homology search against myosin Va clones LF-18, LE-16 and ‘C am bridgeN o
highly significant matches were found. The highest identity percentage for clones LF-18 and 
Cambridge were myosin Vb and for LE-16 was myosin Vb. Species labelled with a line (-) did 
not produce a result.
6.3.3 Non-specific localisation of dynein, dynam itin and PIN
To complement the myosin Va data, the localisation of dynein was also investigated as 
they share the same light chains (Espindola et al. 2000). Preliminary experiments using 
dynein light chain 1, dynein light chain 2 and dynamitin/p50 constructs, as well as a 
dynein antibody all produced a diffuse pattern in infected cells (Figure 6.9A-C). 
Dynein-light chain 2 also labelled the nucleus. In addition, studies with a PIN antibody 
(Santa Cruz; sc-18969) failed to produce a clear localisation in infected cells regardless 
of the fixation condition tested (Figure 6.8D).
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Figure 6.9: Localisation of dynein and PIN within vaccinia virus-infected cells. HeLa cells 
were infected with WR-virus and fixed 8hpi. Cells in (A) were additionally transfected with 
pCMV-myc-dynamitin/p50; cells in (B) were transfected with either (i) pE/L-GFP-LC8/DLC1 or 
(ii) pE/L-GFP-LC8/DLC2 (green). Cells were labelled with DAPI (blue), ‘myosin Va’ (red) in 
(A+B) and PY69 (red) in (C+D). In addition, cells in (C) were co-stained with dynein (green) and 
those in (D) were co-stained with PIN (green) under PT, PM, MeOH (M) and PFA (P) fixation 
conditions (see Section 2.5.1). Scale bar = 10pm.
255
Chapter 6 D oes M yosin Va Plav a Role During the Vaccinia Virus Life-cvcle?
6.4 Sum m ary
Analysis o f three different antibodies raised against myosin Va produced three very 
different localisations in vaccinia virus-infected HeLa cells. The Sigma clone LF-18 
specifically targeted the viral factories, which could be visualised from 4hpi. Treatment 
with BDM and a variety of other drugs that target the cytoskeleton failed to have any 
obvious effect. Myosin Va clone LE-16 was shown to localise predominantly to the 
nucleus and the ‘Cambridge’ antibody exhibited a diffuse, cytoplasmic labelling pattern. 
However, at the time when this research was conducted, only the latter one had been 
published and so was considered to be more reliable result. However, further work is 
obviously necessary to understand the precise location and role of myosin Va in the 
virus life-cycle. This study also demonstrates that not all commercially available 
antibodies detect what they claim to identify. Therefore caution and thorough analysis is 
essential for the verification o f results. Depending on what epitopes the antibodies were 
raised against, their sites may be blocked, making it possible to have three different 
patterns with three different antibodies. However, alternative strategies can be used to 
complement the antibody localisations, including the use of a GFP-tagged myosin Va 
construct, which would circumvent this issue.
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7.1 Perspective
The overall objective o f this thesis was to improve our understanding of and explore the 
relationships between the vaccinia virus proteins F12L, A33R, A36R and kinesin-1, 
during microtubule-based IEV transport. Understanding how these proteins function, 
communicate and influence the mechanisms underlying IEV transport not only has the 
potential to provide insight into the vaccinia virus life-cycle but also has implications on 
a greater scale concerning cell motility and disease as, with the exception o f kinesin-1, 
these proteins are only found in vaccinia virus-infected cells. Deciphering the 
interactions and mechanisms that occur between viruses and the cytoskeleton could also 
provide important new targets for the development o f anti-viral therapy. In particular, 
the ability o f viral proteins to interact with microtubule motors could represent a key 
concept in delivering therapeutic genes to target cells, in addition to viruses themselves 
being used for gene therapy (Lin et al. 2004; Moroziewicz and Kaufman 2005; Thome 
et al. 2005). As microtubule-dependent motility is essential for the cell to function 
efficiently, it is not possible for anti-viral therapy to target the cellular proteins that are 
involved in cellular transport without severely affecting cell-viability (Leopold and 
Pfister 2006). In addition to the cytoskeleton and its motors playing major roles in cell 
organisation and dynamics, viruses may also interact with these transport networks via 
unique sites that are different from those used by their cellular interaction partners. 
Therefore possible targets could prove to be specific host proteins that viruses use in 
order to connect to the cytoplasmic transport machinery (Dohner and Sodeik 2005). The 
egress of viral particles to the cell periphery has been extensively studied in a variety of 
different viral infections, including HIV genomes prior to budding and murine 
leukaemia virus RNP granules in association with endosomal carriers (Mouland et al. 
2001; Basyuk et al. 2003). However, the microtubule-dependent egress o f vaccinia 
virus has been the most well-characterised and has been analysed further in this thesis. 
Vaccinia virus provides a system that genetically traceable and easy to visualise to as 
well as visualise, and hence provides a good system for studying cytoplasmic transport, 
host kinesin function (defects o f which are implicated in many diseases) and 
understanding the mechanisms underlying motor recruitment.
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The impetus for this research project stemmed from work performed in our laboratory, 
which demonstrated that kinesin-1 is recruited to IEV particles via the TPR of its light 
chain, together with the discoveries that the IEV proteins A36R and F12L are required 
for the egress of these virions to the plasma membrane (Rietdorf et al. 2001; Zhang et 
al. 2000). When these findings are considered with respect to the known interaction 
between A33R and A36R, three key candidate proteins and a motor protein were 
identified as the initial basis o f this investigation. At the start o f my research, only the 
direct interaction between the A33R and A36R proteins was known (Figure 7 .1 A) 
(Rottger et al. 1999). However, during the course of this study, this interaction was 
further defined as requiring the cytoplasmic tail o f A33R and amino acids 91-111 of 
A36R (Ward et al. 2003). A direct interaction between A36R and TPR of KLC was 
identified but not between TPR and A33R or TPR and F12L (Figure 7 .IB) (Ward and 
Moss 2004). However, as the lack of interaction between the latter two IEV proteins 
(i.e. A33R and F12L) with TPR has only been published using one protein-protein 
interaction detection method, yeast-two hybrid analysis (which is known to produce 
false-positives), these results need to be validated using complementary techniques. In 
particular, the intracellular trafficking of the F12L protein is o f special interest as the 
protein is highly conserved among poxviruses and is essential for the egress of IEV to 
the plasma membrane (Zhang et al. 2000; Herrero-Martinez et al. 2005).
The results, approaches, relevance, complications and solutions encountered during my 
research are discussed below, together with the experiments and future directions that 
time did not allow. The events o f cytoplasmic transport observed during the vaccinia 
virus life-cycle are considered in the context of vesicular trafficking, as well as drawing 
parallels with other pathogens that adopt similar mechanisms in using the cytoskeleton.
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Figure 7.1: Summary diagrams illustrating the binding relationships between the viral 
proteins F12L, A33R, A36R and kinesin-1 known (A) at the initiation of this research and 
(B) that were established during the course of this thesis. The double-ended arrows 
represent a direct interaction, the blunt-ended lines indicate that no interaction exists and the 
dashed lines imply that the interaction status remains to be established. [Note: the lack of 
interaction detected between A33R-and-kinesin and F12L-and-kinesin (blunt-ended lines) 
requires validation using additional protein-protein interaction detection methods].
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7.2 LEV egress
7.2.1 IEV egress to the cell periphery  is catalysed by kinesin-1
Diffusion is an ineffective method to transport structures that are greater than 500KX)a 
in size, or 20nm in diameter, through the cytoplasm of a cell (Sodeik 2000; Leopold and 
Pfister 2006). Therefore, as viruses range in diameter from 15nm to several hundred 
nanometres they require energy-dependent motility in order to travel through the cells 
viscous cytoplasm along cytoskeletal filaments, in a directed fashion, within a 
reasonable time-frame (Figure 7.2). Moreover, without this active and directed 
cytoplasmic transport, vaccinia virus, with its vast size of ~360nm x ~270nm x ~250nm, 
would be rendered practically immobile (reviewed in Leopold and Pfister 2006; 
Cyrklaff et a l  2005).
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Figure 7.2: Examples of the scale and structures in microtubule-dependent transport.
Viral dependence on microtubule trafficking results from the relatively large size of viral capsids. 
Structures in excess of 20nm require energy-dependent motility to travel through the cytosol. 
Cellular organelles, such as clathrin-coated endocytic vesicles (100nm diameter), required 
molecular motors to move through the cytosol. Therefore, many viruses including adenovirus 
(80nm diameter), adeno-associated virus (AAV, 25nm diameter) and vaccinia virus (360nm x 
270nm x 250nm) can be expected to utilise molecular motors during infection. Because 
cytoplasmic dynein 1 plays a major role in driving motility towards the nucleus, many viruses are 
likely to have evolved strategies for interacting with this motor molecule. (Adapted from Leopold 
and Pfister 2006).
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Many different viral proteins are known to interact with the kinesin and dynein 
microtubule motors, enabling bidirectional transport along microtubules, although their 
precise function during infection remains to be established (Table 7.1; Figure 7.3) 
(reviewed in Greber and Way 2006). It is established that vaccinia virus and the African 
swine fever virus (ASFV) recruit kinesin-1 to facilitate viral transport to the cell 
periphery (Table 7.1-B+J respectively; Rietdorf et al. 2001; Jouvenet et al. 2004). For 
both viruses, it has been shown that over- expression of GFP-tagged TPR repeats of the 
kinesin light chain (ICLC) is sufficient to inhibit viral movement to the plasma 
membrane. This suggests that kinesin-1 is the principal motor involved in IEV during 
their egress, although the nature o f the vesicular cargo receptor(s) o f kinesin-1 is still 
largely unknown (Greber and Way 2006). Similar observations have been made for the 
ASFV, a related large DNA virus (Jouvenet et al. 2004).
Contrary to original findings, which showed that the A36R protein was essential for 
IEV egress to the plasma membrane, Herrero-Martinez et al. have recently reported that 
in the absence of A36R (AA36R), virus particles can still reach the cell periphery 
(Rietdorf et al. 2001; Ward and Moss 2001; Herrero-Martinez et al. 2005). It is 
therefore possible that additional viral receptors for kinesin-1 may reside on IEV 
besides A36R. Nevertheless, A36R is known to interact directly with the TPR of the 
ICLC (Ward and Moss 2004). However, as kinesin-1 is only associated with IEV 
moving to the plasma membrane in vaccinia-infected cells, it appears as though kinesin- 
l recruitment to IEV is a regulated event that takes place after virus particle assembly 
(Table 7.1-J; Newsome et al. 2004; Rietdorf et al. 2001). Although it is known that 
over-expression of TPR in vaccinia-infected cells inhibits the movement of IEV to the 
cell periphery, the precise point at which TPR blocks viral egress remains unclear. After 
all, when GFP-TPR is over-expressed at low levels, it is not seen to co-localise with 
IEV particles, which suggests that it does not act as a dominant-negative at the level of 
IEV. In addition, vaccinia virus IMV particles are also capable o f bidirectional 
movement on microtubules, suggesting that they are able to interact with both kinesin 
and dynein microtubule motors, however, the need for this bidirectional movement is 
currently uncertain (Table 7.1-1; Figure 7.3) (Ward 2005).
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Virus Family Motor Viral
receptor
Evidence & References
A Adenovirus type 2 and 5 
(Ad2/5)
Adenoviridae
d yn ein /
dynactin
cap sid
h ex o n ?
N uclear targeting of fluorophore ta g g e d  A d2 and Ad5 w a s  inhibited by p50/dynam itin o v erex p ressio n  and  
anti-DYNC1l1 injections but apparently in sen sitive  to injected anti-kinesin a n tib od ies (Leopold etal. 2 0 0 0 ;  
Mabit et al. 2 0 0 2 ; S u om ala in en  etai. 1 999). C o-im m unoprecipitation of Ad5 with IC74.1 (D Y N C 111, for 
dynein  nom enclature s e e  Pfister et al. 2 0 0 5 )  and p50/dynam itin (Kelkar etal., 2 0 0 4 ). P e p sc a n  data  
su g g e s te d  that a  s e q u e n c e  KSTQT similar to the Ad2 or Ad5 p ro tea se  s e q u e n c e  109K STQ S binds DLC8 
(M artinez-M oreno etal. 2 0 0 3 ). T he sign ifican ce  is unknown. T he cytop lasm ic dynein  light chain  DYNLT3 
(TCTEL1 or rp3) w a s  found to bind th e  viral E3 1 4 .7  kDa protein in conjunction with the cellular 14 .7  
interacting partner 1 4 .7  interacting protein FIP-1 (L ukashok etal. 2 0 0 0 ).
B African swine fever virus 
(ASFV)
Asfarviridae
d yn ein /
dynactin
glycoprotein
p 54
p50/dynam itin over ex p ress io n  inhibited A SFV  infectious g e n e  ex p ress io n . T he A SFV  glycoprotein  p 5 4  and  
DYNLL1 w ere found to co -lo ca lize  in ce lls . Y ea st 2  hybrid a n a ly sis  defined  a  13 am ino acid dom ain of p 5 4  
sufficient for binding to an SQ T  motif in DYNLL1 (A lonso et at. 2 0 0 1 ; R od riguez-C resp o  et al. 2 0 0 1 ).
kinesin-1 ? Kinesin-1 w a s  found on  cytop lasm ic  v iru ses, TRP over e x p r ess io n  blocked viral e g r e s s  (J o u v en et etal. 
2 0 0 4 ).
C Canine parvovirus (CPV)
Parvoviridae
D ynein ca p sid  (and  
e n d o s o m e s )
Microinjection of anti-D Y N C 111 antib od ies inhibited transport of m icroinjected CPV  to nu cleu s. 
Im m unoprecipitation of CPV with D Y N C 111 in cell extracts. CPV  c a p s id s  iso lated  from infected  c e lls  bound to 
taxol stab ilized  m icrotubules, and co -lo ca lized  with D Y N C 111 in vitro (Su ikkanen etal. 2 0 0 3 ).
D Influenza virus X-31
Orthomyxo viridae
dynein ?
(e n d o so m e s )
D iD (1 , l ,-d io c ta d ecy l-3 ,3 ,3 ,,3 '-tetram ethylindodicarbocyanine) labelled  X-31 particles m oved  bi-directionally 
a long  m icrotubules in en d o so m a l v e s ic le s , in so m e  c a s e s  follow ed by viral fusion at low pH with an  
en d o so m a l m em brane (Lakadam yali etal. 2 0 0 3 ). Anti-DYNC1I1 antibody injections inhibited long range  
transport of DiD labelled virus. M icrotubules and cytop lasm ic dynein are required for long range transport 
and MTs for efficient viral fusion  with a  limiting en d o so m a l m em brane.
k inesin? ? Bi-directional m o v em en ts
E Human foamy virus (HFV),
M ason Pfizer M onkey virus 
(M-PMV)
Retro viridae
d yn ein /
dynactin
G ag H um an foam y virus (HFV) (Petit etal. 2 0 0 3 ) and M-PMV G ag (S fak ian os etal. 2 0 0 3 )  w ere  targeted  to the  
MTOC after entry; foam y virus required LC8 (DYNLL1). In addition, over ex p ress io n  of the central coiled-coil 
dom ain of the dynactin sidearm  subunit p150/G lu ed , or p50/dynam itin b locked  nuclear targeting of HFV and  
M-PMV, respectively .
F Human immune 
deficiency virus type 1 
(HIV1)
Retro viridae
dynein RTC N uclear targeting of HIV1 rev erse  transcription c o m p le x e s  (RTC) positive for p 2 4  cap sid  and the a c c e s so r y  
protein Vpr ta g g ed  with G FP w a s  inhibited by m icroinjected anti-D Y N C 111 antib od ies (M cDonald etal. 2 0 0 2 ).
KIF4 G ag Y east-2-hybrid interactions, co-im m unoprecip itations and GST-pull dow n a s s a y s  dem onstrated  th e  c-term inal 
dom ain of KIF4 can  bind to the G ag polyprotein of various retroviruses, including HIV1 (Kim etal. 1998).
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G Herpes simplex virus 
type 1 (HSV1), pseudo­
rabies virus (PRV)
Herpesviridae
dynein /
dynactin
ca p sid  V P 1-3, 
V P 26, UL37
Im m unolocalisation o f dynein on the HSV1 cap sid  p o ssib ly  invo lves the teg u m en t protein V P 1-3  (S od eik  et al. 
1997; Zhou et al. 1 9 99). p50/dynam itin over  ex p ressio n  inhibited nuclear transport and esta b lish m en t of 
infection (D ohner et al. 2 0 0 2 ). Dynein light ch a in s T ctex and rp3 (DYNLT3 and DYNLT1) interacted with the  
sm all ca p sid  protein V P 26  in yeast-2-hybrid  s c r e e n s  and GST-pull d o w n s (D o u g la s et al. 20 0 4 ).
T he inner teg u m en t proteins UL36 (V P 1/2) and UL37 rem ained a sso c ia te d  with incom ing PRV c a p s id s  in 
exp lanted  dorsal root ganglion  neu ron s (Luxton et al. 2 0 05; Luxton e t al., 2 0 0 6 ). UL36 and 37  are co n serv ed  
am on g  a , 3, and y h erp es v iru ses, and are g o o d  cand id ate  recep tors for dynein /dynactin  recruitm ent.
kinesin-1 U S11 K inesin-1 (res id u es  8 6 7 -8 9 4 )  interacted with recom binant U S11 in vitro (D iefen b ach  etal. 2 0 0 2 ).
H Rabies virus (RV), 
Mokola virus
Rhabdoviridae
Dynein P-protein of 
p o lym erase  
com p lex
Y east-2-hybrid interaction of DYNLL1 with am ino a c id s 1 3 8 -1 7 2  o f the ph osp hoprotein  P (J acob  etal. 2000;  
P o isso n  etal. 2 0 0 1 ; R aux etal. 2 0 0 0 )  and co-loca liza tion s o f the P-protein with DYNLL1 in infected c e lls  (Finke  
et al. 2 0 0 4 ). P e p sc a n  interaction o f LC8 with phospho-protein  P (R od riguez-C resp o  et al. 2 0 0 1 ). A rabies virus 
with a m odified LC8 binding site  had an altered infection pattern in brains o f inoculated m ice (R asa lingam  et al. 
2 0 0 5 ).
I Vaccinia virus (VACV), 
intracellular mature 
virus (IMV)
Poxviridae
dynein /
dynactin
A27L p50/dynam itin o ver  e x p ress io n  inhibited IMV accum ulation at the MTOC, and b locked IEV a sse m b ly  (P loubidou  
etal. 20 00; S a n d erso n  etal. 2 0 00; Ward, 20 0 5 ).
J Vaccinia virus (VACV), 
intracellular enveloped 
virus (IEV)
Poxviridae
kinesin-1 A 36R  and ? D ynam ic co-localization  of kinesin-1 and IEV, T PR  o ver  ex p ress io n  b locked e g r e s s ,  direct interaction of A 36R  
(resid u es 8 1 -1 1 1 ) with T PR  (G ead a  et al. 2001; H errero-M artinez et al. 2 0 05; N e w so m e  et al. 20 04; Rietdorf et 
al., 2001; Ward and M oss, 2 0 01; Ward and M oss, 2 0 0 4 )
Table 7.1: Virus motor interactions. Note: This table describes positive effects of interference. Possible viral receptors are listed irrespective of whether 
their functionality was proven or not. (Reproduced from Greber and Way 2006).
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Figure 7.3: Schematic representation of dynein-dynactin and kinesin-1 in association 
with a hypothetical viral cargo. Cytoplasmic dynein (DYNC1H1), together with the associated 
dynactin complex are responsible for the inward movement of virus particles. The N-terminus of 
DYNC1H1 mediates association with intermediate chains (DYNC1I), the light intermediate chain 
(DYNC1LI1 and 2) and the light chains roadblock (DYNLRB1 and 2), LC8 (DYNLL1 and 2) and 
Tctex-1 (DYNLT1 and 3). The dynein activator is composed of a minifilament of the actin-related 
protein Arp1 terminated with an actin-capping protein, as well as Arp11, p25/p27 dimers and 
p62 (Schroer 2004). The highly flexible projecting side arm p150Glued binds both to dynein 
intermediate chains and microtubules. Kinesin-1 is a heterodimer of a heavy and a light chain 
and is involved in anterograde transport of virus particles (vaccinia virus and African swine fever 
virus). The light chain, which contains the cargo-binding tetratricopeptide repeat region (TPR), 
binds to the globular C-terminal domain of the heavy chain. The heavy chain homo-dimerizes 
through a coiled-coil interaction of the stalk and the two motor domains walk along the 
microtubule surface in a hand-over high processive fashion towards the plus-end (Vale 2003). 
(Reproduced from Greber and Way 2006).
7.2.2 Is F12L requ ired  for egress?
The entire protein o f F12L appears to be needed for the egress of IEV particles. 
Electron microscopy studies originally showed that in the absence of F12L, IEV
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particles are formed but fail to disperse beyond their perinuclear site of assembly (van 
Eijl et al. 2002). As F12L is only associated with IEV during microtubule-based 
transport it may play an accessory role by regulating the interaction between A33R with 
A36R and/or modulate the activity o f kinesin-1. In order to gain a better understanding 
of the role that F12L plays in this process, F12L was tagged with green fluorescent 
protein (GFP) so that it could be visualised by microscopy. A major advantage of using 
a GFP-fusion of F12L is that F12L could be visualised within the cell without 
permeabilisation or the need for pre-treatment with antibodies. The GFP-tag appeared to 
have no deleterious effect, as both the C-terminally and N-terminally tagged F12L 
could rescue the wild-type phenotype (visualised by actin tail formation or extracellular 
B5R staining) upon transfection into AF12L-infected cells. The rescue efficiency was 
slightly higher in the constructs that were tagged at the C-terminus (-77%  compared to 
-63% , upon staining with extracellular B5R). Unfortunately, these statistics were not 
calculated until after the F12L deletion constructs had been generated, with a GFP-tag 
positioned at the N-terminus. Therefore, perhaps analysis of C-terminally tagged 
constructs would be advantageous, as they appear to be slightly more effective. 
Nevertheless, it has previously been proven that the N-terminally tagged constructs are 
functional and live-cell imaging o f these transiently transfected constructs would be 
advantageous and provide more information about the dynamics of F12L.
IEV formation is inhibited in the absence of the majority o f IEV proteins and therefore 
the inability to detect F12L within these backgrounds is not surprising. When no IEVs 
are formed, F12L demonstrates a diffuse pattern with centrosomal aggregates. 
However, virus particles do appear to disperse within the AA36R background, although 
their movements are restricted to a region just past the perinuclear factories. In contrast 
to findings in our laboratory, studies performed by van Eijl et al. and Herrero-Martinez 
et al. reported that IEVs in the AA36R mutant virus are capable of moving to the cell 
surface, which implies that F12L can function in the absence of the A36R protein (van 
Eijl et al. 2000; Herrero-Martinez et al. 2005). Herrero-Martinez et al. recently used 
recombinant viruses and time-lapse confocal microscopy to demonstrate that the speed 
o f IEV egress in AA36R-infected cells was consistent with previous measurements of 
IEV particle movements. This eliminates the possibility that the virions had reached the
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cell periphery by diffusion or that vesicles were being monitored rather than IEV. In 
AFl2L-infected cells, although it has been shown that IEV particles are still able to 
form, they accumulate near the viral factories and are unable to move to the cell 
periphery. However, they are capable o f making actin tails, albeit at a very low level, 
which implies that some of these IEV particles must reach the plasma membrane by 
some means, possibly diffusion.
7.2.2.1 Full-length F12L appears to be needed for viral egress
Upon transfection o f the F12L deletion mutants into the AF12L background, viral 
particle dispersion to the cell periphery was not observed. Therefore, it is possible that 
several different regions of the protein or the whole protein may be required and this 
presents interesting questions regarding the structure of F12L. As the GFP-deletion 
constructs appear to form aggregates in the perinuclear region it is more probable that 
the proteins are mis-folded. This could disrupt essential binding domains, rendering 
F12L inactive and unable to associate with its (currently unknown) cognate-binding 
partners. Biochemical methods can be adopted to elucidate the structure of F12L and its 
binding partners. For example, the protein can be expressed through a baculovirus 
expression system, followed by X-ray crystallography to determine the precise structure 
of the protein (reviewed in Dauter 2006). Alternatively, fusion o f the F12L protein to 
affinity tags and performance o f immunoprecipitation experiments, in both uninfected 
and infected cells, could ascertain its binding partners. Yeast two-hybrid screens have 
already been performed between F12L and TPR, which establishes that there is no 
direct interaction between these proteins by this method (Ward and Moss 2004). This 
approach could be extended in order to identify whether F12L interacts with other IEV 
proteins.
All o f the experiments performed in this thesis (unless otherwise stated) were analysed 
8 hpi, while other reports have examined data at I2hpi (Zhang et al. 2000; van Eijl et al.
2002). 8hpi was chosen since it is the optimal time at which to visualise actin tail 
formation and hence observe completion o f the viral life-cycle. It has also been 
calculated that the abundance o f IEV particles is at its maximum, 37%, at 8 hpi and 
gradually decreases over time: 34% at 12 hpi, 16% at 16 hpi and 1% at 24 hpi (Payne
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and Kristenson 1979; Smith and Law 2004). Investigation of F12L localisation at later 
time-points during infection, e.g. lOhpi, 12hpi and 24hpi, could determine whether there 
is a delayed morphogenesis. Moreover, greater insight could be obtained by further 
refinement o f the F12L deletion constructs, whereby amino acids are progressively 
removed from the N and/or C-terminus. Although the full-length protein is capable of 
rescuing the wild-type phenotype in the AF12L background, perhaps removal of 5, 10 
or 20 amino acids from either end o f the protein has an effect? Are the truncated 
proteins still able to complete the viral life-cycle? What number of amino acids needs to 
be removed in order for this rescue to be prevented? However, even if it was discovered 
that the N-terminal o f F12L is vital for it to function, this would provide little additional 
information.
7.2.2.2 R ecom binant viruses are ideal to study live, real-time, viral egress
It appears unlikely that further analysis o f the F12L deletion constructs will be 
enlightening, moreover, live-cell imaging o f a recombinant GFP-F12L virus would be 
more informative in elucidating the localisation and dynamics of F12L in infected cells.
Viral particle movement from the factory to the cell surface is known to be associated 
with the step-wise association and dissociation of co-factors with the viral particle, 
including viral proteins and host cell proteins. However, the precise order and timing in 
which A33R, A36R, F12L, kinesin-1 (and other players) are associated is still unclear. 
Currently, we are limited to the knowledge acquired from cells fixed or lysed at 
different time-points and ideally the dynamics o f this process needs to be analysed in 
live cells, in real time. Many techniques have now been developed to allow the 
trafficking o f individual virus particles along microtubules, in real-time (Suomalainen et 
al. 1999; Seisenberger et al. 2001; Pelkmans 2005). However, resolution, time and 
space are limiting factors associated with live cell imaging that need to be taken into 
consideration. For example, in order to visualise the viral activity within the dense 
perinuclear factories a high level of resolution would need to be achieved. And, in order 
to distinguish the specific components being studied, multiple colours (channels) and 
simultaneous acquisition of the data would be critical.
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The generation of recombinant viruses in which the endogenous genes are replaced with 
a fluorescently-tagged version of the protein, under the control of the original viral 
promoter, would allow the role and spatio-temporal dynamics of these proteins during 
directed virus particle movement to be elucidated. The initial targeting clones for the 
proposed recombinant viruses, e.g. F12L-YFP and CFP-A33R, have been constructed 
and ultimately the virus would be visualised using fluorescence time-lapse microscopy 
(see Section 2.12). Other recombinant viruses already exist within the laboratory, e.g. 
for A36R and B5R, so they can also be utilised with F12L and A33R. Likewise, they 
can be used in conjunction with stable cell-lines that contain appropriate fluorescent 
markers, e.g. YFP-labelled tubulin. A stable cell line for the KLC, tagged with either 
CFP or YFP, would also complement this investigation.
However, before IEV particles are able to egress, they must first be assembled and this 
is a stage that has not been closely monitored to date. Therefore, the various approaches 
described above could also help to resolve outstanding questions such as: How do IEV 
assemble? How do IEV recruit kinesin-1 and F12L, and in which order they do so? 
How does kinesin-1 dissociate from IEV at the plasma membrane? Alternatively, 
biophysical procedures such as fluorescence recovery after photobleaching (FRAP) and 
fluorescence loss in photobleaching (FLIP) could be used to determine the diffiisional 
mobility (turn-over) o f the GFP-tagged F12L protein within cells (Lippincott-Schwartz 
2001; Misteli 2001; Stephens and Allan 2003).
1 .2 .23  C om parative genom ic studies of F12L could be valuable
An alternative approach for investigating F12L in viral egress is to consider other 
poxviruses and perform comparative genomic/evolution studies. Although vaccinia 
virus F12L is, generally, highly conserved in poxviruses (Table 5.1) the equivalent gene 
in myxoma virus (Leporipoxvirus genus), m 211, only demonstrates a 36% similarity. If 
time had allowed, GFP-tagged constructs (at both the N-terminus and C-terminus) 
would have been generated, containing the m211 gene, amplified from genomic 
myxoma DNA. Upon transfection and analysis o f these constructs in the AF12L 
background, it could be established whether the 36% similarity that they share is 
sufficient to rescue viral egress to the cell periphery. If it proved possible to rescue this
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phenotype then further characterisation would ensue to determine the essential regions 
that are required. Other F12L homologues could also be investigated, including the 
Mollnscum contagiosum virus and fowlpox virus, both o f which only possess a 27% 
amino acid identity with vaccinia virus.
7.3 Potential m echanism s for the recruitm ent o f F12L to IEV
The mechanism by which IEV actually recruits kinesin-1 remains to be established but 
appears to involve at least the IEV proteins A36R and FI2L. F12L is not seen to co- 
localise with A36R at the site o f IEV assembly (TGN), suggesting that there must be 
some kind of signal that results in the recruitment o f F12L to IEVs. Taking previous 
findings of F12L, together with results generated by 2D gel electrophoresis, data is 
highly indicative that F12L is post-translationally modified or interacts with a lipid in 
order to be recruited to IEV particles. Although F12L does not possess a transmembrane 
domain it may be associated with any number o f proteins, not just A33R and A36R. 
This raises the question of what F12L binds to: does it bind cargo, or is F12L itself the 
cargo that is transported? The dynamics of F12L is an interesting question and it would 
be valuable to use video microscopy to study the, previously described, recombinant 
GFP-F12L virus in real-time, in order to determine the rate at which F12L is recruited 
and whether it is recruited before or after kinesin-1, alone or as part of a complex. In 
addition, construction o f a recombinant GST-F12L virus could be useful to purify 
binding proteins and perform a variety of interaction studies, e.g. co- 
immunoprecipitation experiments.
7.3.1 Kinesin function can be regulated by phosphorylation
Motor protein function is commonly regulated by phosphorylation and, in the case of 
the kinesin-superfamily, there is ample evidence to demonstrate that either the motor 
protein itself or its cargo can be the target for phosphorylation (reviewed in Vale 2003; 
Domer 1999). However, our knowledge and understanding of how various cargoes are 
actually attached to kinesin-1 and/or how the kinesin-1/cargo complexes are regulated 
during their movement is limited.
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In the case of the APP, the source of p-amyloid plaques in Alzheimer’s patients, 
research has indicated that this transport may be regulated by cargo phosphorylation 
(Kamal et al. 2000; Kamal and Goldstein 2002). The progression of the disease is 
thought to involve defects in processing and transport o f APP, which interacts directly 
with the TPR of the KLC and can become threonine-phosphorylated by JNK (Verhey et 
al. 2001). This event appears to increase the binding of KLC, although a physiological 
role for this regulation is not yet apparent (Inomata et al. 2003). Further evidence for 
the association and regulation of kinesin with its cargo via kinases, include 
phosphorylation of KLC by glycogen synthase kinase (GSK3). This event is known to 
promote the removal of kinesin from its cargo and this implies that any pathway that 
can activate GSK3 is likely to inhibit kinesin-based motility (Morfini et al. 2002b; 
Szebenyi et al. 2002). GSK3 is a ubiquitous serine/threonine kinase, which plays roles 
in intracellular trafficking, as well as the Wnt pathway, adhesion and apoptosis (Frame 
and Cohen 2001). However, despite many mechanisms being known for the inactivation 
o f GSK, our comprehension of the activation of GSK is limited (Woodgett 2001; Wang 
et al. 1994). GSK3 has been shown to interact with kinesin and inhibit fast anterograde 
(kinesin-based), but not retrograde (dynein-based) axonal transport in squid axoplasm, 
and reduce the amount of kinesin seen bound to membranes (Morfini et al. 2002b). 
Furthermore, inhibition of the CDK5 kinase in axons also specifically reduced the 
anterograde transport rates and led to the activation o f GSK3P (by the protein 
phosphatase 1), resulting in the phosphorylation of KLC (Ratner et a/. 1998; Morfini et 
al. 2004).
Microtubules and GSK3p produce co-localisation patterns in neurons and glia that are 
reminiscent of those seen with kinesin, although GSK3p also exhibits a distinct 
labelling pattern that is separate from microtubules in regions specific for membrane 
delivery, e.g. the tips of elongating processes (Szebenyi et al. 2002). Thus, it would be 
interesting to investigate and compare the localisation of GSK3 and kinesin within 
vaccinia virus-infected cells.
The GSK3 and CDK5 activities are affected in Alzheimer’s disease and, as their 
activities can be regulated via many pathways, it is possible that different pathogenic 
mechanisms may cooperate in order to affect kinesin-based transport (Mandlekow and
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Mandelkow 1998; Morfini et al. 2002a). Pigino et al. also observed that an increase in 
GSK activity was observed in presenilin mutants that cause familial Alzheimer’s 
disease, resulting in defective transport o f kinesin cargo (Pigino et al. 2003). If GSK3 is 
activated inappropriately, kinesin could be released prematurely from its cargo, 
resulting in various unfavourable consequences.
It has been demonstrated that the 14-3-3 protein(s) can bind to kinesin-l through a 
direct interaction with kinesin light chain 2 (KLC2), in a phosphorylation-dependent 
manner (Ichimura et al. 2002). The 14-3-3 proteins comprise a family o f key regulatory 
proteins known to be involved in diverse intracellular-signalling pathways, mediated by 
phosphorylation, e.g. they have been shown to be involved the JNK pathway and in 
stress activation (Nagata et al. 1998; Zhang et al. 2000; Xing et al. 2000). Ichimura et 
al. also showed that the light chain of kinesin-l is capable of binding 14-3-3 but at a site 
separate from the TPR motifs, through its C-terminal tail (Ichimura et al. 2002). 
Therefore, a potential link between these signalling pathways and kinesin is created, in 
response to specific signal inputs. Therefore, perhaps vaccinia virus evokes similar 
signalling mechanisms during viral egress.
7.3.2 W hat is the role of serine phosphorylation of A33R?
The established interaction between the A33R and A36R proteins could be mediated by 
a third IEV protein. Phosphorylation is one of the most important regulatory events in 
eukaryotes and as the phosphorylated state of a protein can influence its ability to 
interact with other factors, it was postulated that this event could be a trigger for 
recruitment of a significant protein (Ward et al. 2003). It would be o f particular interest 
to elucidate whether A33R phosphorylation is necessary for the initial recruitment of 
A36R or if it becomes phosphorylated upon their interaction, or whether both A33R and 
A36R become phosphorylated simultaneously. Data from AA33R-infected cells 
transfected with the A33R-phosphomutant constructs show that they are able to egress 
to the cell periphery and make actin tails successfully, suggesting that A36R must be 
recruited (Figures 3.10 + 3.11).
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Studies performed by Wolffe et al. clearly demonstrated by 2D-phosphoamino acid 
analysis that -93%  of the radioactivity incorporated was phosphoserine and -7%  was 
phosphothreonine (Wolffe et al. 2001). Analysis using the Netphos software 
rhttp://www.cbs.dtu.dk/services/NetPhos) agrees that the majority of phosphorylation is 
predicted to occur on serine residues when considering the entire protein, e.g. the total 
threonine, tyrosine and serine phosphorylation is calculated at -6.5% , of which -3%  is 
due to serine phosphorylation. However, these findings are not substantiated when only 
taking into account the cytoplasmic tail, e.g. -13%  of the A33R tail is predicted to be 
phosphorylated on threonine, tyrosine and serine residues, with serine phosphorylation 
accounting for only -3%  of this phosphorylation, while threonine phosphorylation 
represents -6%  (Table 7.3). Therefore, caution should be exercised when using 
prediction software.
A33R Full-length protein (185aa) Cytoplasmic tail (31 aa)
Total no. of 
residues
Total no. 
predicted to be 
phosphorylated
Total no. of 
residues
Total no. 
predicted to be 
phosphorylated
Threonine 16 4 3 2
Tyrosine 9 3 1 1
Serine 22 5 2 1
Table 7.3: Summary table of the A33R phosphorylation sites presented in Figure 3.2 that 
were identified using the Netphos software. Calculations reveal that -13% of the exposed 
cytoplasmic tail of A33R is predicted to be phosphorylated on threonine, tyrosine and serine 
residues, with serine phosphorylation accounting for -3%  of this phosphorylation.
Wolffe et al. have reported that phosphorylation o f A33R occurs in the absence of 
A36R or IEV assembly, implying that its modification is not related to A36R (Wolffe et 
al. 2001). However, it is possible that phosphorylation o f A33R could trigger F12L 
recruitment to IEV or perhaps they become phosphorylated as a consequence of F12L 
being recruitment? Alternatively, phosphorylation may not play a significant role in 
this stage of the viral life-cycle. To identify sites of phosphorylation, antibodies were 
raised against potential sites of serine phosphorylation exposed on the cytoplasmic tail 
o f A33R. The advantage of using peptides for this investigation is that phosphospecific 
antibodies can be generated. Indeed, peptide competition experiments using A33R- 
PSerl2 and unphosphorylated A33R peptides demonstrated that the antibody raised 
against A33R-PSerl2 competes with its corresponding peptide, suggesting that it is
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specific for the peptide. This specificity can be confirmed by demonstrating that no 
signal is detected within AA33R-infected cells that have been transfected with the 
mutant constructs. The A33R-PSerl2 antibody identifies large peripheral structures that 
co-localise with A33R, which are reminiscent of either fused-virus or endosomes. To 
confirm if  these structures are endosomes, infected cells can be incubated with the fluid- 
phase marker horseradish peroxidase (HRP) (for -20  min) prior to fixation and 
permeabilisation. Subsequent staining with cyanine 3 (cy3)-labelled tyramine (a 
substrate for HRP) is deposited at the site of HRP uptake and thus identifies endosomes 
(van Eijl et al. 2002). Alternatively, the early endosome antigen 1 (EEA1) antibody 
and/or the LAMP2 antibody, which is associated with late endosomes and lysosomes, 
can be used for immunofluorescence labelling (Husain and Moss 2001). In addition, to 
enhance endosomal production, immunofluorescence can be performed after cells have 
been treated with IMCBH, which blocks the formation of IEV particles. This treatment 
implies that IEV particles are transported out via the secretory pathway, which results in 
a lower density of viral particles in the cell periphery and emphasises the presence of 
separate endosomes (rather than actually increasing the absolute numbers of 
endosomes). Perhaps phosphorylation o f A33R could trigger the recycling events back 
to endosomes? Studies using fluid-phase markers have shown that the viral protein 
F13L, as well as A33R, A34R, A36R, A56R, B5R and F12L, co-localise with 
endosomes and that recycling between the endocytic and exocytic compartments is 
increased after infection with vaccinia (Husain and Moss 2003; Schmeltz et al. 1994; 
van Eijl et al. 2002; Lorenzo et al. 2000; reviewed in Smith and Law 2004). The 
potential roles o f endosomes during the vaccinia virus life-cycle are depicted in Figure 
7.4 (Ward et a l  2004).
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Figure 7.4: The potential role of endosomes during the vaccinia virus life-cycle. The figure 
illustrates the cycling of the EEV proteins for re-use during virus wrapping and export. The 
wrapping of IMV, with either early endosomal or TGN-derived membranes that contain IEV- 
specific proteins, form lEVs. An enlarged region of the IEV particle is shown high-lighting its 
proteins and their topologies. After being transported along microtubules to the cell periphery, it 
fuses with the plasma membrane to produce CEV or EEV, which are subsequently detached 
and released. The viral proteins that remain in the plasma membrane after exocytosis are 
recycled via clathrin-mediated endocytosis. Upon reaching the endosomal compartments, these 
proteins may be re-used to wrap additional IMV particles. B5R and F13L have been shown to 
be recycled while other IEV/EEV proteins may also be recycled as a complex with these 
proteins. (Figure reproduced from Smith and Law 2004).
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Experiments performed by Husain et al. clearly described the first mechanism by which 
F13L is reutilised, via clathrin-mediated endocytosis, after it has been deposited in the 
plasma membrane (Husain and Moss 2003). Similarly, plasma membrane retrieval of 
the B5R protein was illustrated by the internalisation of a Fab fragment (fragment 
binding antigen) that specifically associates with the extracellular domain o f B5R 
(Ward et al. 2000). B5R possesses endocytosis retrieval signals within the cytoplasmic 
domain that are not needed for envelopment o f the virus but are required for its 
recycling from the plasma membrane (Ward et al. 2000). As A33R has a proposed role 
in endosome recycling events and as the protein is predominantly labelled on serine 
residues (regardless o f this being a relatively small proportion of the protein), 
phosphorylation of A33R:Serl2 could trigger these events. If not, perhaps the epitope is 
not readily accessible on the virions. Otherwise, perhaps phosphorylation of A33R is 
involved in the recruitment of F12L? It has been implicated that phosphorylation of 
A33R is not required for the dissociation o f F12L from IEV once it reaches the cell 
periphery, as the IEV particles moving to the plasma membrane were already 
positively-labelled with the A33R phosphospecific antibodies. This mechanism could 
only be true if the phosphospecific antibodies solely localised to the CEV particles on 
actin tails, which was not the case.
Transient transfection o f the pEL promotor-driven A33R phospho-mutants (in which 
the candidate serine residues had been mutated to non-phosphorylatable alanine and 
phosphomimetic aspartic acid) into a AA33R background did not affect viral egress to 
the cell periphery. However, monitoring them by video microscopy, in real-time, could 
reveal important evidence of the spatio-temporal behaviour of the virus and establish 
whether it has an effect on viral transport. Perhaps the mutants affect the rate o f IEV 
assembly, move in a processive manner that is faster or slower rate than the wild-type 
protein, or perhaps they acquire the ability to interact with additional or different 
proteins? Therefore, as it seems likely that phosphorylated A33R performs some kind of 
role within the viral life-cycle, it appears as though the approaches and current assays 
investigated within this study are the limitations. Hence, more practical and informative 
approach to this question is the construction o f a recombinant virus, as it is controlled 
under its own promotor and is therefore, inevitably, expressed at the correct time and
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levels. The endogenous A33R gene, with and without the serine mutations, could be 
tagged with a fluorescent marker protein and followed by its reincorporation into the 
genome; the encoded protein will automatically be detectable by its tag (see Section 
1 2 2 2  and 2.12). This extended analysis would enable close examination of the spatio- 
temporal dynamics of IEVs, including investigating delays in IMV wrapping and 
comparing the consequential rates of the microtubule transport of IEV particles. An 
IMV marker (e.g. A14L or A17L) would be required and it would also be useful to 
compare the relationship with other IEV proteins, using various combinations of the 
(deletion) viral backgrounds and tagged-proteins. 2D-phosphoamino acid analysis of the 
A33R mutants containing serine residue substitutions (in comparison with the wild- 
type) could also be performed in a similar manner to that suggested for F12L (see 
Section 5.2.1). It would also be interesting to examine the localisation of 
phosphorylated-A33R at different stages of the viral life-cycle to detect if/when A33R 
acquires and/or loses its phosphorylation state, how this event occurs and what the 
significance of this event is.
Furthermore, identification o f the kinase that is involved in this process could also 
prove to be very informative. The vaccinia virus genome is known to code for one 
functional phosphatase (encoded by the HI gene) and two kinases (encoded by the B1R 
and FIOL genes), with essential roles in vaccinia virus morphogenesis (Rempel and 
Traktman 1992; Lin and Broyles 1994; Guan et al. 1991; Beaud and Beaud 2000). The 
FIOL gene is o f particular interest as it is expressed at late times during infection, is 
encapsidated in the virion and has already been shown to phosphorylate both 
serine/threonine and tyrosine residues of several viral proteins, including: F17R, A14L, 
L4R, A17L, E8R (Betakova et a l  1999; Derrien et al. 1999; Kao et al. 1987; Traktman 
et al. 2000; Yang et al. 1988; Doglio et al. 2002). Therefore, it would be interesting to 
examine whether phosphorylated A33R is detected in F10L null cells.
7.3.3 F12L recruitm ent via protein interactions?
7.3.3.1 No evidence for an interaction between F12L and kinesin-1
The initial focus of this investigation was the interaction between F12L and kinesin-l. 
Although no evidence currently exists to show that these two proteins interact directly,
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it is still possible that F12L may modulate kinesin-1 activity via an indirect mechanism 
(Ward et al. 2004). One approach to identify interactions would be to widen the search 
for novel binding partners o f F12L and kinesin-l (as well as A33R and A36R). This 
could be achieved by scaling up the procedure so that the amount of material pulled- 
down is sufficient to be visualised by coomassie staining o f SDS-PAGE gels and any 
resultant bands analysed by mass-spectroscopy (methodology reviewed in Domon and 
Aebersold 2006). An alternative option for focusing upon specific bands of interest and 
removing false positives would be to perform pull-downs with cell-lysates from 
uninfected and infected cells and then analyse them by ID and/or 2D SDS-PAGE. In 
this way, virus infection-specific binding partners could be distinguished from binding 
partners present only in the non-infected cells. As the A36R protein is modified by 
phosphorylation events it would provide a suitable internal control within infected cells. 
However, the optimal method would be to affinity tag proteins within the viral genome 
e.g. GST-tagged or fluorescently-tagged recombinant F12L virus (see in Section 2.12) 
and perform immunoprecipitation experiments. The advantage of this approach is that 
the target proteins are synthesised within a eukaryotic cell, so that their processing and 
locations are normal. In addition, the viral genome can easily be manipulated for use in 
protein expression and purification techniques, as well as in immunofluorescence and 
live-cell imaging.
Due to the poor solubility o f F12L when expressed in bacteria and the absence o f full 
controls in the pull-down experiments using HeLa cell extracts, it was not possible to 
draw definite conclusions concerning its potential binding partners. Protein solubility is 
critical for successful pull-down experiments and can be improved by optimising the 
growth conditions, such as increasing the aeration during growth, using a higher cell 
density or lower temperature (e.g. 18°C) (Promega). The solubility of fusion proteins 
should be evaluated by centrifuging (I6,000g for 40 min) a small volume of the lysed 
cells expressing the fusion protein, before analysing both the pellet and the supernatant 
fractions by SDS-PAGE, for the presence of the fusion protein. Detection of the protein 
within the pellet could imply that the protein is insoluble or that the cells were not 
efficiently lysed. If this is the case, cell lysis can be enhanced in several ways. These 
include: freeze-thawing the cell pellets prior to the adding the cell lysis buffer; adding
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lysozyme to the reaction; increasing the volume of cell lysis buffer used and/or by using 
sonication as an alternative method (Promega).
Unfortunately, the failure to detect an interaction between F12L and TPR by performing 
ZIP pull-down experiments was not substantiated by the presence o f a positive control. 
Sunday Driver (SYD; 147KDa) would be an ideal positive control to confirm an 
interaction with TPR (Kamal et al. 2000; Bowman et al. 2000; Ginhard and Goldstein 
1996). However, the data generated by the anti-GFP immunoprecipitation analysis 
holds greater validity, due to the inclusion of thorough controls and although 
immunoprecipitation experiments are unable to demonstrate a direct interaction between 
two proteins, they are indicative. Therefore, the lack o f interaction detected between 
F12L and A33R proteins can be regarded as being true. However, the internal positive 
control for the interaction between A33R and A36R was only detected when A36R was 
over expressed and blotted against A33R, as the reciprocal experiment failed to identify 
A36R being pulled-down with over-expressed A33R. Similarly, A36R was not pulled- 
down with over-expressed F12L so, based on this evidence, it cannot be ruled out that 
the interaction between F12L and A36R is not real. The failure to detect an interaction 
could be due to a weak ‘bait-prey’ interaction, low expression of the ‘prey’ protein or 
interference from the identification tags fused to the protein(s). Reducing the stringency 
of the washing stage and/or adding cofactors that optimize and stabilize the protein- 
protein interaction can assist in overcoming such a poor interaction. Also, to date, an 
endogenous complex (i.e. tag-free) between F12L, A36R and kinesin-1 has not yet been 
demonstrated.
1.33 .2  Is there a direct interaction between F12L and A36R?
The ambiguous interaction detected between F12L and A36R by immunoprecipitation 
could provide insight into the mechanism underlying microtubule-based transport in 
vaccinia virus. Presently, the evidence obtained from the GFP-immunoprecipitation 
experiments only implies that it F12L is part o f a complex, so confirmation of a direct 
interaction is required. This could be achieved by expressing A36R in E.coli before 
binding the protein to appropriate beads and using it as bait to pull out F12L. In parallel, 
F12L from a AA36R background could be expressed to see if it interacts in vitro once
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pure. Alternatively, yeast two-hybrid analysis or the use of the recombinant viruses in 
pull-down assays could be adopted. Unfortunately, these methods do not take into 
account any form of post-translational modification. One approach that could be 
adopted to overcome this issue would be to purify A36R from AFl2L-infected cells, as 
in this viral background A36R would be unable to reach the plasma membrane and 
assume its phosphorylated state.
As F12L is specifically required for IEV egress on microtubules, it appears to ‘follow’ 
kinesin-1 rather than A36R, although the latter two proteins do directly interact (Ward 
and Moss 2004). Therefore, it seems more likely that F12L interacts with or modifies 
the motor protein in some manner. However, in comparison to the other IEV proteins, 
A36R is well characterised and several interaction sites have already been determined, 
e.g. the binding site for kinesin-l spans amino acid residues 81-111 of A36R, which 
overlaps with the binding region for A33R (Figure 1.24C; Ward and Moss 2004). As 
these events are mutually exclusive, it has been suggested that A33R competes with 
kinesin-l for its binding to A36R (Ward and Moss 2004). If the association detected 
between F12L and A36R proves to be real, a logical and informative progression would 
be to identify which region of the A36R protein is required for this interaction. 
Therefore, it is proposed that constructs containing various truncations o f the A36R 
protein could be transfected into AA36R-infected cells and the immunoprecipitation 
protocol followed as before. If additional analysis is successful, an immobilized peptide 
array assay of A36R could be performed, according to the SPOT synthesis technique, in 
order to determine the specific region o f the protein that is responsible for the 
interaction (Frank and Overwin 1996). In addition, 2D-phosphoamino acid analysis 
established that A36R is predominantly phosphorylated on serine residues and to a 
lesser extent on threonine and tyrosine residues (Wolffe et al. 2001).
Unlike with the A33R protein, the results obtained for A36R using the Netphos 
programme are in agreement (both for the entire protein and for the cytoplasmic tail) 
with these findings from Wolffe et al. It calculates that ~9% of the exposed cytoplasmic 
tail of A36R is predicted to be phosphorylated on threonine, tyrosine and serine
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residues, with serine phosphorylation expected to account for ~6% of this 
phosphorylation (Table 7.3).
A36R Full-length protein (221 aa) Cytoplasmic tail (196aa)
Total No. of 
residues
No. predicted to be Total No. of 
residues
No. predicted to be
nhrKznhnrx/lz*fari /*\
Threonine 8 4 6 4
Tyrosine 16 2 13 2
Serine 27 2 27 12
Table 7.3: Summary table of the A36R phosphorylation sites presented in Figure 3.6 that 
were identified using the Netphos software. Calculations reveal that -9% of the exposed 
cytoplasmic tail of A33R is predicted to be phosphorylated on threonine, tyrosine and serine 
residues, with serine phosphorylation accounting for - 6% of this phosphorylation.
Since A36R is a transmembrane protein, any phosphorylation event would be limited to 
the cytoplasmic tail. It is this region that mediates binding to both A33R and kinesin-l, 
as well as containing the sites of tyrosine phosphorylation, the interaction site for Nek 
and is required for actin tail formation (see Figure 1.24C). However, the identity of the 
serine residues that undergo phosphorylation and the exact role o f A36R serine 
phosphorylation is currently unknown. Perhaps serine phosphorylation of A36R has an 
effect on the recruitment o f kinesin-l, F12L or on IEV transport? The NetPhos software 
identified seven serine residues on the cytoplasmic tail of A36R that are the best 
candidates for phosphorylation (i.e. probability scores >0.9), in addition to predicting 
one threonine residue and four tyrosine residues (Figure 3.2A). This latter prediction, 
once again, questions the reliability o f the programme, as it identifies the following 
tyrosine residues and significance scores (in brackets): Yl 12 (0.97), Y132 (0.95), Y158 
(0.96) and Y200 (0.97). These scores all appear to be highly significant, however, it has 
been methodically demonstrated that only T y rll2  and Tyrl32 are phosphorylated, 
therefore, it is important to be aware that results generated from such programmes can 
be misleading (Frischknecht et al. 1999b).
The transmembrane region of A36R spans amino acids 4-25 of the total 221 amino acid 
protein and these seven candidate serine residues are found grouped together, close to 
the transmembrane domain between amino acids 51-62, which is near the kinesin-l 
binding site (Figure 3.6). This appears to be an unusual sequence, as it is very
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serine/tyrosine rich and possesses clusters of residues with low complexity, suggesting 
that it may be responsible for performing a specialised function.
Experiments performed by Wolffe et al., involving total 32P metabolically-labelled and 
phosphotyrosine-labelled proteins, suggested that A36R serine and tyrosine 
phosphorylation were differentially regulated (Wolffe et al. 2001). They also 
established that serine phosphorylation of A36R is not dependent on the presence of 
either the A34R or F13L proteins and they are not required to mediate the binding of 
A36R to A33R. Interestingly, differences in the metabolic labelling revealed that the 
A36R protein was more highly phosphorylated than the A33R proteins. However, 
perhaps this is simply due to the fact that A36R possesses a significantly larger 
cytoplasmic tail than A33R (i.e. 196 amino acids compared to 31 amino acids) and thus 
contains a higher number of phosphorylatable residues (compare Figure 3.2 and Figure 
3.6). Consequently, a greater percentage o f the A36R tail is predicted to be 
phosphorylated, i.e. -6%  compared to -3 %  on A33R. In addition, serine 
phosphorylation and formation of the A33R-A36R protein complex occurred despite 
virus assembly being blocked with rifampicin at an early stage during infection (Wolffe 
et al. 2001). Therefore, both proteins can become phosphorylated within the complex 
and independently of each other, prior to IEV movement.
7.3.4 F12L recruitm ent via post-translational modification?
F12L and kinesin-l are clearly functionally associated (either directly or indirectly), as 
they are both required for IEV egress on microtubules. However, whether F12L 
functions as part of the motor, or is the cargo itself still remains to be established. 
Phosphorylation of F12L could play a significant role. And, to assess whether F12L is 
actually phosphorylated, proteins from vaccinia virus-infected cells can be 
metabolically labelled and subjected to immunoprecipitation, SDS-PAGE and 
autoradiography, as performed for the A33R and A36R proteins (Wolffe et al. 2001).
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7.3.4.1 F12L is m em brane-associated
7.3.4.1.1 F12L is unlikely to be myristoylated
F12L shows no sequence homology to any with known microtubule-binding proteins, 
although these sites can be difficult to identify. There is also no data to suggest that an 
interaction between F12L and microtubules occurs (Zhang et al. 2000). in spite o f this, 
the opportunity to examine the sequence o f F12L for homology to other functional 
domains, i.e. protein-protein interaction domains or phosphorylation sites, was taken. In 
conjunction with the Bioinformatics and Biostatistics Department at Cancer Research 
UK, advanced computational techniques were employed to deduce the presence of 
putative domains within F12L, in the hope that these predictions would give rise to 
more educated choices for possible F12L mutant constructs. Unfortunately, with the 
exception of the two putative myristoylation sites (G124 and G546), no significant data 
was produced, including uninformative outputs regarding the possible secondary 
structure(s) or 3D folds.
Myristoylated viral proteins have roles in assembly, structure, budding, intracellular 
host interactions and viral entry (Maurer-Stroh and Eisenhaber 2004; Martin et al. 1997; 
Heath et al. 2003; Grosenbach and Hruby 1998; Towler et al. 1988). The myristoyl 
moiety is responsible for targeting the modified protein to membranes and membrane 
sub-compartments as well as being involved in direct interactions with other proteins 
(Hayashi 2002; Liemann 2002; Maurer-Stroh and Eisenhaber 2004). Before 
investigating whether F12L is myristoylated, it needed to be established whether F12L 
possessed the capacity to become associated with membranes. Membrane-pelleting 
assays demonstrated that F12L does associate with the membrane fraction, as well 
being located in the soluble cellular fraction. This result verifies the observations 
recorded by immunofluorescence analysis, i.e. that F12L localises to discrete virus 
particles, as well as producing a high cytoplasmic background. However, optimization 
of variables, such as the elution conditions, is necessary to determine the nature o f this 
association. Elution conditions have the capacity to dissociate binding partners, for 
example, by extremes o f pH, high salt (ionic strength) or the use of detergents. 
Unfortunately, due to the lack of sufficient positive and negative control proteins it is 
difficult draw any definite conclusions from this work. Also, as F12L is recruited to
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IEV, its association with membranes is not necessarily surprising. It is possible that 
analysing and comparing the point mutation constructs by 2D gel analysis could high­
light any differences between them. However, it is more probable that the recruitment of 
F12L to IEV is due to a protein-protein interaction rather than an association with 
membranes via myristoylation. After all, F12L is released prior to, or as a consequence 
o f virion fusion with the plasma membrane. If this did not happen, then 
demyristoylation would have to occur. Nevertheless, this raises an interesting question 
concerning how much membrane is actually exposed on the surface of the IEV particle. 
For example, if the virion coat it almost completely covered with viral proteins, then 
this would further decrease the likelihood of F12L interacting by membrane- 
association.
Experimental evidence has reported that the vaccinia virus proteins L1R, A16L, 
G9R/FI, E7R are all subjected to glycine myristoylation and all undergo myristoylation 
at the N-terminus (Martin et al. 1997; Martin et al. 1999). However, in order for F12L 
to be myristoylated the protein would have to be cleaved, due to both of the identified 
sites, G124 and G546, being internal rather than exposed at the N-terminus of the 
protein, as is typical. However, no evidence was seen o f a higher of lower molecular 
weight pre-cursor to suggest the possibility o f protein cleavage. Also, myristoylation 
does not create a detectable size shift that can be visualised by SDS-PAGE, otherwise a 
difference may have been seen between the spots identified by 2D analysis. Inhibiting 
the potential activity of G124 and G546 by mutating them to alanines does not affect 
the rescue of viral egress in the AF12L background. However, although this analysis has 
not determined whether F12L is myristoylated, the true status of F12L could be 
determined by in vitro transcription-translation of F12L cDNA that is labelled with
C -5
either S-methione or H-myristic acid, followed by SDS-PAGE. As positive controls 
for this experiment, the vaccinia virus proteins L1R, A16L, G9R/F1, E7R, or the small 
GTPase ARF (ADP ribosylation factor) could be used (Hinners et al. 2003). Although 
this in vitro translation system should be a reflection o f the in vivo situation, artefacts of 
the in vitro conditions may occur. Nevertheless, there are also several circumstances in 
which in vitro translation systems can have advantages over in vivo gene expression. 
For example, when the over-expressed product is either toxic to the host cell, is
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insoluble or forms inclusion bodies, or when the protein is proteolytically degraded by 
intracellular proteases (http://www.ambion.com). It should, technically, be possible to 
prepare a cell-free extract for in vitro translation of mRNAs from any type of cell. 
However, in practice there are only a few cell-free systems that have been developed for 
in vitro protein synthesis and on the whole, these systems are derived from cells that 
function at a high rate of protein synthesis, which implies that they would not represent 
the environment in which F 12L is endogenously produced.
7.3.4.1.2 Is F12L palmitoylated?
As it seems highly unlikely that F12L is myristoylated, an alternative line of 
investigation would be to examine whether F12L is palmitoylated, as is F13L. F13L is 
required for the formation of IEV particles and associates peripherally with the 
wrapping membranes, via palmitoylation of cysteine residues 185 and 186 (Hiller and 
Weber 1985; Grosenbach et al. 1997; Husain et al. 2003). IEV formation is regulated 
through the phospholipase activity of F13L (analogous to that reported for 
phospholipase D (PLD)), due to the presence of a variant o f the HKD motif that is 
possessed by members of the phospholipase superfamily (Husain and Moss 2002; Ward 
2005). PLD catalyzes the hydrolysis of phosphatidylcholine to phosphatidic acid and 
choline, inducing coatomer binding and vesicle formation at the TGN (Ktistakis 1998; 
Husain and Moss 2002). Viral membrane proteins present within the Golgi apparatus 
are found in the induced vesicles and up until this stage of the viral life-cycle PLD1 can 
be substituted for F13L. However, the subsequent stages are reliant on F13L (Husain 
and Moss 2002). B5R and A36R also showed co-localisation with PLD I when cells 
expressing PLD1 were infected with the AF13L virus (Husain and Moss 2002). 
Unfortunately, this was not complemented with studies using the endogenous PLD1.
F12L possesses some similar characteristics to the F13L, e.g. they both lack 
transmembrane domains and are known to associate with membranes. Likewise, F12L 
also co-localises with endosomes in infected cells, as seen by the uptake of a fluid phase 
marker (Figure 7.4) (Husain and Moss 2001; reviewed in Smith and Law 2004). F12L 
was shown to move to the cell surface without being associated with IEV particles and 
this co-localisation between F12L and endosomes was demonstrated in vaccinia virus-
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infected cells after treatment with IMCBH (which enhances the presence of endosomes 
by blocking the formation of IEV particles). Also, as yet, it has not been confirmed 
whether F12L co-localises with endosomes in uninfected cells, although this seems 
unlikely considering the diffuse, cytoplasmic pattern produced by F12L in uninfected 
cells (Figure 4.9). Therefore, this suggests the involvement of additional viral proteins.
There is potential that FI 3L could play additional roles in the trafficking of IEV through 
the cytoplasm or in its fusion with the plasma membrane. Also, as F13L lacks a 
transmembrane domain and exists as a single domain, it is plausible that F13L and 
F12L could interact or be associated in some manner, e.g. perhaps F12L is recruited to 
IEV particles via a lipid product downstream of F13L? However, if F12L behaves in a 
simitar manner to F13L, then it should be recruited to lipid vesicles in non-infected 
cells, which is not observed. It would also be of interest to examine the dual localisation 
of F12L and F13L in different viral backgrounds, particularly AA36R as it is also 
involved in viral egress. The lipid environment of the IEV may enable this interaction; 
F13L is able to convert phosphatidylcholine into phosphatidic acid, therefore, it could 
be speculated that F12L may be recruited to phosphatidic acid. However, F12L is not 
seen localised to membranes in non-infected cells, as would be expected if they 
contained this lipid. This would suggest that F12L could associate with F13L, as a 
means o f being recruited to IEV particles. This relationship could be investigated 
indirectly by using PIP Strips ™ that contain all eight phosphophinositides, providing 
an indication of the protein-lipid interaction potential (Echelon Biosciences Inc., Salt 
Lake City, Utah, USA). However, in order to determine whether F12L and F13L 
interact directly, the more conventional methods of immunoprecipitation, pull-down 
assays and yeast-two hybrid analysis should be conducted, as described previously.
7.3.4.2 How and why is F12L post-translationally modified?
My work suggests that F12L is subjected to some form of post-translational 
modification, based upon analysis by 2D gel electrophoresis, unless the results are due 
to F12L possessing an unusual structure. However, multiple spots can also be detected 
in the absence of protein modification, due to poor sample preparation and/or the 
presence o f artefacts. Therefore, in order to confirm that F12L is modified, samples
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prepared in both uninfected and infected viral backgrounds (e.g. produced in E.coli or 
from rabbit reticulocytes) can be compared and analysed. If the same pattern is 
produced in all o f the resultant 2D gels, this would imply that the protein is not 
modified and the results are likely to be due to F12L possessing a rare structure. 
Conversely, if  the infected samples demonstrate different patterns, this would suggest 
that some form of protein modification of F12L is occurring. This technique would be 
able to identify modifications that create a change in size of the protein (as well as 
charge). Amongst the modifications investigated in this thesis, phosphorylation affects 
both charge and size and would therefore be detectable, in contrast to myristoylation, 
which cannot be identified by a change in size. Furthermore, palmitoylation is also able 
to alter the size and may affect the charge o f the protein (Valdez-Taubas and Pelham 
2005).
Although the exact nature of the putative F12L modification is still unresolved, it is 
possible that this altered version of F12L plays a key role in motor recruitment. It may 
also be responsible for mediating various protein-protein interactions. For example, 
perhaps F12L needs to be modified in order to be recruited to IEV particles? Or, 
perhaps recruitment of F12L to IEV induces a modification event that initiates viral 
egress or promotion of interactions between other proteins? Similarly, upon the IEV 
reaching the plasma membrane to form CEV, perhaps de-modification of F12L is 
responsible for the dissociation of F12L from the viral complex and/or activating the 
subsequent actin-based motility events. However, this sounds unlikely, so perhaps Src is 
solely responsible for phosphorylating A36R and this mechanism is strong enough to 
trigger actin tail formation, as well as cause other components within the viral complex 
to dissociate?
Despite the 2D analysis being performed in both a wild-type and a AF12L-infected 
background, for validation purposes, the result produced could be verified by examining 
uninfected and infected HeLa cell samples, over-expressing GFP-F12L. In order to 
determine whether the presence of additional proteins is required for F12L to be 
modified, or to function efficiently, this analysis could be extended by examining the 
effect in other deletion backgrounds (e.g. AA36R).
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Clarification of the potential phosphorylation state of F12L could be achieved by 
adopting a variety of different techniques. Initially, the traditional approach could be 
explored by using radioactive, inorganic phosphate isotopes (e.g. P) to label the 
phosphorylated protein(s) of interest, followed by SDS-PAGE and autoradiography. As 
a safer alternative, western blot analysis on whole cell lysates, or IP samples, could be 
performed prior to probing the membranes with antibodies that specifically bind to 
phosphorylated proteins, i.e. PTyr, PSer and/or PThr antibodies. A36R could be used as 
a suitable positive control. Phosphospecific antibodies can be arduous to produce, 
however, there are many commercially available antibodies. However, in contrast to the 
pan-PTyr antibodies that are available, the pan-PSer and pan-PThr antibodies have, 
generally, demonstrated poorer sensitivity and reliability. In addition, antibodies are not 
as sensitive as radioactivity and they can also be affected by surrounding sequences 
whereas radioactivity is not. Therefore, although antibody detection is a safer method, it 
is much less reliable. Phosphospecific antibodies are specifically directed against the 
phosphorylated antigens, so they do not recognize the unphosphorylated form of the 
protein. They can be used for studying phosphorylation events by several techniques, 
including: western blot analysis, ELISA, flow cytometry and immunohistochemical 
analysis (http://biocompare.corn). However, in some experiments it may advantageous 
to use both the phosphospecific and pan (non-phosphospecific) antibodies, as the 
phosphospecific antibody will detect the fraction of protein that is phosphorylated, 
whereas the pan antibody will detect the total amount of protein. However, the 
specificity of the phosphospecific antibodies is a larger concern, as certainly by 
immunofluorescence it can cross-react. One way in which associations between the 
quantity of total protein and the phosphorylated protein can be determined is by 
employing phosphodetection ELISAs (e.g. phosphoELISA™ Kits, Biosource 
International). However, the current priority is to determine whether phosphorylation 
occurs or not and this can be achieved by the use o f pan-antibodies on the 2D gels to 
reveal which, if any, of the identified spots are phospho-specific. Once this data is 
established, the specific site responsible can be investigated.
Similarly, if time had allowed, the resulting nitrocellulose membranes from either ID or 
2D gel electrophoresis could have been treated with the Pro-Q® Diamond
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Phosphoprotein Blot Stain, which directly and selectively binds to the phosphate 
moieties within the samples (Molecular Probes, Invitrogen; P-33356). It enables PTyr, 
PSer and PThr to be identified directly on the membrane(s) using a unique 
fluorescence-based detection system that does not require the use o f radioactivity 
(Goodman et al. 2004). This simple, specific and highly sensitive technique can detect 
l-16ng of phosphoprotein per band and could prove to be a rapid and instrumental 
means for determining the nature of the potential modifications. In order to ascertain the 
intensity of the phosphorylation event(s), this technique can be used in conjunction with 
the SYPRO® Ruby Protein Blot Stain (Molecular Probes, Invitrogen; S-11791), which 
labels the total protein content. When the two stains are used together, it is claimed that 
it is possible to identify a lightly-phosphorylated, high-abundance protein from a 
heavily-phosphorylated, low-abundance phosphoprotein (Molecular Probes, 
Invitrogen). Alternatively, Pro-Q® Diamond Phosphoprotein Gel Stain (Molecular 
Probes, Invitrogen; P-33301) can be used to directly identify phosphoproteins within ID 
or 2D gels, eliminating the need for western blotting or the use of antibodies.
Alternatively, the sample extracts could also be treated with sodium orthovanadate 
and/or XPP (as described in Section 5.2.1.1) and examined by 2D gel electrophoresis, to 
determine whether phosphorylation events are either maintained or prevented, 
respectively. The ideal approach to gain reliable and valid data would be to conduct 
these experiments on a larger scale, with subsequent analysis and characterisation o f the 
spots being performed by mass spectrometry. Mass spectrometry has the power to 
measure the mass-to-charge ratio of ions and to identify the composition of unknown 
protein and compound samples. Of particular relevance is the ability of mass 
spectrometry to identify protein modifications. However, phosphopeptides do not tend 
to perform well in mass spectrometry analyses. As phosphorylated proteins are 
relatively low in abundance they can prove problematic to detect and even by mass 
spectrometry it can be challenging, without additional knowledge. Even if the nature of 
the desired modification is known, problems still exist concerning the modified-peptide, 
e.g. it may not be found in the initial digest of the protein (Goodman et al. 2004; Roof 
et al. 1998; Kuster and Mann 1998). In addition, purification of a protein that is able to 
maintain the phosphorylated state can also be a problem, as well as the phosphate
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groups having a tendency to dissociate, and therefore missed, when being analysed by 
the mass spectrometer. Indeed, the identification of phosphorylation sites by mass 
spectrometry is estimated to have only an approximate 1 in 10 chance of success, which 
could also be due to a reduced sensitivity in detection and/or low stiochiometry of 
phosphorylation (Roof et al. 1998). Notwithstanding this, in contrast to the fluorescent 
stain methods described previously, mass spectrometry is capable of defining whether a 
protein is singly or multiply phosphorylated and, more specifically, it can locate the 
exact amino acid which undergoes phosphorylation (Wolschin et al. 2005b). In addition 
to metabolically labelling proteins, using antibodies, applying specialist stains, 
performing electrophoresis and mass spectrometry to detect phosphorylation events, 
Edman sequencing and chromatographic methods (e.g. high-performance liquid 
chromatography, HPLC and thin-layer chromatography, TLC) are also still commonly 
used (reviewed in Yan et al. 1998).
To help overcome the difficult issue of detecting low-abundance phosphorylated 
proteins, several methods are now available for amplifying the signal o f phosphorylated 
proteins prior to detection. These include the Pro-Q® Diamond Phosphoprotein 
Enrichment Kit that uses a column to isolate, wash, concentrate and elute 
phosphoproteins (Molecular Probes, Invitrogen; P-33359), as well as a novel strategy 
recently described by Wolschin et al. (Wolschin et al. 2005a). This method combines 
the enrichment of phosphoproteins, using a technique call metaloxide affinity 
chromatography (MOAC), together with selective ion trap spectrometry. It has been 
shown to reliably detect serine/threonine phosphorylation, although this method is 
unable to detect the precise sites subjected to phosphorylation.
7.3.4.3 How and why is F12L released from IEV particles?
Upon fusion of IEV with the plasma membrane to form CEV, both F12L and kinesin-l 
have already become dissociated from IEVs. It is unlikely that this dissociation is a 
direct consequence of virion fusion with the plasma membrane, as both kinesin-l and 
F12L preferentially label cells infected with the YdF virus (which cannot make actin 
tails but in which Src is still activated). Therefore, another factor must be responsible 
for a ‘switch’ that relates the activities of Src and the subsequent phosphorylation of
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A36R. Technically, it is uncertain whether F12L and kinesin-l dissociate prior to IEV 
fusion with the plasma membrane but the YdF virus provides good evidence that this is 
not the case. Ideally, further investigation needs to be performed with a virus that is able 
to fuse with the plasma membrane but is unable to activate Src or make actin tails. A 
suitable approach would be to infect PP1-treated cells (in which the phosphorylation of 
A36R by Src will be inhibited) with the YdF virus, as kinesin-l will either still be 
present or it will have been kicked off (Frischknecht et al. 1999b) This approach will 
enable the event of fusion to be separated from that of phosphorylation. In YdF-infected 
cells, kinesin-l and Src are both present, thus the dissociation mechanism is related to 
phosphorylation of A36R, possibly as a result o f a conformational change.
It could be speculated that the release of F12L from beneath CEV at the plasma 
membrane is a passive process, as the virus switches to actin-based motility. The event 
of A36R phosphorylation is likely to induce a conformational change in the (A36R) 
protein and consequently influence the kinesin-l/F12L binding activity. Also, if a direct 
interaction is established between F12L and A36R, localising the binding region and 
comparing it with other sites, could provide valuable insight into the physical and 
temporal relationships of these players. Once again, ideally, we want to use live-cell, 
high-speed imaging to determine the temporal sequence in which F12L and kinesin-l 
are recruited and dissociated from IEV, thus establishing whether they are released 
together or sequentially. The structure of A36R, in both its phosphorylated and 
unphosphorylated states, would also be invaluable to learn more about the action of 
F12L, kinesin-l and Src at the plasma membrane.
7.4 Switching from m icrotubule-based to actin-based motility
7.4.1 The importance of cross-talk between microtubules and actin filaments
Microtubule-actin interactions underlie numerous fundamental cellular processes, 
including cell motility, cell division and cortical flow (reviewed in Rodriguez et al.
2003). This cross-talk between the cytoskeletal filaments is seen in a diverse range of 
cell-types (e.g. epithelia, neurons, fibroblasts, oocytes, early-embryo) and across species 
from yeast to humans, emphasising the importance that this interaction has for life 
(Rodriguez et al. 2003). In particular, the co-operation between the microtubule and
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actin cytoskeletons during cytoplasmic transport has been reported in a variety of 
situations (Goode et al. 2000; Rogers et al. 2000). As a result, several hypotheses have 
been proposed to explain how cells use ‘structural’ actin-microtubule interactions (i.e. 
in which they are physically linked), as well as ‘regulatory’ ones (i.e. whereby two 
systems indirectly control each other through their effects on signalling cascades) to 
generate movement (Wittman and Waterman-Storer 2001; Waterman-Storer et al. 
2000). In each case, the microtubule dynamics and motor activity contribute to the 
regulation of the actin cytoskeleton. Within migrating cells there are three principle 
regions in which actin and microtubules have been observed and, consequently, 
microtubule-actin interactions have been divided into three conserved 
‘mechanochemical modules’, consisting o f either ‘structural’ or ‘regulatory’ 
interactions, or both (Figure 7.5) (Rodriguez et al. 2003). Firstly, microtubules have 
been seen coupled to F-actin undergoing retrograde flow in the lamellum, which 
invokes the ‘polymerisation/contraction treadmill module’ (Figure 7.5, box I). 
Secondly, microtubules are also seen targeted to focal adhesions by cross-linking to and 
growing along actin-bundles that are associated with focal adhesions (Palazzo and 
Gundersen 2002). This interaction employs the ‘actin bundle/microtubule guidance 
module’ and several candidate molecular mechanisms through which microtubules 
cross-talk with actin have been identified (Figure 7.5, box 2) (Palazzo and Gundersen; 
Krylyshkina et al. 2002; Krendel et al. 2002; Jimbo et al. 2002). And, thirdly, 
microtubules can be seen anchored in the cell cortex via interactions between plus-end 
binding proteins and actin-binding proteins, by utilising the ‘plus-end/cortex anchor’ 
(Figure 7.5, box 3) (reviewed in Rodriguez et al. 2003). It is this latter interaction that is 
of particular interest to this thesis. The microtubule-actin ‘plus end/cortex anchor 
module’ is the most well-characterised and has already been defined within 
Saccharomyces cerevisiae (Figure 7.5, box3b) (Gundersen 2002; Yarm et al. 2001; 
Dujardin and Vallee 2002). Therefore, it is possible that a similar module may exist in 
other cell types, although how well-conserved this yeast ‘module’ is and what other 
molecules are involved is still unclear.
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OVERLEAF
Figure 7.5: Schematic representation of microtubule-actin interactions. (A) In migrating 
cells, microtubule (green) minus ends are organized by the centrosome, which is positioned 
between the nucleus and the leading edge, and their plus ends are orientated towards the 
leading edge plasma membrane. In lamellipodia, F-actin (red) is in a meshwork that undergoes 
retrograde flow towards the convergence zone (CZ), where myosin (blue dots) is concentrated 
and contractility is high. Stress fibres are contractile actomyosin bundles with their ends 
anchored in focal adhesions. Insets show putative microtubule-actin interactions in different 
regions of a migrating cell, in the iamellum (box 1), microtubules are coupled to F-actin 
undergoing retrograde flow. This process compresses and breaks microtubules to promote 
regional micro tubule turnover. Microtubules could target focal adhesions (box 2) by crosslinking 
to and growing along focal-adhesion-associated actin bundles. Microtubule plus ends may be 
anchored at the cell cortex (box 3a) through interactions between plus-end-binding proteins and 
actin-binding proteins to orientate the MTOC towards the direction of migration. (Box 3b) The 
'plus end/cortex anchor' module is well characterized in S.cerevisiae, where plus-ends of 
individual microtubules become bound by stable attachments to sites in the actin cortex, defined 
by Cdc42. This is important for positioning the mitotic spindle. Microtubules may attach to the 
actin cortex and find the bud tip by a complex consisting of the microtubule-end-binding protein 
Bim1, Kar9 and Myo2, and the spindle may then be positioned in a cytoplasmic dynein- 
dependent manner. Cytoplasmic dynein linked to the cortex by -catenin may be important for 
MTOC orientation during cell migration. (B) Model for cytoskeletal regulation by Arg through 
direct interactions with F-actin and microtubules (MTs). Schematic representation of F-actin, 
MTs and Arg in a cultured cell. A protrusive area enlarged in the pink box. Arg can directly 
organize the cytoskeleton by bundling F-actin. Arg binds to F-actin cooperatively in vitro, 
suggesting that the binding o f one Arg molecule to F-actin promotes the binding of other Arg 
molecules; this mechanism might contribute to Arg clustering in cells. Arg crosslinks F-actin and 
MTs in vitro and co-localises with them at the cell periphery. (Figure reproduced from (A) 
Rodriguez et al. 2003 and (B) Hernandez et al. 2004).
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7.4.2 How does vaccinia virus make the transition from microtubule- to actin- 
based motility?
Vaccinia virus utilises both the microtubule and actin cytoskeletons to enhance its 
spread o f infection, as IEVs must switch from microtubule-based transport to actin- 
based transport in the cell periphery. Upon fusion o f IEV with the plasma membrane, 
virus-induced signalling directly modulates the release o f kinesin-1 in vaccinia-infected 
cells, as a consequence o f Src-mediated phosphorylation on A36R (Figure 7.6) (Hall 
2004; Newsome et al. 2004; Reeves et al. 2005; Newsome et al. 2006). It has been 
suggested that phosphorylation of A36R, as opposed to the motor, is responsible for 
promoting kinesin-l release from the virus, as it has been shown that the YdF virus is 
still able to recruit and activate Src but it does not kick off kinesin-l (Newsome et al. 
2004). The underlying mechanisms have yet to be established but the Src family kinase 
phosphorylation site in A36R is known to be adjacent to the KLC-binding site in A36R 
(Frischknecht et al. 1999a; Newsome et al. 2006; Ward and Moss 2004). This raises the 
question as to whether Src-mediated kinesin release is commonly used to co-ordinate 
microtubule and actin-based motility in non-infected cells. Additionally, it has recently 
been postulated that vaccinia may be mimicking a regulatory pathway that is normally 
used within the cell (Hall 2004). Studies have also shown that kinesin-l is recruited to 
the N-terminus o f p 120 catenin during vesicular transport of the cadherin complexes to 
adherens junctions (Chen et al. 2003; Yanagisawa et al. 2004). This region also 
contains Src phosphorylation sites, which implies that Src regulates motor recruitment 
and detachment, in a similar respect to that seen with A36R.
In addition to Src-family kinases, the Abl-family kinases, Abl and Arg are also capable 
of phosphorylating A36R in vitro and are recruited in vivo (Newsome et al. 2006). They 
are known to regulate the dynamics of the cytoskeleton and are recruited to vaccinia- 
induced actin tails. Also, the treatment of SYF (Src/Yes/Fyn) null cells with Gleevec 
[STI-571; Imatinib] directly demonstrated that Abl-kinases play an active role in this 
process (Newsome et al. 2006). Abl-family kinases are specific non-receptor tyrosine 
kinases that have the ability to bind directly to F-actin and, in the case of Arg, can also 
bind to microtubules (Figure 7.5 B) (Hernandez et al. 2004). Arg contains a
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Figure 7.6: Schematic representation of the Src-mediated transition from microtubule- to 
actin-based motility of vaccinia virus. The steps involved in the transfer from microtubule- 
based motility to actin tail formation are out-lined. IEV particles are delivered to the plasma 
membrane on microtubules via an interaction between A36R and kinesin-1 (1). Following fusion 
with the plasma membrane to form CEV (2), a localised B5R-dependent outside-in signalling 
cascade activates Src (3), which subsequently phosphorylates A36R and releases kinesin-1 
from the complex (4). Phosphorylated A36R then recruits the vaccinia actin tail nucleation 
complex, which results in the localised activation of the Arp2/3 complex and actin 
polymerisation. (Figure modified from Newsome et al. 2004).
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microtubule-binding domain positioned between two F-actin-binding domains and uses 
these regions to bind to their respective filaments with high affinity and to cross-link 
them together in vitro (Gertler et al. 1995; Galkin et al. 2005). It has also been 
suggested that Arg requires this cross-linking activity in order to promote membrane 
protrusion/ruffling and mediate interactions between the cytoskeletal networks (Miller 
et al. 2004; Hernandez et al. 2004). Furthermore, Abl and D-Abl also contain the F- 
actin binding domain that is located closest to the C-terminus in Arg, although it is 
unknown whether they also possess microtubule-binding domains or additional F-actin 
binding domains (Van Etten et al. 1994). Therefore, it is plausible that the binding of 
Abl-family kinases to F-actin and microtubules could tether these kinases near their 
regulators and substrates, which facilitate the interaction(s) between these networks, as 
many o f them are associated with the cytoskeleton. Consequently, the cytoskeletal 
proteins may also regulate the activity of other Abl-family members (Hernandez et al.
2004).
7.4.3 Is myosin Va involved in the vaccinia virus life-cycle?
Microtubules radiate from the MTOC and towards the cell periphery until they reach 
the dense actin cortex concentrated at the cell periphery, immediately beneath the 
plasma membrane (Figure 7.5, box 3). Therefore, as microtubules do not extend in 
entirety to the plasma membrane there must be an additional, as yet uncharacterised 
transition stage, by which the virion passes from the microtubule network to the plasma 
membrane. Taking this into account, together with the well-documented importance of 
kinesin-l and dynein during (microtubule-based) transport o f vaccinia virus, it is 
surprising that the involvement o f the myosin motor proteins have not also been 
thoroughly investigated. Especially as the slower IEV movements observed in the 
absence of microtubules indicate that they could be due to the action of myosin motors 
as well as due to the induction of actin tails (Geada et al. 2001). Therefore, systematic 
analysis o f the myosin family could divulge important developments regarding the viral 
entry or exit processes, both of which utilise the actin cytoskeleton.
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Myosin Va was selected as the initial candidate to investigate, due to its established role 
in membrane trafficking and its ability to interact directly with both the microtubule and 
actin cytoskeletons (Huang et al. 1999; Karcher et al. 2002; Cao et al. 2004). Three 
different myosin Va antibodies were tested by immunofluorescence, however, they each 
produced three strikingly different localisations, making it difficult to draw any valid 
conclusions as to the true nature o f myosin Va within infected cells. Extended 
immunofluorescence experiments are therefore essential to determine the true 
localisation o f myosin Va in infected and uninfected HeLa cells. Only once this is 
achieved will it become clearer if myosin Va is involved in vaccinia virus life-cycle. 
Several tools have been identified that could be used in order to address these questions, 
including a GFP-tagged myosin Va construct and a myosin Va null (and control) cell 
line from the dilute mouse, both o f which have been characterised in previously 
published reports (Lionne et al. 2001; Hume et al. 2002). The myosin Va antibodies 
(clone LF-18, clone LE-16 and ‘Cambridge’) could be tested on the knock-out (and 
control) cells to test whether the original antibody specifically recognises myosin Va. 
The antibodies can then be used to stain vaccinia virus-infected HeLa cells, to confirm 
or refute the previous observations on myosin Va localisation during infection. Finally, 
assuming that the knock-out (and control) cells are compatible with vaccinia virus 
infection, both cell lines can be infected and analysed whether the virus behaviour is 
altered between the two cell-types, i.e. compare and quantify both the viral 
morphogenesis and egress. As an alternative approach, myosin Va function can be 
perturbed in infected HeLa cells by either using a pharmacological inhibitor of myosin 
Va, e.g. 2,3-butanedione monoxime (BDM) (although its ability as an inhibitor is 
ambiguous, due to its interference with intracellular calcium levels, as well as effecting 
myosin II) or by suppressing myosin Va expression using RNAi. Although initial 
studies have indicated that BDM appears to have no effect on myosin Va, its activity 
has not been thoroughly tested. Also, in concordance with these preliminary negative 
findings, experiments performed by Geada et al. also failed to block IEV egress using 
the same concentration (lOmM) o f BDM (Geada et al. 2001). Nevertheless, their 
investigation also concluded that a potential role for myosin motors in viral transport 
cannot be ruled out based on these experiments. Instead, monitoring the formation of 
actin tails, viral factories etc. could prove informative about its role in vaccinia virus
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morphogenesis. This could also be complemented by monitoring the effects of the 
inhibitor blebbistatin, as a suitable control, which only inhibits the activity of myosin II 
(Kovacs et al. 2004). However, the efficacy and specificity of the available myosin Va 
inhibitors is controversial and use of siRNA primers for effective, specific myosin Va 
knock down may require optimization and therefore more time. However, the RNAi 
HeLa cell based strategy may be better than using knock-out cells because infected 
HeLa cells are a reputable, well-characterised model for vaccinia virus infection. 
Therefore, an RNAi systems biology approach could be performed on all myosin 
motors.
7.4.3.1 Does LC8 (DYNLL1) mediate microtubule- to actin-based transport in 
vaccinia virus?
As myosin Va and dynein share the same light chains it is of interest to note that yeast 
two-hybrid, confocal and co-immunoprecipitation studies have revealed that 
cytoplasmic dynein LC8 (DYNLLl) interacts strongly with the phosphoprotein (P) of 
two lyssaviruses: Rabies virus and Mokola virus (Table 7.1-H) (Espindola et al. 2000; 
Jacob et al. 2000; Raux et al. 2000). O f particular relevance is their emergent theory 
that this interaction could be common to all lyssaviruses due to the high amino acid 
identity (46%) calculated between these two P proteins. In addition, Alonso et al. 
demonstrated that ASFV can hijack the dynein motor complex in order to facilitate its 
transport through its host cell, via direct binding of the viral protein p54 with LC8 
(DYNLLl) (Table 7.1-B)(Alonso et al. 2001). In light of these studies, as dynein LC8 
(DYNLLl) is also a component of myosin V, perhaps it constitutes a mechanism for 
transferring from microtubule- to actin-mediated transport?
7.4.3.2 Do any o f the myosin V isoforms have a role in the vaccinia virus life-cycle?
Bioinformatic analysis of myosin Va has proposed that myosin Vb and myosin Vc also 
possess similar structural organisations (Rodriguez and Cheney 2002; Zhao et al. 1996). 
Overall, the motor domains of the three isoforms share ~68% identity, while the coiled- 
coil regions o f myosin Va and myosin Vb share a -42%  identity and the coiled-coil 
region o f myosin Vc shares 20-30% identity with these regions in myosin Va and 
myosin Vb (Rodriguez and Cheney 2002).
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Each myosin V isoform appears to be strongly associated with specific membrane 
transport events and their functions are not solely restricted to the cortex. Research by 
Rodriguez and Cheney has suggested that the class V myosins could also play important 
roles in budding, tethering and fusion events (Rodriguez and Cheney 2002). It has 
comprehensively been reported that myosin Va is involved in the trafficking of 
melanosomes in melanocytes and participates in the transport of an inositol triphosphate 
receptor-containing compartment in neurons (Takagishi et al. 1996). Myosin Vb has 
been implicated in the function of a rabl la-associated recycling endosome in HeLa 
cells, as well as in a rabl la-associated recycling compartment that is required for 
transcytosis in polarised Madin-Darby Canine Kidney (MDCK) cells (Lapierre et al. 
2001; Hales et al. 2002; Watanabe et al. 2006). Myosin Vc is thought to be associated 
with the transferrin-accessible compartment within HeLa cells that is different and 
separate from the myosin Va/rabl la recycling compartment, as well as the endogenous 
myosin Va compartment (Rodriguez and Cheney 2002).
Likewise, the different isoforms of myosin V exhibit different expression patterns. 
Myosin Va is most abundant within the brain and is also highly expressed in 
melanocytes, whereas myosin Vb is found predominantly in kidney and myosin Vc is 
particularly profuse in the epithelial cells of the pancreas, colon and stomach 
(Rodriguez and Cheney 2002). HeLa cells are known to express low levels o f all three 
o f the myosin V isoforms and a proposed model for their membrane-trafficking within 
HeLa cells is depicted in Figure 7.7 (Rodriguez and Cheney 2002; Lapierre et al. 2001). 
Immunofluorescence indicates that myosin Va adopts a punctate localisation in the cell 
periphery, despite the myosin Va antibodies tested in this thesis (clone LF-18, clone 
LE-16 and ‘Cambridge’) failing to adopt such a staining pattern. However, to date, 
these structures remain undefined, although they are not considered to be endosomal as 
they fail to co-localise with the transferrin receptor (Rodriguez and Cheney 2002). The 
tail of myosin Vb localises to the recycling endosome that contains the transferrin 
receptor and rabl la  and myosin Vc has been shown to associate with a different 
compartment containing the transferrin receptor and rab 8 (Lapierre et al. 2001; 
Rodriguez and Cheney 2002). Several other cell-types are also capable of expressing 
multiple class V myosins (Rodriguez and Cheney 2002; Lapierre et al. 2001).
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Therefore, upon consideration of the above details, an extended characterisation of 
myosin Va, together with analysis of myosin Vb and myosin Vc could reveal some 
interesting insights into a potential role(s) for the class V myosins during the vaccinia 
virus life-cycle.
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Figure 7.7; Schematic model of the class V myosins in membrane-trafficking in HeLa 
cells. Myosin Va exhibits a striking localisation to small punctate structures of an unknown 
identity in the cell periphery. In HeLa cells, myosin Vb appears to associate with a major 
recycling component containing rab11a, as a dominant-negative construct consisting of the 
myosin Vb-tail inhibits transferrin recycling and co-localises with the transferrin receptor and 
rab11a (Lapierre et al. 2001). In contrast, the myosin Vc-tail associates with an apparently 
distinct transferrin-accessible compartment containing rab8 but not rab11a. Although the 
precise nature of the pathway associated with myosin Vc in HeLa cells is unclear. (Figure 
reproduced from Rodriguez and Cheney 2002).
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7.5 Conclusions
This research has provided further insight into the relationship between F12L, A33R, 
A36R and kinesin-1.
• F12L is associated with IEV during viral egress and it clearly plays a significant 
role in vaccinia virus morphogenesis.
• 2D gel electrophoresis analysis indicates that F12L undergoes some form of 
post-translational modification, although the nature of this modification remains 
unclear.
• Mutation of two putative myristoylation sites does not block the egress o f F12L 
to the cell surface.
• Construction o f a series of F12L deletion mutants failed to identify a specific 
region of the protein that was sufficient for viral egress to the cell periphery, 
implying that F12L is a single-folded domain.
• A33R was shown to be serine phosphorylated in cells and removal o f these 
serine residues had no apparent effect on viral transport.
• GFP-tagged F12L is localised to IEV particles, co-localises with kinesin and 
associates with microtubules.
• No positive data has been acquired to show that F12L interacts with 
conventional kinesin, in vitro.
• Immunoprecipitation experiments demonstrated that there is no apparent 
interaction between: (i) F12L and A33R, (ii) F12L and TPR, and (iii) A33R and 
TPR.
• A putative interaction has been detected between F12L and A36R by 
immunoprecipitation. These additional findings are high-lighted in Figure 7.8 
and Table 7.4.
The challenge remains to elucidate the mechanisms that underlie IEV transport in 
vaccinia virus and in particular the role of F12L.
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A33R \ * -----------------------■ [ F12L
>  KINESINA36R
Figure 7.8: Revised summary diagram illustrating the binding relationships between the 
viral proteins F12L, A33R, A36R and kinesin-1. The double-ended arrows represent an 
interaction; the blunt-ended lines indicate that no interaction exists; the dashed line and 
question mark implies that the interaction status remains to be established or confirmed.
Vaccinia Virus Protein (IEV) 
A33R A34R A36R
Kinesin-
F12L F13L A56R B5R
F12L
</> _ 
IS F13LA33R
A34R
A36R
ro q_ A56R
B5R
Kinesin-1
Table 7.4: Revised version of Table 1.6 illustrating the interactions between IEV vaccinia 
virus proteins and kinesin-1. Key: V = interaction; X  = no interaction; green boxes identify 
those interaction that were known at the start of this study, blue boxes indicate those that were 
identified during the course of this research and the red boxes high-light the potential 
interactions identified as a result o f this thesis.
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